_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,b1,b2,confirmids1,confirmids2,e1,e2,factor1,factor2,firstfactor,saveselectionids1,saveselectionids2,secondfactor,sentence,wordid1,wordid2,orig_b1,orig_b2,orig_e1,orig_e2,expertdecision,relation,sent_id,orig_sentence,term1,term2
502912884,7/14/2014 12:56:00,,1322818815,7/14/2014 12:55:54,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,144,66,,,148,76,PAIN,VULVODYNIA,robust reduction in PAIN 55.,124-131-141-144-151,49-53-63-66-77-83-88-124,the treatment of VULVODYNIA found that 17 robust,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55.",144,66,144,66,148,76,-1,RO-has_definitional_manifestation,904958,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55",pain,vulvodynia
502912884,7/14/2014 12:56:29,,1322819212,7/14/2014 12:56:12,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,144,66,,,148,76,PAIN,VULVODYNIA,PAIN,144,66,VULVODYNIA,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55.",144,66,144,66,148,76,-1,RO-has_definitional_manifestation,904958,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55",pain,vulvodynia
502912884,7/14/2014 13:04:50,,1322824615,7/14/2014 13:04:29,gifthulk,1,25566511,USA,"","",24.164.11.173,144,66,,,148,76,PAIN,VULVODYNIA,PAIN,144,66,VULVODYNIA,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55.",144,66,144,66,148,76,-1,RO-has_definitional_manifestation,904958,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55",pain,vulvodynia
502912884,7/14/2014 13:22:25,,1322836683,7/14/2014 13:21:39,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,144,66,,,148,76,PAIN,VULVODYNIA,lamotrigine vulvodynia robust reduction PAIN,33-66-124-131-144,33-66-124-131-144,lamotrigine VULVODYNIA robust reduction pain,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55.",144,66,144,66,148,76,-1,RO-has_definitional_manifestation,904958,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55",pain,vulvodynia
502912884,7/14/2014 13:29:17,,1322841267,7/14/2014 13:28:43,prodege,1,2107590,CAN,ON,Ottawa,99.245.226.211,144,66,,,148,76,PAIN,VULVODYNIA,robust reduction in PAIN,124-131-141-144,33-49-53-63-66,lamotrigine the treatment of VULVODYNIA,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55.",144,66,144,66,148,76,-1,RO-has_definitional_manifestation,904958,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55",pain,vulvodynia
502912884,7/14/2014 13:29:59,,1322841798,7/14/2014 13:29:40,fusioncash,1,6340814,USA,FL,Saint Petersburg,216.186.230.135,144,66,,,148,76,PAIN,VULVODYNIA,robust reduction in PAIN 55.,124-131-141-144-151,49-53-63-66-77-83-88,the treatment of VULVODYNIA found that 17,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55.",144,66,144,66,148,76,-1,RO-has_definitional_manifestation,904958,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55",pain,vulvodynia
502912884,7/14/2014 13:45:43,,1322853100,7/14/2014 13:45:22,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,144,66,,,148,76,PAIN,VULVODYNIA,PAIN,144,66,VULVODYNIA,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55.",144,66,144,66,148,76,-1,RO-has_definitional_manifestation,904958,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55",pain,vulvodynia
502912884,7/14/2014 13:46:24,,1322853765,7/14/2014 13:46:06,elite,1,26544151,GBR,"","",188.29.127.144,144,66,,,148,76,PAIN,VULVODYNIA,PAIN,144,66,VULVODYNIA,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55.",144,66,144,66,148,76,-1,RO-has_definitional_manifestation,904958,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55",pain,vulvodynia
502912884,7/14/2014 14:00:27,,1322863587,7/14/2014 13:59:46,prodege,1,28140821,CAN,ON,Peterborough,24.235.135.244,144,66,,,148,76,PAIN,VULVODYNIA,PAIN,144,66,VULVODYNIA,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55.",144,66,144,66,148,76,-1,RO-has_definitional_manifestation,904958,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55",pain,vulvodynia
502912884,7/14/2014 14:22:23,,1322878502,7/14/2014 14:22:18,fusioncash,1,17395678,USA,OK,Oklahoma City,67.67.9.94,144,66,,,148,76,PAIN,VULVODYNIA,robust reduction in PAIN 55.,124-131-141-144-151,49-53-63-66-77-83-88,the treatment of VULVODYNIA found that 17,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55.",144,66,144,66,148,76,-1,RO-has_definitional_manifestation,904958,"? An open-label, 8-week trial of lamotrigine for the treatment of vulvodynia found that 17 of 31 participants experienced a robust reduction in pain ( 55",pain,vulvodynia
502912885,7/14/2014 12:54:04,,1322817578,7/14/2014 12:53:59,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,132,173,,,154,197,PLEXIFORM NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,tumor in a retroperitoneal PLEXIFORM NEUROFIBROMA in a patient,111-114-116-132-142-155-158-160-97,158-160-168-173-191-196-97,tumor a patient with NEUROFIBROMATOSIS TYPE 1.,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1.,132 142,173 191 196,132,173,154,197,-1,RO-has_manifestation,906462,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1,plexiform neurofibroma,neurofibromatosis type 1
502912885,7/14/2014 13:01:41,,1322822604,7/14/2014 13:01:13,gifthulk,1.0,25566511,USA,"","",24.164.11.173,132,173,,,154,197,PLEXIFORM NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,retroperitoneal PLEXIFORM NEUROFIBROMA,116-132-142,173-191-196,NEUROFIBROMATOSIS TYPE 1.,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1.,132 142,173 191 196,132,173,154,197,-1,RO-has_manifestation,906462,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1,plexiform neurofibroma,neurofibromatosis type 1
502912885,7/14/2014 13:32:46,,1322843705,7/14/2014 13:32:20,clixsense,1,6500439,AUS,02,Ingleburn,115.146.65.99,132,173,,,154,197,PLEXIFORM NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,retroperitoneal PLEXIFORM NEUROFIBROMA,116-132-142,116-132-142-155-160-168-173-191-196-158,retroperitoneal plexiform neurofibroma in a patient with NEUROFIBROMATOSIS TYPE 1.,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1.,132 142,173 191 196,132,173,154,197,-1,RO-has_manifestation,906462,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1,plexiform neurofibroma,neurofibromatosis type 1
502912885,7/14/2014 13:34:48,,1322845230,7/14/2014 13:34:42,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,132,173,,,154,197,PLEXIFORM NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,in a retroperitoneal PLEXIFORM NEUROFIBROMA in a patient,111-114-116-132-142-155-158-160,158-160-168-173-191-196,a patient with NEUROFIBROMATOSIS TYPE 1.,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1.,132 142,173 191 196,132,173,154,197,-1,RO-has_manifestation,906462,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1,plexiform neurofibroma,neurofibromatosis type 1
502912885,7/14/2014 13:40:24,,1322849390,7/14/2014 13:40:21,clixsense,1,7415230,GBR,A7,Birmingham,147.188.47.242,132,173,,,154,197,PLEXIFORM NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,in a retroperitoneal PLEXIFORM NEUROFIBROMA in a patient,111-114-116-132-142-155-158-160,158-160-168-173-191-196,a patient with NEUROFIBROMATOSIS TYPE 1.,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1.,132 142,173 191 196,132,173,154,197,-1,RO-has_manifestation,906462,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1,plexiform neurofibroma,neurofibromatosis type 1
502912885,7/14/2014 13:44:08,,1322852112,7/14/2014 13:43:45,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,132,173,,,154,197,PLEXIFORM NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,PLEXIFORM NEUROFIBROMA,132-142,173-191-196,NEUROFIBROMATOSIS TYPE 1.,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1.,132 142,173 191 196,132,173,154,197,-1,RO-has_manifestation,906462,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1,plexiform neurofibroma,neurofibromatosis type 1
502912885,7/14/2014 13:51:09,,1322857290,7/14/2014 13:50:51,elite,1.0,26544151,GBR,"","",188.29.127.144,132,173,,,154,197,PLEXIFORM NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,PLEXIFORM NEUROFIBROMA,132-142,173-191-196,NEUROFIBROMATOSIS TYPE 1.,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1.,132 142,173 191 196,132,173,154,197,-1,RO-has_manifestation,906462,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1,plexiform neurofibroma,neurofibromatosis type 1
502912885,7/14/2014 13:57:38,,1322861715,7/14/2014 13:57:01,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,132,173,,,154,197,PLEXIFORM NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,a retroperitoneal PLEXIFORM NEUROFIBROMA,114-116-132-142,173-191-196,NEUROFIBROMATOSIS TYPE 1.,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1.,132 142,173 191 196,132,173,154,197,-1,RO-has_manifestation,906462,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1,plexiform neurofibroma,neurofibromatosis type 1
502912885,7/14/2014 14:22:31,,1322878585,7/14/2014 14:22:25,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,132,173,,,154,197,PLEXIFORM NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,in a retroperitoneal PLEXIFORM NEUROFIBROMA in a patient,111-114-116-132-142-155-158-160,158-160-168-173-191-196,a patient with NEUROFIBROMATOSIS TYPE 1.,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1.,132 142,173 191 196,132,173,154,197,-1,RO-has_manifestation,906462,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1,plexiform neurofibroma,neurofibromatosis type 1
502912885,7/14/2014 14:22:42,,1322878686,7/14/2014 14:22:36,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,132,173,,,154,197,PLEXIFORM NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,in a retroperitoneal PLEXIFORM NEUROFIBROMA in a patient,111-114-116-132-142-155-158-160,158-160-168-173-191-196,a patient with NEUROFIBROMATOSIS TYPE 1.,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1.,132 142,173 191 196,132,173,154,197,-1,RO-has_manifestation,906462,We present the diffusion-weighted imaging (DWI) findings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neurofibroma in a patient with neurofibromatosis type 1,plexiform neurofibroma,neurofibromatosis type 1
502912886,7/14/2014 12:44:46,,1322811246,7/14/2014 12:44:40,clixsense,1,24763049,GBR,"","",86.133.47.213,74,40,,,76,48,AF,WARFARIN,with placebo in AF showed a relative,58-63-71-74-77-84-86,23-26-35-40-49-58-63,of adjusted dose WARFARIN compared with placebo,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2).,74,40,74,40,76,48,1,RO-may_treat,907923,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2),AF,warfarin
502912886,7/14/2014 12:50:22,,1322814950,7/14/2014 12:50:07,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,74,40,,,76,48,AF,WARFARIN,AF,74,23-26-35-40,of adjusted dose WARFARIN,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2).,74,40,74,40,76,48,1,RO-may_treat,907923,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2),AF,warfarin
502912886,7/14/2014 13:06:27,,1322825642,7/14/2014 13:06:03,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,74,40,,,76,48,AF,WARFARIN,warfarin placebo AF a,40-63-74-84,40-63,WARFARIN placebo,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2).,74,40,74,40,76,48,1,RO-may_treat,907923,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2),AF,warfarin
502912886,7/14/2014 13:17:34,,1322833306,7/14/2014 13:17:16,clixsense,1,8422649,GBR,B4,Bradford,86.185.23.95,74,40,,,76,48,AF,WARFARIN,AF,74,40,WARFARIN,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2).,74,40,74,40,76,48,1,RO-may_treat,907923,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2),AF,warfarin
502912886,7/14/2014 13:17:51,,1322833494,7/14/2014 13:17:34,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,74,40,,,76,48,AF,WARFARIN,AF,74,40,WARFARIN,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2).,74,40,74,40,76,48,1,RO-may_treat,907923,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2),AF,warfarin
502912886,7/14/2014 13:30:27,,1322842087,7/14/2014 13:30:10,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,74,40,,,76,48,AF,WARFARIN,placebo in AF,63-71-74,26-35-40-49-58-63,adjusted dose WARFARIN compared with placebo,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2).,74,40,74,40,76,48,1,RO-may_treat,907923,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2),AF,warfarin
502912886,7/14/2014 13:32:24,,1322843387,7/14/2014 13:31:59,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,74,40,,,76,48,AF,WARFARIN,AF,74,40,WARFARIN,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2).,74,40,74,40,76,48,1,RO-may_treat,907923,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2),AF,warfarin
502912886,7/14/2014 13:42:01,,1322850441,7/14/2014 13:41:37,gifthulk,1,22552178,AUS,05,Adelaide,14.2.58.19,74,40,,,76,48,AF,WARFARIN,AF,74,40,WARFARIN,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2).,74,40,74,40,76,48,1,RO-may_treat,907923,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2),AF,warfarin
502912886,7/14/2014 14:20:38,,1322877307,7/14/2014 14:20:34,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,74,40,,,76,48,AF,WARFARIN,with placebo in AF showed a relative,58-63-71-74-77-84-86,23-26-35-40-49-58-63,of adjusted dose WARFARIN compared with placebo,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2).,74,40,74,40,76,48,1,RO-may_treat,907923,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2),AF,warfarin
502912886,7/14/2014 14:24:40,,1322880149,7/14/2014 14:24:36,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,74,40,,,76,48,AF,WARFARIN,with placebo in AF showed a relative,58-63-71-74-77-84-86,23-26-35-40-49-58-63,of adjusted dose WARFARIN compared with placebo,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2).,74,40,74,40,76,48,1,RO-may_treat,907923,A recent meta-analysis of adjusted-dose warfarin compared with placebo in AF showed a relative risk reduction (RRR) of 64% and absolute risk reduction (ARR) of 2.7%/y for stroke with warfarin  (2),AF,warfarin
502912887,7/14/2014 12:45:43,,1322811842,7/14/2014 12:45:38,clixsense,1.0,24763049,GBR,"","",86.133.47.213,48,0,,,55,10,ANXIETY,NIGHTMARES,a larger (ANXIETY) syndrome and need,38-40-47-57-66-70,0-11-15-20,NIGHTMARES are more than,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment.,,0,48,0,55,10,-1,RO-has_definitional_manifestation,904702,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment,anxiety,Nightmares
502912887,7/14/2014 12:49:12,,1322814157,7/14/2014 12:48:54,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,48,0,,,55,10,ANXIETY,NIGHTMARES,larger (ANXIETY) syndrome,40-47-57,0,NIGHTMARES,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment.,,0,48,0,55,10,-1,RO-has_definitional_manifestation,904702,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment,anxiety,Nightmares
502912887,7/14/2014 13:01:30,,1322822438,7/14/2014 13:00:52,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,48,0,,,55,10,ANXIETY,NIGHTMARES,Nightmares (ANXIETY) syndrome,0-47-57,0-47-57,NIGHTMARES (anxiety) syndrome,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment.,,0,48,0,55,10,-1,RO-has_definitional_manifestation,904702,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment,anxiety,Nightmares
502912887,7/14/2014 13:21:45,,1322836160,7/14/2014 13:21:03,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,48,0,,,55,10,ANXIETY,NIGHTMARES,(ANXIETY),47,0,NIGHTMARES,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment.,,0,48,0,55,10,-1,RO-has_definitional_manifestation,904702,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment,anxiety,Nightmares
502912887,7/14/2014 13:45:23,,1322852910,7/14/2014 13:45:10,elite,1.0,26544151,GBR,"","",188.29.127.144,48,0,,,55,10,ANXIETY,NIGHTMARES,(ANXIETY),47,0,NIGHTMARES,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment.,,0,48,0,55,10,-1,RO-has_definitional_manifestation,904702,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment,anxiety,Nightmares
502912887,7/14/2014 14:20:19,,1322876989,7/14/2014 14:20:13,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,48,0,,,55,10,ANXIETY,NIGHTMARES,a larger (ANXIETY) syndrome and need,38-40-47-57-66-70,0-11-15-20,NIGHTMARES are more than,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment.,,0,48,0,55,10,-1,RO-has_definitional_manifestation,904702,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment,anxiety,Nightmares
502912887,7/14/2014 14:34:50,,1322887472,7/14/2014 14:34:40,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,48,0,,,55,10,ANXIETY,NIGHTMARES,(ANXIETY) syndrome,47-57,0,NIGHTMARES,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment.,,0,48,0,55,10,-1,RO-has_definitional_manifestation,904702,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment,anxiety,Nightmares
502912887,7/14/2014 14:39:06,,1322890381,7/14/2014 14:39:02,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,48,0,,,55,10,ANXIETY,NIGHTMARES,a larger (ANXIETY) syndrome and need,38-40-47-57-66-70,0-11-15-20,NIGHTMARES are more than,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment.,,0,48,0,55,10,-1,RO-has_definitional_manifestation,904702,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment,anxiety,Nightmares
502912887,7/14/2014 14:40:24,,1322891334,7/14/2014 14:40:11,prodege,1.0,28209666,,,"",24.156.173.34,48,0,,,55,10,ANXIETY,NIGHTMARES,(ANXIETY) syndrome,47-57,0,NIGHTMARES,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment.,,0,48,0,55,10,-1,RO-has_definitional_manifestation,904702,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment,anxiety,Nightmares
502912887,7/14/2014 14:48:00,,1322896209,7/14/2014 14:47:50,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,48,0,,,55,10,ANXIETY,NIGHTMARES,(ANXIETY) syndrome,47-57,0,NIGHTMARES,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment.,,0,48,0,55,10,-1,RO-has_definitional_manifestation,904702,Nightmares are more than a symptom of a larger (anxiety) syndrome and need to be viewed from a sleep medicine perspective: nightmares are a highly prevalent and separate sleep disorder that can and should receive specific treatment,anxiety,Nightmares
502912888,7/14/2014 12:58:15,,1322820335,7/14/2014 12:58:02,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,97,141,,,99,157,TB,ANTITUBERCULOSIS,TB;,97,141,ANTITUBERCULOSIS,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents.,97,141,97,141,99,157,1,RO-may_treat,907860,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents,TB,antituberculosis
502912888,7/14/2014 13:00:36,,1322821888,7/14/2014 13:00:16,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,97,141,,,99,157,TB,ANTITUBERCULOSIS,TB;,97,141-158,ANTITUBERCULOSIS agents.,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents.,97,141,97,141,99,157,1,RO-may_treat,907860,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents,TB,antituberculosis
502912888,7/14/2014 13:20:23,,1322835140,7/14/2014 13:19:36,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,97,141,,,99,157,TB,ANTITUBERCULOSIS,TB; antituberculosis agents.,97-141-158,141-97,TB; ANTITUBERCULOSIS,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents.,97,141,97,141,99,157,1,RO-may_treat,907860,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents,TB,antituberculosis
502912888,7/14/2014 13:38:41,,1322848111,7/14/2014 13:37:53,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,97,141,,,99,157,TB,ANTITUBERCULOSIS,treatment of TB;,84-94-97,84-97-109-115-118-130-135-141-158-94,treatment of TB; given in conjunction with other ANTITUBERCULOSIS agents.,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents.,97,141,97,141,99,157,1,RO-may_treat,907860,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents,TB,antituberculosis
502912888,7/14/2014 13:50:31,,1322856754,7/14/2014 13:50:16,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,97,141,,,99,157,TB,ANTITUBERCULOSIS,TB;,97,141,ANTITUBERCULOSIS,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents.,97,141,97,141,99,157,1,RO-may_treat,907860,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents,TB,antituberculosis
502912888,7/14/2014 13:51:45,,1322857715,7/14/2014 13:51:10,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,97,141,,,99,157,TB,ANTITUBERCULOSIS,TB;,97,141,ANTITUBERCULOSIS,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents.,97,141,97,141,99,157,1,RO-may_treat,907860,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents,TB,antituberculosis
502912888,7/14/2014 13:54:41,,1322859773,7/14/2014 13:54:26,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,97,141,,,99,157,TB,ANTITUBERCULOSIS,TB;,97,141-158,ANTITUBERCULOSIS agents.,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents.,97,141,97,141,99,157,1,RO-may_treat,907860,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents,TB,antituberculosis
502912888,7/14/2014 13:58:59,,1322862622,7/14/2014 13:58:43,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,97,141,,,99,157,TB,ANTITUBERCULOSIS,TB;,97,141,ANTITUBERCULOSIS,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents.,97,141,97,141,99,157,1,RO-may_treat,907860,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents,TB,antituberculosis
502912888,7/14/2014 14:39:04,,1322890346,7/14/2014 14:38:51,prodege,1.0,28209666,,,"",24.156.173.34,97,141,,,99,157,TB,ANTITUBERCULOSIS,TB;,97,141,ANTITUBERCULOSIS,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents.,97,141,97,141,99,157,1,RO-may_treat,907860,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents,TB,antituberculosis
502912888,7/14/2014 14:47:28,,1322895886,7/14/2014 14:47:15,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,97,141,,,99,157,TB,ANTITUBERCULOSIS,TB;,97,141-158,ANTITUBERCULOSIS agents.,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents.,97,141,97,141,99,157,1,RO-may_treat,907860,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other antituberculosis agents,TB,antituberculosis
502912889,7/14/2014 13:02:33,,1322823137,7/14/2014 13:01:42,gifthulk,1.0,25566511,USA,"","",24.164.11.173,26,0,,,30,17,BONE,FIBROUS DYSPLASIA,Fibrous dysplasia (FD) of BONE,8-18-23-26-0,0-8-23-26,FIBROUS DYSPLASIA of bone,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development.,26,0 8,26,0,30,17,1,RO-has_finding_site,905274,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development,bone,Fibrous dysplasia
502912889,7/14/2014 13:10:13,,1322828363,7/14/2014 13:09:54,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,26,0,,,30,17,BONE,FIBROUS DYSPLASIA,dysplasia BONE anomalies of skeletal,8-26-73-86-83,0-8-61-73,FIBROUS DYSPLASIA encountered anomalies,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development.,26,0 8,26,0,30,17,1,RO-has_finding_site,905274,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development,bone,Fibrous dysplasia
502912889,7/14/2014 13:32:20,,1322843283,7/14/2014 13:32:04,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,26,0,,,30,17,BONE,FIBROUS DYSPLASIA,Fibrous dysplasia (FD) of BONE,8-18-23-26-0,0-8-23-26-18,FIBROUS DYSPLASIA (FD) of bone,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development.,26,0 8,26,0,30,17,1,RO-has_finding_site,905274,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development,bone,Fibrous dysplasia
502912889,7/14/2014 13:46:08,,1322853495,7/14/2014 13:45:53,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,26,0,,,30,17,BONE,FIBROUS DYSPLASIA,BONE,26,0-8,FIBROUS DYSPLASIA,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development.,26,0 8,26,0,30,17,1,RO-has_finding_site,905274,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development,bone,Fibrous dysplasia
502912889,7/14/2014 13:48:52,,1322855658,7/14/2014 13:48:38,elite,1.0,26544151,GBR,"","",188.29.127.144,26,0,,,30,17,BONE,FIBROUS DYSPLASIA,BONE,26,0-8,FIBROUS DYSPLASIA,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development.,26,0 8,26,0,30,17,1,RO-has_finding_site,905274,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development,bone,Fibrous dysplasia
502912889,7/14/2014 14:23:09,,1322879011,7/14/2014 14:23:04,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,26,0,,,30,17,BONE,FIBROUS DYSPLASIA,dysplasia (FD) of BONE is one of,8-18-23-26-31-34-38,0-8-23-26,FIBROUS DYSPLASIA of bone,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development.,26,0 8,26,0,30,17,1,RO-has_finding_site,905274,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development,bone,Fibrous dysplasia
502912889,7/14/2014 14:29:36,,1322883776,7/14/2014 14:29:33,instagc,1.0,27753923,GBR,"","",188.30.192.65,26,0,,,30,17,BONE,FIBROUS DYSPLASIA,dysplasia (FD) of BONE is one of,8-18-23-26-31-34-38,0-8-23-26,FIBROUS DYSPLASIA of bone,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development.,26,0 8,26,0,30,17,1,RO-has_finding_site,905274,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development,bone,Fibrous dysplasia
502912889,7/14/2014 14:33:11,,1322886433,7/14/2014 14:33:04,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,26,0,,,30,17,BONE,FIBROUS DYSPLASIA,dysplasia (FD) of BONE,8-18-23-26,0-8-23-26-18,FIBROUS DYSPLASIA (FD) of bone,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development.,26,0 8,26,0,30,17,1,RO-has_finding_site,905274,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development,bone,Fibrous dysplasia
502912889,7/14/2014 14:43:03,,1322893073,7/14/2014 14:42:53,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,26,0,,,30,17,BONE,FIBROUS DYSPLASIA,Fibrous dysplasia (FD) of BONE is one of,8-18-23-26-31-34-38-0,0-8-23-26,FIBROUS DYSPLASIA of bone,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development.,26,0 8,26,0,30,17,1,RO-has_finding_site,905274,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development,bone,Fibrous dysplasia
502912889,7/14/2014 14:43:06,,1322893076,7/14/2014 14:42:30,prodege,1.0,28209666,,,"",24.156.173.34,26,0,,,30,17,BONE,FIBROUS DYSPLASIA,Fibrous dysplasia (FD) of BONE,8-18-23-26-0,0-8,FIBROUS DYSPLASIA,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development.,26,0 8,26,0,30,17,1,RO-has_finding_site,905274,Fibrous dysplasia (FD) of bone is one of the most frequently encountered anomalies of skeletal development,bone,Fibrous dysplasia
502912890,7/14/2014 12:48:20,,1322813533,7/14/2014 12:48:01,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,86,11,,,102,18,PHEOCHROMOCYTOMA,MEA IIB,PHEOCHROMOCYTOMA with neurocutaneous and skeletal anomalies,86-103-108-123-127-136,11-15,MEA IIB,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon.,86,11 15,86,11,102,18,1,RO-has_manifestation,906168,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon,pheochromocytoma,MEA IIb
502912890,7/14/2014 12:58:22,,1322820417,7/14/2014 12:58:00,gifthulk,1.0,25566511,USA,"","",24.164.11.173,86,11,,,102,18,PHEOCHROMOCYTOMA,MEA IIB,PHEOCHROMOCYTOMA,86,11-15,MEA IIB,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon.,86,11 15,86,11,102,18,1,RO-has_manifestation,906168,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon,pheochromocytoma,MEA IIb
502912890,7/14/2014 13:11:42,,1322829279,7/14/2014 13:11:14,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,86,11,,,102,18,PHEOCHROMOCYTOMA,MEA IIB,gland a PHEOCHROMOCYTOMA neurocutaneous megacolon.,74-84-86-108-219,11-15-86-108-219,MEA IIB pheochromocytoma neurocutaneous megacolon.,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon.,86,11 15,86,11,102,18,1,RO-has_manifestation,906168,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon,pheochromocytoma,MEA IIb
502912890,7/14/2014 13:13:33,,1322830621,7/14/2014 13:13:27,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,86,11,,,102,18,PHEOCHROMOCYTOMA,MEA IIB,gland and a PHEOCHROMOCYTOMA with neurocutaneous and,74-80-84-86-103-108-123,0-8-11-15-19-22-24,Typical in MEA IIB is a combination,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon.,86,11 15,86,11,102,18,1,RO-has_manifestation,906168,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon,pheochromocytoma,MEA IIb
502912890,7/14/2014 13:28:02,,1322840438,7/14/2014 13:26:49,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,86,11,,,102,18,PHEOCHROMOCYTOMA,MEA IIB,MEA IIb medullary carcinoma thyroid gland PHEOCHROMOCYTOMA neurocutaneous skeletal anomalies hyperplasia nervous system GI tract megacolon.,11-15-39-49-66-74-86-108-127-136-152-183-191-205-208-219,11-15-39-49-66-74-86-108-127-136-152-183-191-205-208-219,MEA IIB medullary carcinoma thyroid gland pheochromocytoma neurocutaneous skeletal anomalies hyperplasia nervous system GI tract megacolon.,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon.,86,11 15,86,11,102,18,1,RO-has_manifestation,906168,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon,pheochromocytoma,MEA IIb
502912890,7/14/2014 13:42:11,,1322850604,7/14/2014 13:41:57,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,86,11,,,102,18,PHEOCHROMOCYTOMA,MEA IIB,PHEOCHROMOCYTOMA,86,11-15,MEA IIB,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon.,86,11 15,86,11,102,18,1,RO-has_manifestation,906168,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon,pheochromocytoma,MEA IIb
502912890,7/14/2014 13:46:28,,1322853794,7/14/2014 13:46:09,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,86,11,,,102,18,PHEOCHROMOCYTOMA,MEA IIB,PHEOCHROMOCYTOMA,86,11-15,MEA IIB,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon.,86,11 15,86,11,102,18,1,RO-has_manifestation,906168,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon,pheochromocytoma,MEA IIb
502912890,7/14/2014 14:02:25,,1322865090,7/14/2014 14:02:12,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,86,11,,,102,18,PHEOCHROMOCYTOMA,MEA IIB,PHEOCHROMOCYTOMA with neurocutaneous,86-103-108,11-15,MEA IIB,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon.,86,11 15,86,11,102,18,1,RO-has_manifestation,906168,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon,pheochromocytoma,MEA IIb
502912890,7/14/2014 14:29:57,,1322884058,7/14/2014 14:29:54,instagc,1.0,27753923,GBR,"","",188.30.192.65,86,11,,,102,18,PHEOCHROMOCYTOMA,MEA IIB,gland and a PHEOCHROMOCYTOMA with neurocutaneous and,74-80-84-86-103-108-123,0-8-11-15-19-22-24,Typical in MEA IIB is a combination,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon.,86,11 15,86,11,102,18,1,RO-has_manifestation,906168,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon,pheochromocytoma,MEA IIb
502912890,7/14/2014 14:39:27,,1322890660,7/14/2014 14:39:14,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,86,11,,,102,18,PHEOCHROMOCYTOMA,MEA IIB,PHEOCHROMOCYTOMA and,86-123,11-15,MEA IIB,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon.,86,11 15,86,11,102,18,1,RO-has_manifestation,906168,Typical in MEA IIb is a combination of medullary carcinoma of the thyroid gland and a pheochromocytoma with neurocutaneous and skeletal anomalies and a hyperplasia of the sympathetic nervous system of the GI tract with megacolon,pheochromocytoma,MEA IIb
502912891,7/14/2014 12:45:11,,1322811497,7/14/2014 12:45:07,clixsense,1.0,24763049,GBR,"","",86.133.47.213,352,298,,,356,311,DRUG,DRUG TOXICITY,for which the DRUG is being used,338-342-348-352-357-360-366,284-286-295-298-303-314-327-330,? Evidence of DRUG TOXICITY Exacerbation of disease,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment.",352,298 303,352,298,356,311,-1,RO-has_causative_agent,903983,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment",drug,drug toxicity
502912891,7/14/2014 12:59:49,,1322821374,7/14/2014 12:59:34,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,352,298,,,356,311,DRUG,DRUG TOXICITY,DRUG,352,298-303,DRUG TOXICITY,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment.",352,298 303,352,298,356,311,-1,RO-has_causative_agent,903983,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment",drug,drug toxicity
502912891,7/14/2014 13:04:28,,1322824371,7/14/2014 13:03:56,gifthulk,1.0,25566511,USA,"","",24.164.11.173,352,298,,,356,311,DRUG,DRUG TOXICITY,DRUG,352,298-303,DRUG TOXICITY,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment.",352,298 303,352,298,356,311,-1,RO-has_causative_agent,903983,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment",drug,drug toxicity
502912891,7/14/2014 13:15:05,,1322831597,7/14/2014 13:15:01,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,352,298,,,356,311,DRUG,DRUG TOXICITY,for which the DRUG is being used,338-342-348-352-357-360-366,284-286-295-298-303-314-327-330,? Evidence of DRUG TOXICITY Exacerbation of disease,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment.",352,298 303,352,298,356,311,-1,RO-has_causative_agent,903983,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment",drug,drug toxicity
502912891,7/14/2014 13:30:58,,1322842436,7/14/2014 13:29:57,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,352,298,,,356,311,DRUG,DRUG TOXICITY,DRUG,352,298-303,DRUG TOXICITY,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment.",352,298 303,352,298,356,311,-1,RO-has_causative_agent,903983,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment",drug,drug toxicity
502912891,7/14/2014 13:37:10,,1322846930,7/14/2014 13:36:52,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,352,298,,,356,311,DRUG,DRUG TOXICITY,DRUG,352,298-303,DRUG TOXICITY,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment.",352,298 303,352,298,356,311,-1,RO-has_causative_agent,903983,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment",drug,drug toxicity
502912891,7/14/2014 13:39:25,,1322848597,7/14/2014 13:39:22,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,352,298,,,356,311,DRUG,DRUG TOXICITY,for which the DRUG is being used,338-342-348-352-357-360-366,284-286-295-298-303-314-327-330,? Evidence of DRUG TOXICITY Exacerbation of disease,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment.",352,298 303,352,298,356,311,-1,RO-has_causative_agent,903983,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment",drug,drug toxicity
502912891,7/14/2014 13:45:02,,1322852579,7/14/2014 13:44:42,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,352,298,,,356,311,DRUG,DRUG TOXICITY,DRUG,352,298-303,DRUG TOXICITY,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment.",352,298 303,352,298,356,311,-1,RO-has_causative_agent,903983,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment",drug,drug toxicity
502912891,7/14/2014 14:05:37,,1322867173,7/14/2014 14:05:07,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,352,298,,,356,311,DRUG,DRUG TOXICITY,DRUG,352,298-303,DRUG TOXICITY,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment.",352,298 303,352,298,356,311,-1,RO-has_causative_agent,903983,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment",drug,drug toxicity
502912891,7/14/2014 14:29:31,,1322883706,7/14/2014 14:29:28,instagc,1.0,27753923,GBR,"","",188.30.192.65,352,298,,,356,311,DRUG,DRUG TOXICITY,for which the DRUG is being used,338-342-348-352-357-360-366,284-286-295-298-303-314-327-330,? Evidence of DRUG TOXICITY Exacerbation of disease,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment.",352,298 303,352,298,356,311,-1,RO-has_causative_agent,903983,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of drug toxicity ? Exacerbation of disease for which the drug is being used  Data Elements: ? Efficacy assessment",drug,drug toxicity
502912892,7/14/2014 12:46:14,,1322812195,7/14/2014 12:46:09,clixsense,1.0,24763049,GBR,"","",86.133.47.213,93,78,,,98,91,FEVER,MONONUCLEOSIS,"mononucleosis fever, phaRYNGItis, lymphadenopathy, and splenomegaly,",68-83-90-103-120-124,53-57-68-83-90-103,"vis infectious mononucleoSIS FEVER, Pharyngitis, lymphadenopathy,","Recognition of the syndrome ""glandular fever,"" vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century.",,,93,78,98,91,1,RO-disease_has_finding,901677,"Recognition of the syndrome &quot;glandular fever,&quot; vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century",fever,mononucleosis
502912892,7/14/2014 13:09:26,,1322827753,7/14/2014 13:09:02,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,93,78,,,98,91,FEVER,MONONUCLEOSIS,"mononucleosis lymphadenopathy,",68-103,57-68-83-90-103,"infectious mononucleoSIS FEVER, Pharyngitis, lymphadenopathy,","Recognition of the syndrome ""glandular fever,"" vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century.",,,93,78,98,91,1,RO-disease_has_finding,901677,"Recognition of the syndrome &quot;glandular fever,&quot; vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century",fever,mononucleosis
502912892,7/14/2014 13:13:24,,1322830532,7/14/2014 13:12:29,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,93,78,,,98,91,FEVER,MONONUCLEOSIS,"""glandular fever,"" infectious mononucleosis fever, phaRYNGItis, lymphadenopathy, and splenomegaly, peripheral blood leukocytes",28-39-57-68-83-90-103-120-124-173-184-190,28-39-53-57-68-83-90-103-124-173-184-190,"""glandular fever,"" vis infectious mononucleoSIS FEVER, Pharyngitis, lymphadenopathy, splenomegaly, peripheral blood leukocytes","Recognition of the syndrome ""glandular fever,"" vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century.",,,93,78,98,91,1,RO-disease_has_finding,901677,"Recognition of the syndrome &quot;glandular fever,&quot; vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century",fever,mononucleosis
502912892,7/14/2014 13:54:02,,1322859268,7/14/2014 13:53:34,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,93,78,,,98,91,FEVER,MONONUCLEOSIS,"infectious mononucleosis  fever, phaRYNGItis, lymphadenopathy, and splenomegaly,",57-68-83-90-103-120-124-82,57-68-82-83-90-103-120-124,"infectious mononucleoSIS  FEVER, Pharyngitis, lymphadenopathy, and splenomegaly,","Recognition of the syndrome ""glandular fever,"" vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century.",,,93,78,98,91,1,RO-disease_has_finding,901677,"Recognition of the syndrome &quot;glandular fever,&quot; vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century",fever,mononucleosis
502912892,7/14/2014 14:23:59,,1322879589,7/14/2014 14:23:55,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,93,78,,,98,91,FEVER,MONONUCLEOSIS,"mononucleosis fever, phaRYNGItis, lymphadenopathy, and splenomegaly,",68-83-90-103-120-124,53-57-68-83-90-103,"vis infectious mononucleoSIS FEVER, Pharyngitis, lymphadenopathy,","Recognition of the syndrome ""glandular fever,"" vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century.",,,93,78,98,91,1,RO-disease_has_finding,901677,"Recognition of the syndrome &quot;glandular fever,&quot; vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century",fever,mononucleosis
502912892,7/14/2014 14:37:39,,1322889431,7/14/2014 14:37:34,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,93,78,,,98,91,FEVER,MONONUCLEOSIS,"mononucleosis fever, phaRYNGItis, lymphadenopathy, and splenomegaly,",68-83-90-103-120-124,53-57-68-83-90-103,"vis infectious mononucleoSIS FEVER, Pharyngitis, lymphadenopathy,","Recognition of the syndrome ""glandular fever,"" vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century.",,,93,78,98,91,1,RO-disease_has_finding,901677,"Recognition of the syndrome &quot;glandular fever,&quot; vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century",fever,mononucleosis
502912892,7/14/2014 14:44:11,,1322893911,7/14/2014 14:43:48,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,93,78,,,98,91,FEVER,MONONUCLEOSIS,mononucleosis,68,57-68,infectious mononucleoSIS,"Recognition of the syndrome ""glandular fever,"" vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century.",,,93,78,98,91,1,RO-disease_has_finding,901677,"Recognition of the syndrome &quot;glandular fever,&quot; vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century",fever,mononucleosis
502912892,7/14/2014 14:46:52,,1322895575,7/14/2014 14:46:22,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,93,78,,,98,91,FEVER,MONONUCLEOSIS,"mononucleosis fever, phaRYNGItis, lymphadenopathy, and splenomegaly,",68-83-90-103-120-124,53-57-68-83-90-103,"vis infectious mononucleoSIS FEVER, Pharyngitis, lymphadenopathy,","Recognition of the syndrome ""glandular fever,"" vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century.",,,93,78,98,91,1,RO-disease_has_finding,901677,"Recognition of the syndrome &quot;glandular fever,&quot; vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century",fever,mononucleosis
502912892,7/14/2014 14:47:14,,1322895764,7/14/2014 14:46:48,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,93,78,,,98,91,FEVER,MONONUCLEOSIS,"phaRYNGItis,",90,90,"Pharyngitis,","Recognition of the syndrome ""glandular fever,"" vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century.",,,93,78,98,91,1,RO-disease_has_finding,901677,"Recognition of the syndrome &quot;glandular fever,&quot; vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century",fever,mononucleosis
502912892,7/14/2014 14:47:33,,1322895949,7/14/2014 14:47:17,prodege,1.0,28209666,,,"",24.156.173.34,93,78,,,98,91,FEVER,MONONUCLEOSIS,"mononucleosis fever, phaRYNGItis, lymphadenopathy, and splenomegaly,",68-83-90-103-120-124,53-57-68-83-90-103,"vis infectious mononucleoSIS FEVER, Pharyngitis, lymphadenopathy,","Recognition of the syndrome ""glandular fever,"" vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century.",,,93,78,98,91,1,RO-disease_has_finding,901677,"Recognition of the syndrome &quot;glandular fever,&quot; vis-a-vis infectious mononucleosis--fever, pharyngitis, lymphadenopathy, and splenomegaly, with characteristic changes in the peripheral blood leukocytes--dates back over a half a century",fever,mononucleosis
502912893,7/14/2014 12:55:54,,1322818764,7/14/2014 12:55:23,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,22,43,,,31,51,HEADACHES,MIGRAINE,"HEADACHES,",22,43,"MIGRAINE,","Many women experience headaches, including migraine, in association with their menstrual cycles.",22,43,22,43,31,51,-1,RO-has_definitional_manifestation,904754,"Many women experience headaches, including migraine, in association with their menstrual cycles",headaches,migraine
502912893,7/14/2014 13:01:21,,1322822378,7/14/2014 13:01:07,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,22,43,,,31,51,HEADACHES,MIGRAINE,"HEADACHES,",22,43,"MIGRAINE,","Many women experience headaches, including migraine, in association with their menstrual cycles.",22,43,22,43,31,51,-1,RO-has_definitional_manifestation,904754,"Many women experience headaches, including migraine, in association with their menstrual cycles",headaches,migraine
502912893,7/14/2014 13:04:10,,1322824191,7/14/2014 13:03:51,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,22,43,,,31,51,HEADACHES,MIGRAINE,"HEADACHES, menstrual",22-79,22-43-79,"headaches, MIGRAINE, menstrual","Many women experience headaches, including migraine, in association with their menstrual cycles.",22,43,22,43,31,51,-1,RO-has_definitional_manifestation,904754,"Many women experience headaches, including migraine, in association with their menstrual cycles",headaches,migraine
502912893,7/14/2014 13:11:55,,1322829430,7/14/2014 13:11:41,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,22,43,,,31,51,HEADACHES,MIGRAINE,"HEADACHES,",22,43,"MIGRAINE,","Many women experience headaches, including migraine, in association with their menstrual cycles.",22,43,22,43,31,51,-1,RO-has_definitional_manifestation,904754,"Many women experience headaches, including migraine, in association with their menstrual cycles",headaches,migraine
502912893,7/14/2014 13:18:59,,1322834197,7/14/2014 13:17:53,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,22,43,,,31,51,HEADACHES,MIGRAINE,"HEADACHES,",22,43,"MIGRAINE,","Many women experience headaches, including migraine, in association with their menstrual cycles.",22,43,22,43,31,51,-1,RO-has_definitional_manifestation,904754,"Many women experience headaches, including migraine, in association with their menstrual cycles",headaches,migraine
502912893,7/14/2014 13:21:59,,1322836317,7/14/2014 13:21:47,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,22,43,,,31,51,HEADACHES,MIGRAINE,"HEADACHES,",22,43,"MIGRAINE,","Many women experience headaches, including migraine, in association with their menstrual cycles.",22,43,22,43,31,51,-1,RO-has_definitional_manifestation,904754,"Many women experience headaches, including migraine, in association with their menstrual cycles",headaches,migraine
502912893,7/14/2014 13:34:34,,1322845104,7/14/2014 13:34:23,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,22,43,,,31,51,HEADACHES,MIGRAINE,"HEADACHES,",22,43,"MIGRAINE,","Many women experience headaches, including migraine, in association with their menstrual cycles.",22,43,22,43,31,51,-1,RO-has_definitional_manifestation,904754,"Many women experience headaches, including migraine, in association with their menstrual cycles",headaches,migraine
502912893,7/14/2014 13:36:42,,1322846655,7/14/2014 13:36:21,clixsense,1.0,27969116,NLD,"","",91.213.37.165,22,43,,,31,51,HEADACHES,MIGRAINE,"HEADACHES,",22,43,"MIGRAINE,","Many women experience headaches, including migraine, in association with their menstrual cycles.",22,43,22,43,31,51,-1,RO-has_definitional_manifestation,904754,"Many women experience headaches, including migraine, in association with their menstrual cycles",headaches,migraine
502912893,7/14/2014 13:40:33,,1322849468,7/14/2014 13:39:25,elite,1.0,26544151,GBR,"","",188.29.127.144,22,43,,,31,51,HEADACHES,MIGRAINE,"Many women experience HEADACHES, including migraine, in",0-5-11-22-33-43-53,43,"MIGRAINE,","Many women experience headaches, including migraine, in association with their menstrual cycles.",22,43,22,43,31,51,-1,RO-has_definitional_manifestation,904754,"Many women experience headaches, including migraine, in association with their menstrual cycles",headaches,migraine
502912893,7/14/2014 13:48:10,,1322855091,7/14/2014 13:47:52,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,22,43,,,31,51,HEADACHES,MIGRAINE,"HEADACHES, including migraine,",22-33-43,22-33-43,"headaches, including MIGRAINE,","Many women experience headaches, including migraine, in association with their menstrual cycles.",22,43,22,43,31,51,-1,RO-has_definitional_manifestation,904754,"Many women experience headaches, including migraine, in association with their menstrual cycles",headaches,migraine
502912894,7/14/2014 12:56:06,,1322818906,7/14/2014 12:55:55,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,53,122,,,77,136,NEURONAL DIFFERENTIATION,GANGLIOGLIOMAS,NEURONAL DIFFERENTIATION,53-62,122,GANGLIOGLIOMAS.,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas.",53 62,122,53,122,77,136,-1,RO-disease_has_finding,902000,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas",neuronal differentiation,gangliogliomas
502912894,7/14/2014 13:41:55,,1322850353,7/14/2014 13:41:41,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,53,122,,,77,136,NEURONAL DIFFERENTIATION,GANGLIOGLIOMAS,NEURONAL DIFFERENTIATION,53-62,122,GANGLIOGLIOMAS.,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas.",53 62,122,53,122,77,136,-1,RO-disease_has_finding,902000,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas",neuronal differentiation,gangliogliomas
502912894,7/14/2014 13:44:54,,1322852526,7/14/2014 13:44:34,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,53,122,,,77,136,NEURONAL DIFFERENTIATION,GANGLIOGLIOMAS,NEURONAL DIFFERENTIATION,53-62,122,GANGLIOGLIOMAS.,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas.",53 62,122,53,122,77,136,-1,RO-disease_has_finding,902000,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas",neuronal differentiation,gangliogliomas
502912894,7/14/2014 13:47:34,,1322854728,7/14/2014 13:46:55,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,53,122,,,77,136,NEURONAL DIFFERENTIATION,GANGLIOGLIOMAS,NEURONAL DIFFERENTIATION,53-62,122,GANGLIOGLIOMAS.,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas.",53 62,122,53,122,77,136,-1,RO-disease_has_finding,902000,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas",neuronal differentiation,gangliogliomas
502912894,7/14/2014 13:49:28,,1322856110,7/14/2014 13:49:03,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,53,122,,,77,136,NEURONAL DIFFERENTIATION,GANGLIOGLIOMAS,NEURONAL DIFFERENTIATION,53-62,122,GANGLIOGLIOMAS.,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas.",53 62,122,53,122,77,136,-1,RO-disease_has_finding,902000,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas",neuronal differentiation,gangliogliomas
502912894,7/14/2014 14:22:29,,1322878551,7/14/2014 14:22:24,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,53,122,,,77,136,NEURONAL DIFFERENTIATION,GANGLIOGLIOMAS,"and NFM, suggesting NEURONAL DIFFERENTIATION of the CD34",33-37-42-53-62-78-81-85,101-110-119-122,cellular elements in GANGLIOGLIOMAS.,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas.",53 62,122,53,122,77,136,-1,RO-disease_has_finding,902000,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas",neuronal differentiation,gangliogliomas
502912894,7/14/2014 14:29:27,,1322883677,7/14/2014 14:29:20,instagc,1.0,27753923,GBR,"","",188.30.192.65,53,122,,,77,136,NEURONAL DIFFERENTIATION,GANGLIOGLIOMAS,"and NFM, suggesting NEURONAL DIFFERENTIATION of the CD34",33-37-42-53-62-78-81-85,101-110-119-122,cellular elements in GANGLIOGLIOMAS.,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas.",53 62,122,53,122,77,136,-1,RO-disease_has_finding,902000,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas",neuronal differentiation,gangliogliomas
502912894,7/14/2014 14:37:51,,1322889536,7/14/2014 14:37:41,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,53,122,,,77,136,NEURONAL DIFFERENTIATION,GANGLIOGLIOMAS,NEURONAL DIFFERENTIATION of the CD34,53-62-78-81-85,101-110-119-122,cellular elements in GANGLIOGLIOMAS.,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas.",53 62,122,53,122,77,136,-1,RO-disease_has_finding,902000,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas",neuronal differentiation,gangliogliomas
502912894,7/14/2014 14:43:26,,1322893332,7/14/2014 14:43:05,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,53,122,,,77,136,NEURONAL DIFFERENTIATION,GANGLIOGLIOMAS,"observed CD34 and NFM, suggesting NEURONAL DIFFERENTIATION of the CD34",28-33-37-42-53-62-78-81-85-3,101-110-119-122,cellular elements in GANGLIOGLIOMAS.,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas.",53 62,122,53,122,77,136,-1,RO-disease_has_finding,902000,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas",neuronal differentiation,gangliogliomas
502912894,7/14/2014 14:44:00,,1322893770,7/14/2014 14:43:49,instagc,1.0,13763729,USA,"","",75.182.89.225,53,122,,,77,136,NEURONAL DIFFERENTIATION,GANGLIOGLIOMAS,NEURONAL DIFFERENTIATION,53-62,122,GANGLIOGLIOMAS.,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas.",53 62,122,53,122,77,136,-1,RO-disease_has_finding,902000,"We observed coexpression of CD34 and NFM, suggesting neuronal differentiation of the CD34 expressing cellular elements in gangliogliomas",neuronal differentiation,gangliogliomas
502912895,7/14/2014 12:53:01,,1322816845,7/14/2014 12:52:47,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,37,88,,,61,105,FOLATE DEFICIENCY ANEMIA,FOLATE DEFICIENCY,FOLATE DEFICIENCY ANEMIA:,37-44-55,88-95,FOLATE DEFICIENCY,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome.",37 44 55,88 95,37,88,61,105,-1,RO-cause_of,900371,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome",Folate deficiency anemia,Folate Deficiency
502912895,7/14/2014 13:05:04,,1322824685,7/14/2014 13:04:46,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,37,88,,,61,105,FOLATE DEFICIENCY ANEMIA,FOLATE DEFICIENCY,MCV FOLATE DEFICIENCY ANEMIA: Megaloblastic Macrocytic Anemias,29-37-44-55-112-126-137,88-95-107-112-126,FOLATE DEFICIENCY and Megaloblastic Macrocytic,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome.",37 44 55,88 95,37,88,61,105,-1,RO-cause_of,900371,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome",Folate deficiency anemia,Folate Deficiency
502912895,7/14/2014 13:22:11,,1322836476,7/14/2014 13:21:59,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,37,88,,,61,105,FOLATE DEFICIENCY ANEMIA,FOLATE DEFICIENCY,FOLATE DEFICIENCY ANEMIA:,37-44-55,88-95,FOLATE DEFICIENCY,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome.",37 44 55,88 95,37,88,61,105,-1,RO-cause_of,900371,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome",Folate deficiency anemia,Folate Deficiency
502912895,7/14/2014 13:50:24,,1322856704,7/14/2014 13:50:03,elite,1.0,26544151,GBR,"","",188.29.127.144,37,88,,,61,105,FOLATE DEFICIENCY ANEMIA,FOLATE DEFICIENCY,FOLATE DEFICIENCY ANEMIA:,37-44-55,88-95,FOLATE DEFICIENCY,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome.",37 44 55,88 95,37,88,61,105,-1,RO-cause_of,900371,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome",Folate deficiency anemia,Folate Deficiency
502912895,7/14/2014 13:59:24,,1322862919,7/14/2014 13:58:48,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,37,88,,,61,105,FOLATE DEFICIENCY ANEMIA,FOLATE DEFICIENCY,FOLATE DEFICIENCY ANEMIA: Folate Deficiency,37-44-55-88-95,64-88-95-112-126,Folate FOLATE DEFICIENCY Megaloblastic Macrocytic,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome.",37 44 55,88 95,37,88,61,105,-1,RO-cause_of,900371,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome",Folate deficiency anemia,Folate Deficiency
502912895,7/14/2014 14:06:07,,1322867527,7/14/2014 14:05:40,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,37,88,,,61,105,FOLATE DEFICIENCY ANEMIA,FOLATE DEFICIENCY,FOLATE DEFICIENCY ANEMIA:,37-44-55,88-95,FOLATE DEFICIENCY,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome.",37 44 55,88 95,37,88,61,105,-1,RO-cause_of,900371,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome",Folate deficiency anemia,Folate Deficiency
502912895,7/14/2014 14:21:04,,1322877595,7/14/2014 14:21:00,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,37,88,,,61,105,FOLATE DEFICIENCY ANEMIA,FOLATE DEFICIENCY,and MCV is FOLATE DEFICIENCY ANEMIA: Folate deficiency,25-29-33-37-44-55-64-71,64-71-82-88-95-107-112-126,Folate deficiency (see FOLATE DEFICIENCY and Megaloblastic Macrocytic,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome.",37 44 55,88 95,37,88,61,105,-1,RO-cause_of,900371,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome",Folate deficiency anemia,Folate Deficiency
502912895,7/14/2014 14:31:01,,1322884894,7/14/2014 14:30:52,instagc,1.0,27753923,GBR,"","",188.30.192.65,37,88,,,61,105,FOLATE DEFICIENCY ANEMIA,FOLATE DEFICIENCY,and MCV is FOLATE DEFICIENCY ANEMIA: Folate deficiency,25-29-33-37-44-55-64-71,64-71-82-88-95-107-112-126,Folate deficiency (see FOLATE DEFICIENCY and Megaloblastic Macrocytic,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome.",37 44 55,88 95,37,88,61,105,-1,RO-cause_of,900371,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome",Folate deficiency anemia,Folate Deficiency
502912895,7/14/2014 14:46:45,,1322895497,7/14/2014 14:46:27,prodege,1.0,28209666,,,"",24.156.173.34,37,88,,,61,105,FOLATE DEFICIENCY ANEMIA,FOLATE DEFICIENCY,FOLATE DEFICIENCY ANEMIA: Folate deficiency,37-44-55-64-71,88-95,FOLATE DEFICIENCY,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome.",37 44 55,88 95,37,88,61,105,-1,RO-cause_of,900371,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome",Folate deficiency anemia,Folate Deficiency
502912895,7/14/2014 14:47:09,,1322895740,7/14/2014 14:46:53,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,37,88,,,61,105,FOLATE DEFICIENCY ANEMIA,FOLATE DEFICIENCY,FOLATE DEFICIENCY ANEMIA: Folate deficiency,37-44-55-64-71,64-71-82-88-95-107-112-126-137,Folate deficiency (see FOLATE DEFICIENCY and Megaloblastic Macrocytic Anemias,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome.",37 44 55,88 95,37,88,61,105,-1,RO-cause_of,900371,"Typically, Hct is ? 30%, and MCV is  Folate deficiency anemia:  Folate deficiency (see  Folate Deficiency  and  Megaloblastic Macrocytic Anemias ) increases risk of neural tube defects and possibly fetal alcohol syndrome",Folate deficiency anemia,Folate Deficiency
502912896,7/14/2014 12:57:44,,1322819966,7/14/2014 12:57:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,152,125,,,158,144,LARYNX,SUPRAGLOTTIC CANCER,LARYNX.,152,125-138,SUPRAGLOTTIC CANCER,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx.",152,125 138,152,125,158,144,1,RO-disease_has_primary_anatomic_site,902074,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx",larynx,supraglottic cancer
502912896,7/14/2014 13:07:06,,1322826109,7/14/2014 13:06:17,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,152,125,,,158,144,LARYNX,SUPRAGLOTTIC CANCER,LARYNX.,152,125-138,SUPRAGLOTTIC CANCER,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx.",152,125 138,152,125,158,144,1,RO-disease_has_primary_anatomic_site,902074,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx",larynx,supraglottic cancer
502912896,7/14/2014 13:14:00,,1322830877,7/14/2014 13:13:54,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,152,125,,,158,144,LARYNX,SUPRAGLOTTIC CANCER,cancer of the LARYNX.,138-145-148-152,106-114-121-125-138-145-148-152,staging system for SUPRAGLOTTIC CANCER of the larynx.,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx.",152,125 138,152,125,158,144,1,RO-disease_has_primary_anatomic_site,902074,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx",larynx,supraglottic cancer
502912896,7/14/2014 13:24:59,,1322838429,7/14/2014 13:22:21,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,152,125,,,158,144,LARYNX,SUPRAGLOTTIC CANCER,supraglottic cancer of the LARYNX.,138-145-148-152-125,106-114-121-125-138-145-148-152,staging system for SUPRAGLOTTIC CANCER of the larynx.,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx.",152,125 138,152,125,158,144,1,RO-disease_has_primary_anatomic_site,902074,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx",larynx,supraglottic cancer
502912896,7/14/2014 13:36:20,,1322846382,7/14/2014 13:35:57,clixsense,1.0,27969116,NLD,"","",91.213.37.165,152,125,,,158,144,LARYNX,SUPRAGLOTTIC CANCER,LARYNX.,152,125-138,SUPRAGLOTTIC CANCER,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx.",152,125 138,152,125,158,144,1,RO-disease_has_primary_anatomic_site,902074,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx",larynx,supraglottic cancer
502912896,7/14/2014 13:48:24,,1322855300,7/14/2014 13:48:11,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,152,125,,,158,144,LARYNX,SUPRAGLOTTIC CANCER,cancer of the LARYNX.,138-145-148-152,114-121-125-138-145-148-152,system for SUPRAGLOTTIC CANCER of the larynx.,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx.",152,125 138,152,125,158,144,1,RO-disease_has_primary_anatomic_site,902074,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx",larynx,supraglottic cancer
502912896,7/14/2014 14:20:12,,1322876898,7/14/2014 14:20:06,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,152,125,,,158,144,LARYNX,SUPRAGLOTTIC CANCER,cancer of the LARYNX.,138-145-148-152,106-114-121-125-138-145-148-152,staging system for SUPRAGLOTTIC CANCER of the larynx.,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx.",152,125 138,152,125,158,144,1,RO-disease_has_primary_anatomic_site,902074,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx",larynx,supraglottic cancer
502912896,7/14/2014 14:23:45,,1322879435,7/14/2014 14:23:40,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,152,125,,,158,144,LARYNX,SUPRAGLOTTIC CANCER,cancer of the LARYNX.,138-145-148-152,106-114-121-125-138-145-148-152,staging system for SUPRAGLOTTIC CANCER of the larynx.,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx.",152,125 138,152,125,158,144,1,RO-disease_has_primary_anatomic_site,902074,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx",larynx,supraglottic cancer
502912896,7/14/2014 14:27:04,,1322881849,7/14/2014 14:26:56,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,152,125,,,158,144,LARYNX,SUPRAGLOTTIC CANCER,cancer of the LARYNX.,138-145-148-152,106-114-121-125-138-145-148-152,staging system for SUPRAGLOTTIC CANCER of the larynx.,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx.",152,125 138,152,125,158,144,1,RO-disease_has_primary_anatomic_site,902074,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx",larynx,supraglottic cancer
502912896,7/14/2014 14:37:33,,1322889286,7/14/2014 14:37:17,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,152,125,,,158,144,LARYNX,SUPRAGLOTTIC CANCER,supraglottic cancer of the LARYNX.,138-145-148-152-125,125-138-145-148-152,SUPRAGLOTTIC CANCER of the larynx.,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx.",152,125 138,152,125,158,144,1,RO-disease_has_primary_anatomic_site,902074,"In 1977, The American Joint Committee for Cancer Staging and End-Results Reporting (AJC) revised its 1972 staging system for supraglottic cancer of the larynx",larynx,supraglottic cancer
502912897,7/14/2014 12:50:52,,1322815329,7/14/2014 12:50:29,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,241,278,,,249,284,PELLAGRA,NIACIN,PELLAGRA resulting from insufficient niacin;,241-250-260-265-278,241-250-260-265-278,pellagra resulting from insufficient NIACIN;,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron.,241,278,241,278,249,284,1,RO-may_treat,908051,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron,pellagra,niacin
502912897,7/14/2014 12:51:19,,1322815621,7/14/2014 12:51:07,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,241,278,,,249,284,PELLAGRA,NIACIN,PELLAGRA,241,265-278,insufficient NIACIN;,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron.,241,278,241,278,249,284,1,RO-may_treat,908051,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron,pellagra,niacin
502912897,7/14/2014 13:06:22,,1322825569,7/14/2014 13:05:56,gifthulk,1.0,25566511,USA,"","",24.164.11.173,241,278,,,249,284,PELLAGRA,NIACIN,PELLAGRA,241,278,NIACIN;,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron.,241,278,241,278,249,284,1,RO-may_treat,908051,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron,pellagra,niacin
502912897,7/14/2014 13:16:00,,1322832198,7/14/2014 13:15:54,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,241,278,,,249,284,PELLAGRA,NIACIN,of inadequate thiamin; PELLAGRA resulting from insufficient,218-221-232-241-250-260-265,250-260-265-278-286-297-304,resulting from insufficient NIACIN; macrocytic anemia due,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron.,241,278,241,278,249,284,1,RO-may_treat,908051,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron,pellagra,niacin
502912897,7/14/2014 13:25:30,,1322838738,7/14/2014 13:24:19,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,241,278,,,249,284,PELLAGRA,NIACIN,of inadequate thiamin; PELLAGRA resulting from insufficient,218-221-232-241-250-260-265,250-260-265-278-286-297-304,resulting from insufficient NIACIN; macrocytic anemia due,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron.,241,278,241,278,249,284,1,RO-may_treat,908051,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron,pellagra,niacin
502912897,7/14/2014 13:57:08,,1322861360,7/14/2014 13:55:31,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,241,278,,,249,284,PELLAGRA,NIACIN,PELLAGRA insufficient niacin;,241-265-278,241-265-278-286-297,pellagra insufficient NIACIN; macrocytic anemia,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron.,241,278,241,278,249,284,1,RO-may_treat,908051,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron,pellagra,niacin
502912897,7/14/2014 14:42:33,,1322892740,7/14/2014 14:42:06,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,241,278,,,249,284,PELLAGRA,NIACIN,inadequate thiamin; PELLAGRA,221-232-241,278-286-297,NIACIN; macrocytic anemia,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron.,241,278,241,278,249,284,1,RO-may_treat,908051,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron,pellagra,niacin
502912897,7/14/2014 14:43:36,,1322893501,7/14/2014 14:43:20,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,241,278,,,249,284,PELLAGRA,NIACIN,thiamin; PELLAGRA,232-241,278-286-297,NIACIN; macrocytic anemia,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron.,241,278,241,278,249,284,1,RO-may_treat,908051,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron,pellagra,niacin
502912897,7/14/2014 14:45:08,,1322894447,7/14/2014 14:45:00,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,241,278,,,249,284,PELLAGRA,NIACIN,of inadequate thiamin; PELLAGRA resulting from insufficient,218-221-232-241-250-260-265,250-260-265-278-286-297-304,resulting from insufficient NIACIN; macrocytic anemia due,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron.,241,278,241,278,249,284,1,RO-may_treat,908051,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron,pellagra,niacin
502912897,7/14/2014 14:45:50,,1322894891,7/14/2014 14:45:34,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,241,278,,,249,284,PELLAGRA,NIACIN,PELLAGRA,241,278,NIACIN;,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron.,241,278,241,278,249,284,1,RO-may_treat,908051,Classical nutritional deficiencies precipitated by infection in individuals with borderline nutrient depletion include: keratomalacia due t avitaminosis-A; scurvey from lack of ascorbic acid; beriberi as a consequence of inadequate thiamin; pellagra resulting from insufficient niacin; macrocytic anemia due to folic acid or vitamin B12 deficiency; and microcytic anemia resulting from a shortage of iron,pellagra,niacin
502912898,7/14/2014 12:47:26,,1322813004,7/14/2014 12:47:12,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,107,66,,,113,80,GLUTEN,CELIAC DISEASE,GLUTEN free diet.,107-114-119,66-73,CELIAC DISEASE,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet.",107,66 73,107,66,113,80,-1,RO-has_causative_agent,903777,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet",gluten,celiac disease
502912898,7/14/2014 13:09:07,,1322827542,7/14/2014 13:08:36,gifthulk,1.0,25566511,USA,"","",24.164.11.173,107,66,,,113,80,GLUTEN,CELIAC DISEASE,GLUTEN free diet.,107-114-119,66-73,CELIAC DISEASE,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet.",107,66 73,107,66,113,80,-1,RO-has_causative_agent,903777,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet",gluten,celiac disease
502912898,7/14/2014 13:12:59,,1322830178,7/14/2014 13:12:42,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,107,66,,,113,80,GLUTEN,CELIAC DISEASE,GLUTEN free diet.,107-114-119,66-73,CELIAC DISEASE,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet.",107,66 73,107,66,113,80,-1,RO-has_causative_agent,903777,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet",gluten,celiac disease
502912898,7/14/2014 13:22:25,,1322836685,7/14/2014 13:22:12,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,107,66,,,113,80,GLUTEN,CELIAC DISEASE,GLUTEN free,107-114,66-73,CELIAC DISEASE,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet.",107,66 73,107,66,113,80,-1,RO-has_causative_agent,903777,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet",gluten,celiac disease
502912898,7/14/2014 13:26:41,,1322839545,7/14/2014 13:25:48,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,107,66,,,113,80,GLUTEN,CELIAC DISEASE,oats considered toxic GLUTEN free diet.,13-23-107-114-119-40,46-49-61-66-73-81-85-90-94-107-113-114-119,to individuals with CELIAC DISEASE and were not allowed gluten - free diet.,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet.",107,66 73,107,66,113,80,-1,RO-has_causative_agent,903777,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet",gluten,celiac disease
502912898,7/14/2014 13:43:06,,1322851333,7/14/2014 13:42:40,elite,1.0,26544151,GBR,"","",188.29.127.144,107,66,,,113,80,GLUTEN,CELIAC DISEASE,GLUTEN,107,66-73,CELIAC DISEASE,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet.",107,66 73,107,66,113,80,-1,RO-has_causative_agent,903777,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet",gluten,celiac disease
502912898,7/14/2014 13:43:14,,1322851418,7/14/2014 13:43:00,clixsense,1.0,27969116,NLD,"","",91.213.37.165,107,66,,,113,80,GLUTEN,CELIAC DISEASE,GLUTEN free diet.,107-114-119,66-73,CELIAC DISEASE,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet.",107,66 73,107,66,113,80,-1,RO-has_causative_agent,903777,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet",gluten,celiac disease
502912898,7/14/2014 13:55:30,,1322860300,7/14/2014 13:54:51,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,107,66,,,113,80,GLUTEN,CELIAC DISEASE,celiac disease GLUTEN,66-73-107,66-73,CELIAC DISEASE,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet.",107,66 73,107,66,113,80,-1,RO-has_causative_agent,903777,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet",gluten,celiac disease
502912898,7/14/2014 13:58:35,,1322862309,7/14/2014 13:58:13,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,107,66,,,113,80,GLUTEN,CELIAC DISEASE,GLUTEN free diet.,107-114-119,66-73,CELIAC DISEASE,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet.",107,66 73,107,66,113,80,-1,RO-has_causative_agent,903777,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet",gluten,celiac disease
502912898,7/14/2014 14:19:59,,1322876829,7/14/2014 14:19:46,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,107,66,,,113,80,GLUTEN,CELIAC DISEASE,celiac disease GLUTEN,66-73-107,66-73,CELIAC DISEASE,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet.",107,66 73,107,66,113,80,-1,RO-has_causative_agent,903777,"In the past, oats were considered to be toxic to individuals with celiac disease and were not allowed in a gluten-free diet",gluten,celiac disease
502912899,7/14/2014 12:47:41,,1322813121,7/14/2014 12:47:35,clixsense,1.0,24763049,GBR,"","",86.133.47.213,69,14,,,83,24,ONCHOCERCIASIS,IVERMECTIN,the treatment of ONCHOCERCIASIS.,52-56-66-69,0-11-14-25-29-48,Comparison of IVERMECTIN and diethylcarbamazine for,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis.,69,14,69,14,83,24,1,RO-may_treat,907881,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis,onchocerciasis,ivermectin
502912899,7/14/2014 12:49:37,,1322814414,7/14/2014 12:49:11,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,69,14,,,83,24,ONCHOCERCIASIS,IVERMECTIN,ONCHOCERCIASIS.,69,14-25-29,IVERMECTIN and diethylcarbamazine,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis.,69,14,69,14,83,24,1,RO-may_treat,907881,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis,onchocerciasis,ivermectin
502912899,7/14/2014 13:06:01,,1322825361,7/14/2014 13:05:46,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,69,14,,,83,24,ONCHOCERCIASIS,IVERMECTIN,diethylcarbamazine ONCHOCERCIASIS.,69-29,14-29-69,IVERMECTIN diethylcarbamazine onchocerciasis.,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis.,69,14,69,14,83,24,1,RO-may_treat,907881,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis,onchocerciasis,ivermectin
502912899,7/14/2014 13:16:09,,1322832349,7/14/2014 13:15:56,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,69,14,,,83,24,ONCHOCERCIASIS,IVERMECTIN,ONCHOCERCIASIS.,69,14,IVERMECTIN,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis.,69,14,69,14,83,24,1,RO-may_treat,907881,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis,onchocerciasis,ivermectin
502912899,7/14/2014 13:29:19,,1322841290,7/14/2014 13:28:03,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,69,14,,,83,24,ONCHOCERCIASIS,IVERMECTIN,ONCHOCERCIASIS.,69,14-25-29,IVERMECTIN and diethylcarbamazine,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis.,69,14,69,14,83,24,1,RO-may_treat,907881,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis,onchocerciasis,ivermectin
502912899,7/14/2014 13:31:58,,1322843044,7/14/2014 13:31:31,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,69,14,,,83,24,ONCHOCERCIASIS,IVERMECTIN,ONCHOCERCIASIS.,69,14,IVERMECTIN,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis.,69,14,69,14,83,24,1,RO-may_treat,907881,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis,onchocerciasis,ivermectin
502912899,7/14/2014 14:40:39,,1322891464,7/14/2014 14:40:25,prodege,1.0,28209666,,,"",24.156.173.34,69,14,,,83,24,ONCHOCERCIASIS,IVERMECTIN,ONCHOCERCIASIS.,69,14,IVERMECTIN,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis.,69,14,69,14,83,24,1,RO-may_treat,907881,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis,onchocerciasis,ivermectin
502912899,7/14/2014 14:46:19,,1322895228,7/14/2014 14:46:08,instagc,1.0,13763729,USA,"","",75.182.89.225,69,14,,,83,24,ONCHOCERCIASIS,IVERMECTIN,ONCHOCERCIASIS.,69,14,IVERMECTIN,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis.,69,14,69,14,83,24,1,RO-may_treat,907881,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis,onchocerciasis,ivermectin
502912899,7/14/2014 14:47:22,,1322895834,7/14/2014 14:47:10,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,69,14,,,83,24,ONCHOCERCIASIS,IVERMECTIN,ONCHOCERCIASIS.,69,14,IVERMECTIN,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis.,69,14,69,14,83,24,1,RO-may_treat,907881,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis,onchocerciasis,ivermectin
502912899,7/14/2014 14:48:27,,1322896470,7/14/2014 14:48:20,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,69,14,,,83,24,ONCHOCERCIASIS,IVERMECTIN,ONCHOCERCIASIS.,69,14,IVERMECTIN,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis.,69,14,69,14,83,24,1,RO-may_treat,907881,Comparison of ivermectin and diethylcarbamazine for the treatment of onchocerciasis,onchocerciasis,ivermectin
502912900,7/14/2014 12:45:25,,1322811703,7/14/2014 12:45:06,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,79,44,,,90,68,WEIGHT LOSS,HEPATOCELLULAR CARCINOMA,"WEIGHT LOSS, abdominal mass",79-86-92-102,44-59,HEPATOCELLULAR CARCINOMA,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear.",79 86,44 59,79,44,90,68,1,RO-disease_may_have_finding,902845,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear",weight loss,hepatocellular carcinoma
502912900,7/14/2014 12:48:33,,1322813710,7/14/2014 12:48:21,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,79,44,,,90,68,WEIGHT LOSS,HEPATOCELLULAR CARCINOMA,"WEIGHT LOSS,",79-86,44-59,HEPATOCELLULAR CARCINOMA,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear.",79 86,44 59,79,44,90,68,1,RO-disease_may_have_finding,902845,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear",weight loss,hepatocellular carcinoma
502912900,7/14/2014 12:55:53,,1322818756,7/14/2014 12:55:50,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,79,44,,,90,68,WEIGHT LOSS,HEPATOCELLULAR CARCINOMA,"carcinoma Look for WEIGHT LOSS, abdominal mass Every screening",59-70-75-79-86-92-102-108-276,21-27-40-44-59-70-75-79,exam Surveillance for HEPATOCELLULAR CARCINOMA Look for weight,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear.",79 86,44 59,79,44,90,68,1,RO-disease_may_have_finding,902845,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear",weight loss,hepatocellular carcinoma
502912900,7/14/2014 13:16:30,,1322832612,7/14/2014 13:16:24,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,79,44,,,90,68,WEIGHT LOSS,HEPATOCELLULAR CARCINOMA,"carcinoma Look for WEIGHT LOSS, abdominal mass Every",59-70-75-79-86-92-102-108,21-27-40-44-59-70-75-79,exam Surveillance for HEPATOCELLULAR CARCINOMA Look for weight,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear.",79 86,44 59,79,44,90,68,1,RO-disease_may_have_finding,902845,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear",weight loss,hepatocellular carcinoma
502912900,7/14/2014 13:23:26,,1322837507,7/14/2014 13:22:21,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,79,44,,,90,68,WEIGHT LOSS,HEPATOCELLULAR CARCINOMA,"carcinoma Look for WEIGHT LOSS, abdominal mass Every",59-70-75-79-86-92-102-108,21-27-40-44-59-70-75-79,exam Surveillance for HEPATOCELLULAR CARCINOMA Look for weight,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear.",79 86,44 59,79,44,90,68,1,RO-disease_may_have_finding,902845,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear",weight loss,hepatocellular carcinoma
502912900,7/14/2014 13:25:51,,1322838994,7/14/2014 13:24:50,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,79,44,,,90,68,WEIGHT LOSS,HEPATOCELLULAR CARCINOMA,"hepatocellular carcinoma WEIGHT LOSS, abdominal mass Serum AFP endemic",44-59-79-86-92-102-186-192-249,44-59-79-86-92-102-186-249-192,"HEPATOCELLULAR CARCINOMA weight loss, abdominal mass Serum AFP endemic","History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear.",79 86,44 59,79,44,90,68,1,RO-disease_may_have_finding,902845,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear",weight loss,hepatocellular carcinoma
502912900,7/14/2014 13:28:13,,1322840600,7/14/2014 13:27:27,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,79,44,,,90,68,WEIGHT LOSS,HEPATOCELLULAR CARCINOMA,"hepatocellular carcinoma Look for WEIGHT LOSS,",44-59-70-75-79-86,0-21-27-40-44-59-70-75-79-86-92-102-108-114-116-12,"History physical exam Surveillance for HEPATOCELLULAR CARCINOMA Look for weight loss, abdominal mass Every 6 months","History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear.",79 86,44 59,79,44,90,68,1,RO-disease_may_have_finding,902845,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear",weight loss,hepatocellular carcinoma
502912900,7/14/2014 13:39:35,,1322848735,7/14/2014 13:39:32,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,79,44,,,90,68,WEIGHT LOSS,HEPATOCELLULAR CARCINOMA,"carcinoma Look for WEIGHT LOSS, abdominal mass Every",59-70-75-79-86-92-102-108,21-27-40-44-59-70-75-79,exam Surveillance for HEPATOCELLULAR CARCINOMA Look for weight,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear.",79 86,44 59,79,44,90,68,1,RO-disease_may_have_finding,902845,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear",weight loss,hepatocellular carcinoma
502912900,7/14/2014 13:51:41,,1322857671,7/14/2014 13:51:25,elite,1.0,26544151,GBR,"","",188.29.127.144,79,44,,,90,68,WEIGHT LOSS,HEPATOCELLULAR CARCINOMA,"WEIGHT LOSS,",79-86,44-59,HEPATOCELLULAR CARCINOMA,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear.",79 86,44 59,79,44,90,68,1,RO-disease_may_have_finding,902845,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear",weight loss,hepatocellular carcinoma
502912900,7/14/2014 14:19:33,,1322876496,7/14/2014 14:19:28,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,79,44,,,90,68,WEIGHT LOSS,HEPATOCELLULAR CARCINOMA,"carcinoma Look for WEIGHT LOSS, abdominal mass Every",59-70-75-79-86-92-102-108,21-27-40-44-59-70-75-79,exam Surveillance for HEPATOCELLULAR CARCINOMA Look for weight,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear.",79 86,44 59,79,44,90,68,1,RO-disease_may_have_finding,902845,"History and physical exam  Surveillance for hepatocellular carcinoma  Look for weight loss, abdominal mass  Every 6 months Laboratory testing  Surveillance for hepatocellular carcinoma  Serum AFP  Every 6 months in high-risk patients and those from endemic areas  Combination screening likely more useful; will have false-positives; optimal age to start unclear",weight loss,hepatocellular carcinoma
502912901,7/14/2014 13:16:05,,1322832298,7/14/2014 13:16:01,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,33,69,,,49,86,HYPERSENSITIVITY,ALLERGIC REACTION,10 Sensitivity Reactions HYPERSENSITIVITY Reactions Risk of,6-10-22-33-50-61-66,50-61-66-69-78-87-92-103,Reactions Risk of ALLERGIC REACTION with parenteral administration,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide.",33,69 78,33,69,49,86,-1,RO-cause_of,900008,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide",Hypersensitivity,allergic reaction
502912901,7/14/2014 13:43:00,,1322851240,7/14/2014 13:42:46,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,33,69,,,49,86,HYPERSENSITIVITY,ALLERGIC REACTION,HYPERSENSITIVITY,33,69-78,ALLERGIC REACTION,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide.",33,69 78,33,69,49,86,-1,RO-cause_of,900008,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide",Hypersensitivity,allergic reaction
502912901,7/14/2014 13:54:49,,1322859853,7/14/2014 13:54:23,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,33,69,,,49,86,HYPERSENSITIVITY,ALLERGIC REACTION,Sensitivity Reactions HYPERSENSITIVITY,10-22-33,50-61-66-69-78,Reactions Risk of ALLERGIC REACTION,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide.",33,69 78,33,69,49,86,-1,RO-cause_of,900008,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide",Hypersensitivity,allergic reaction
502912901,7/14/2014 14:05:07,,1322866859,7/14/2014 14:04:32,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,33,69,,,49,86,HYPERSENSITIVITY,ALLERGIC REACTION,HYPERSENSITIVITY allergic reaction,33-69-78,33-69-78,Hypersensitivity ALLERGIC REACTION,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide.",33,69 78,33,69,49,86,-1,RO-cause_of,900008,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide",Hypersensitivity,allergic reaction
502912901,7/14/2014 14:22:04,,1322878334,7/14/2014 14:22:00,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,33,69,,,49,86,HYPERSENSITIVITY,ALLERGIC REACTION,10 Sensitivity Reactions HYPERSENSITIVITY Reactions Risk of,6-10-22-33-50-61-66,50-61-66-69-78-87-92-103,Reactions Risk of ALLERGIC REACTION with parenteral administration,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide.",33,69 78,33,69,49,86,-1,RO-cause_of,900008,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide",Hypersensitivity,allergic reaction
502912901,7/14/2014 14:27:29,,1322882157,7/14/2014 14:27:18,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,33,69,,,49,86,HYPERSENSITIVITY,ALLERGIC REACTION,10 Sensitivity Reactions HYPERSENSITIVITY,6-10-22-33,69-78,ALLERGIC REACTION,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide.",33,69 78,33,69,49,86,-1,RO-cause_of,900008,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide",Hypersensitivity,allergic reaction
502912901,7/14/2014 14:33:03,,1322886332,7/14/2014 14:32:51,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,33,69,,,49,86,HYPERSENSITIVITY,ALLERGIC REACTION,HYPERSENSITIVITY,33,69-78,ALLERGIC REACTION,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide.",33,69 78,33,69,49,86,-1,RO-cause_of,900008,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide",Hypersensitivity,allergic reaction
502912901,7/14/2014 14:44:57,,1322894344,7/14/2014 14:44:46,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,33,69,,,49,86,HYPERSENSITIVITY,ALLERGIC REACTION,HYPERSENSITIVITY Reactions,33-50,69-78,ALLERGIC REACTION,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide.",33,69 78,33,69,49,86,-1,RO-cause_of,900008,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide",Hypersensitivity,allergic reaction
502912901,7/14/2014 14:45:01,,1322894394,7/14/2014 14:44:45,instagc,1.0,13763729,USA,"","",75.182.89.225,33,69,,,49,86,HYPERSENSITIVITY,ALLERGIC REACTION,HYPERSENSITIVITY,33,69-78,ALLERGIC REACTION,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide.",33,69 78,33,69,49,86,-1,RO-cause_of,900008,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide",Hypersensitivity,allergic reaction
502912901,7/14/2014 14:47:03,,1322895650,7/14/2014 14:46:46,prodege,1.0,28209666,,,"",24.156.173.34,33,69,,,49,86,HYPERSENSITIVITY,ALLERGIC REACTION,HYPERSENSITIVITY,33,69-78,ALLERGIC REACTION,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide.",33,69 78,33,69,49,86,-1,RO-cause_of,900008,"1 ,   10  Sensitivity Reactions  Hypersensitivity Reactions  Risk of allergic reaction with parenteral administration of proteins or  Escherichia coli -derived products; however, no serious allergic or anaphylactic reactions reported to date with nesiritide",Hypersensitivity,allergic reaction
502912902,7/14/2014 12:44:59,,1322811370,7/14/2014 12:44:54,clixsense,1.0,24763049,GBR,"","",86.133.47.213,80,12,,,93,24,LEISHMANIASIS,KETOCONAZOLE,braziliensis panamensis cutaneous LEISHMANIASIS.,45-58-70-80,0-9-12-25-34-45,Efficacy of KETOCONAZOLE against Leishmania braziliensis,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis.,80,12,80,12,93,24,1,RO-may_treat,907587,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis,leishmaniasis,ketoconazole
502912902,7/14/2014 12:54:59,,1322818190,7/14/2014 12:54:26,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,80,12,,,93,24,LEISHMANIASIS,KETOCONAZOLE,Leishmania braziliensis panamensis cutaneous LEISHMANIASIS.,45-58-70-80-34,12,KETOCONAZOLE,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis.,80,12,80,12,93,24,1,RO-may_treat,907587,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis,leishmaniasis,ketoconazole
502912902,7/14/2014 13:15:42,,1322832015,7/14/2014 13:15:37,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,80,12,,,93,24,LEISHMANIASIS,KETOCONAZOLE,braziliensis panamensis cutaneous LEISHMANIASIS.,45-58-70-80,0-9-12-25-34-45,Efficacy of KETOCONAZOLE against Leishmania braziliensis,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis.,80,12,80,12,93,24,1,RO-may_treat,907587,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis,leishmaniasis,ketoconazole
502912902,7/14/2014 13:37:52,,1322847475,7/14/2014 13:36:40,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,80,12,,,93,24,LEISHMANIASIS,KETOCONAZOLE,Leishmania braziliensis panamensis cutaneous LEISHMANIASIS.,45-58-70-80-34,12,KETOCONAZOLE,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis.,80,12,80,12,93,24,1,RO-may_treat,907587,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis,leishmaniasis,ketoconazole
502912902,7/14/2014 13:39:53,,1322848998,7/14/2014 13:39:51,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,80,12,,,93,24,LEISHMANIASIS,KETOCONAZOLE,braziliensis panamensis cutaneous LEISHMANIASIS.,45-58-70-80,0-9-12-25-34-45,Efficacy of KETOCONAZOLE against Leishmania braziliensis,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis.,80,12,80,12,93,24,1,RO-may_treat,907587,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis,leishmaniasis,ketoconazole
502912902,7/14/2014 13:41:23,,1322850015,7/14/2014 13:40:34,elite,1.0,26544151,GBR,"","",188.29.127.144,80,12,,,93,24,LEISHMANIASIS,KETOCONAZOLE,Leishmania braziliensis panamensis cutaneous LEISHMANIASIS.,45-58-70-80-34,12,KETOCONAZOLE,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis.,80,12,80,12,93,24,1,RO-may_treat,907587,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis,leishmaniasis,ketoconazole
502912902,7/14/2014 13:54:49,,1322859854,7/14/2014 13:52:12,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,80,12,,,93,24,LEISHMANIASIS,KETOCONAZOLE,Leishmania braziliensis panamensis cutaneous LEISHMANIASIS.,45-58-70-80-34,0-9-12-25-34-45-58-70-80,Efficacy of KETOCONAZOLE against Leishmania braziliensis panamensis cutaneous leishmaniasis.,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis.,80,12,80,12,93,24,1,RO-may_treat,907587,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis,leishmaniasis,ketoconazole
502912902,7/14/2014 14:24:52,,1322880283,7/14/2014 14:24:36,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,80,12,,,93,24,LEISHMANIASIS,KETOCONAZOLE,Leishmania braziliensis panamensis cutaneous LEISHMANIASIS.,45-58-70-80-34,12-34-45-58-70-80,KETOCONAZOLE Leishmania braziliensis panamensis cutaneous leishmaniasis.,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis.,80,12,80,12,93,24,1,RO-may_treat,907587,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis,leishmaniasis,ketoconazole
502912902,7/14/2014 14:37:15,,1322889124,7/14/2014 14:37:05,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,80,12,,,93,24,LEISHMANIASIS,KETOCONAZOLE,Leishmania braziliensis panamensis cutaneous LEISHMANIASIS.,45-58-70-80-34,12,KETOCONAZOLE,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis.,80,12,80,12,93,24,1,RO-may_treat,907587,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis,leishmaniasis,ketoconazole
502912902,7/14/2014 14:40:41,,1322891486,7/14/2014 14:40:34,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,80,12,,,93,24,LEISHMANIASIS,KETOCONAZOLE,braziliensis panamensis cutaneous LEISHMANIASIS.,45-58-70-80,0-9-12-25-34-45,Efficacy of KETOCONAZOLE against Leishmania braziliensis,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis.,80,12,80,12,93,24,1,RO-may_treat,907587,Efficacy of ketoconazole against  Leishmania braziliensis panamensis  cutaneous leishmaniasis,leishmaniasis,ketoconazole
502912903,7/14/2014 13:19:53,,1322834850,7/14/2014 13:19:33,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,165,236,,,188,248,ELEVATED BLOOD PRESSURE,HYPERTENSION,ELEVATED BLOOD PRESSURE,165-174-180,236,HYPERTENSION.,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension.",165 174 180,236,165,236,188,248,-1,RO-has_definitional_manifestation,904990,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension",elevated blood pressure,hypertension
502912903,7/14/2014 13:39:40,,1322848831,7/14/2014 13:39:28,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,165,236,,,188,248,ELEVATED BLOOD PRESSURE,HYPERTENSION,ELEVATED BLOOD PRESSURE,165-174-180,236,HYPERTENSION.,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension.",165 174 180,236,165,236,188,248,-1,RO-has_definitional_manifestation,904990,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension",elevated blood pressure,hypertension
502912903,7/14/2014 13:49:57,,1322856319,7/14/2014 13:49:42,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,165,236,,,188,248,ELEVATED BLOOD PRESSURE,HYPERTENSION,ELEVATED BLOOD PRESSURE,165-174-180,236,HYPERTENSION.,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension.",165 174 180,236,165,236,188,248,-1,RO-has_definitional_manifestation,904990,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension",elevated blood pressure,hypertension
502912903,7/14/2014 14:04:45,,1322866645,7/14/2014 14:04:28,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,165,236,,,188,248,ELEVATED BLOOD PRESSURE,HYPERTENSION,ELEVATED BLOOD PRESSURE,165-174-180,236,HYPERTENSION.,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension.",165 174 180,236,165,236,188,248,-1,RO-has_definitional_manifestation,904990,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension",elevated blood pressure,hypertension
502912903,7/14/2014 14:24:10,,1322879687,7/14/2014 14:24:05,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,165,236,,,188,248,ELEVATED BLOOD PRESSURE,HYPERTENSION,compensate for the ELEVATED BLOOD PRESSURE and thus may,146-157-161-165-174-180-189-193-198,216-220-233-236,the acceleration of HYPERTENSION.,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension.",165 174 180,236,165,236,188,248,-1,RO-has_definitional_manifestation,904990,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension",elevated blood pressure,hypertension
502912903,7/14/2014 14:24:38,,1322880053,7/14/2014 14:24:27,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,165,236,,,188,248,ELEVATED BLOOD PRESSURE,HYPERTENSION,ELEVATED BLOOD PRESSURE,165-174-180,220-233-236,acceleration of HYPERTENSION.,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension.",165 174 180,236,165,236,188,248,-1,RO-has_definitional_manifestation,904990,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension",elevated blood pressure,hypertension
502912903,7/14/2014 14:29:07,,1322883378,7/14/2014 14:28:47,instagc,1.0,27753923,GBR,"","",188.30.192.65,165,236,,,188,248,ELEVATED BLOOD PRESSURE,HYPERTENSION,compensate for the ELEVATED BLOOD PRESSURE and thus may,146-157-161-165-174-180-189-193-198,216-220-233-236,the acceleration of HYPERTENSION.,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension.",165 174 180,236,165,236,188,248,-1,RO-has_definitional_manifestation,904990,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension",elevated blood pressure,hypertension
502912903,7/14/2014 14:34:16,,1322887072,7/14/2014 14:34:04,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,165,236,,,188,248,ELEVATED BLOOD PRESSURE,HYPERTENSION,ELEVATED BLOOD PRESSURE,165-174-180,220-233-236,acceleration of HYPERTENSION.,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension.",165 174 180,236,165,236,188,248,-1,RO-has_definitional_manifestation,904990,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension",elevated blood pressure,hypertension
502912903,7/14/2014 14:43:51,,1322893664,7/14/2014 14:43:27,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,165,236,,,188,248,ELEVATED BLOOD PRESSURE,HYPERTENSION,compensate for the ELEVATED BLOOD PRESSURE and thus may,146-157-161-165-174-180-189-193-198,202-216-220-233-236-213,contribute to the acceleration of HYPERTENSION.,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension.",165 174 180,236,165,236,188,248,-1,RO-has_definitional_manifestation,904990,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension",elevated blood pressure,hypertension
502912903,7/14/2014 14:45:14,,1322894511,7/14/2014 14:45:02,instagc,1.0,13763729,USA,"","",75.182.89.225,165,236,,,188,248,ELEVATED BLOOD PRESSURE,HYPERTENSION,ELEVATED BLOOD PRESSURE,165-174-180,236,HYPERTENSION.,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension.",165 174 180,236,165,236,188,248,-1,RO-has_definitional_manifestation,904990,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the elevated blood pressure and thus may contribute to the acceleration of hypertension",elevated blood pressure,hypertension
502912904,7/14/2014 13:06:50,,1322825906,7/14/2014 13:06:29,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,109,149,,,114,163,PANIC,PANIC DISORDER,Overstimulation PANIC panic disorder,109-149-155-0,0-149-155,Overstimulation PANIC DISORDER,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects.",109,149 155,109,149,114,163,-1,RO-has_definitional_manifestation,904717,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects",panic,panic disorder
502912904,7/14/2014 13:19:05,,1322834261,7/14/2014 13:18:51,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,109,149,,,114,163,PANIC,PANIC DISORDER,PANIC,109,149-155,PANIC DISORDER,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects.",109,149 155,109,149,114,163,-1,RO-has_definitional_manifestation,904717,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects",panic,panic disorder
502912904,7/14/2014 13:38:56,,1322848261,7/14/2014 13:38:16,clixsense,1.0,27969116,NLD,"","",91.213.37.165,109,149,,,114,163,PANIC,PANIC DISORDER,PANIC anxiety with panic disorder,109-119-149-155-144,149-155-164,PANIC DISORDER and,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects.",109,149 155,109,149,114,163,-1,RO-has_definitional_manifestation,904717,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects",panic,panic disorder
502912904,7/14/2014 13:41:22,,1322850011,7/14/2014 13:41:07,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,109,149,,,114,163,PANIC,PANIC DISORDER,PANIC,109,149-155,PANIC DISORDER,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects.",109,149 155,109,149,114,163,-1,RO-has_definitional_manifestation,904717,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects",panic,panic disorder
502912904,7/14/2014 13:47:54,,1322854993,7/14/2014 13:47:32,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,109,149,,,114,163,PANIC,PANIC DISORDER,PANIC,109,149-155,PANIC DISORDER,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects.",109,149 155,109,149,114,163,-1,RO-has_definitional_manifestation,904717,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects",panic,panic disorder
502912904,7/14/2014 13:59:45,,1322863182,7/14/2014 13:59:24,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,109,149,,,114,163,PANIC,PANIC DISORDER,PANIC anxiety,109-119,149-155,PANIC DISORDER,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects.",109,149 155,109,149,114,163,-1,RO-has_definitional_manifestation,904717,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects",panic,panic disorder
502912904,7/14/2014 14:40:39,,1322891474,7/14/2014 14:40:25,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,109,149,,,114,163,PANIC,PANIC DISORDER,cause feelings of PANIC and anxiety,91-97-106-109-115-119,130-135-144-149-155-164-168-176,both patients with PANIC DISORDER and control subjects.,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects.",109,149 155,109,149,114,163,-1,RO-has_definitional_manifestation,904717,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects",panic,panic disorder
502912904,7/14/2014 14:44:07,,1322893850,7/14/2014 14:43:56,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,109,149,,,114,163,PANIC,PANIC DISORDER,PANIC,109,149-155,PANIC DISORDER,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects.",109,149 155,109,149,114,163,-1,RO-has_definitional_manifestation,904717,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects",panic,panic disorder
502912904,7/14/2014 14:48:51,,1322896682,7/14/2014 14:48:40,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,109,149,,,114,163,PANIC,PANIC DISORDER,PANIC,109,149-155,PANIC DISORDER,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects.",109,149 155,109,149,114,163,-1,RO-has_definitional_manifestation,904717,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects",panic,panic disorder
502912904,7/14/2014 14:50:28,,1322897637,7/14/2014 14:50:08,instagc,1.0,13763729,USA,"","",75.182.89.225,109,149,,,114,163,PANIC,PANIC DISORDER,PANIC and anxiety,109-115-119,149-155,PANIC DISORDER,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects.",109,149 155,109,149,114,163,-1,RO-has_definitional_manifestation,904717,"Overstimulation of the locus ceruleus by yohimbine, sodium lactate, and carbon dioxide can cause feelings of panic and anxiety in both patients with panic disorder and control subjects",panic,panic disorder
502912905,7/14/2014 13:02:11,,1322822906,7/14/2014 13:01:54,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS:,109-119,75,METRONIDAZOLE,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907602,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
502912905,7/14/2014 13:05:14,,1322824765,7/14/2014 13:04:50,gifthulk,1.0,25566511,USA,"","",24.164.11.173,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS:,109-119,75,METRONIDAZOLE,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907602,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
502912905,7/14/2014 13:28:15,,1322840611,7/14/2014 13:27:57,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS:,109-119,70-75,oral METRONIDAZOLE,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907602,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
502912905,7/14/2014 13:55:00,,1322859962,7/14/2014 13:54:31,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS:,109-119,75,METRONIDAZOLE,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907602,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
502912905,7/14/2014 14:03:48,,1322865980,7/14/2014 14:03:30,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS:,109-119,70-75,oral METRONIDAZOLE,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907602,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
502912905,7/14/2014 14:24:35,,1322880055,7/14/2014 14:24:32,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,the treatment of BACTERIAL VAGINOSIS: a prospective double,92-96-106-109-119-130-132-144,57-63-70-75-89-92-96,cream versus oral METRONIDAZOLE in the treatment,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907602,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
502912905,7/14/2014 14:39:52,,1322890954,7/14/2014 14:39:42,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,the treatment of BACTERIAL VAGINOSIS: a prospective double,92-96-106-109-119-130-132-144,57-63-70-75-89-92-96,cream versus oral METRONIDAZOLE in the treatment,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907602,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
502912905,7/14/2014 14:45:46,,1322894863,7/14/2014 14:45:27,prodege,1.0,28209666,,,"",24.156.173.34,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS:,109-119,75,METRONIDAZOLE,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907602,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
502912905,7/14/2014 14:46:35,,1322895380,7/14/2014 14:46:27,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS:,109-119,70-75,oral METRONIDAZOLE,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907602,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
502912905,7/14/2014 14:46:46,,1322895517,7/14/2014 14:46:33,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS:,109-119,75,METRONIDAZOLE,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907602,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
502912906,7/14/2014 12:46:21,,1322812262,7/14/2014 12:46:16,clixsense,1.0,24763049,GBR,"","",86.133.47.213,198,187,,,211,194,PSEUDOALLERGY,ALLERGY,to allergy or PSEUDOALLERGY.,184-187-195-198,172-177-184-187-195-198,with regard to ALLERGY or pseudoallergy.,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy.,198,187,198,187,211,194,-1,RO-cause_of,900466,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy,pseudoallergy,allergy
502912906,7/14/2014 12:53:15,,1322816975,7/14/2014 12:52:35,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,198,187,,,211,194,PSEUDOALLERGY,ALLERGY,PSEUDOALLERGY.,198,187,ALLERGY,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy.,198,187,198,187,211,194,-1,RO-cause_of,900466,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy,pseudoallergy,allergy
502912906,7/14/2014 13:03:03,,1322823554,7/14/2014 13:02:52,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,198,187,,,211,194,PSEUDOALLERGY,ALLERGY,PSEUDOALLERGY.,198,187,ALLERGY,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy.,198,187,198,187,211,194,-1,RO-cause_of,900466,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy,pseudoallergy,allergy
502912906,7/14/2014 13:09:37,,1322827881,7/14/2014 13:09:08,gifthulk,1.0,25566511,USA,"","",24.164.11.173,198,187,,,211,194,PSEUDOALLERGY,ALLERGY,PSEUDOALLERGY.,198,187,ALLERGY,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy.,198,187,198,187,211,194,-1,RO-cause_of,900466,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy,pseudoallergy,allergy
502912906,7/14/2014 13:28:53,,1322841031,7/14/2014 13:28:07,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,198,187,,,211,194,PSEUDOALLERGY,ALLERGY,Drug Allergy pyrazol analgetics allergy PSEUDOALLERGY.,56-61-139-147-187-198,56-61-139-187-198-147,Drug Allergy pyrazol analgetics ALLERGY pseudoallergy.,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy.,198,187,198,187,211,194,-1,RO-cause_of,900466,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy,pseudoallergy,allergy
502912906,7/14/2014 13:35:37,,1322845798,7/14/2014 13:35:23,clixsense,1.0,27969116,NLD,"","",91.213.37.165,198,187,,,211,194,PSEUDOALLERGY,ALLERGY,PSEUDOALLERGY.,198,187,ALLERGY,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy.,198,187,198,187,211,194,-1,RO-cause_of,900466,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy,pseudoallergy,allergy
502912906,7/14/2014 13:41:54,,1322850351,7/14/2014 13:41:42,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,198,187,,,211,194,PSEUDOALLERGY,ALLERGY,PSEUDOALLERGY.,198,187,ALLERGY,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy.,198,187,198,187,211,194,-1,RO-cause_of,900466,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy,pseudoallergy,allergy
502912906,7/14/2014 13:49:08,,1322855833,7/14/2014 13:48:54,elite,1.0,26544151,GBR,"","",188.29.127.144,198,187,,,211,194,PSEUDOALLERGY,ALLERGY,PSEUDOALLERGY.,198,187,ALLERGY,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy.,198,187,198,187,211,194,-1,RO-cause_of,900466,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy,pseudoallergy,allergy
502912906,7/14/2014 14:26:46,,1322881647,7/14/2014 14:26:37,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,198,187,,,211,194,PSEUDOALLERGY,ALLERGY,PSEUDOALLERGY.,198,177-184-187,regard to ALLERGY,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy.,198,187,198,187,211,194,-1,RO-cause_of,900466,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy,pseudoallergy,allergy
502912906,7/14/2014 14:43:01,,1322893065,7/14/2014 14:42:52,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,198,187,,,211,194,PSEUDOALLERGY,ALLERGY,PSEUDOALLERGY.,198,187,ALLERGY,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy.,198,187,198,187,211,194,-1,RO-cause_of,900466,In a multicentric study by the European Study Group for Drug Allergy 58 patients suffering from an immediate type reaction after intake of pyrazol analgetics were examined with regard to allergy or pseudoallergy,pseudoallergy,allergy
502912907,7/14/2014 12:45:24,,1322811696,7/14/2014 12:45:19,clixsense,1.0,24763049,GBR,"","",86.133.47.213,182,129,,,198,139,MULTIPLE MYELOMA,BORTEZOMIB,of relapsed refractory MULTIPLE MYELOMA.,159-162-171-182-191,101-107-118-129-141-145-149,"first proteasome inhibitor, BORTEZOMIB, for the treatment","The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma.",182 191,129,182,129,198,139,1,RO-may_treat,908005,"The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma",multiple myeloma,bortezomib
502912907,7/14/2014 12:52:38,,1322816561,7/14/2014 12:52:26,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,182,129,,,198,139,MULTIPLE MYELOMA,BORTEZOMIB,relapsed refractory MULTIPLE MYELOMA.,162-171-182-191,129,"BORTEZOMIB,","The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma.",182 191,129,182,129,198,139,1,RO-may_treat,908005,"The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma",multiple myeloma,bortezomib
502912907,7/14/2014 13:15:00,,1322831527,7/14/2014 13:14:55,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,182,129,,,198,139,MULTIPLE MYELOMA,BORTEZOMIB,of relapsed refractory MULTIPLE MYELOMA.,159-162-171-182-191,101-107-118-129-141-145-149,"first proteasome inhibitor, BORTEZOMIB, for the treatment","The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma.",182 191,129,182,129,198,139,1,RO-may_treat,908005,"The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma",multiple myeloma,bortezomib
502912907,7/14/2014 13:19:35,,1322834581,7/14/2014 13:18:46,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,182,129,,,198,139,MULTIPLE MYELOMA,BORTEZOMIB,MULTIPLE MYELOMA.,182-191,129-182-191,"BORTEZOMIB, multiple myeloma.","The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma.",182 191,129,182,129,198,139,1,RO-may_treat,908005,"The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma",multiple myeloma,bortezomib
502912907,7/14/2014 13:29:47,,1322841630,7/14/2014 13:28:59,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,182,129,,,198,139,MULTIPLE MYELOMA,BORTEZOMIB,"proteasomes proteasome inhibitor, bortezomib, relapsed refractory MULTIPLE MYELOMA.",40-118-129-162-171-182-191-107,40-107-118-129-162-171-182-191,"proteasomes proteasome inhibitor, BORTEZOMIB, relapsed refractory multiple myeloma.","The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma.",182 191,129,182,129,198,139,1,RO-may_treat,908005,"The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma",multiple myeloma,bortezomib
502912907,7/14/2014 13:34:04,,1322844659,7/14/2014 13:32:25,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,182,129,,,198,139,MULTIPLE MYELOMA,BORTEZOMIB,relapsed refractory MULTIPLE MYELOMA.,162-171-182-191,129,"BORTEZOMIB,","The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma.",182 191,129,182,129,198,139,1,RO-may_treat,908005,"The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma",multiple myeloma,bortezomib
502912907,7/14/2014 14:06:22,,1322867737,7/14/2014 14:06:08,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,182,129,,,198,139,MULTIPLE MYELOMA,BORTEZOMIB,relapsed refractory MULTIPLE MYELOMA.,162-171-182-191,129,"BORTEZOMIB,","The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma.",182 191,129,182,129,198,139,1,RO-may_treat,908005,"The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma",multiple myeloma,bortezomib
502912907,7/14/2014 14:21:25,,1322877808,7/14/2014 14:21:18,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,182,129,,,198,139,MULTIPLE MYELOMA,BORTEZOMIB,of relapsed refractory MULTIPLE MYELOMA.,159-162-171-182-191,101-107-118-129-141-145-149,"first proteasome inhibitor, BORTEZOMIB, for the treatment","The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma.",182 191,129,182,129,198,139,1,RO-may_treat,908005,"The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma",multiple myeloma,bortezomib
502912907,7/14/2014 14:24:50,,1322880254,7/14/2014 14:24:47,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,182,129,,,198,139,MULTIPLE MYELOMA,BORTEZOMIB,of relapsed refractory MULTIPLE MYELOMA.,159-162-171-182-191,101-107-118-129-141-145-149,"first proteasome inhibitor, BORTEZOMIB, for the treatment","The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma.",182 191,129,182,129,198,139,1,RO-may_treat,908005,"The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma",multiple myeloma,bortezomib
502912907,7/14/2014 14:27:40,,1322882291,7/14/2014 14:27:30,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,182,129,,,198,139,MULTIPLE MYELOMA,BORTEZOMIB,relapsed refractory MULTIPLE MYELOMA.,162-171-182-191,101-107-118-129,"first proteasome inhibitor, BORTEZOMIB,","The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma.",182 191,129,182,129,198,139,1,RO-may_treat,908005,"The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma",multiple myeloma,bortezomib
502912908,7/14/2014 13:15:55,,1322832159,7/14/2014 13:14:47,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,159,179,,,177,194,METASTATIC LESIONS,BONE METASTASES,METASTATIC LESIONS,159-170,178-184,(BONE METASTASES),A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot.,159 170,184,159,179,177,194,-1,RO-disease_has_finding,901664,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot,metastatic lesions,bone metastases
502912908,7/14/2014 13:36:51,,1322846741,7/14/2014 13:36:18,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,159,179,,,177,194,METASTATIC LESIONS,BONE METASTASES,METASTATIC LESIONS (bone metastases),159-170-178-184,159-170-178-184-196-199-208,metastatic lesions (BONE METASTASES) of prostate cancer,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot.,159 170,184,159,179,177,194,-1,RO-disease_has_finding,901664,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot,metastatic lesions,bone metastases
502912908,7/14/2014 13:42:06,,1322850497,7/14/2014 13:41:25,elite,1.0,26544151,GBR,"","",188.29.127.144,159,179,,,177,194,METASTATIC LESIONS,BONE METASTASES,METASTATIC LESIONS,159-170,178-184,(BONE METASTASES),A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot.,159 170,184,159,179,177,194,-1,RO-disease_has_finding,901664,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot,metastatic lesions,bone metastases
502912908,7/14/2014 13:56:32,,1322861043,7/14/2014 13:56:03,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,159,179,,,177,194,METASTATIC LESIONS,BONE METASTASES,METASTATIC LESIONS,159-170,178-184,(BONE METASTASES),A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot.,159 170,184,159,179,177,194,-1,RO-disease_has_finding,901664,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot,metastatic lesions,bone metastases
502912908,7/14/2014 14:22:52,,1322878798,7/14/2014 14:22:48,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,159,179,,,177,194,METASTATIC LESIONS,BONE METASTASES,particularly found in METASTATIC LESIONS metastases) of,137-150-156-159-170-184-196,159-170-178-184-196-199-208,metastatic lesions (BONE METASTASES) of prostate cancer,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot.,159 170,184,159,179,177,194,-1,RO-disease_has_finding,901664,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot,metastatic lesions,bone metastases
502912908,7/14/2014 14:28:46,,1322883143,7/14/2014 14:28:43,instagc,1.0,27753923,GBR,"","",188.30.192.65,159,179,,,177,194,METASTATIC LESIONS,BONE METASTASES,particularly found in METASTATIC LESIONS metastases) of,137-150-156-159-170-184-196,159-170-178-184-196-199-208,metastatic lesions (BONE METASTASES) of prostate cancer,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot.,159 170,184,159,179,177,194,-1,RO-disease_has_finding,901664,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot,metastatic lesions,bone metastases
502912908,7/14/2014 14:44:11,,1322893878,7/14/2014 14:43:52,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,159,179,,,177,194,METASTATIC LESIONS,BONE METASTASES,particularly found in METASTATIC LESIONS metastases) of,137-150-156-159-170-184-196,159-170-178-184-196-199-208,metastatic lesions (BONE METASTASES) of prostate cancer,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot.,159 170,184,159,179,177,194,-1,RO-disease_has_finding,901664,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot,metastatic lesions,bone metastases
502912908,7/14/2014 14:44:41,,1322894177,7/14/2014 14:44:25,prodege,1.0,28209666,,,"",24.156.173.34,159,179,,,177,194,METASTATIC LESIONS,BONE METASTASES,METASTATIC LESIONS,159-170,184-178,(BONE METASTASES),A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot.,159 170,184,159,179,177,194,-1,RO-disease_has_finding,901664,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot,metastatic lesions,bone metastases
502912908,7/14/2014 14:47:18,,1322895778,7/14/2014 14:47:04,instagc,1.0,13763729,USA,"","",75.182.89.225,159,179,,,177,194,METASTATIC LESIONS,BONE METASTASES,METASTATIC LESIONS,159-170,178-184,(BONE METASTASES),A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot.,159 170,184,159,179,177,194,-1,RO-disease_has_finding,901664,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot,metastatic lesions,bone metastases
502912908,7/14/2014 14:47:43,,1322896055,7/14/2014 14:47:23,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,159,179,,,177,194,METASTATIC LESIONS,BONE METASTASES,METASTATIC LESIONS,159-170,178-184,(BONE METASTASES),A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot.,159 170,184,159,179,177,194,-1,RO-disease_has_finding,901664,A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot,metastatic lesions,bone metastases
502912909,7/14/2014 12:54:44,,1322818055,7/14/2014 12:54:39,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,103,36,,,115,45,INFLAMMATION,IBUPROFEN,"its actions in controlling INFLAMMATION, pain and fever,",80-88-91-103-117-122-126-76,23-26-33-36-46-50-61-103,"of action of IBUPROFEN are considered in inflammation,","The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug.",103,36,103,36,115,45,1,RO-may_treat,908220,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug",inflammation,ibuprofen
502912909,7/14/2014 13:07:51,,1322826645,7/14/2014 13:07:05,prodege,1,22031444,GBR,B7,Bristol,77.98.139.82,103,36,,,115,45,INFLAMMATION,IBUPROFEN,"INFLAMMATION,",103,36,IBUPROFEN,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug.",103,36,103,36,115,45,1,RO-may_treat,908220,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug",inflammation,ibuprofen
502912909,7/14/2014 13:12:15,,1322829607,7/14/2014 13:11:45,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,103,36,,,115,45,INFLAMMATION,IBUPROFEN,"ibuprofen INFLAMMATION, fever,",36-103-126,36-103-126,"IBUPROFEN inflammation, fever,","The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug.",103,36,103,36,115,45,1,RO-may_treat,908220,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug",inflammation,ibuprofen
502912909,7/14/2014 13:20:45,,1322835371,7/14/2014 13:20:22,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,103,36,,,115,45,INFLAMMATION,IBUPROFEN,"INFLAMMATION,",103,36,IBUPROFEN,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug.",103,36,103,36,115,45,1,RO-may_treat,908220,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug",inflammation,ibuprofen
502912909,7/14/2014 13:49:10,,1322855871,7/14/2014 13:48:50,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,103,36,,,115,45,INFLAMMATION,IBUPROFEN,"controlling INFLAMMATION, pain and fever,",91-103-117-122-126,26-33-36,action of IBUPROFEN,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug.",103,36,103,36,115,45,1,RO-may_treat,908220,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug",inflammation,ibuprofen
502912909,7/14/2014 14:01:52,,1322864713,7/14/2014 14:01:06,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,103,36,,,115,45,INFLAMMATION,IBUPROFEN,"INFLAMMATION,",103,36,IBUPROFEN,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug.",103,36,103,36,115,45,1,RO-may_treat,908220,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug",inflammation,ibuprofen
502912909,7/14/2014 14:39:57,,1322891014,7/14/2014 14:39:44,prodege,1,28209666,,,"",24.156.173.34,103,36,,,115,45,INFLAMMATION,IBUPROFEN,"INFLAMMATION,",103,36,IBUPROFEN,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug.",103,36,103,36,115,45,1,RO-may_treat,908220,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug",inflammation,ibuprofen
502912909,7/14/2014 14:46:19,,1322895185,7/14/2014 14:46:04,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,103,36,,,115,45,INFLAMMATION,IBUPROFEN,"INFLAMMATION,",103,36,IBUPROFEN,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug.",103,36,103,36,115,45,1,RO-may_treat,908220,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug",inflammation,ibuprofen
502912909,7/14/2014 14:47:56,,1322896177,7/14/2014 14:47:47,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,103,36,,,115,45,INFLAMMATION,IBUPROFEN,"INFLAMMATION,",103,36,IBUPROFEN,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug.",103,36,103,36,115,45,1,RO-may_treat,908220,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug",inflammation,ibuprofen
502912909,7/14/2014 14:49:13,,1322896856,7/14/2014 14:48:42,clixsense,1,6610277,CAN,ON,Oshawa,174.117.79.122,103,36,,,115,45,INFLAMMATION,IBUPROFEN,"actions in controlling INFLAMMATION, pain and fever,",80-88-91-103-117-122-126,36-91-103,"IBUPROFEN controlling inflammation,","The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug.",103,36,103,36,115,45,1,RO-may_treat,908220,"The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug",inflammation,ibuprofen
502912910,7/14/2014 12:51:54,,1322816107,7/14/2014 12:51:33,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,55,0,,,83,29,USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS,"Idiopathic pulmonary fibrosis USUAL INTERSTITIAL PNEUMONIA,",0-11-55-61-74-21,0-11-21-61-74-55,"IDIOPATHIC PULMONARY FIBROSIS usual interstitial pneumonia,","Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern.",55 61 74,0 11 21,55,0,83,29,-1,RO-has_manifestation,906127,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern",usual interstitial pneumonia,Idiopathic pulmonary fibrosis
502912910,7/14/2014 12:53:42,,1322817383,7/14/2014 12:53:34,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,55,0,,,83,29,USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS,"USUAL INTERSTITIAL PNEUMONIA,",55-61-74,0-11-21,IDIOPATHIC PULMONARY FIBROSIS,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern.",55 61 74,0 11 21,55,0,83,29,-1,RO-has_manifestation,906127,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern",usual interstitial pneumonia,Idiopathic pulmonary fibrosis
502912910,7/14/2014 13:07:21,,1322826268,7/14/2014 13:06:52,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,55,0,,,83,29,USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS,"pulmonary fibrosis USUAL INTERSTITIAL PNEUMONIA, heterogeneity, honeycomb",11-21-55-61-74-162-280,0-11-21-74-185-280-162,"IDIOPATHIC PULMONARY FIBROSIS pneumonia, heterogeneity, radiologic honeycomb","Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern.",55 61 74,0 11 21,55,0,83,29,-1,RO-has_manifestation,906127,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern",usual interstitial pneumonia,Idiopathic pulmonary fibrosis
502912910,7/14/2014 13:10:42,,1322828656,7/14/2014 13:09:06,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,55,0,,,83,29,USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS,"Idiopathic pulmonary fibrosis USUAL INTERSTITIAL PNEUMONIA, interstitial fibrosis temporal heterogeneity, subpleural",0-11-21-55-61-74-126-139-153-162-217,0-11-21-55-61-74-126-139-153-162-217,"IDIOPATHIC PULMONARY FIBROSIS usual interstitial pneumonia, interstitial fibrosis temporal heterogeneity, subpleural","Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern.",55 61 74,0 11 21,55,0,83,29,-1,RO-has_manifestation,906127,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern",usual interstitial pneumonia,Idiopathic pulmonary fibrosis
502912910,7/14/2014 13:22:31,,1322836743,7/14/2014 13:22:16,clixsense,1.0,27969116,NLD,"","",91.213.37.165,55,0,,,83,29,USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS,"USUAL INTERSTITIAL PNEUMONIA,",55-61-74,0-11-21,IDIOPATHIC PULMONARY FIBROSIS,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern.",55 61 74,0 11 21,55,0,83,29,-1,RO-has_manifestation,906127,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern",usual interstitial pneumonia,Idiopathic pulmonary fibrosis
502912910,7/14/2014 13:48:50,,1322855596,7/14/2014 13:48:31,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,55,0,,,83,29,USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS,"USUAL INTERSTITIAL PNEUMONIA,",55-61-74,0-11-21,IDIOPATHIC PULMONARY FIBROSIS,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern.",55 61 74,0 11 21,55,0,83,29,-1,RO-has_manifestation,906127,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern",usual interstitial pneumonia,Idiopathic pulmonary fibrosis
502912910,7/14/2014 14:19:45,,1322876664,7/14/2014 14:19:40,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,55,0,,,83,29,USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS,"clinical term for USUAL INTERSTITIAL PNEUMONIA, the characteristic histologic",37-46-51-55-61-74-85-89-104,0-11-21-30-33-37,IDIOPATHIC PULMONARY FIBROSIS is the clinical,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern.",55 61 74,0 11 21,55,0,83,29,-1,RO-has_manifestation,906127,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern",usual interstitial pneumonia,Idiopathic pulmonary fibrosis
502912910,7/14/2014 14:20:45,,1322877414,7/14/2014 14:20:27,clixsense,1,17648398,GBR,K4,Plymouth,78.145.138.150,55,0,,,83,29,USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS,"Idiopathic pulmonary fibrosis USUAL INTERSTITIAL PNEUMONIA,",0-11-21-55-61-74,0-11-21-74-61,"IDIOPATHIC PULMONARY FIBROSIS interstitial pneumonia,","Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern.",55 61 74,0 11 21,55,0,83,29,-1,RO-has_manifestation,906127,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern",usual interstitial pneumonia,Idiopathic pulmonary fibrosis
502912910,7/14/2014 14:31:10,,1322884973,7/14/2014 14:31:07,instagc,1,27753923,GBR,"","",188.30.192.65,55,0,,,83,29,USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS,"clinical term for USUAL INTERSTITIAL PNEUMONIA, the characteristic histologic",37-46-51-55-61-74-85-89-104,0-11-21-30-33-37,IDIOPATHIC PULMONARY FIBROSIS is the clinical,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern.",55 61 74,0 11 21,55,0,83,29,-1,RO-has_manifestation,906127,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern",usual interstitial pneumonia,Idiopathic pulmonary fibrosis
502912910,7/14/2014 14:42:50,,1322892957,7/14/2014 14:42:32,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,55,0,,,83,29,USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS,"USUAL INTERSTITIAL PNEUMONIA,",55-61-74,0-11-21,IDIOPATHIC PULMONARY FIBROSIS,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern.",55 61 74,0 11 21,55,0,83,29,-1,RO-has_manifestation,906127,"Idiopathic pulmonary fibrosis is the clinical term for usual interstitial pneumonia, the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground-glass and reticular attenuation and honeycomb pattern",usual interstitial pneumonia,Idiopathic pulmonary fibrosis
502912911,7/14/2014 12:54:31,,1322817908,7/14/2014 12:54:27,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,82,156,,,89,174,DENTURE,DENTURE STOMATITIS,"side of the DENTURE is unquestionably a hyperplasia,",70-75-78-82-90-93-108-199,136-140-153-156-164-176-189-199-93,"unquestionably the pathogenesis of DENTURE STOMATITIS, inflammatory papillary hyperplasia,","The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures.",82,156 164,82,156,89,174,-1,RO-has_causative_agent,903810,"The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures",denture,denture stomatitis
502912911,7/14/2014 13:11:24,,1322829023,7/14/2014 13:11:05,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,82,156,,,89,174,DENTURE,DENTURE STOMATITIS,DENTURE,82,156-164,"DENTURE STOMATITIS,","The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures.",82,156 164,82,156,89,174,-1,RO-has_causative_agent,903810,"The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures",denture,denture stomatitis
502912911,7/14/2014 13:23:09,,1322837282,7/14/2014 13:22:58,prodege,1,27979711,CAN,ON,Stouffville,99.247.121.227,82,156,,,89,174,DENTURE,DENTURE STOMATITIS,DENTURE,82,156-164,"DENTURE STOMATITIS,","The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures.",82,156 164,82,156,89,174,-1,RO-has_causative_agent,903810,"The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures",denture,denture stomatitis
502912911,7/14/2014 13:35:11,,1322845465,7/14/2014 13:33:19,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,82,156,,,89,174,DENTURE,DENTURE STOMATITIS,"DENTURE etiologic factor pathogenesis of denture stomatitis, papillary hyperplasia, chronic candidiasis",82-116-126-140-153-156-164-189-199-216-224,82-116-126-140-153-156-164-189-199-216-224,"denture etiologic factor pathogenesis of DENTURE STOMATITIS, papillary hyperplasia, chronic candidiasis","The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures.",82,156 164,82,156,89,174,-1,RO-has_causative_agent,903810,"The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures",denture,denture stomatitis
502912911,7/14/2014 13:39:41,,1322848833,7/14/2014 13:39:26,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,82,156,,,89,174,DENTURE,DENTURE STOMATITIS,DENTURE,82,140-153-156-164,"pathogenesis of DENTURE STOMATITIS,","The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures.",82,156 164,82,156,89,174,-1,RO-has_causative_agent,903810,"The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures",denture,denture stomatitis
502912911,7/14/2014 13:40:50,,1322849682,7/14/2014 13:40:36,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,82,156,,,89,174,DENTURE,DENTURE STOMATITIS,DENTURE,82,156-164,"DENTURE STOMATITIS,","The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures.",82,156 164,82,156,89,174,-1,RO-has_causative_agent,903810,"The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures",denture,denture stomatitis
502912911,7/14/2014 13:40:55,,1322849732,7/14/2014 13:40:31,clixsense,1.0,27969116,NLD,"","",91.213.37.165,82,156,,,89,174,DENTURE,DENTURE STOMATITIS,DENTURE,82,140-153-156-164-176-189-199,"pathogenesis of DENTURE STOMATITIS, inflammatory papillary hyperplasia,","The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures.",82,156 164,82,156,89,174,-1,RO-has_causative_agent,903810,"The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures",denture,denture stomatitis
502912911,7/14/2014 14:21:33,,1322877907,7/14/2014 14:21:27,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,82,156,,,89,174,DENTURE,DENTURE STOMATITIS,side of the DENTURE is unquestionably a,70-75-78-82-90-93-108,136-140-153-156-164-176-189-199,"the pathogenesis of DENTURE STOMATITIS, inflammatory papillary hyperplasia,","The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures.",82,156 164,82,156,89,174,-1,RO-has_causative_agent,903810,"The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures",denture,denture stomatitis
502912911,7/14/2014 14:24:00,,1322879599,7/14/2014 14:23:32,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,82,156,,,89,174,DENTURE,DENTURE STOMATITIS,"DENTURE denture stomatitis, inflammatory papillary hyperplasia, chronic candidiasis",82-156-164-176-189-199-216-224,156-164-176-189-199-216-224,"DENTURE STOMATITIS, inflammatory papillary hyperplasia, chronic candidiasis","The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures.",82,156 164,82,156,89,174,-1,RO-has_causative_agent,903810,"The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures",denture,denture stomatitis
502912911,7/14/2014 14:26:35,,1322881513,7/14/2014 14:26:27,clixsense,1,27812714,NLD,06,Tilburg,84.31.160.155,82,156,,,89,174,DENTURE,DENTURE STOMATITIS,side of the DENTURE,70-75-78-82,136-140-153-156-164,"the pathogenesis of DENTURE STOMATITIS,","The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures.",82,156 164,82,156,89,174,-1,RO-has_causative_agent,903810,"The literature reports indicate that (1) plaque on the tissue surface side of the denture is unquestionably a major etiologic factor in the pathogenesis of denture stomatitis, inflammatory papillary hyperplasia, and chronic candidiasis and (2) there are shortcomings in the popular products used by the public to clean their dentures",denture,denture stomatitis
502912912,7/14/2014 12:47:03,,1322812678,7/14/2014 12:46:58,clixsense,1.0,24763049,GBR,"","",86.133.47.213,66,108,,,70,120,BONE,OSTEOPOROSIS,constituents in osteoporotic BONE relative to controls,37-50-53-66-71-80-83,92-100-105-108-121-125-136,"suggest that in OSTEOPOROSIS and fractures, not","The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",66,108,66,108,70,120,1,RO-disease_has_primary_anatomic_site,902461,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength",bone,osteoporosis
502912912,7/14/2014 13:10:38,,1322828614,7/14/2014 13:10:15,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,66,108,,,70,120,BONE,OSTEOPOROSIS,constituents BONE osteoporosis,37-66-108,108-37,constituents OSTEOPOROSIS,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",66,108,66,108,70,120,1,RO-disease_has_primary_anatomic_site,902461,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength",bone,osteoporosis
502912912,7/14/2014 13:36:17,,1322846281,7/14/2014 13:35:55,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,66,108,,,70,120,BONE,OSTEOPOROSIS,constituents in osteoporotic BONE,37-50-53-66,108,OSTEOPOROSIS,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",66,108,66,108,70,120,1,RO-disease_has_primary_anatomic_site,902461,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength",bone,osteoporosis
502912912,7/14/2014 13:45:56,,1322853280,7/14/2014 13:45:38,zoombucks,1,5919735,USA,PA,Doylestown,173.49.91.231,66,108,,,70,120,BONE,OSTEOPOROSIS,BONE,66,108,OSTEOPOROSIS,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",66,108,66,108,70,120,1,RO-disease_has_primary_anatomic_site,902461,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength",bone,osteoporosis
502912912,7/14/2014 13:49:52,,1322856312,7/14/2014 13:49:15,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,66,108,,,70,120,BONE,OSTEOPOROSIS,BONE,66,108,OSTEOPOROSIS,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",66,108,66,108,70,120,1,RO-disease_has_primary_anatomic_site,902461,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength",bone,osteoporosis
502912912,7/14/2014 14:22:17,,1322878456,7/14/2014 14:22:13,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,66,108,,,70,120,BONE,OSTEOPOROSIS,constituents in osteoporotic BONE relative to controls,37-50-53-66-71-80-83,92-100-105-108-121-125-136,"suggest that in OSTEOPOROSIS and fractures, not","The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",66,108,66,108,70,120,1,RO-disease_has_primary_anatomic_site,902461,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength",bone,osteoporosis
502912912,7/14/2014 14:24:19,,1322879797,7/14/2014 14:24:01,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,66,108,,,70,120,BONE,OSTEOPOROSIS,BONE osteoporosis,66-108,108,OSTEOPOROSIS,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",66,108,66,108,70,120,1,RO-disease_has_primary_anatomic_site,902461,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength",bone,osteoporosis
502912912,7/14/2014 14:38:20,,1322889875,7/14/2014 14:38:04,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,66,108,,,70,120,BONE,OSTEOPOROSIS,constituents in osteoporotic BONE relative to controls,37-50-53-66-71-80-83,92-100-105-108-121-125-136-140-145-150-155,"suggest that in OSTEOPOROSIS and fractures, not only bone mass changes,","The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",66,108,66,108,70,120,1,RO-disease_has_primary_anatomic_site,902461,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength",bone,osteoporosis
502912912,7/14/2014 14:38:51,,1322890245,7/14/2014 14:38:36,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,66,108,,,70,120,BONE,OSTEOPOROSIS,osteoporotic BONE,53-66,108,OSTEOPOROSIS,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",66,108,66,108,70,120,1,RO-disease_has_primary_anatomic_site,902461,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength",bone,osteoporosis
502912912,7/14/2014 14:46:26,,1322895289,7/14/2014 14:46:11,prodege,1.0,28209666,,,"",24.156.173.34,66,108,,,70,120,BONE,OSTEOPOROSIS,BONE,66,108,OSTEOPOROSIS,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",66,108,66,108,70,120,1,RO-disease_has_primary_anatomic_site,902461,"The alterations found in bone matrix constituents in osteoporotic bone relative to controls suggest that in osteoporosis and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength",bone,osteoporosis
502912913,7/14/2014 12:59:03,,1322820926,7/14/2014 12:58:48,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,208,249,,,219,282,TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,"TACHYCARDIA,",208,249-259-271,SUSTAINED VENTRICULAR TACHYCARDIA,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied.",208,249 259 271,208,249,219,282,-1,RO-has_definitional_manifestation,904545,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied",tachycardia,sustained ventricular tachycardia
502912913,7/14/2014 13:05:39,,1322825084,7/14/2014 13:05:23,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,208,249,,,219,282,TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,"TACHYCARDIA,",208,249-259-271,SUSTAINED VENTRICULAR TACHYCARDIA,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied.",208,249 259 271,208,249,219,282,-1,RO-has_definitional_manifestation,904545,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied",tachycardia,sustained ventricular tachycardia
502912913,7/14/2014 13:09:07,,1322827521,7/14/2014 13:07:56,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,208,249,,,219,282,TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,"TACHYCARDIA,",208,249-259-271,SUSTAINED VENTRICULAR TACHYCARDIA,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied.",208,249 259 271,208,249,219,282,-1,RO-has_definitional_manifestation,904545,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied",tachycardia,sustained ventricular tachycardia
502912913,7/14/2014 13:16:57,,1322832928,7/14/2014 13:16:32,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,208,249,,,219,282,TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,"TACHYCARDIA,",208,249-259-271,SUSTAINED VENTRICULAR TACHYCARDIA,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied.",208,249 259 271,208,249,219,282,-1,RO-has_definitional_manifestation,904545,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied",tachycardia,sustained ventricular tachycardia
502912913,7/14/2014 13:24:06,,1322837808,7/14/2014 13:23:57,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,208,249,,,219,282,TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,"TACHYCARDIA,",208,249-259-271,SUSTAINED VENTRICULAR TACHYCARDIA,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied.",208,249 259 271,208,249,219,282,-1,RO-has_definitional_manifestation,904545,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied",tachycardia,sustained ventricular tachycardia
502912913,7/14/2014 13:32:03,,1322843099,7/14/2014 13:31:40,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,208,249,,,219,282,TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,"induction of TACHYCARDIA,",195-205-208,224-233-238-249-259-271-283-286-290-298-301,"patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic","To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied.",208,249 259 271,208,249,219,282,-1,RO-has_definitional_manifestation,904545,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied",tachycardia,sustained ventricular tachycardia
502912913,7/14/2014 13:50:14,,1322856563,7/14/2014 13:49:58,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,208,249,,,219,282,TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,"TACHYCARDIA,",208,249-259-271,SUSTAINED VENTRICULAR TACHYCARDIA,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied.",208,249 259 271,208,249,219,282,-1,RO-has_definitional_manifestation,904545,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied",tachycardia,sustained ventricular tachycardia
502912913,7/14/2014 13:58:42,,1322862380,7/14/2014 13:58:11,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,208,249,,,219,282,TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,"TACHYCARDIA,",208,238-249-259-271,"inducible, SUSTAINED VENTRICULAR TACHYCARDIA","To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied.",208,249 259 271,208,249,219,282,-1,RO-has_definitional_manifestation,904545,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied",tachycardia,sustained ventricular tachycardia
502912913,7/14/2014 14:20:47,,1322877432,7/14/2014 14:20:40,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,208,249,,,219,282,TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,"preventing induction of TACHYCARDIA, 15 patients with",184-195-205-208-221-224-233,224-233-238-249-259-271-283-286-290,"patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting","To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied.",208,249 259 271,208,249,219,282,-1,RO-has_definitional_manifestation,904545,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied",tachycardia,sustained ventricular tachycardia
502912913,7/14/2014 14:39:42,,1322890862,7/14/2014 14:39:28,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,208,249,,,219,282,TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,"TACHYCARDIA,",208,238-249-259-271,"inducible, SUSTAINED VENTRICULAR TACHYCARDIA","To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied.",208,249 259 271,208,249,219,282,-1,RO-has_definitional_manifestation,904545,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of tachycardia, 15 patients with inducible, sustained ventricular tachycardia in the setting of chronic coronary artery disease were studied",tachycardia,sustained ventricular tachycardia
502912914,7/14/2014 12:55:03,,1322818264,7/14/2014 12:54:57,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,80,44,,,93,54,SCHIZOPHRENIA,OLANZAPINE,"olanzapine similar efficacy in SCHIZOPHRENIA, but there are",60-68-77-80-95-99-105-44,15-27-40-44-55-60-68-99,"quetiapine, risperidone, and OLANZAPINE have similar efficacy there","In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents.",80,44,80,44,93,54,1,RO-may_treat,908004,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents",schizophrenia,olanzapine
502912914,7/14/2014 12:56:53,,1322819436,7/14/2014 12:56:28,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,80,44,,,93,54,SCHIZOPHRENIA,OLANZAPINE,"SCHIZOPHRENIA,",80,44,OLANZAPINE,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents.",80,44,80,44,93,54,1,RO-may_treat,908004,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents",schizophrenia,olanzapine
502912914,7/14/2014 12:59:12,,1322821008,7/14/2014 12:57:27,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,80,44,,,93,54,SCHIZOPHRENIA,OLANZAPINE,"SCHIZOPHRENIA,",80,44,OLANZAPINE,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents.",80,44,80,44,93,54,1,RO-may_treat,908004,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents",schizophrenia,olanzapine
502912914,7/14/2014 13:12:47,,1322829945,7/14/2014 13:12:31,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,80,44,,,93,54,SCHIZOPHRENIA,OLANZAPINE,"SCHIZOPHRENIA,",80,44,OLANZAPINE,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents.",80,44,80,44,93,54,1,RO-may_treat,908004,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents",schizophrenia,olanzapine
502912914,7/14/2014 13:14:24,,1322831162,7/14/2014 13:14:20,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,80,44,,,93,54,SCHIZOPHRENIA,OLANZAPINE,"similar efficacy in SCHIZOPHRENIA, but there are",60-68-77-80-95-99-105,15-27-40-44-55-60-68,"quetiapine, risperidone, and OLANZAPINE have similar efficacy","In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents.",80,44,80,44,93,54,1,RO-may_treat,908004,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents",schizophrenia,olanzapine
502912914,7/14/2014 13:21:37,,1322836027,7/14/2014 13:19:26,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,80,44,,,93,54,SCHIZOPHRENIA,OLANZAPINE,"quetiapine, risperidone, olanzapine have similar efficacy in SCHIZOPHRENIA,",15-27-44-60-68-77-80-55,15-27-40-44-60-68-80,"quetiapine, risperidone, and OLANZAPINE similar efficacy schizophrenia,","In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents.",80,44,80,44,93,54,1,RO-may_treat,908004,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents",schizophrenia,olanzapine
502912914,7/14/2014 13:34:22,,1322844939,7/14/2014 13:33:51,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,80,44,,,93,54,SCHIZOPHRENIA,OLANZAPINE,"similar efficacy in SCHIZOPHRENIA, but there are",60-68-77-80-95-99-105,15-27-40-44-55-60-68-80,"quetiapine, risperidone, and OLANZAPINE have similar efficacy schizophrenia,","In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents.",80,44,80,44,93,54,1,RO-may_treat,908004,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents",schizophrenia,olanzapine
502912914,7/14/2014 13:50:27,,1322856723,7/14/2014 13:50:12,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,80,44,,,93,54,SCHIZOPHRENIA,OLANZAPINE,"SCHIZOPHRENIA,",80,44,OLANZAPINE,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents.",80,44,80,44,93,54,1,RO-may_treat,908004,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents",schizophrenia,olanzapine
502912914,7/14/2014 13:54:23,,1322859600,7/14/2014 13:54:04,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,80,44,,,93,54,SCHIZOPHRENIA,OLANZAPINE,"similar efficacy in SCHIZOPHRENIA,",60-68-77-80,15-27-40-44-55-60-68-77-80,"quetiapine, risperidone, and OLANZAPINE have similar efficacy in schizophrenia,","In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents.",80,44,80,44,93,54,1,RO-may_treat,908004,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents",schizophrenia,olanzapine
502912914,7/14/2014 14:04:31,,1322866469,7/14/2014 14:04:02,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,80,44,,,93,54,SCHIZOPHRENIA,OLANZAPINE,"SCHIZOPHRENIA,",80,44-80,"OLANZAPINE schizophrenia,","In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents.",80,44,80,44,93,54,1,RO-may_treat,908004,"In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents",schizophrenia,olanzapine
502912915,7/14/2014 12:46:39,,1322812425,7/14/2014 12:46:34,clixsense,1.0,24763049,GBR,"","",86.133.47.213,173,247,,,185,255,CONSTIPATION,SORBITOL,D Glucitol Uses CONSTIPATION Glycerin 238,155-157-167-173-187-209,233-237-241-247-269-273,"241 , 242 SORBITOL a and","a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation.",173,247,173,247,185,255,1,RO-may_treat,907867,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation",Constipation,sorbitol
502912915,7/14/2014 12:51:16,,1322815596,7/14/2014 12:51:09,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,173,247,,,185,255,CONSTIPATION,SORBITOL,D Glucitol Uses CONSTIPATION Glycerin 238,155-157-167-173-187-209,233-237-241-247-269-273,"241 , 242 SORBITOL a and","a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation.",173,247,173,247,185,255,1,RO-may_treat,907867,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation",Constipation,sorbitol
502912915,7/14/2014 12:55:16,,1322818371,7/14/2014 12:55:10,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,173,247,,,185,255,CONSTIPATION,SORBITOL,"D Glucitol Uses CONSTIPATION Glycerin 238 (rectally),",155-157-167-173-187-209-256,233-237-241-247-269-273-277,"241 , 242 SORBITOL a and polyethylene","a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation.",173,247,173,247,185,255,1,RO-may_treat,907867,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation",Constipation,sorbitol
502912915,7/14/2014 13:03:55,,1322824076,7/14/2014 13:03:10,gifthulk,1.0,25566511,USA,"","",24.164.11.173,173,247,,,185,255,CONSTIPATION,SORBITOL,CONSTIPATION,173,247,SORBITOL,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation.",173,247,173,247,185,255,1,RO-may_treat,907867,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation",Constipation,sorbitol
502912915,7/14/2014 13:34:01,,1322844615,7/14/2014 13:33:25,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,173,247,,,185,255,CONSTIPATION,SORBITOL,CONSTIPATION,173,247,SORBITOL,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation.",173,247,173,247,185,255,1,RO-may_treat,907867,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation",Constipation,sorbitol
502912915,7/14/2014 13:40:01,,1322849080,7/14/2014 13:39:58,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,173,247,,,185,255,CONSTIPATION,SORBITOL,D Glucitol Uses CONSTIPATION Glycerin 238,155-157-167-173-187-209,233-237-241-247-269-273,"241 , 242 SORBITOL a and","a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation.",173,247,173,247,185,255,1,RO-may_treat,907867,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation",Constipation,sorbitol
502912915,7/14/2014 13:48:19,,1322855231,7/14/2014 13:47:43,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,173,247,,,185,255,CONSTIPATION,SORBITOL,CONSTIPATION,173,247-381,SORBITOL constipation.,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation.",173,247,173,247,185,255,1,RO-may_treat,907867,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation",Constipation,sorbitol
502912915,7/14/2014 13:48:36,,1322855400,7/14/2014 13:48:19,elite,1.0,26544151,GBR,"","",188.29.127.144,173,247,,,185,255,CONSTIPATION,SORBITOL,CONSTIPATION,173,247,SORBITOL,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation.",173,247,173,247,185,255,1,RO-may_treat,907867,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation",Constipation,sorbitol
502912915,7/14/2014 13:49:14,,1322855948,7/14/2014 13:48:56,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,173,247,,,185,255,CONSTIPATION,SORBITOL,CONSTIPATION,173,247,SORBITOL,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation.",173,247,173,247,185,255,1,RO-may_treat,907867,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation",Constipation,sorbitol
502912915,7/14/2014 13:49:50,,1322856259,7/14/2014 13:49:29,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,173,247,,,185,255,CONSTIPATION,SORBITOL,CONSTIPATION Glycerin,173-187,247,SORBITOL,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation.",173,247,173,247,185,255,1,RO-may_treat,907867,"a ,   b ,   238 ,   245 ,   246 ,   247 ,   248 ,   253  Class:  Cathartics and Laxatives 56:12; IR100 (VA); A06AG (ATC)  Synonyms:  Glycerol; D-Glucitol; D-Glucitol  Uses  Constipation  Glycerin (rectally),  238 ,   239 ,   240 ,   241 ,   242   sorbitol (rectally),  a   and polyethylene glycol (PEG) 3350 (MiraLAX orally)  244   may be used for relief of occasional constipation",Constipation,sorbitol
502912916,7/14/2014 12:48:36,,1322813725,7/14/2014 12:48:21,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,30,56,,,50,66,HYPERCHOLESTEROLEMIA,LOVASTATIN,primary moderate HYPERCHOLESTEROLEMIA with lovastatin (mevinolin) and colestipol.,13-21-30-51-56-67-79-83,21-30-51-56-79-83-67,moderate hypercholesterolemia with LOVASTATIN (mevinolin) and colestipol.,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.,30,56,30,56,50,66,1,RO-may_treat,907635,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol,hypercholesterolemia,lovastatin
502912916,7/14/2014 12:48:53,,1322813916,7/14/2014 12:48:44,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,30,56,,,50,66,HYPERCHOLESTEROLEMIA,LOVASTATIN,primary moderate HYPERCHOLESTEROLEMIA,13-21-30,56,LOVASTATIN,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.,30,56,30,56,50,66,1,RO-may_treat,907635,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol,hypercholesterolemia,lovastatin
502912916,7/14/2014 12:54:02,,1322817574,7/14/2014 12:53:29,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,30,56,,,50,66,HYPERCHOLESTEROLEMIA,LOVASTATIN,primary moderate HYPERCHOLESTEROLEMIA,13-30-21,56,LOVASTATIN,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.,30,56,30,56,50,66,1,RO-may_treat,907635,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol,hypercholesterolemia,lovastatin
502912916,7/14/2014 13:01:06,,1322822200,7/14/2014 13:00:52,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,30,56,,,50,66,HYPERCHOLESTEROLEMIA,LOVASTATIN,HYPERCHOLESTEROLEMIA,30,56,LOVASTATIN,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.,30,56,30,56,50,66,1,RO-may_treat,907635,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol,hypercholesterolemia,lovastatin
502912916,7/14/2014 13:11:28,,1322829083,7/14/2014 13:11:06,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,30,56,,,50,66,HYPERCHOLESTEROLEMIA,LOVASTATIN,HYPERCHOLESTEROLEMIA,30,56,LOVASTATIN,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.,30,56,30,56,50,66,1,RO-may_treat,907635,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol,hypercholesterolemia,lovastatin
502912916,7/14/2014 13:22:21,,1322836618,7/14/2014 13:21:14,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,30,56,,,50,66,HYPERCHOLESTEROLEMIA,LOVASTATIN,of primary moderate HYPERCHOLESTEROLEMIA with lovastatin,10-13-21-30-51-56,21-30-51-56-79-83,moderate hypercholesterolemia with LOVASTATIN and colestipol.,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.,30,56,30,56,50,66,1,RO-may_treat,907635,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol,hypercholesterolemia,lovastatin
502912916,7/14/2014 13:39:10,,1322848455,7/14/2014 13:38:22,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,30,56,,,50,66,HYPERCHOLESTEROLEMIA,LOVASTATIN,primary moderate HYPERCHOLESTEROLEMIA,13-21-30,56,LOVASTATIN,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.,30,56,30,56,50,66,1,RO-may_treat,907635,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol,hypercholesterolemia,lovastatin
502912916,7/14/2014 13:40:42,,1322849563,7/14/2014 13:40:22,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,30,56,,,50,66,HYPERCHOLESTEROLEMIA,LOVASTATIN,primary moderate HYPERCHOLESTEROLEMIA,13-21-30,56,LOVASTATIN,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.,30,56,30,56,50,66,1,RO-may_treat,907635,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol,hypercholesterolemia,lovastatin
502912916,7/14/2014 13:55:38,,1322860426,7/14/2014 13:55:19,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,30,56,,,50,66,HYPERCHOLESTEROLEMIA,LOVASTATIN,primary moderate HYPERCHOLESTEROLEMIA with,13-21-30-51,56-67,LOVASTATIN (mevinolin),Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.,30,56,30,56,50,66,1,RO-may_treat,907635,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol,hypercholesterolemia,lovastatin
502912916,7/14/2014 14:34:02,,1322886935,7/14/2014 14:33:46,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,30,56,,,50,66,HYPERCHOLESTEROLEMIA,LOVASTATIN,primary moderate HYPERCHOLESTEROLEMIA,13-21-30,56-67,LOVASTATIN (mevinolin),Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.,30,56,30,56,50,66,1,RO-may_treat,907635,Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol,hypercholesterolemia,lovastatin
502912917,7/14/2014 12:45:40,,1322811829,7/14/2014 12:45:26,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,248,274,,,264,300,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,"SEVERE DYSPLASIA,",248-255,274-283-293-296,"SQUAMOUS CARCINOMA IN SITU,","Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",248 255,274 283 293 296,248,274,264,300,-1,RO-disease_has_finding,901857,"Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma",severe dysplasia,squamous carcinoma in situ
502912917,7/14/2014 12:54:38,,1322817977,7/14/2014 12:54:33,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,248,274,,,264,300,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,"moderate dysplasia, six had SEVERE DYSPLASIA, six had squamous",229-240-244-248-255-266-270-274-220,255-266-270-274-283-293-296-302-307-311-80,"least dysplasia, six had SQUAMOUS CARCINOMA IN SITU, five had adenocarcinoma","Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",248 255,274 283 293 296,248,274,264,300,-1,RO-disease_has_finding,901857,"Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma",severe dysplasia,squamous carcinoma in situ
502912917,7/14/2014 12:55:24,,1322818452,7/14/2014 12:54:54,gifthulk,1.0,25566511,USA,"","",24.164.11.173,248,274,,,264,300,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,"SEVERE DYSPLASIA,",248-255,274-283-293-296,"SQUAMOUS CARCINOMA IN SITU,","Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",248 255,274 283 293 296,248,274,264,300,-1,RO-disease_has_finding,901857,"Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma",severe dysplasia,squamous carcinoma in situ
502912917,7/14/2014 12:59:25,,1322821081,7/14/2014 12:59:04,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,248,274,,,264,300,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,"SEVERE DYSPLASIA,",248-255,274-283-293-296,"SQUAMOUS CARCINOMA IN SITU,","Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",248 255,274 283 293 296,248,274,264,300,-1,RO-disease_has_finding,901857,"Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma",severe dysplasia,squamous carcinoma in situ
502912917,7/14/2014 13:00:30,,1322821838,7/14/2014 12:59:48,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,248,274,,,264,300,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,"SEVERE DYSPLASIA,",248-255,274-283-293-296,"SQUAMOUS CARCINOMA IN SITU,","Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",248 255,274 283 293 296,248,274,264,300,-1,RO-disease_has_finding,901857,"Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma",severe dysplasia,squamous carcinoma in situ
502912917,7/14/2014 13:03:49,,1322824012,7/14/2014 13:03:33,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,248,274,,,264,300,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,"dysplasia, SEVERE DYSPLASIA,",229-248-255,255-274-283-293-296-311,"dysplasia, SQUAMOUS CARCINOMA IN SITU, adenocarcinoma","Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",248 255,274 283 293 296,248,274,264,300,-1,RO-disease_has_finding,901857,"Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma",severe dysplasia,squamous carcinoma in situ
502912917,7/14/2014 13:10:46,,1322828681,7/14/2014 13:10:30,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,248,274,,,264,300,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,"SEVERE DYSPLASIA,",248-255,274-283-293-296,"SQUAMOUS CARCINOMA IN SITU,","Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",248 255,274 283 293 296,248,274,264,300,-1,RO-disease_has_finding,901857,"Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma",severe dysplasia,squamous carcinoma in situ
502912917,7/14/2014 13:48:55,,1322855706,7/14/2014 13:48:36,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,248,274,,,264,300,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,"SEVERE DYSPLASIA,",248-255,274-283-293-296,"SQUAMOUS CARCINOMA IN SITU,","Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",248 255,274 283 293 296,248,274,264,300,-1,RO-disease_has_finding,901857,"Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma",severe dysplasia,squamous carcinoma in situ
502912917,7/14/2014 13:49:40,,1322856191,7/14/2014 13:49:23,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,248,274,,,264,300,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,"SEVERE DYSPLASIA,",248-255,274-283-293-296,"SQUAMOUS CARCINOMA IN SITU,","Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",248 255,274 283 293 296,248,274,264,300,-1,RO-disease_has_finding,901857,"Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma",severe dysplasia,squamous carcinoma in situ
502912917,7/14/2014 14:02:36,,1322865203,7/14/2014 14:02:10,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,248,274,,,264,300,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,"SEVERE DYSPLASIA,",248-255,274-283-293-296,"SQUAMOUS CARCINOMA IN SITU,","Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",248 255,274 283 293 296,248,274,264,300,-1,RO-disease_has_finding,901857,"Follow-up was available on 63 cases: Seven had negative follow-up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had severe dysplasia, six had squamous carcinoma in situ, five had adenocarcinoma in situ, and two had invasive adenocarcinoma",severe dysplasia,squamous carcinoma in situ
502912918,7/14/2014 12:54:56,,1322818157,7/14/2014 12:54:52,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,99,126,,,104,147,DRUGS,ADVERSE DRUG REACTION,the of symptoms and DRUGS reported to cause,83-86-95-99-105-114-117-73,114-117-123-126-134-139-86,symptoms to cause an ADVERSE DRUG REACTION.,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction.,99,126 134 139,99,126,104,147,1,RO-has_causative_agent,903731,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction,drugs,adverse drug reaction
502912918,7/14/2014 13:00:49,,1322821981,7/14/2014 13:00:07,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,99,126,,,104,147,DRUGS,ADVERSE DRUG REACTION,symptoms DRUGS,86-99,117-126-134-139-86,symptoms cause ADVERSE DRUG REACTION.,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction.,99,126 134 139,99,126,104,147,1,RO-has_causative_agent,903731,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction,drugs,adverse drug reaction
502912918,7/14/2014 13:20:44,,1322835362,7/14/2014 13:20:11,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,99,126,,,104,147,DRUGS,ADVERSE DRUG REACTION,DRUGS,99,126-134-139,ADVERSE DRUG REACTION.,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction.,99,126 134 139,99,126,104,147,1,RO-has_causative_agent,903731,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction,drugs,adverse drug reaction
502912918,7/14/2014 13:44:23,,1322852236,7/14/2014 13:44:03,elite,1.0,26544151,GBR,"","",188.29.127.144,99,126,,,104,147,DRUGS,ADVERSE DRUG REACTION,DRUGS,99,126-134-139,ADVERSE DRUG REACTION.,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction.,99,126 134 139,99,126,104,147,1,RO-has_causative_agent,903731,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction,drugs,adverse drug reaction
502912918,7/14/2014 13:46:44,,1322854005,7/14/2014 13:46:29,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,99,126,,,104,147,DRUGS,ADVERSE DRUG REACTION,DRUGS,99,126-134-139,ADVERSE DRUG REACTION.,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction.,99,126 134 139,99,126,104,147,1,RO-has_causative_agent,903731,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction,drugs,adverse drug reaction
502912918,7/14/2014 13:50:26,,1322856713,7/14/2014 13:50:02,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,99,126,,,104,147,DRUGS,ADVERSE DRUG REACTION,DRUGS adverse drug reaction.,99-126-134-139,126-134-139,ADVERSE DRUG REACTION.,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction.,99,126 134 139,99,126,104,147,1,RO-has_causative_agent,903731,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction,drugs,adverse drug reaction
502912918,7/14/2014 13:50:58,,1322857124,7/14/2014 13:50:38,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,99,126,,,104,147,DRUGS,ADVERSE DRUG REACTION,DRUGS reported,99-105,114-117-123-126-134-139,to cause an ADVERSE DRUG REACTION.,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction.,99,126 134 139,99,126,104,147,1,RO-has_causative_agent,903731,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction,drugs,adverse drug reaction
502912918,7/14/2014 13:51:03,,1322857208,7/14/2014 13:50:49,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,99,126,,,104,147,DRUGS,ADVERSE DRUG REACTION,DRUGS,99,126-134-139,ADVERSE DRUG REACTION.,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction.,99,126 134 139,99,126,104,147,1,RO-has_causative_agent,903731,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction,drugs,adverse drug reaction
502912918,7/14/2014 14:19:27,,1322876418,7/14/2014 14:19:22,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,99,126,,,104,147,DRUGS,ADVERSE DRUG REACTION,of symptoms and DRUGS reported to cause,83-86-95-99-105-114-117,114-117-123-126-134-139,to cause an ADVERSE DRUG REACTION.,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction.,99,126 134 139,99,126,104,147,1,RO-has_causative_agent,903731,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction,drugs,adverse drug reaction
502912918,7/14/2014 14:39:43,,1322890914,7/14/2014 14:39:26,prodege,1.0,28209666,,,"",24.156.173.34,99,126,,,104,147,DRUGS,ADVERSE DRUG REACTION,DRUGS,99,126-134-139,ADVERSE DRUG REACTION.,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction.,99,126 134 139,99,126,104,147,1,RO-has_causative_agent,903731,The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction,drugs,adverse drug reaction
502912919,7/14/2014 12:49:42,,1322814490,7/14/2014 12:49:31,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,41,6,,,50,15,CAPTOPRIL,PREGNANCY,CAPTOPRIL,41,6,PREGNANCY,"?  If pregnancy is detected, discontinue captopril as soon as possible.",41,6,41,6,50,15,1,RO-contraindicated_drug,901494,"?  If pregnancy is detected, discontinue captopril as soon as possible",captopril,pregnancy
502912919,7/14/2014 12:54:22,,1322817845,7/14/2014 12:54:03,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,41,6,,,50,15,CAPTOPRIL,PREGNANCY,CAPTOPRIL,41,6,PREGNANCY,"?  If pregnancy is detected, discontinue captopril as soon as possible.",41,6,41,6,50,15,1,RO-contraindicated_drug,901494,"?  If pregnancy is detected, discontinue captopril as soon as possible",captopril,pregnancy
502912919,7/14/2014 13:14:13,,1322831030,7/14/2014 13:13:59,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,41,6,,,50,15,CAPTOPRIL,PREGNANCY,CAPTOPRIL,41,6,PREGNANCY,"?  If pregnancy is detected, discontinue captopril as soon as possible.",41,6,41,6,50,15,1,RO-contraindicated_drug,901494,"?  If pregnancy is detected, discontinue captopril as soon as possible",captopril,pregnancy
502912919,7/14/2014 13:23:47,,1322837660,7/14/2014 13:23:19,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,41,6,,,50,15,CAPTOPRIL,PREGNANCY,pregnancy CAPTOPRIL,6-41,6-41,PREGNANCY captopril,"?  If pregnancy is detected, discontinue captopril as soon as possible.",41,6,41,6,50,15,1,RO-contraindicated_drug,901494,"?  If pregnancy is detected, discontinue captopril as soon as possible",captopril,pregnancy
502912919,7/14/2014 13:32:56,,1322843895,7/14/2014 13:32:44,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,41,6,,,50,15,CAPTOPRIL,PREGNANCY,CAPTOPRIL,41,6,PREGNANCY,"?  If pregnancy is detected, discontinue captopril as soon as possible.",41,6,41,6,50,15,1,RO-contraindicated_drug,901494,"?  If pregnancy is detected, discontinue captopril as soon as possible",captopril,pregnancy
502912919,7/14/2014 13:39:39,,1322848794,7/14/2014 13:39:36,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,41,6,,,50,15,CAPTOPRIL,PREGNANCY,"is detected, discontinue CAPTOPRIL as soon as",16-19-29-41-51-54-59,0-3-6-16-19-29,"? If PREGNANCY is detected, discontinue","?  If pregnancy is detected, discontinue captopril as soon as possible.",41,6,41,6,50,15,1,RO-contraindicated_drug,901494,"?  If pregnancy is detected, discontinue captopril as soon as possible",captopril,pregnancy
502912919,7/14/2014 13:49:52,,1322856311,7/14/2014 13:49:28,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,41,6,,,50,15,CAPTOPRIL,PREGNANCY,discontinue CAPTOPRIL,29-41,6-16-19,"PREGNANCY is detected,","?  If pregnancy is detected, discontinue captopril as soon as possible.",41,6,41,6,50,15,1,RO-contraindicated_drug,901494,"?  If pregnancy is detected, discontinue captopril as soon as possible",captopril,pregnancy
502912919,7/14/2014 14:26:25,,1322881434,7/14/2014 14:26:09,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,41,6,,,50,15,CAPTOPRIL,PREGNANCY,discontinue CAPTOPRIL,29-41,6,PREGNANCY,"?  If pregnancy is detected, discontinue captopril as soon as possible.",41,6,41,6,50,15,1,RO-contraindicated_drug,901494,"?  If pregnancy is detected, discontinue captopril as soon as possible",captopril,pregnancy
502912919,7/14/2014 14:35:41,,1322888028,7/14/2014 14:35:31,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,41,6,,,50,15,CAPTOPRIL,PREGNANCY,CAPTOPRIL,41,6,PREGNANCY,"?  If pregnancy is detected, discontinue captopril as soon as possible.",41,6,41,6,50,15,1,RO-contraindicated_drug,901494,"?  If pregnancy is detected, discontinue captopril as soon as possible",captopril,pregnancy
502912919,7/14/2014 14:38:48,,1322890225,7/14/2014 14:38:22,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,41,6,,,50,15,CAPTOPRIL,PREGNANCY,"If pregnancy is detected, discontinue CAPTOPRIL as soon as",3-16-19-29-41-51-54-59-6,3-6-16-19-29,"If PREGNANCY is detected, discontinue","?  If pregnancy is detected, discontinue captopril as soon as possible.",41,6,41,6,50,15,1,RO-contraindicated_drug,901494,"?  If pregnancy is detected, discontinue captopril as soon as possible",captopril,pregnancy
502912920,7/14/2014 12:46:08,,1322812075,7/14/2014 12:46:04,clixsense,1.0,24763049,GBR,"","",86.133.47.213,136,61,,,163,73,MESENCHYMAL DIFFERENTIATION,GLIOSARCOMAS,due to aberrant MESENCHYMAL DIFFERENTIATION in a highly,120-124-127-136-148-164-167-169,40-51-58-61-74-78-81,monoclonal origin of GLIOSARCOMAS and an evolution,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm.,136 148,61,136,61,163,73,-1,RO-disease_has_finding,901559,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm,mesenchymal differentiation,gliosarcomas
502912920,7/14/2014 12:56:37,,1322819279,7/14/2014 12:56:31,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,136,61,,,163,73,MESENCHYMAL DIFFERENTIATION,GLIOSARCOMAS,the due to aberrant MESENCHYMAL DIFFERENTIATION in a highly,120-124-127-136-148-164-167-169-94,40-51-58-61-74-78-81-98,monoclonal origin of GLIOSARCOMAS and an evolution sarcomatous,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm.,136 148,61,136,61,163,73,-1,RO-disease_has_finding,901559,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm,mesenchymal differentiation,gliosarcomas
502912920,7/14/2014 13:00:25,,1322821757,7/14/2014 13:00:01,gifthulk,1.0,25566511,USA,"","",24.164.11.173,136,61,,,163,73,MESENCHYMAL DIFFERENTIATION,GLIOSARCOMAS,MESENCHYMAL DIFFERENTIATION,136-148,61,GLIOSARCOMAS,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm.,136 148,61,136,61,163,73,-1,RO-disease_has_finding,901559,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm,mesenchymal differentiation,gliosarcomas
502912920,7/14/2014 13:10:39,,1322828616,7/14/2014 13:10:21,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,136,61,,,163,73,MESENCHYMAL DIFFERENTIATION,GLIOSARCOMAS,MESENCHYMAL DIFFERENTIATION,136-148,61,GLIOSARCOMAS,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm.,136 148,61,136,61,163,73,-1,RO-disease_has_finding,901559,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm,mesenchymal differentiation,gliosarcomas
502912920,7/14/2014 13:18:20,,1322833780,7/14/2014 13:17:56,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,136,61,,,163,73,MESENCHYMAL DIFFERENTIATION,GLIOSARCOMAS,aberrant MESENCHYMAL DIFFERENTIATION,127-136-148,61,GLIOSARCOMAS,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm.,136 148,61,136,61,163,73,-1,RO-disease_has_finding,901559,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm,mesenchymal differentiation,gliosarcomas
502912920,7/14/2014 13:23:20,,1322837479,7/14/2014 13:23:10,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,136,61,,,163,73,MESENCHYMAL DIFFERENTIATION,GLIOSARCOMAS,MESENCHYMAL DIFFERENTIATION,136-148,61,GLIOSARCOMAS,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm.,136 148,61,136,61,163,73,-1,RO-disease_has_finding,901559,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm,mesenchymal differentiation,gliosarcomas
502912920,7/14/2014 13:39:42,,1322848841,7/14/2014 13:39:40,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,136,61,,,163,73,MESENCHYMAL DIFFERENTIATION,GLIOSARCOMAS,due to aberrant MESENCHYMAL DIFFERENTIATION in a highly,120-124-127-136-148-164-167-169,40-51-58-61-74-78-81,monoclonal origin of GLIOSARCOMAS and an evolution,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm.,136 148,61,136,61,163,73,-1,RO-disease_has_finding,901559,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm,mesenchymal differentiation,gliosarcomas
502912920,7/14/2014 13:41:44,,1322850233,7/14/2014 13:41:20,clixsense,1.0,27969116,NLD,"","",91.213.37.165,136,61,,,163,73,MESENCHYMAL DIFFERENTIATION,GLIOSARCOMAS,aberrant MESENCHYMAL DIFFERENTIATION malignant astrocytic neoplasm.,127-136-148-176-186-197,40-51-58-61,monoclonal origin of GLIOSARCOMAS,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm.,136 148,61,136,61,163,73,-1,RO-disease_has_finding,901559,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm,mesenchymal differentiation,gliosarcomas
502912920,7/14/2014 14:20:05,,1322876842,7/14/2014 14:20:01,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,136,61,,,163,73,MESENCHYMAL DIFFERENTIATION,GLIOSARCOMAS,due to aberrant MESENCHYMAL DIFFERENTIATION in a highly,120-124-127-136-148-164-167-169,40-51-58-61-74-78-81,monoclonal origin of GLIOSARCOMAS and an evolution,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm.,136 148,61,136,61,163,73,-1,RO-disease_has_finding,901559,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm,mesenchymal differentiation,gliosarcomas
502912920,7/14/2014 14:30:16,,1322884331,7/14/2014 14:30:13,instagc,1.0,27753923,GBR,"","",188.30.192.65,136,61,,,163,73,MESENCHYMAL DIFFERENTIATION,GLIOSARCOMAS,due to aberrant MESENCHYMAL DIFFERENTIATION in a highly,120-124-127-136-148-164-167-169,40-51-58-61-74-78-81,monoclonal origin of GLIOSARCOMAS and an evolution,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm.,136 148,61,136,61,163,73,-1,RO-disease_has_finding,901559,This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm,mesenchymal differentiation,gliosarcomas
502912921,7/14/2014 12:53:28,,1322817162,7/14/2014 12:52:56,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,86,24,,,109,43,SICKLE CELL NEPHROPATHY,SICKLE CELL DISEASE,SICKLE CELL NEPHROPATHY.,86-93-98,24-31-36,SICKLE CELL DISEASE,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy.,86 93 98,24 31 36,86,24,109,43,1,RO-cause_of,900396,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy,sickle cell nephropathy,sickle cell disease
502912921,7/14/2014 13:15:11,,1322831644,7/14/2014 13:15:07,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,86,24,,,109,43,SICKLE CELL NEPHROPATHY,SICKLE CELL DISEASE,in patients with SICKLE CELL NEPHROPATHY.,69-72-81-86-93-98,4-10-19-24-31-36-44-53-61,study suggests that SICKLE CELL DISEASE produces similar lesions,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy.,86 93 98,24 31 36,86,24,109,43,1,RO-cause_of,900396,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy,sickle cell nephropathy,sickle cell disease
502912921,7/14/2014 13:25:50,,1322838998,7/14/2014 13:25:43,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,86,24,,,109,43,SICKLE CELL NEPHROPATHY,SICKLE CELL DISEASE,SICKLE CELL NEPHROPATHY.,86-93-98,24-31-36,SICKLE CELL DISEASE,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy.,86 93 98,24 31 36,86,24,109,43,1,RO-cause_of,900396,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy,sickle cell nephropathy,sickle cell disease
502912921,7/14/2014 13:26:43,,1322839585,7/14/2014 13:25:56,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,86,24,,,109,43,SICKLE CELL NEPHROPATHY,SICKLE CELL DISEASE,sickle cell disease lesions SICKLE CELL NEPHROPATHY.,24-31-36-86-93-98-61,24-31-36-61-86-93-98,SICKLE CELL DISEASE lesions sickle cell nephropathy.,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy.,86 93 98,24 31 36,86,24,109,43,1,RO-cause_of,900396,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy,sickle cell nephropathy,sickle cell disease
502912921,7/14/2014 13:27:30,,1322840157,7/14/2014 13:27:25,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,86,24,,,109,43,SICKLE CELL NEPHROPATHY,SICKLE CELL DISEASE,in patients with SICKLE CELL NEPHROPATHY.,69-72-81-86-93-98,4-10-19-24-31-36-44-53-61,study suggests that SICKLE CELL DISEASE produces similar lesions,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy.,86 93 98,24 31 36,86,24,109,43,1,RO-cause_of,900396,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy,sickle cell nephropathy,sickle cell disease
502912921,7/14/2014 13:34:03,,1322844619,7/14/2014 13:33:45,clixsense,1.0,27969116,NLD,"","",91.213.37.165,86,24,,,109,43,SICKLE CELL NEPHROPATHY,SICKLE CELL DISEASE,SICKLE CELL NEPHROPATHY.,86-93-98,24-31-36,SICKLE CELL DISEASE,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy.,86 93 98,24 31 36,86,24,109,43,1,RO-cause_of,900396,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy,sickle cell nephropathy,sickle cell disease
502912921,7/14/2014 13:55:28,,1322860286,7/14/2014 13:55:18,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,86,24,,,109,43,SICKLE CELL NEPHROPATHY,SICKLE CELL DISEASE,SICKLE CELL NEPHROPATHY.,86-93-98,24-31-36,SICKLE CELL DISEASE,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy.,86 93 98,24 31 36,86,24,109,43,1,RO-cause_of,900396,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy,sickle cell nephropathy,sickle cell disease
502912921,7/14/2014 14:22:17,,1322878444,7/14/2014 14:22:02,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,86,24,,,109,43,SICKLE CELL NEPHROPATHY,SICKLE CELL DISEASE,sickle cell disease SICKLE CELL NEPHROPATHY.,24-31-36-86-93-98,24-31-36-86-98-93,SICKLE CELL DISEASE sickle cell nephropathy.,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy.,86 93 98,24 31 36,86,24,109,43,1,RO-cause_of,900396,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy,sickle cell nephropathy,sickle cell disease
502912921,7/14/2014 14:30:11,,1322884243,7/14/2014 14:30:08,instagc,1.0,27753923,GBR,"","",188.30.192.65,86,24,,,109,43,SICKLE CELL NEPHROPATHY,SICKLE CELL DISEASE,in patients with SICKLE CELL NEPHROPATHY.,69-72-81-86-93-98,4-10-19-24-31-36-44-53-61,study suggests that SICKLE CELL DISEASE produces similar lesions,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy.,86 93 98,24 31 36,86,24,109,43,1,RO-cause_of,900396,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy,sickle cell nephropathy,sickle cell disease
502912921,7/14/2014 14:42:52,,1322892970,7/14/2014 14:41:51,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,86,24,,,109,43,SICKLE CELL NEPHROPATHY,SICKLE CELL DISEASE,in patients with SICKLE CELL NEPHROPATHY.,69-72-81-86-93-98,4-10-19-24-31-36-44-53-61-69-72-81,study suggests that SICKLE CELL DISEASE produces similar lesions in patients with,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy.,86 93 98,24 31 36,86,24,109,43,1,RO-cause_of,900396,Our study suggests that sickle cell disease produces similar lesions in patients with sickle cell nephropathy,sickle cell nephropathy,sickle cell disease
502912922,7/14/2014 12:54:25,,1322817861,7/14/2014 12:54:11,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,105,44,,,124,52,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,105-114,44,DIABETES,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy.",105 114,44,105,44,124,52,-1,RO-cause_of,900157,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy",diabetic neuropathy,diabetes
502912922,7/14/2014 12:55:48,,1322818719,7/14/2014 12:55:30,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,105,44,,,124,52,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,105-114,44,DIABETES,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy.",105 114,44,105,44,124,52,-1,RO-cause_of,900157,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy",diabetic neuropathy,diabetes
502912922,7/14/2014 13:13:54,,1322830830,7/14/2014 13:13:49,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,105,44,,,124,52,DIABETIC NEUROPATHY,DIABETES,other manifestations of DIABETIC NEUROPATHY.,81-87-102-105-114,31-33-41-44-53-56-61,"a history of DIABETES of long duration,","The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy.",105 114,44,105,44,124,52,-1,RO-cause_of,900157,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy",diabetic neuropathy,diabetes
502912922,7/14/2014 13:24:18,,1322838012,7/14/2014 13:24:06,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,105,44,,,124,52,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,105-114,44,DIABETES,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy.",105 114,44,105,44,124,52,-1,RO-cause_of,900157,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy",diabetic neuropathy,diabetes
502912922,7/14/2014 13:34:48,,1322845235,7/14/2014 13:34:37,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,105,44,,,124,52,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,105-114,44,DIABETES,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy.",105 114,44,105,44,124,52,-1,RO-cause_of,900157,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy",diabetic neuropathy,diabetes
502912922,7/14/2014 13:35:55,,1322846023,7/14/2014 13:35:39,clixsense,1.0,27969116,NLD,"","",91.213.37.165,105,44,,,124,52,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,105-114,44,DIABETES,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy.",105 114,44,105,44,124,52,-1,RO-cause_of,900157,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy",diabetic neuropathy,diabetes
502912922,7/14/2014 13:44:41,,1322852395,7/14/2014 13:44:26,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,105,44,,,124,52,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,105-114,44,DIABETES,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy.",105 114,44,105,44,124,52,-1,RO-cause_of,900157,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy",diabetic neuropathy,diabetes
502912922,7/14/2014 13:45:17,,1322852799,7/14/2014 13:45:02,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,105,44,,,124,52,DIABETIC NEUROPATHY,DIABETES,manifestations of DIABETIC NEUROPATHY.,87-102-105-114,33-41-44-53-56-61,"history of DIABETES of long duration,","The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy.",105 114,44,105,44,124,52,-1,RO-cause_of,900157,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy",diabetic neuropathy,diabetes
502912922,7/14/2014 14:31:42,,1322885425,7/14/2014 14:31:38,instagc,1.0,27753923,GBR,"","",188.30.192.65,105,44,,,124,52,DIABETIC NEUROPATHY,DIABETES,other manifestations of DIABETIC NEUROPATHY.,81-87-102-105-114,31-33-41-44-53-56-61,"a history of DIABETES of long duration,","The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy.",105 114,44,105,44,124,52,-1,RO-cause_of,900157,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy",diabetic neuropathy,diabetes
502912922,7/14/2014 14:46:25,,1322895287,7/14/2014 14:46:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,105,44,,,124,52,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,105-114,44,DIABETES,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy.",105 114,44,105,44,124,52,-1,RO-cause_of,900157,"The physician should ask about a history of diabetes of long duration, including other manifestations of diabetic neuropathy",diabetic neuropathy,diabetes
502912923,7/14/2014 12:51:48,,1322816027,7/14/2014 12:51:20,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,126,75,,,145,81,PARKINSON'S DISEASE,L-DOPA,UPDRS (Unified PARKINSON'S DISEASE Rating Scale),111-117-126-138-146-153,75-77,L DOPA,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",126 138,75 77,126,75,145,81,1,RO-may_treat,908169,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan",Parkinson's Disease,L-DOPA
502912923,7/14/2014 12:53:34,,1322817255,7/14/2014 12:53:17,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,126,75,,,145,81,PARKINSON'S DISEASE,L-DOPA,UPDRS (Unified PARKINSON'S DISEASE Rating Scale),111-117-126-138-146-153,75-77,L DOPA,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",126 138,75 77,126,75,145,81,1,RO-may_treat,908169,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan",Parkinson's Disease,L-DOPA
502912923,7/14/2014 13:01:23,,1322822381,7/14/2014 13:00:32,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,126,75,,,145,81,PARKINSON'S DISEASE,L-DOPA,PARKINSON'S DISEASE,126-138,75-77,L DOPA,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",126 138,75 77,126,75,145,81,1,RO-may_treat,908169,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan",Parkinson's Disease,L-DOPA
502912923,7/14/2014 13:02:51,,1322823359,7/14/2014 13:02:36,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,126,75,,,145,81,PARKINSON'S DISEASE,L-DOPA,PARKINSON'S DISEASE,126-138,75-77,L DOPA,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",126 138,75 77,126,75,145,81,1,RO-may_treat,908169,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan",Parkinson's Disease,L-DOPA
502912923,7/14/2014 13:05:44,,1322825139,7/14/2014 13:05:27,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,126,75,,,145,81,PARKINSON'S DISEASE,L-DOPA,pramipexole UPDRS PARKINSON'S DISEASE,111-126-138-21,75-77-111,L DOPA UPDRS,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",126 138,75 77,126,75,145,81,1,RO-may_treat,908169,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan",Parkinson's Disease,L-DOPA
502912923,7/14/2014 13:15:47,,1322832106,7/14/2014 13:15:21,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,126,75,,,145,81,PARKINSON'S DISEASE,L-DOPA,(Unified PARKINSON'S DISEASE Rating Scale),117-126-138-146-153,75-77,L DOPA,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",126 138,75 77,126,75,145,81,1,RO-may_treat,908169,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan",Parkinson's Disease,L-DOPA
502912923,7/14/2014 13:21:47,,1322836177,7/14/2014 13:20:45,clixsense,1.0,27969116,NLD,"","",91.213.37.165,126,75,,,145,81,PARKINSON'S DISEASE,L-DOPA,UPDRS (Unified PARKINSON'S DISEASE Rating Scale) II,111-117-126-138-146-153-160,75-77,L DOPA,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",126 138,75 77,126,75,145,81,1,RO-may_treat,908169,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan",Parkinson's Disease,L-DOPA
502912923,7/14/2014 13:41:18,,1322849919,7/14/2014 13:40:49,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,126,75,,,145,81,PARKINSON'S DISEASE,L-DOPA,(Unified PARKINSON'S DISEASE Rating Scale),117-126-138-146-153,75-77,L DOPA,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",126 138,75 77,126,75,145,81,1,RO-may_treat,908169,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan",Parkinson's Disease,L-DOPA
502912923,7/14/2014 13:47:09,,1322854441,7/14/2014 13:46:38,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,126,75,,,145,81,PARKINSON'S DISEASE,L-DOPA,PARKINSON'S DISEASE,126-138,75-77-126-138,L DOPA Parkinson's Disease,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",126 138,75 77,126,75,145,81,1,RO-may_treat,908169,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan",Parkinson's Disease,L-DOPA
502912923,7/14/2014 14:02:11,,1322864941,7/14/2014 14:01:59,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,126,75,,,145,81,PARKINSON'S DISEASE,L-DOPA,UPDRS (Unified PARKINSON'S DISEASE Rating Scale) II,111-117-126-138-146-153-160,75-77,L DOPA,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",126 138,75 77,126,75,145,81,1,RO-may_treat,908169,"Clinical efficacy of pramipexole both in monotherapy and combined use with L-DOPA were confirmed evaluating by UPDRS (Unified Parkinson's Disease Rating Scale) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan",Parkinson's Disease,L-DOPA
502912924,7/14/2014 12:51:32,,1322815776,7/14/2014 12:51:17,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,0,88,,,17,111,PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,PERIPHERAL NERVES,0-11,88-99-112-120-130-133-141-154-168-183,"PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes)","Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",0 11,88 99,0,88,17,111,1,RO-has_finding_site,905462,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available",Peripheral nerves,peripheral neuropathies
502912924,7/14/2014 13:02:30,,1322823089,7/14/2014 13:02:19,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,0,88,,,17,111,PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,PERIPHERAL NERVES,0-11,88-99,PERIPHERAL NEUROPATHIES,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",0 11,88 99,0,88,17,111,1,RO-has_finding_site,905462,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available",Peripheral nerves,peripheral neuropathies
502912924,7/14/2014 13:03:30,,1322823778,7/14/2014 13:03:19,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,0,88,,,17,111,PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,PERIPHERAL NERVES,0-11,88-99,PERIPHERAL NEUROPATHIES,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",0 11,88 99,0,88,17,111,1,RO-has_finding_site,905462,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available",Peripheral nerves,peripheral neuropathies
502912924,7/14/2014 13:16:53,,1322832870,7/14/2014 13:15:43,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,0,88,,,17,111,PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,PERIPHERAL NERVES,0-11,88-99,PERIPHERAL NEUROPATHIES,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",0 11,88 99,0,88,17,111,1,RO-has_finding_site,905462,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available",Peripheral nerves,peripheral neuropathies
502912924,7/14/2014 13:33:51,,1322844495,7/14/2014 13:33:28,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,0,88,,,17,111,PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,PERIPHERAL NERVES,0-11,88-99-112-120-130-133-141-154-168-183,"PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes)","Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",0 11,88 99,0,88,17,111,1,RO-has_finding_site,905462,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available",Peripheral nerves,peripheral neuropathies
502912924,7/14/2014 13:55:42,,1322860500,7/14/2014 13:55:29,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,0,88,,,17,111,PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,PERIPHERAL NERVES,0-11,88-99,PERIPHERAL NEUROPATHIES,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",0 11,88 99,0,88,17,111,1,RO-has_finding_site,905462,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available",Peripheral nerves,peripheral neuropathies
502912924,7/14/2014 14:21:10,,1322877658,7/14/2014 14:21:05,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,0,88,,,17,111,PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,PERIPHERAL NERVES show spontaneous regenerative,0-11-18-23-35,72-78-85-88-99-120-130,"after injury or PERIPHERAL NEUROPATHIES diabetic, or","Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",0 11,88 99,0,88,17,111,1,RO-has_finding_site,905462,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available",Peripheral nerves,peripheral neuropathies
502912924,7/14/2014 14:25:46,,1322880994,7/14/2014 14:25:31,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,0,88,,,17,111,PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,"PERIPHERAL NERVES show spontaneous regenerative responses,",0-11-18-23-35-48,78-85-88-99,injury or PERIPHERAL NEUROPATHIES,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",0 11,88 99,0,88,17,111,1,RO-has_finding_site,905462,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available",Peripheral nerves,peripheral neuropathies
502912924,7/14/2014 14:43:44,,1322893579,7/14/2014 14:43:33,prodege,1.0,28209666,,,"",24.156.173.34,0,88,,,17,111,PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,PERIPHERAL NERVES,0-11,88-99,PERIPHERAL NEUROPATHIES,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",0 11,88 99,0,88,17,111,1,RO-has_finding_site,905462,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available",Peripheral nerves,peripheral neuropathies
502912924,7/14/2014 14:47:03,,1322895670,7/14/2014 14:46:53,instagc,1.0,13763729,USA,"","",75.182.89.225,0,88,,,17,111,PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,PERIPHERAL NERVES,0-11,88-99,PERIPHERAL NEUROPATHIES,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",0 11,88 99,0,88,17,111,1,RO-has_finding_site,905462,"Peripheral nerves show spontaneous regenerative responses, but recovery after injury or peripheral neuropathies (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available",Peripheral nerves,peripheral neuropathies
502912925,7/14/2014 12:54:09,,1322817655,7/14/2014 12:53:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,69,36,,,90,46,MYCOPLASMA PNEUMONIAE,MYCOPLASMA,"MYCOPLASMA PNEUMONIAE,",69-80,36-47,"MYCOPLASMA infections,","Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined.",69 80,36,69,36,90,46,1,RO-has_causative_agent,903932,"Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined",Mycoplasma pneumoniae,mycoplasma
502912925,7/14/2014 12:55:38,,1322818595,7/14/2014 12:55:35,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,69,36,,,90,46,MYCOPLASMA PNEUMONIAE,MYCOPLASMA,"mycoplasma infections, including MYCOPLASMA PNEUMONIAE, the phenotype of",36-47-59-69-80-92-96-106,22-27-30-36-47-59-69-96,"seen in other MYCOPLASMA infections, including Mycoplasma phenotype","Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined.",69 80,36,69,36,90,46,1,RO-has_causative_agent,903932,"Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined",Mycoplasma pneumoniae,mycoplasma
502912925,7/14/2014 13:00:04,,1322821503,7/14/2014 12:58:47,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,69,36,,,90,46,MYCOPLASMA PNEUMONIAE,MYCOPLASMA,"mycoplasma infections, MYCOPLASMA PNEUMONIAE,",36-47-69-80,36-69,MYCOPLASMA Mycoplasma,"Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined.",69 80,36,69,36,90,46,1,RO-has_causative_agent,903932,"Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined",Mycoplasma pneumoniae,mycoplasma
502912925,7/14/2014 13:16:28,,1322832605,7/14/2014 13:15:44,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,69,36,,,90,46,MYCOPLASMA PNEUMONIAE,MYCOPLASMA,"mycoplasma infections, MYCOPLASMA PNEUMONIAE, phenotype of the lymphocytes",36-47-69-80-96-106-109-113,36-47-69-80-96-106-109-113,"MYCOPLASMA infections, Mycoplasma pneumoniae, phenotype of the lymphocytes","Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined.",69 80,36,69,36,90,46,1,RO-has_causative_agent,903932,"Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined",Mycoplasma pneumoniae,mycoplasma
502912925,7/14/2014 13:17:37,,1322833339,7/14/2014 13:16:40,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,69,36,,,90,46,MYCOPLASMA PNEUMONIAE,MYCOPLASMA,"MYCOPLASMA PNEUMONIAE,",69-80,36,MYCOPLASMA,"Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined.",69 80,36,69,36,90,46,1,RO-has_causative_agent,903932,"Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined",Mycoplasma pneumoniae,mycoplasma
502912925,7/14/2014 13:39:49,,1322848943,7/14/2014 13:39:47,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,69,36,,,90,46,MYCOPLASMA PNEUMONIAE,MYCOPLASMA,"mycoplasma infections, including MYCOPLASMA PNEUMONIAE, the phenotype of",36-47-59-69-80-92-96-106,22-27-30-36-47-59-69,"seen in other MYCOPLASMA infections, including Mycoplasma","Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined.",69 80,36,69,36,90,46,1,RO-has_causative_agent,903932,"Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined",Mycoplasma pneumoniae,mycoplasma
502912925,7/14/2014 13:44:05,,1322852033,7/14/2014 13:43:47,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,69,36,,,90,46,MYCOPLASMA PNEUMONIAE,MYCOPLASMA,"MYCOPLASMA PNEUMONIAE,",69-80,36,MYCOPLASMA,"Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined.",69 80,36,69,36,90,46,1,RO-has_causative_agent,903932,"Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined",Mycoplasma pneumoniae,mycoplasma
502912925,7/14/2014 13:52:27,,1322858270,7/14/2014 13:52:04,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,69,36,,,90,46,MYCOPLASMA PNEUMONIAE,MYCOPLASMA,"MYCOPLASMA PNEUMONIAE, the phenotype of the lymphocytes",69-80-92-96-106-109-113,36-47,"MYCOPLASMA infections,","Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined.",69 80,36,69,36,90,46,1,RO-has_causative_agent,903932,"Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined",Mycoplasma pneumoniae,mycoplasma
502912925,7/14/2014 14:20:25,,1322877067,7/14/2014 14:20:20,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,69,36,,,90,46,MYCOPLASMA PNEUMONIAE,MYCOPLASMA,"mycoplasma infections, including MYCOPLASMA PNEUMONIAE, the phenotype of",36-47-59-69-80-92-96-106,22-27-30-36-47-59-69,"seen in other MYCOPLASMA infections, including Mycoplasma","Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined.",69 80,36,69,36,90,46,1,RO-has_causative_agent,903932,"Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined",Mycoplasma pneumoniae,mycoplasma
502912925,7/14/2014 14:24:15,,1322879719,7/14/2014 14:24:10,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,69,36,,,90,46,MYCOPLASMA PNEUMONIAE,MYCOPLASMA,"mycoplasma infections, including MYCOPLASMA PNEUMONIAE, the phenotype of",36-47-59-69-80-92-96-106,22-27-30-36-47-59-69,"seen in other MYCOPLASMA infections, including Mycoplasma","Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined.",69 80,36,69,36,90,46,1,RO-has_causative_agent,903932,"Although this is also seen in other mycoplasma infections, including Mycoplasma pneumoniae, the phenotype of the lymphocytes infiltrating the respiratory tract has not been determined",Mycoplasma pneumoniae,mycoplasma
502912926,7/14/2014 12:46:40,,1322812434,7/14/2014 12:46:30,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,76,0,,,96,9,BORDETELLA PERTUSSIS,PERTUSSIS,bacterium BORDETELLA PERTUSSIS.,66-76-87,0,PERTUSSIS,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis.,76 87,0,76,0,96,9,1,RO-has_causative_agent,903902,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis,Bordetella pertussis,Pertussis
502912926,7/14/2014 12:48:43,,1322813807,7/14/2014 12:48:34,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,76,0,,,96,9,BORDETELLA PERTUSSIS,PERTUSSIS,BORDETELLA PERTUSSIS.,76-87,0,PERTUSSIS,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis.,76 87,0,76,0,96,9,1,RO-has_causative_agent,903902,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis,Bordetella pertussis,Pertussis
502912926,7/14/2014 12:55:22,,1322818446,7/14/2014 12:55:17,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,76,0,,,96,9,BORDETELLA PERTUSSIS,PERTUSSIS,caused by the bacterium BORDETELLA PERTUSSIS.,59-62-66-76-87-52,0-10-13-16-62,PERTUSSIS is an acute the,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis.,76 87,0,76,0,96,9,1,RO-has_causative_agent,903902,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis,Bordetella pertussis,Pertussis
502912926,7/14/2014 12:57:01,,1322819506,7/14/2014 12:56:50,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,76,0,,,96,9,BORDETELLA PERTUSSIS,PERTUSSIS,BORDETELLA PERTUSSIS.,76-87,0,PERTUSSIS,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis.,76 87,0,76,0,96,9,1,RO-has_causative_agent,903902,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis,Bordetella pertussis,Pertussis
502912926,7/14/2014 13:02:26,,1322823035,7/14/2014 13:02:06,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,76,0,,,96,9,BORDETELLA PERTUSSIS,PERTUSSIS,Pertussis bacterium BORDETELLA PERTUSSIS.,66-76-87-0,0-66-76-87,PERTUSSIS bacterium Bordetella pertussis.,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis.,76 87,0,76,0,96,9,1,RO-has_causative_agent,903902,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis,Bordetella pertussis,Pertussis
502912926,7/14/2014 13:07:05,,1322826076,7/14/2014 13:06:28,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,76,0,,,96,9,BORDETELLA PERTUSSIS,PERTUSSIS,BORDETELLA PERTUSSIS.,76-87,0,PERTUSSIS,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis.,76 87,0,76,0,96,9,1,RO-has_causative_agent,903902,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis,Bordetella pertussis,Pertussis
502912926,7/14/2014 13:10:20,,1322828455,7/14/2014 13:10:09,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,76,0,,,96,9,BORDETELLA PERTUSSIS,PERTUSSIS,BORDETELLA PERTUSSIS.,76-87,0,PERTUSSIS,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis.,76 87,0,76,0,96,9,1,RO-has_causative_agent,903902,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis,Bordetella pertussis,Pertussis
502912926,7/14/2014 13:14:14,,1322831065,7/14/2014 13:13:59,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,76,0,,,96,9,BORDETELLA PERTUSSIS,PERTUSSIS,bacterium BORDETELLA PERTUSSIS.,66-76-87,0,PERTUSSIS,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis.,76 87,0,76,0,96,9,1,RO-has_causative_agent,903902,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis,Bordetella pertussis,Pertussis
502912926,7/14/2014 13:14:54,,1322831474,7/14/2014 13:14:49,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,76,0,,,96,9,BORDETELLA PERTUSSIS,PERTUSSIS,by the bacterium BORDETELLA PERTUSSIS.,59-62-66-76-87,0-10-13-16,PERTUSSIS is an acute,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis.,76 87,0,76,0,96,9,1,RO-has_causative_agent,903902,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis,Bordetella pertussis,Pertussis
502912926,7/14/2014 13:23:46,,1322837644,7/14/2014 13:23:35,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,76,0,,,96,9,BORDETELLA PERTUSSIS,PERTUSSIS,BORDETELLA PERTUSSIS.,76-87,0,PERTUSSIS,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis.,76 87,0,76,0,96,9,1,RO-has_causative_agent,903902,Pertussis is an acute respiratory disease of humans caused by the bacterium Bordetella pertussis,Bordetella pertussis,Pertussis
502912927,7/14/2014 12:44:53,,1322811284,7/14/2014 12:44:48,clixsense,1.0,24763049,GBR,"","",86.133.47.213,57,100,,,72,107,TYPE 2 DIABETES,INSULIN,factor for developing TYPE 2 DIABETES caused by the,35-42-46-57-62-64-73-80-83,83-87-97-100-108-115-123,the inability of INSULIN target tissues to,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity.",57 62 64,100,57,100,72,107,1,RO-may_treat,908348,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity",type 2 diabetes,insulin
502912927,7/14/2014 12:55:22,,1322818426,7/14/2014 12:54:46,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,57,100,,,72,107,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,57-62-64,100,INSULIN,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity.",57 62 64,100,57,100,72,107,1,RO-may_treat,908348,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity",type 2 diabetes,insulin
502912927,7/14/2014 12:57:23,,1322819734,7/14/2014 12:56:53,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,57,100,,,72,107,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,57-62-64,100,INSULIN,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity.",57 62 64,100,57,100,72,107,1,RO-may_treat,908348,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity",type 2 diabetes,insulin
502912927,7/14/2014 13:00:00,,1322821464,7/14/2014 12:59:41,gifthulk,1.0,25566511,USA,"","",24.164.11.173,57,100,,,72,107,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,57-62-64,100-108-115,INSULIN target tissues,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity.",57 62 64,100,57,100,72,107,1,RO-may_treat,908348,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity",type 2 diabetes,insulin
502912927,7/14/2014 13:13:40,,1322830671,7/14/2014 13:13:25,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,57,100,,,72,107,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,57-62-64,100,INSULIN,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity.",57 62 64,100,57,100,72,107,1,RO-may_treat,908348,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity",type 2 diabetes,insulin
502912927,7/14/2014 13:15:17,,1322831730,7/14/2014 13:15:14,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,57,100,,,72,107,TYPE 2 DIABETES,INSULIN,factor for developing TYPE 2 DIABETES caused by the,35-42-46-57-62-64-73-80-83,83-87-97-100-108-115-123,the inability of INSULIN target tissues to,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity.",57 62 64,100,57,100,72,107,1,RO-may_treat,908348,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity",type 2 diabetes,insulin
502912927,7/14/2014 13:21:14,,1322835706,7/14/2014 13:19:59,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,57,100,,,72,107,TYPE 2 DIABETES,INSULIN,factor for developing TYPE 2 DIABETES caused by the,35-42-46-57-62-64-73-80-83,83-87-97-100-115-123,the inability of INSULIN tissues to,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity.",57 62 64,100,57,100,72,107,1,RO-may_treat,908348,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity",type 2 diabetes,insulin
502912927,7/14/2014 13:40:03,,1322849077,7/14/2014 13:39:42,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,57,100,,,72,107,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,57-62-64,100,INSULIN,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity.",57 62 64,100,57,100,72,107,1,RO-may_treat,908348,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity",type 2 diabetes,insulin
502912927,7/14/2014 13:40:42,,1322849561,7/14/2014 13:40:39,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,57,100,,,72,107,TYPE 2 DIABETES,INSULIN,factor for developing TYPE 2 DIABETES caused by the,35-42-46-57-62-64-73-80-83,83-87-97-100-108-115-123,the inability of INSULIN target tissues to,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity.",57 62 64,100,57,100,72,107,1,RO-may_treat,908348,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity",type 2 diabetes,insulin
502912927,7/14/2014 13:42:57,,1322851201,7/14/2014 13:42:39,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,57,100,,,72,107,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,57-62-64,100,INSULIN,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity.",57 62 64,100,57,100,72,107,1,RO-may_treat,908348,"Insulin resistance is a major risk factor for developing type 2 diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity",type 2 diabetes,insulin
502912928,7/14/2014 12:52:10,,1322816267,7/14/2014 12:51:50,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,88,11,,,99,22,ANAPHYLAXIS,EPINEPHRINE,ANAPHYLAXIS,88,0-2-11-6,"1 , 108 EPINEPHRINE","1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs.",88,11,88,11,99,22,1,RO-may_treat,907651,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs",anaphylaxis,Epinephrine
502912928,7/14/2014 13:05:25,,1322824885,7/14/2014 13:05:06,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,88,11,,,99,22,ANAPHYLAXIS,EPINEPHRINE,Epinephrine ANAPHYLAXIS,88-11,2-11-88,", EPINEPHRINE anaphylaxis","1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs.",88,11,88,11,99,22,1,RO-may_treat,907651,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs",anaphylaxis,Epinephrine
502912928,7/14/2014 13:07:14,,1322826201,7/14/2014 13:06:35,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,88,11,,,99,22,ANAPHYLAXIS,EPINEPHRINE,Epinephrine ANAPHYLAXIS allergic reaction,11-88-117-126,11-88-117-126,EPINEPHRINE anaphylaxis allergic reaction,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs.",88,11,88,11,99,22,1,RO-may_treat,907651,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs",anaphylaxis,Epinephrine
502912928,7/14/2014 13:11:05,,1322828843,7/14/2014 13:10:40,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,88,11,,,99,22,ANAPHYLAXIS,EPINEPHRINE,ANAPHYLAXIS,88,11,EPINEPHRINE,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs.",88,11,88,11,99,22,1,RO-may_treat,907651,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs",anaphylaxis,Epinephrine
502912928,7/14/2014 13:13:48,,1322830760,7/14/2014 13:13:42,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,88,11,,,99,22,ANAPHYLAXIS,EPINEPHRINE,available in case ANAPHYLAXIS or other serious,70-80-83-88-100-103-109,0-2-6-11-23-27-33,"1 , 108 EPINEPHRINE and other appropriate","1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs.",88,11,88,11,99,22,1,RO-may_treat,907651,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs",anaphylaxis,Epinephrine
502912928,7/14/2014 13:24:40,,1322838218,7/14/2014 13:24:18,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,88,11,,,99,22,ANAPHYLAXIS,EPINEPHRINE,ANAPHYLAXIS,88,6-11,108 EPINEPHRINE,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs.",88,11,88,11,99,22,1,RO-may_treat,907651,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs",anaphylaxis,Epinephrine
502912928,7/14/2014 13:29:39,,1322841554,7/14/2014 13:29:02,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,88,11,,,99,22,ANAPHYLAXIS,EPINEPHRINE,available in case ANAPHYLAXIS or other serious,70-80-83-88-100-103-109,0-2-6-11-23-27-33,"1 , 108 EPINEPHRINE and other appropriate","1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs.",88,11,88,11,99,22,1,RO-may_treat,907651,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs",anaphylaxis,Epinephrine
502912928,7/14/2014 13:41:20,,1322849953,7/14/2014 13:40:56,clixsense,1.0,27969116,NLD,"","",91.213.37.165,88,11,,,99,22,ANAPHYLAXIS,EPINEPHRINE,ANAPHYLAXIS allergic reaction,88-117-126,2-11-45,", EPINEPHRINE agents","1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs.",88,11,88,11,99,22,1,RO-may_treat,907651,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs",anaphylaxis,Epinephrine
502912928,7/14/2014 13:50:40,,1322856856,7/14/2014 13:50:17,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,88,11,,,99,22,ANAPHYLAXIS,EPINEPHRINE,ANAPHYLAXIS,88,11,EPINEPHRINE,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs.",88,11,88,11,99,22,1,RO-may_treat,907651,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs",anaphylaxis,Epinephrine
502912928,7/14/2014 14:00:09,,1322863411,7/14/2014 13:59:50,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,88,11,,,99,22,ANAPHYLAXIS,EPINEPHRINE,ANAPHYLAXIS,88,11,EPINEPHRINE,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs.",88,11,88,11,99,22,1,RO-may_treat,907651,"1 ,   108  Epinephrine and other appropriate agents should be readily available in case anaphylaxis or other serious allergic reaction occurs",anaphylaxis,Epinephrine
502912929,7/14/2014 12:50:01,,1322814702,7/14/2014 12:47:18,bitcoinget,1,28371854,GBR,K9,Middlesbrough,79.170.75.76,107,30,,,114,63,ASCITES,MALIGNANT PERITONEAL MESOTHELIOMA,ASCITES of unknown origin.,107-115-118-126,22-30-40-51,diffuse MALIGNANT PERITONEAL MESOTHELIOMA,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin.,107,30 40 51,107,30,114,63,1,RO-disease_may_have_finding,902717,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin,ascites,malignant peritoneal mesothelioma
502912929,7/14/2014 12:54:26,,1322817865,7/14/2014 12:54:20,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,107,30,,,114,63,ASCITES,MALIGNANT PERITONEAL MESOTHELIOMA,in year man who presented ASCITES of unknown origin.,72-89-93-97-107-115-118-126-80,14-19-22-30-40-51-64-72-75-89-97,case of diffuse MALIGNANT PERITONEAL MESOTHELIOMA arising in a man presented,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin.,107,30 40 51,107,30,114,63,1,RO-disease_may_have_finding,902717,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin,ascites,malignant peritoneal mesothelioma
502912929,7/14/2014 13:11:50,,1322829375,7/14/2014 13:11:29,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,107,30,,,114,63,ASCITES,MALIGNANT PERITONEAL MESOTHELIOMA,ASCITES,107,30-40-51,MALIGNANT PERITONEAL MESOTHELIOMA,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin.,107,30 40 51,107,30,114,63,1,RO-disease_may_have_finding,902717,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin,ascites,malignant peritoneal mesothelioma
502912929,7/14/2014 13:13:58,,1322830838,7/14/2014 13:13:41,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,107,30,,,114,63,ASCITES,MALIGNANT PERITONEAL MESOTHELIOMA,ASCITES,107,30-40-51,MALIGNANT PERITONEAL MESOTHELIOMA,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin.,107,30 40 51,107,30,114,63,1,RO-disease_may_have_finding,902717,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin,ascites,malignant peritoneal mesothelioma
502912929,7/14/2014 13:19:46,,1322834775,7/14/2014 13:19:06,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,107,30,,,114,63,ASCITES,MALIGNANT PERITONEAL MESOTHELIOMA,diffuse malignant peritoneal mesothelioma ASCITES,22-30-40-51-107,22-30-40-51-107,diffuse MALIGNANT PERITONEAL MESOTHELIOMA ascites,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin.,107,30 40 51,107,30,114,63,1,RO-disease_may_have_finding,902717,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin,ascites,malignant peritoneal mesothelioma
502912929,7/14/2014 13:22:58,,1322837080,7/14/2014 13:22:26,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,107,30,,,114,63,ASCITES,MALIGNANT PERITONEAL MESOTHELIOMA,ASCITES,107,30-40-51,MALIGNANT PERITONEAL MESOTHELIOMA,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin.,107,30 40 51,107,30,114,63,1,RO-disease_may_have_finding,902717,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin,ascites,malignant peritoneal mesothelioma
502912929,7/14/2014 13:34:24,,1322844976,7/14/2014 13:34:04,clixsense,1.0,27969116,NLD,"","",91.213.37.165,107,30,,,114,63,ASCITES,MALIGNANT PERITONEAL MESOTHELIOMA,ASCITES,107,22-30-40-51,diffuse MALIGNANT PERITONEAL MESOTHELIOMA,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin.,107,30 40 51,107,30,114,63,1,RO-disease_may_have_finding,902717,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin,ascites,malignant peritoneal mesothelioma
502912929,7/14/2014 13:35:36,,1322845785,7/14/2014 13:35:12,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,107,30,,,114,63,ASCITES,MALIGNANT PERITONEAL MESOTHELIOMA,ASCITES of unknown origin.,107-118-126-115,14-19-22-30-40-51,case of diffuse MALIGNANT PERITONEAL MESOTHELIOMA,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin.,107,30 40 51,107,30,114,63,1,RO-disease_may_have_finding,902717,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin,ascites,malignant peritoneal mesothelioma
502912929,7/14/2014 13:40:20,,1322849346,7/14/2014 13:40:03,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,107,30,,,114,63,ASCITES,MALIGNANT PERITONEAL MESOTHELIOMA,ASCITES,107,30-40-51,MALIGNANT PERITONEAL MESOTHELIOMA,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin.,107,30 40 51,107,30,114,63,1,RO-disease_may_have_finding,902717,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin,ascites,malignant peritoneal mesothelioma
502912929,7/14/2014 13:46:48,,1322854059,7/14/2014 13:46:27,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,107,30,,,114,63,ASCITES,MALIGNANT PERITONEAL MESOTHELIOMA,presented ASCITES of unknown origin.,97-107-115-118-126,14-19-22-30-40-51,case of diffuse MALIGNANT PERITONEAL MESOTHELIOMA,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin.,107,30 40 51,107,30,114,63,1,RO-disease_may_have_finding,902717,We describe a case of diffuse malignant peritoneal mesothelioma arising in a 65-year old man who presented ascites of unknown origin,ascites,malignant peritoneal mesothelioma
502912930,7/14/2014 12:44:39,,1322811139,7/14/2014 12:44:31,clixsense,1.0,24763049,GBR,"","",86.133.47.213,66,103,,,71,111,BRAIN,EPILEPSY,alterations in the BRAIN on the age,47-59-62-66-72-75-79,83-86-100-103-112-116-129,of manifestation of EPILEPSY was investigated by,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",66,103,66,103,71,111,1,RO-disease_has_primary_anatomic_site,902366,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents",brain,epilepsy
502912930,7/14/2014 12:50:55,,1322815369,7/14/2014 12:50:44,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,66,103,,,71,111,BRAIN,EPILEPSY,BRAIN,66,103,EPILEPSY,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",66,103,66,103,71,111,1,RO-disease_has_primary_anatomic_site,902366,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents",brain,epilepsy
502912930,7/14/2014 13:19:20,,1322834403,7/14/2014 13:19:03,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,66,103,,,71,111,BRAIN,EPILEPSY,BRAIN,66,103,EPILEPSY,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",66,103,66,103,71,111,1,RO-disease_has_primary_anatomic_site,902366,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents",brain,epilepsy
502912930,7/14/2014 13:27:26,,1322840088,7/14/2014 13:26:42,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,66,103,,,71,111,BRAIN,EPILEPSY,alterations in the BRAIN on the age manifestation epilepsy,47-59-62-66-72-75-79-86-103,86-100-103-141-149-158-169,manifestation of EPILEPSY cranial computer tomography (CCT),"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",66,103,66,103,71,111,1,RO-disease_has_primary_anatomic_site,902366,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents",brain,epilepsy
502912930,7/14/2014 13:40:07,,1322849160,7/14/2014 13:39:55,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,66,103,,,71,111,BRAIN,EPILEPSY,BRAIN,66,103,EPILEPSY,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",66,103,66,103,71,111,1,RO-disease_has_primary_anatomic_site,902366,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents",brain,epilepsy
502912930,7/14/2014 13:42:43,,1322851001,7/14/2014 13:42:19,clixsense,1.0,27969116,NLD,"","",91.213.37.165,66,103,,,71,111,BRAIN,EPILEPSY,organic alterations in the BRAIN on the age of manifestation of epilepsy,39-47-59-62-66-72-75-79-83-86-103-100,83-86-100-103,of manifestation of EPILEPSY,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",66,103,66,103,71,111,1,RO-disease_has_primary_anatomic_site,902366,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents",brain,epilepsy
502912930,7/14/2014 13:48:35,,1322855402,7/14/2014 13:47:35,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,66,103,,,71,111,BRAIN,EPILEPSY,BRAIN,66,103,EPILEPSY,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",66,103,66,103,71,111,1,RO-disease_has_primary_anatomic_site,902366,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents",brain,epilepsy
502912930,7/14/2014 14:47:48,,1322896108,7/14/2014 14:47:34,prodege,1.0,28209666,,,"",24.156.173.34,66,103,,,71,111,BRAIN,EPILEPSY,BRAIN,66,103,EPILEPSY,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",66,103,66,103,71,111,1,RO-disease_has_primary_anatomic_site,902366,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents",brain,epilepsy
502912930,7/14/2014 14:49:22,,1322896939,7/14/2014 14:49:07,instagc,1.0,13763729,USA,"","",75.182.89.225,66,103,,,71,111,BRAIN,EPILEPSY,BRAIN,66,103,EPILEPSY,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",66,103,66,103,71,111,1,RO-disease_has_primary_anatomic_site,902366,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents",brain,epilepsy
502912930,7/14/2014 14:50:28,,1322897646,7/14/2014 14:50:11,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,66,103,,,71,111,BRAIN,EPILEPSY,BRAIN,66,103,EPILEPSY,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",66,103,66,103,71,111,1,RO-disease_has_primary_anatomic_site,902366,"In the present study, the influence of organic alterations in the brain on the age of manifestation of epilepsy was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents",brain,epilepsy
502912931,7/14/2014 13:00:47,,1322821965,7/14/2014 13:00:37,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,59,0,,,63,10,PAIN,GABAPENTIN,PAIN,59,0,GABAPENTIN,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus.,59,0,59,0,63,10,1,RO-may_treat,908302,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus,pain,Gabapentin
502912931,7/14/2014 13:20:35,,1322835256,7/14/2014 13:20:09,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,59,0,,,63,10,PAIN,GABAPENTIN,PAIN,59,0,GABAPENTIN,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus.,59,0,59,0,63,10,1,RO-may_treat,908302,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus,pain,Gabapentin
502912931,7/14/2014 13:31:13,,1322842573,7/14/2014 13:30:28,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,59,0,,,63,10,PAIN,GABAPENTIN,the treatment of PAIN associated with phantom,42-46-56-59-64-75-80,0-11-15-29,GABAPENTIN was significantly effective,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus.,59,0,59,0,63,10,1,RO-may_treat,908302,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus,pain,Gabapentin
502912931,7/14/2014 13:40:48,,1322849664,7/14/2014 13:40:46,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,59,0,,,63,10,PAIN,GABAPENTIN,the treatment of PAIN associated with phantom,42-46-56-59-64-75-80,0-11-15-29,GABAPENTIN was significantly effective,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus.,59,0,59,0,63,10,1,RO-may_treat,908302,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus,pain,Gabapentin
502912931,7/14/2014 13:44:24,,1322852290,7/14/2014 13:44:11,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,59,0,,,63,10,PAIN,GABAPENTIN,PAIN,59,0,GABAPENTIN,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus.,59,0,59,0,63,10,1,RO-may_treat,908302,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus,pain,Gabapentin
502912931,7/14/2014 13:47:56,,1322855023,7/14/2014 13:47:43,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,59,0,,,63,10,PAIN,GABAPENTIN,PAIN,59,0,GABAPENTIN,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus.,59,0,59,0,63,10,1,RO-may_treat,908302,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus,pain,Gabapentin
502912931,7/14/2014 13:59:49,,1322863227,7/14/2014 13:59:29,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,59,0,,,63,10,PAIN,GABAPENTIN,PAIN,59,0,GABAPENTIN,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus.,59,0,59,0,63,10,1,RO-may_treat,908302,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus,pain,Gabapentin
502912931,7/14/2014 14:29:40,,1322883847,7/14/2014 14:29:37,instagc,1.0,27753923,GBR,"","",188.30.192.65,59,0,,,63,10,PAIN,GABAPENTIN,the treatment of PAIN associated with phantom,42-46-56-59-64-75-80,0-11-15-29,GABAPENTIN was significantly effective,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus.,59,0,59,0,63,10,1,RO-may_treat,908302,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus,pain,Gabapentin
502912931,7/14/2014 14:41:03,,1322891767,7/14/2014 14:40:58,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,59,0,,,63,10,PAIN,GABAPENTIN,the treatment of PAIN associated with phantom,42-46-56-59-64-75-80,0-11-15-29,GABAPENTIN was significantly effective,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus.,59,0,59,0,63,10,1,RO-may_treat,908302,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus,pain,Gabapentin
502912931,7/14/2014 14:42:29,,1322892722,7/14/2014 14:42:18,prodege,1.0,28209666,,,"",24.156.173.34,59,0,,,63,10,PAIN,GABAPENTIN,PAIN,59,0,GABAPENTIN,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus.,59,0,59,0,63,10,1,RO-may_treat,908302,Gabapentin was significantly effective in the treatment of pain associated with phantom limb pain after amputation and traumatic avulsion of the brachial plexus,pain,Gabapentin
502912932,7/14/2014 12:46:29,,1322812334,7/14/2014 12:46:11,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,152,185,,,158,193,VESSEL,ISCHEMIA,rat four VESSEL occlusion model of global ischemia.,143-147-152-159-169-175-178-185,178-185,global ISCHEMIA.,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia.,152,185,152,185,158,193,1,RO-has_finding_site,905062,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia,vessel,ischemia
502912932,7/14/2014 13:08:07,,1322826878,7/14/2014 13:07:24,gifthulk,1.0,25566511,USA,"","",24.164.11.173,152,185,,,158,193,VESSEL,ISCHEMIA,VESSEL occlusion,152-159,185,ISCHEMIA.,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia.,152,185,152,185,158,193,1,RO-has_finding_site,905062,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia,vessel,ischemia
502912932,7/14/2014 13:10:24,,1322828499,7/14/2014 13:09:45,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,152,185,,,158,193,VESSEL,ISCHEMIA,VESSEL,152,185,ISCHEMIA.,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia.,152,185,152,185,158,193,1,RO-has_finding_site,905062,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia,vessel,ischemia
502912932,7/14/2014 13:13:24,,1322830531,7/14/2014 13:13:03,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,152,185,,,158,193,VESSEL,ISCHEMIA,rat four VESSEL occlusion model,147-152-159-169-143,185-178,global ISCHEMIA.,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia.,152,185,152,185,158,193,1,RO-has_finding_site,905062,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia,vessel,ischemia
502912932,7/14/2014 13:16:31,,1322832643,7/14/2014 13:16:08,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,152,185,,,158,193,VESSEL,ISCHEMIA,four VESSEL occlusion,147-152-159,185,ISCHEMIA.,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia.,152,185,152,185,158,193,1,RO-has_finding_site,905062,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia,vessel,ischemia
502912932,7/14/2014 13:21:24,,1322835898,7/14/2014 13:20:55,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,152,185,,,158,193,VESSEL,ISCHEMIA,four VESSEL occlusion,147-152-159,185,ISCHEMIA.,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia.,152,185,152,185,158,193,1,RO-has_finding_site,905062,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia,vessel,ischemia
502912932,7/14/2014 13:27:16,,1322839933,7/14/2014 13:26:44,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,152,185,,,158,193,VESSEL,ISCHEMIA,the rat four VESSEL occlusion model of global ischemia.,139-143-147-152-159-169-175-178-185,143-147-152-169-175-178-185-159,rat four vessel occlusion model of global ISCHEMIA.,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia.,152,185,152,185,158,193,1,RO-has_finding_site,905062,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia,vessel,ischemia
502912932,7/14/2014 13:45:39,,1322853046,7/14/2014 13:45:25,elite,1.0,26544151,GBR,"","",188.29.127.144,152,185,,,158,193,VESSEL,ISCHEMIA,VESSEL,152,185,ISCHEMIA.,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia.,152,185,152,185,158,193,1,RO-has_finding_site,905062,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia,vessel,ischemia
502912932,7/14/2014 13:53:35,,1322859013,7/14/2014 13:53:17,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,152,185,,,158,193,VESSEL,ISCHEMIA,VESSEL,152,185,ISCHEMIA.,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia.,152,185,152,185,158,193,1,RO-has_finding_site,905062,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia,vessel,ischemia
502912932,7/14/2014 13:56:01,,1322860691,7/14/2014 13:55:39,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,152,185,,,158,193,VESSEL,ISCHEMIA,four VESSEL occlusion model,147-152-159-169,178-185,global ISCHEMIA.,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia.,152,185,152,185,158,193,1,RO-has_finding_site,905062,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the rat four-vessel occlusion model of global ischemia,vessel,ischemia
502912933,7/14/2014 12:47:09,,1322812781,7/14/2014 12:47:04,clixsense,1.0,24763049,GBR,"","",86.133.47.213,173,114,,,180,132,ALLERGY,ALLERGIC REACTIONS,beekeepers with previous ALLERGY stings) and,148-159-164-173-187-195,87-98-103-114-123-139-148,"beekeepers with persistent ALLERGIC REACTIONS stings), beekeepers","We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings.",173,114 123,173,114,180,132,-1,RO-cause_of,900243,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings",allergy,allergic reactions
502912933,7/14/2014 12:59:11,,1322820973,7/14/2014 12:58:49,gifthulk,1.0,25566511,USA,"","",24.164.11.173,173,114,,,180,132,ALLERGY,ALLERGIC REACTIONS,ALLERGY,173,114-123,ALLERGIC REACTIONS,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings.",173,114 123,173,114,180,132,-1,RO-cause_of,900243,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings",allergy,allergic reactions
502912933,7/14/2014 13:09:17,,1322827669,7/14/2014 13:08:58,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,173,114,,,180,132,ALLERGY,ALLERGIC REACTIONS,ALLERGY,173,114-123,ALLERGIC REACTIONS,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings.",173,114 123,173,114,180,132,-1,RO-cause_of,900243,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings",allergy,allergic reactions
502912933,7/14/2014 13:16:07,,1322832333,7/14/2014 13:15:48,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,173,114,,,180,132,ALLERGY,ALLERGIC REACTIONS,ALLERGY,173,114-123,ALLERGIC REACTIONS,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings.",173,114 123,173,114,180,132,-1,RO-cause_of,900243,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings",allergy,allergic reactions
502912933,7/14/2014 13:30:09,,1322841918,7/14/2014 13:29:20,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,173,114,,,180,132,ALLERGY,ALLERGIC REACTIONS,beekeepers with previous ALLERGY stings),148-159-164-173-187,87-98-103-114-123-139-148-133,"beekeepers with persistent ALLERGIC REACTIONS (17.5 stings), beekeepers","We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings.",173,114 123,173,114,180,132,-1,RO-cause_of,900243,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings",allergy,allergic reactions
502912933,7/14/2014 13:40:38,,1322849530,7/14/2014 13:40:35,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,173,114,,,180,132,ALLERGY,ALLERGIC REACTIONS,beekeepers with previous ALLERGY stings) and,148-159-164-173-187-195,87-98-103-114-123-139-148,"beekeepers with persistent ALLERGIC REACTIONS stings), beekeepers","We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings.",173,114 123,173,114,180,132,-1,RO-cause_of,900243,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings",allergy,allergic reactions
502912933,7/14/2014 14:19:52,,1322876707,7/14/2014 14:19:46,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,173,114,,,180,132,ALLERGY,ALLERGIC REACTIONS,beekeepers with previous ALLERGY stings) and,148-159-164-173-187-195,87-98-103-114-123-139-148,"beekeepers with persistent ALLERGIC REACTIONS stings), beekeepers","We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings.",173,114 123,173,114,180,132,-1,RO-cause_of,900243,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings",allergy,allergic reactions
502912933,7/14/2014 14:39:41,,1322890835,7/14/2014 14:39:35,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,173,114,,,180,132,ALLERGY,ALLERGIC REACTIONS,beekeepers with previous ALLERGY stings) and,148-159-164-173-187-195,87-98-103-114-123-139-148,"beekeepers with persistent ALLERGIC REACTIONS stings), beekeepers","We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings.",173,114 123,173,114,180,132,-1,RO-cause_of,900243,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings",allergy,allergic reactions
502912933,7/14/2014 14:46:09,,1322895128,7/14/2014 14:45:57,prodege,1.0,28209666,,,"",24.156.173.34,173,114,,,180,132,ALLERGY,ALLERGIC REACTIONS,ALLERGY,173,114-123,ALLERGIC REACTIONS,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings.",173,114 123,173,114,180,132,-1,RO-cause_of,900243,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings",allergy,allergic reactions
502912933,7/14/2014 14:48:04,,1322896233,7/14/2014 14:47:57,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,173,114,,,180,132,ALLERGY,ALLERGIC REACTIONS,ALLERGY,173,114-123,ALLERGIC REACTIONS,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings.",173,114 123,173,114,180,132,-1,RO-cause_of,900243,"We also found significant differences about the number of stings received in a year by beekeepers with persistent allergic reactions (17.5 stings), beekeepers with previous allergy (89.8 stings) and immune subjects (126.9 stings",allergy,allergic reactions
502912934,7/14/2014 13:15:30,,1322831845,7/14/2014 13:15:25,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,29,72,,,47,96,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME,patients with peripheral PRECOCIOUS PUBERTY included six girls,4-13-18-29-40-48-57-61,57-61-67-72-79-88-97-101-105,six girls with MCCUNE ALBRIGHT SYNDROME and six boys,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty.,29 40,72 79 88,29,72,47,96,1,RO-disease_has_finding,901705,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty,precocious puberty,McCune-Albright syndrome
502912934,7/14/2014 13:15:40,,1322832003,7/14/2014 13:15:11,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,29,72,,,47,96,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME,PRECOCIOUS PUBERTY,29-40,72-79-88,MCCUNE ALBRIGHT SYNDROME,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty.,29 40,72 79 88,29,72,47,96,1,RO-disease_has_finding,901705,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty,precocious puberty,McCune-Albright syndrome
502912934,7/14/2014 13:30:40,,1322842271,7/14/2014 13:29:52,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,29,72,,,47,96,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME,peripheral PRECOCIOUS PUBERTY McCune Albright syndrome male precocious puberty.,18-29-40-72-79-88-124-129-140,18-29-72-79-88-124-129-140-40,peripheral precocious puberty MCCUNE ALBRIGHT SYNDROME male precocious puberty.,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty.,29 40,72 79 88,29,72,47,96,1,RO-disease_has_finding,901705,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty,precocious puberty,McCune-Albright syndrome
502912934,7/14/2014 13:40:08,,1322849162,7/14/2014 13:40:06,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,29,72,,,47,96,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME,patients with peripheral PRECOCIOUS PUBERTY included six girls,4-13-18-29-40-48-57-61,57-61-67-72-79-88-97-101-105,six girls with MCCUNE ALBRIGHT SYNDROME and six boys,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty.,29 40,72 79 88,29,72,47,96,1,RO-disease_has_finding,901705,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty,precocious puberty,McCune-Albright syndrome
502912934,7/14/2014 13:40:30,,1322849449,7/14/2014 13:40:07,clixsense,1,27969116,NLD,"","",91.213.37.165,29,72,,,47,96,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME,PRECOCIOUS PUBERTY McCune Albright syndrome,29-40-72-79-88,72-79-88-129-140,MCCUNE ALBRIGHT SYNDROME precocious puberty.,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty.,29 40,72 79 88,29,72,47,96,1,RO-disease_has_finding,901705,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty,precocious puberty,McCune-Albright syndrome
502912934,7/14/2014 13:50:16,,1322856576,7/14/2014 13:49:53,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,29,72,,,47,96,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME,PRECOCIOUS PUBERTY,29-40,72-79-88,MCCUNE ALBRIGHT SYNDROME,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty.,29 40,72 79 88,29,72,47,96,1,RO-disease_has_finding,901705,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty,precocious puberty,McCune-Albright syndrome
502912934,7/14/2014 14:21:56,,1322878259,7/14/2014 14:21:50,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,29,72,,,47,96,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME,patients with peripheral PRECOCIOUS PUBERTY included six girls,4-13-18-29-40-48-57-61,57-61-67-72-79-88-97-101-105,six girls with MCCUNE ALBRIGHT SYNDROME and six boys,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty.,29 40,72 79 88,29,72,47,96,1,RO-disease_has_finding,901705,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty,precocious puberty,McCune-Albright syndrome
502912934,7/14/2014 14:37:41,,1322889422,7/14/2014 14:36:59,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,29,72,,,47,96,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME,patients with peripheral PRECOCIOUS PUBERTY included six girls with McCune Albright syndrome,4-13-18-29-40-48-57-61-67-72-79-88,57-61-67-72-79-88-97-101-105-110-115-124-129-140,six girls with MCCUNE ALBRIGHT SYNDROME and six boys with familial male precocious puberty.,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty.,29 40,72 79 88,29,72,47,96,1,RO-disease_has_finding,901705,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty,precocious puberty,McCune-Albright syndrome
502912934,7/14/2014 14:41:16,,1322891864,7/14/2014 14:40:55,prodege,1.0,28209666,,,"",24.156.173.34,29,72,,,47,96,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME,peripheral PRECOCIOUS PUBERTY,18-29-40,72-79-88,MCCUNE ALBRIGHT SYNDROME,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty.,29 40,72 79 88,29,72,47,96,1,RO-disease_has_finding,901705,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty,precocious puberty,McCune-Albright syndrome
502912934,7/14/2014 14:48:52,,1322896680,7/14/2014 14:48:39,instagc,1,13763729,USA,"","",75.182.89.225,29,72,,,47,96,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME,PRECOCIOUS PUBERTY,29-40,72-79-88,MCCUNE ALBRIGHT SYNDROME,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty.,29 40,72 79 88,29,72,47,96,1,RO-disease_has_finding,901705,The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty,precocious puberty,McCune-Albright syndrome
502912935,7/14/2014 12:50:28,,1322815019,7/14/2014 12:50:14,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,23,109,,,42,119,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE (PD),23-35-43,109-120,AMANTADINE treatment.,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment.,23 35,109,23,109,42,119,1,RO-may_treat,908349,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment,Parkinson's disease,amantadine
502912935,7/14/2014 13:04:10,,1322824205,7/14/2014 13:01:58,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,23,109,,,42,119,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE,23-35,109,AMANTADINE,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment.,23 35,109,23,109,42,119,1,RO-may_treat,908349,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment,Parkinson's disease,amantadine
502912935,7/14/2014 13:09:41,,1322827951,7/14/2014 13:09:27,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,23,109,,,42,119,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE (PD),23-35-43,109,AMANTADINE,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment.,23 35,109,23,109,42,119,1,RO-may_treat,908349,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment,Parkinson's disease,amantadine
502912935,7/14/2014 13:09:50,,1322828031,7/14/2014 13:09:38,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,23,109,,,42,119,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE,23-35,109,AMANTADINE,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment.,23 35,109,23,109,42,119,1,RO-may_treat,908349,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment,Parkinson's disease,amantadine
502912935,7/14/2014 13:20:10,,1322834996,7/14/2014 13:19:54,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,23,109,,,42,119,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE,23-35,109,AMANTADINE,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment.,23 35,109,23,109,42,119,1,RO-may_treat,908349,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment,Parkinson's disease,amantadine
502912935,7/14/2014 13:30:45,,1322842324,7/14/2014 13:30:28,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,23,109,,,42,119,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE (PD),23-35-43,95-106-109-120,initiation of AMANTADINE treatment.,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment.,23 35,109,23,109,42,119,1,RO-may_treat,908349,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment,Parkinson's disease,amantadine
502912935,7/14/2014 13:39:52,,1322848974,7/14/2014 13:39:41,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,23,109,,,42,119,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE (PD),23-35-43,109,AMANTADINE,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment.,23 35,109,23,109,42,119,1,RO-may_treat,908349,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment,Parkinson's disease,amantadine
502912935,7/14/2014 14:20:58,,1322877530,7/14/2014 14:20:54,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,23,109,,,42,119,PARKINSON'S DISEASE,AMANTADINE,old man with PARKINSON'S DISEASE developed sudden,10-14-18-23-35-48-58,89-95-106-109-120,after initiation of AMANTADINE treatment.,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment.,23 35,109,23,109,42,119,1,RO-may_treat,908349,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment,Parkinson's disease,amantadine
502912935,7/14/2014 14:31:20,,1322885103,7/14/2014 14:31:17,instagc,1.0,27753923,GBR,"","",188.30.192.65,23,109,,,42,119,PARKINSON'S DISEASE,AMANTADINE,old man with PARKINSON'S DISEASE developed sudden,10-14-18-23-35-48-58,89-95-106-109-120,after initiation of AMANTADINE treatment.,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment.,23 35,109,23,109,42,119,1,RO-may_treat,908349,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment,Parkinson's disease,amantadine
502912935,7/14/2014 14:39:25,,1322890629,7/14/2014 14:39:05,prodege,1.0,28209666,,,"",24.156.173.34,23,109,,,42,119,PARKINSON'S DISEASE,AMANTADINE,PARKINSON'S DISEASE,23-35,109,AMANTADINE,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment.,23 35,109,23,109,42,119,1,RO-may_treat,908349,A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment,Parkinson's disease,amantadine
502912936,7/14/2014 13:04:44,,1322824532,7/14/2014 13:04:12,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,0,67,,,6,89,BREAST,INVASIVE BREAST CANCER,BREAST CANCER situ,0-7-143,0-67-76-83-96-7,BREAST CANCER INVASIVE BREAST CANCER be,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",0,67 76 83,0,67,6,89,1,RO-disease_has_primary_anatomic_site,902286,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease",BREAST,invasive breast cancer
502912936,7/14/2014 13:09:44,,1322827990,7/14/2014 13:09:12,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,0,67,,,6,89,BREAST,INVASIVE BREAST CANCER,BREAST,0,67-76-83,INVASIVE BREAST CANCER,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",0,67 76 83,0,67,6,89,1,RO-disease_has_primary_anatomic_site,902286,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease",BREAST,invasive breast cancer
502912936,7/14/2014 13:10:44,,1322828675,7/14/2014 13:09:34,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,0,67,,,6,89,BREAST,INVASIVE BREAST CANCER,BREAST CANCER,0-7,67-76-83,INVASIVE BREAST CANCER,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",0,67 76 83,0,67,6,89,1,RO-disease_has_primary_anatomic_site,902286,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease",BREAST,invasive breast cancer
502912936,7/14/2014 13:35:22,,1322845547,7/14/2014 13:35:08,clixsense,1.0,27969116,NLD,"","",91.213.37.165,0,67,,,6,89,BREAST,INVASIVE BREAST CANCER,BREAST CANCER,0-7,67-76-83,INVASIVE BREAST CANCER,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",0,67 76 83,0,67,6,89,1,RO-disease_has_primary_anatomic_site,902286,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease",BREAST,invasive breast cancer
502912936,7/14/2014 13:42:52,,1322851071,7/14/2014 13:42:20,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,0,67,,,6,89,BREAST,INVASIVE BREAST CANCER,BREAST,0,67-76-83,INVASIVE BREAST CANCER,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",0,67 76 83,0,67,6,89,1,RO-disease_has_primary_anatomic_site,902286,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease",BREAST,invasive breast cancer
502912936,7/14/2014 13:45:18,,1322852902,7/14/2014 13:44:55,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,0,67,,,6,89,BREAST,INVASIVE BREAST CANCER,BREAST CANCER,0-7,67-76-83,INVASIVE BREAST CANCER,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",0,67 76 83,0,67,6,89,1,RO-disease_has_primary_anatomic_site,902286,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease",BREAST,invasive breast cancer
502912936,7/14/2014 14:05:05,,1322866852,7/14/2014 14:04:46,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,0,67,,,6,89,BREAST,INVASIVE BREAST CANCER,BREAST CANCER,0-7,67-76-83,INVASIVE BREAST CANCER,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",0,67 76 83,0,67,6,89,1,RO-disease_has_primary_anatomic_site,902286,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease",BREAST,invasive breast cancer
502912936,7/14/2014 14:40:10,,1322891181,7/14/2014 14:39:58,prodege,1.0,28209666,,,"",24.156.173.34,0,67,,,6,89,BREAST,INVASIVE BREAST CANCER,BREAST CANCER,0-7,67-76-83,INVASIVE BREAST CANCER,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",0,67 76 83,0,67,6,89,1,RO-disease_has_primary_anatomic_site,902286,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease",BREAST,invasive breast cancer
502912936,7/14/2014 14:44:26,,1322894027,7/14/2014 14:44:15,instagc,1.0,13763729,USA,"","",75.182.89.225,0,67,,,6,89,BREAST,INVASIVE BREAST CANCER,BREAST CANCER,0-7,67-76-83,INVASIVE BREAST CANCER,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",0,67 76 83,0,67,6,89,1,RO-disease_has_primary_anatomic_site,902286,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease",BREAST,invasive breast cancer
502912936,7/14/2014 14:48:20,,1322896388,7/14/2014 14:48:13,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,0,67,,,6,89,BREAST,INVASIVE BREAST CANCER,BREAST CANCER,0-7,67-76-83,INVASIVE BREAST CANCER,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",0,67 76 83,0,67,6,89,1,RO-disease_has_primary_anatomic_site,902286,"BREAST CANCER  It was predicted that in the United States in 2007, invasive breast cancer would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease",BREAST,invasive breast cancer
502912937,7/14/2014 12:45:56,,1322811927,7/14/2014 12:45:50,clixsense,1.0,24763049,GBR,"","",86.133.47.213,89,97,,,93,117,PAIN,TRIGEMINAL NEURALGIA,compared with the PAIN of trigeminal neuralgia,71-80-85-89-94-97-108,85-89-94-97-108-118-122-131,the pain of TRIGEMINAL NEURALGIA and possible similar,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms.,89,97 108,89,97,93,117,-1,RO-has_definitional_manifestation,904743,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms,pain,trigeminal neuralgia
502912937,7/14/2014 12:57:59,,1322820118,7/14/2014 12:55:25,gifthulk,1.0,25566511,USA,"","",24.164.11.173,89,97,,,93,117,PAIN,TRIGEMINAL NEURALGIA,PAIN of trigeminal neuralgia,89-94-97-108,97-108,TRIGEMINAL NEURALGIA,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms.,89,97 108,89,97,93,117,-1,RO-has_definitional_manifestation,904743,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms,pain,trigeminal neuralgia
502912937,7/14/2014 13:11:39,,1322829212,7/14/2014 13:11:25,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,89,97,,,93,117,PAIN,TRIGEMINAL NEURALGIA,PAIN,89,97-108,TRIGEMINAL NEURALGIA,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms.,89,97 108,89,97,93,117,-1,RO-has_definitional_manifestation,904743,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms,pain,trigeminal neuralgia
502912937,7/14/2014 13:37:30,,1322847233,7/14/2014 13:37:12,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,89,97,,,93,117,PAIN,TRIGEMINAL NEURALGIA,the PAIN of trigeminal neuralgia,89-94-97-108-85,85-89-94-97-108-118-122-131-139-152,the pain of TRIGEMINAL NEURALGIA and possible similar pathogenetic mechanisms.,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms.,89,97 108,89,97,93,117,-1,RO-has_definitional_manifestation,904743,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms,pain,trigeminal neuralgia
502912937,7/14/2014 13:44:33,,1322852363,7/14/2014 13:42:14,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,89,97,,,93,117,PAIN,TRIGEMINAL NEURALGIA,PAIN trigeminal neuralgia,89-97-108,97-108,TRIGEMINAL NEURALGIA,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms.,89,97 108,89,97,93,117,-1,RO-has_definitional_manifestation,904743,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms,pain,trigeminal neuralgia
502912937,7/14/2014 13:49:22,,1322856009,7/14/2014 13:49:08,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,89,97,,,93,117,PAIN,TRIGEMINAL NEURALGIA,PAIN,89,97-108,TRIGEMINAL NEURALGIA,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms.,89,97 108,89,97,93,117,-1,RO-has_definitional_manifestation,904743,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms,pain,trigeminal neuralgia
502912937,7/14/2014 13:52:01,,1322857925,7/14/2014 13:51:46,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,89,97,,,93,117,PAIN,TRIGEMINAL NEURALGIA,PAIN,89,97-108,TRIGEMINAL NEURALGIA,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms.,89,97 108,89,97,93,117,-1,RO-has_definitional_manifestation,904743,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms,pain,trigeminal neuralgia
502912937,7/14/2014 13:54:24,,1322859611,7/14/2014 13:54:08,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,89,97,,,93,117,PAIN,TRIGEMINAL NEURALGIA,PAIN of trigeminal neuralgia,89-94-97-108,97-108,TRIGEMINAL NEURALGIA,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms.,89,97 108,89,97,93,117,-1,RO-has_definitional_manifestation,904743,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms,pain,trigeminal neuralgia
502912937,7/14/2014 14:21:52,,1322878206,7/14/2014 14:21:46,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,89,97,,,93,117,PAIN,TRIGEMINAL NEURALGIA,compared with the PAIN of trigeminal neuralgia,71-80-85-89-94-97-108,85-89-94-97-108-118-122-131,the pain of TRIGEMINAL NEURALGIA and possible similar,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms.,89,97 108,89,97,93,117,-1,RO-has_definitional_manifestation,904743,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms,pain,trigeminal neuralgia
502912937,7/14/2014 14:40:47,,1322891552,7/14/2014 14:40:42,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,89,97,,,93,117,PAIN,TRIGEMINAL NEURALGIA,compared with the PAIN of trigeminal neuralgia,71-80-85-89-94-97-108,85-89-94-97-108-118-122-131,the pain of TRIGEMINAL NEURALGIA and possible similar,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms.,89,97 108,89,97,93,117,-1,RO-has_definitional_manifestation,904743,The characteristic of this patient's pain is compared with the pain is compared with the pain of trigeminal neuralgia and possible similar pathogenetic mechanisms,pain,trigeminal neuralgia
502912938,7/14/2014 12:45:37,,1322811793,7/14/2014 12:45:32,clixsense,1.0,24763049,GBR,"","",86.133.47.213,177,98,,,195,102,MENTAL RETARDATION,HSAS,"Sylvius), MASA (MENTAL RETARDATION, Aphasia, Shuffling gait,",161-171-176-184-197-206-216,75-77-84-98-118-121,X linked hydrocephalus HSAS as a,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC.",184,98,177,98,195,102,-1,RO-has_manifestation,906021,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC",Mental retardation,HSAS
502912938,7/14/2014 12:54:11,,1322817664,7/14/2014 12:54:06,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,177,98,,,195,102,MENTAL RETARDATION,HSAS,"Sylvius), MASA (MENTAL RETARDATION, Aphasia, Shuffling gait, syndrome,",161-171-176-184-197-206-216-243,75-77-84-98-118-121-103,X linked hydrocephalus HSAS (Hydrocephalus as a,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC.",184,98,177,98,195,102,-1,RO-has_manifestation,906021,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC",Mental retardation,HSAS
502912938,7/14/2014 13:00:15,,1322821667,7/14/2014 12:59:51,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,177,98,,,195,102,MENTAL RETARDATION,HSAS,"(MENTAL RETARDATION,",176-184,75-76-77-84-98,X - linked hydrocephalus HSAS,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC.",184,98,177,98,195,102,-1,RO-has_manifestation,906021,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC",Mental retardation,HSAS
502912938,7/14/2014 13:12:23,,1322829706,7/14/2014 13:10:48,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,177,98,,,195,102,MENTAL RETARDATION,HSAS,"L1CAM X linked hydrocephalus HSAS (Hydrocephalus Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION, Aphasia, Agenesis of the Corpus Callosum",17-75-77-84-98-103-133-142-145-149-161-171-176-184-197-320-329-332-336-343-158,17-75-77-84-98-103-133-142-145-149-158-161-171-176-184-197-320-329-332-336-343,"L1CAM X linked hydrocephalus HSAS (Hydrocephalus Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Agenesis of the Corpus Callosum","Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC.",184,98,177,98,195,102,-1,RO-has_manifestation,906021,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC",Mental retardation,HSAS
502912938,7/14/2014 13:14:29,,1322831199,7/14/2014 13:14:06,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,177,98,,,195,102,MENTAL RETARDATION,HSAS,"(MENTAL RETARDATION,",176-184,98,HSAS,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC.",184,98,177,98,195,102,-1,RO-has_manifestation,906021,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC",Mental retardation,HSAS
502912938,7/14/2014 13:42:39,,1322851000,7/14/2014 13:41:56,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,177,98,,,195,102,MENTAL RETARDATION,HSAS,"(MENTAL RETARDATION, Aphasia, Shuffling gait, and Adducted thumbs)",176-184-197-206-216-222-226-235,75-77-84-98,X linked hydrocephalus HSAS,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC.",184,98,177,98,195,102,-1,RO-has_manifestation,906021,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC",Mental retardation,HSAS
502912938,7/14/2014 13:51:09,,1322857262,7/14/2014 13:50:41,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,177,98,,,195,102,MENTAL RETARDATION,HSAS,"RETARDATION,",184,98,HSAS,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC.",184,98,177,98,195,102,-1,RO-has_manifestation,906021,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC",Mental retardation,HSAS
502912938,7/14/2014 14:23:08,,1322878972,7/14/2014 14:22:43,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,177,98,,,195,102,MENTAL RETARDATION,HSAS,"(MENTAL RETARDATION,",176-184,98-176-184,"HSAS (Mental retardation,","Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC.",184,98,177,98,195,102,-1,RO-has_manifestation,906021,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC",Mental retardation,HSAS
502912938,7/14/2014 14:39:12,,1322890466,7/14/2014 14:38:52,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,177,98,,,195,102,MENTAL RETARDATION,HSAS,"MASA (MENTAL RETARDATION,",171-176-184,75-77-84-98,X linked hydrocephalus HSAS,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC.",184,98,177,98,195,102,-1,RO-has_manifestation,906021,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC",Mental retardation,HSAS
502912938,7/14/2014 14:45:33,,1322894781,7/14/2014 14:45:18,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,177,98,,,195,102,MENTAL RETARDATION,HSAS,"RETARDATION,",184,98,HSAS,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC.",184,98,177,98,195,102,-1,RO-has_manifestation,906021,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X-linked hydrocephalus/HSAS (Hydrocephalus as a result of Stenosis of the Aqueduct of Sylvius), MASA (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X-linked complicated spastic paraplegia type I (SPG1) and X-linked Agenesis of the Corpus Callosum (ACC",Mental retardation,HSAS
502912939,7/14/2014 12:52:34,,1322816516,7/14/2014 12:52:08,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,125,48,,,150,61,COMPLICATION OF PREGNANCY,PRE-ECLAMPTIC,COMPLICATION OF PREGNANCY.,125-138-141,48-52,PRE ECLAMPTIC,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy.",125 138 141,48 52,125,48,150,61,-1,RO-disease_has_finding,901512,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy",complication of pregnancy,pre-eclamptic
502912939,7/14/2014 13:09:52,,1322828086,7/14/2014 13:09:29,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,125,48,,,150,61,COMPLICATION OF PREGNANCY,PRE-ECLAMPTIC,postpartum eclampsia pre eclamptic COMPLICATION OF PREGNANCY.,5-16-52-125-138-141-48,5-16-48-52-68-76-92,"postpartum eclampsia PRE ECLAMPTIC oedema, proteinuria hypertension","Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy.",125 138 141,48 52,125,48,150,61,-1,RO-disease_has_finding,901512,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy",complication of pregnancy,pre-eclamptic
502912939,7/14/2014 13:14:56,,1322831464,7/14/2014 13:14:32,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,125,48,,,150,61,COMPLICATION OF PREGNANCY,PRE-ECLAMPTIC,COMPLICATION OF PREGNANCY.,125-138-141,48-52,PRE ECLAMPTIC,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy.",125 138 141,48 52,125,48,150,61,-1,RO-disease_has_finding,901512,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy",complication of pregnancy,pre-eclamptic
502912939,7/14/2014 13:21:25,,1322835917,7/14/2014 13:21:06,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,125,48,,,150,61,COMPLICATION OF PREGNANCY,PRE-ECLAMPTIC,COMPLICATION OF PREGNANCY.,125-138-141,48-52,PRE ECLAMPTIC,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy.",125 138 141,48 52,125,48,150,61,-1,RO-disease_has_finding,901512,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy",complication of pregnancy,pre-eclamptic
502912939,7/14/2014 13:22:20,,1322836617,7/14/2014 13:21:39,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,125,48,,,150,61,COMPLICATION OF PREGNANCY,PRE-ECLAMPTIC,Late postpartum eclampsia a rarely noticed COMPLICATION OF PREGNANCY.,0-5-108-110-117-125-138-141-16,0-5-16-34-38-48-52-62-68-76-92,"Late postpartum eclampsia the classical PRE ECLAMPTIC signs oedema, proteinuria hypertension","Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy.",125 138 141,48 52,125,48,150,61,-1,RO-disease_has_finding,901512,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy",complication of pregnancy,pre-eclamptic
502912939,7/14/2014 13:24:45,,1322838260,7/14/2014 13:23:52,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,125,48,,,150,61,COMPLICATION OF PREGNANCY,PRE-ECLAMPTIC,"postpartum eclampsia pre eclamptic oedema, proteinuria hypertension COMPLICATION OF PREGNANCY.",5-16-48-52-68-76-92-125-138-141,5-48-52-68-76-92-125-138-141-16,"postpartum eclampsia PRE ECLAMPTIC oedema, proteinuria hypertension complication of pregnancy.","Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy.",125 138 141,48 52,125,48,150,61,-1,RO-disease_has_finding,901512,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy",complication of pregnancy,pre-eclamptic
502912939,7/14/2014 13:46:54,,1322854169,7/14/2014 13:46:22,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,125,48,,,150,61,COMPLICATION OF PREGNANCY,PRE-ECLAMPTIC,COMPLICATION OF PREGNANCY.,125-138-141,48-52,PRE ECLAMPTIC,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy.",125 138 141,48 52,125,48,150,61,-1,RO-disease_has_finding,901512,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy",complication of pregnancy,pre-eclamptic
502912939,7/14/2014 13:47:24,,1322854606,7/14/2014 13:47:09,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,125,48,,,150,61,COMPLICATION OF PREGNANCY,PRE-ECLAMPTIC,COMPLICATION OF PREGNANCY.,125-138-141,48-52-62-68,"PRE ECLAMPTIC signs oedema,","Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy.",125 138 141,48 52,125,48,150,61,-1,RO-disease_has_finding,901512,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy",complication of pregnancy,pre-eclamptic
502912939,7/14/2014 14:23:39,,1322879325,7/14/2014 14:23:21,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,125,48,,,150,61,COMPLICATION OF PREGNANCY,PRE-ECLAMPTIC,a rarely noticed COMPLICATION OF PREGNANCY.,108-110-117-125-138-141,26-34-38-48-52-62-68-76,"without the classical PRE ECLAMPTIC signs oedema, proteinuria","Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy.",125 138 141,48 52,125,48,150,61,-1,RO-disease_has_finding,901512,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy",complication of pregnancy,pre-eclamptic
502912939,7/14/2014 14:47:39,,1322896039,7/14/2014 14:47:26,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,125,48,,,150,61,COMPLICATION OF PREGNANCY,PRE-ECLAMPTIC,COMPLICATION OF PREGNANCY.,125-138-141,48-52-62-68-76,"PRE ECLAMPTIC signs oedema, proteinuria","Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy.",125 138 141,48 52,125,48,150,61,-1,RO-disease_has_finding,901512,"Late postpartum eclampsia without the classical pre-eclamptic signs oedema, proteinuria and hypertension is a rarely noticed complication of pregnancy",complication of pregnancy,pre-eclamptic
502912940,7/14/2014 12:49:30,,1322814337,7/14/2014 12:49:13,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,152,100,,,164,110,ENDOCARDITIS,GENTAMICIN,ENDOCARDITIS,152,91-95-100,low dose GENTAMICIN,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.",152,100,152,100,164,110,1,RO-may_treat,907941,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic",endocarditis,gentamicin
502912940,7/14/2014 12:54:44,,1322818040,7/14/2014 12:54:23,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,152,100,,,164,110,ENDOCARDITIS,GENTAMICIN,ENDOCARDITIS,152,91-95-100,low dose GENTAMICIN,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.",152,100,152,100,164,110,1,RO-may_treat,907941,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic",endocarditis,gentamicin
502912940,7/14/2014 13:14:59,,1322831526,7/14/2014 13:14:34,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,152,100,,,164,110,ENDOCARDITIS,GENTAMICIN,ENDOCARDITIS,152,91-95-100,low dose GENTAMICIN,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.",152,100,152,100,164,110,1,RO-may_treat,907941,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic",endocarditis,gentamicin
502912940,7/14/2014 13:29:01,,1322841117,7/14/2014 13:28:26,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,152,100,,,164,110,ENDOCARDITIS,GENTAMICIN,aureus bacteremia and ENDOCARDITIS is nephrotoxic.,130-137-148-152-165-168,83-91-95-100-111-115-130,Initial low dose GENTAMICIN for Staphylococcus aureus,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.",152,100,152,100,164,110,1,RO-may_treat,907941,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic",endocarditis,gentamicin
502912940,7/14/2014 13:43:57,,1322851923,7/14/2014 13:43:30,elite,1.0,26544151,GBR,"","",188.29.127.144,152,100,,,164,110,ENDOCARDITIS,GENTAMICIN,ENDOCARDITIS,152,100,GENTAMICIN,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.",152,100,152,100,164,110,1,RO-may_treat,907941,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic",endocarditis,gentamicin
502912940,7/14/2014 13:54:08,,1322859360,7/14/2014 13:53:43,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,152,100,,,164,110,ENDOCARDITIS,GENTAMICIN,and ENDOCARDITIS,148-152,91-95-100,low dose GENTAMICIN,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.",152,100,152,100,164,110,1,RO-may_treat,907941,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic",endocarditis,gentamicin
502912940,7/14/2014 13:55:02,,1322859973,7/14/2014 13:54:31,inboxpounds,1,18398050,GBR,"","",87.113.18.171,152,100,,,164,110,ENDOCARDITIS,GENTAMICIN,aureus bacteremia and ENDOCARDITIS is nephrotoxic.,130-137-148-152-165-168,83-91-95-100-111-115-130,Initial low dose GENTAMICIN for Staphylococcus aureus,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.",152,100,152,100,164,110,1,RO-may_treat,907941,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic",endocarditis,gentamicin
502912940,7/14/2014 14:31:32,,1322885299,7/14/2014 14:31:22,instagc,1.0,27753923,GBR,"","",188.30.192.65,152,100,,,164,110,ENDOCARDITIS,GENTAMICIN,aureus bacteremia and ENDOCARDITIS is nephrotoxic.,130-137-148-152-165-168,83-91-95-100-111-115-130,Initial low dose GENTAMICIN for Staphylococcus aureus,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.",152,100,152,100,164,110,1,RO-may_treat,907941,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic",endocarditis,gentamicin
502912940,7/14/2014 14:40:33,,1322891396,7/14/2014 14:40:28,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,152,100,,,164,110,ENDOCARDITIS,GENTAMICIN,aureus bacteremia and ENDOCARDITIS is nephrotoxic.,130-137-148-152-165-168,83-91-95-100-111-115-130,Initial low dose GENTAMICIN for Staphylococcus aureus,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.",152,100,152,100,164,110,1,RO-may_treat,907941,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic",endocarditis,gentamicin
502912940,7/14/2014 14:44:48,,1322894250,7/14/2014 14:44:31,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,152,100,,,164,110,ENDOCARDITIS,GENTAMICIN,ENDOCARDITIS,152,100,GENTAMICIN,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.",152,100,152,100,164,110,1,RO-may_treat,907941,"2]  Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic",endocarditis,gentamicin
502912941,7/14/2014 13:12:41,,1322829892,7/14/2014 13:12:25,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,105,173,,,121,186,SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI,105-116,173-181,TYPHOID FEVER.,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever.,105 116,173 181,105,173,121,186,1,RO-has_causative_agent,903564,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever,Salmonella typhi,typhoid fever
502912941,7/14/2014 13:33:27,,1322844278,7/14/2014 13:33:09,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,105,173,,,121,186,SALMONELLA TYPHI,TYPHOID FEVER,proteins (OMPs) of SALMONELLA TYPHI,86-95-102-105-116,173-181,TYPHOID FEVER.,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever.,105 116,173 181,105,173,121,186,1,RO-has_causative_agent,903564,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever,Salmonella typhi,typhoid fever
502912941,7/14/2014 14:04:27,,1322866444,7/14/2014 14:04:10,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,105,173,,,121,186,SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI,105-116,173-181,TYPHOID FEVER.,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever.,105 116,173 181,105,173,121,186,1,RO-has_causative_agent,903564,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever,Salmonella typhi,typhoid fever
502912941,7/14/2014 14:19:45,,1322876663,7/14/2014 14:19:19,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,105,173,,,121,186,SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI typhoid fever.,105-116-173-181,173-181,TYPHOID FEVER.,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever.,105 116,173 181,105,173,121,186,1,RO-has_causative_agent,903564,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever,Salmonella typhi,typhoid fever
502912941,7/14/2014 14:29:53,,1322884013,7/14/2014 14:29:50,instagc,1.0,27753923,GBR,"","",188.30.192.65,105,173,,,121,186,SALMONELLA TYPHI,TYPHOID FEVER,proteins (OMPs) of SALMONELLA TYPHI to induce a,86-95-102-105-116-122-125-132,158-161-168-173-181,in humans with TYPHOID FEVER.,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever.,105 116,173 181,105,173,121,186,1,RO-has_causative_agent,903564,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever,Salmonella typhi,typhoid fever
502912941,7/14/2014 14:46:22,,1322895273,7/14/2014 14:46:01,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,105,173,,,121,186,SALMONELLA TYPHI,TYPHOID FEVER,proteins (OMPs) of SALMONELLA TYPHI,86-95-102-105-116,173-181,TYPHOID FEVER.,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever.,105 116,173 181,105,173,121,186,1,RO-has_causative_agent,903564,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever,Salmonella typhi,typhoid fever
502912941,7/14/2014 14:49:38,,1322897123,7/14/2014 14:49:28,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,105,173,,,121,186,SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI,105-116,173-181,TYPHOID FEVER.,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever.,105 116,173 181,105,173,121,186,1,RO-has_causative_agent,903564,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever,Salmonella typhi,typhoid fever
502912941,7/14/2014 14:49:40,,1322897154,7/14/2014 14:49:26,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,105,173,,,121,186,SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI,105-116,173-181,TYPHOID FEVER.,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever.,105 116,173 181,105,173,121,186,1,RO-has_causative_agent,903564,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever,Salmonella typhi,typhoid fever
502912941,7/14/2014 14:50:09,,1322897447,7/14/2014 14:49:51,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,105,173,,,121,186,SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI,105-116,173-181,TYPHOID FEVER.,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever.,105 116,173 181,105,173,121,186,1,RO-has_causative_agent,903564,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever,Salmonella typhi,typhoid fever
502912941,7/14/2014 14:50:41,,1322897728,7/14/2014 14:50:29,instagc,1.0,13763729,USA,"","",75.182.89.225,105,173,,,121,186,SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI,105-116,173-181,TYPHOID FEVER.,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever.,105 116,173 181,105,173,121,186,1,RO-has_causative_agent,903564,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of Salmonella typhi to induce a humoral immune response in humans with typhoid fever,Salmonella typhi,typhoid fever
502912942,7/14/2014 12:46:45,,1322812511,7/14/2014 12:46:41,clixsense,1.0,24763049,GBR,"","",86.133.47.213,42,122,,,73,135,ANEMIA OF CHRONIC RENAL FAILURE,RENAL FAILURE,"treatment of the ANEMIA OF CHRONIC RENAL FAILURE, both in progressive",25-35-38-42-49-52-60-66-75-80-83,101-109-113-122-128,failure and endstage RENAL FAILURE,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD.",42 49 52 60 66,122 128,42,122,73,135,-1,RO-cause_of,900181,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD",anemia of chronic renal failure,renal failure
502912942,7/14/2014 12:56:03,,1322818867,7/14/2014 12:56:01,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,42,122,,,73,135,ANEMIA OF CHRONIC RENAL FAILURE,RENAL FAILURE,"treatment of the ANEMIA OF CHRONIC RENAL FAILURE, both in progressive",25-35-38-42-49-52-60-66-75-80-83,101-109-113-122-128-95,renal failure and endstage RENAL FAILURE,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD.",42 49 52 60 66,122 128,42,122,73,135,-1,RO-cause_of,900181,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD",anemia of chronic renal failure,renal failure
502912942,7/14/2014 13:01:49,,1322822679,7/14/2014 13:01:33,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,42,122,,,73,135,ANEMIA OF CHRONIC RENAL FAILURE,RENAL FAILURE,"ANEMIA OF CHRONIC RENAL FAILURE,",42-49-52-60-66,122-128-113,endstage RENAL FAILURE,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD.",42 49 52 60 66,122 128,42,122,73,135,-1,RO-cause_of,900181,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD",anemia of chronic renal failure,renal failure
502912942,7/14/2014 13:10:16,,1322828422,7/14/2014 13:09:38,gifthulk,1.0,25566511,USA,"","",24.164.11.173,42,122,,,73,135,ANEMIA OF CHRONIC RENAL FAILURE,RENAL FAILURE,"ANEMIA OF CHRONIC RENAL FAILURE,",42-49-52-60-66,113-122-128,endstage RENAL FAILURE,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD.",42 49 52 60 66,122 128,42,122,73,135,-1,RO-cause_of,900181,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD",anemia of chronic renal failure,renal failure
502912942,7/14/2014 13:26:37,,1322839509,7/14/2014 13:26:04,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,42,122,,,73,135,ANEMIA OF CHRONIC RENAL FAILURE,RENAL FAILURE,"ANEMIA OF CHRONIC RENAL FAILURE,",42-49-52-60-66,113-122-128,endstage RENAL FAILURE,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD.",42 49 52 60 66,122 128,42,122,73,135,-1,RO-cause_of,900181,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD",anemia of chronic renal failure,renal failure
502912942,7/14/2014 13:42:45,,1322851007,7/14/2014 13:42:16,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,42,122,,,73,135,ANEMIA OF CHRONIC RENAL FAILURE,RENAL FAILURE,"ANEMIA OF CHRONIC RENAL FAILURE,",42-49-52-60-66,113-122-128-136,endstage RENAL FAILURE (ESRD.,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD.",42 49 52 60 66,122 128,42,122,73,135,-1,RO-cause_of,900181,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD",anemia of chronic renal failure,renal failure
502912942,7/14/2014 13:46:34,,1322853870,7/14/2014 13:46:20,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,42,122,,,73,135,ANEMIA OF CHRONIC RENAL FAILURE,RENAL FAILURE,"ANEMIA OF CHRONIC RENAL FAILURE,",42-49-52-60-66,122-128,RENAL FAILURE,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD.",42 49 52 60 66,122 128,42,122,73,135,-1,RO-cause_of,900181,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD",anemia of chronic renal failure,renal failure
502912942,7/14/2014 14:33:45,,1322886743,7/14/2014 14:33:27,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,42,122,,,73,135,ANEMIA OF CHRONIC RENAL FAILURE,RENAL FAILURE,"ANEMIA OF CHRONIC RENAL FAILURE,",42-49-52-60-66,122-128-136,RENAL FAILURE (ESRD.,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD.",42 49 52 60 66,122 128,42,122,73,135,-1,RO-cause_of,900181,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD",anemia of chronic renal failure,renal failure
502912942,7/14/2014 14:42:56,,1322892990,7/14/2014 14:42:33,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,42,122,,,73,135,ANEMIA OF CHRONIC RENAL FAILURE,RENAL FAILURE,"ANEMIA OF CHRONIC RENAL FAILURE,",42-49-52-60-66,122-128,RENAL FAILURE,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD.",42 49 52 60 66,122 128,42,122,73,135,-1,RO-cause_of,900181,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD",anemia of chronic renal failure,renal failure
502912942,7/14/2014 14:45:46,,1322894862,7/14/2014 14:45:39,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,42,122,,,73,135,ANEMIA OF CHRONIC RENAL FAILURE,RENAL FAILURE,"ANEMIA OF CHRONIC RENAL FAILURE,",42-49-52-60-66,122-128,RENAL FAILURE,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD.",42 49 52 60 66,122 128,42,122,73,135,-1,RO-cause_of,900181,"It has been approved for treatment of the anemia of chronic renal failure, both in progressive renal failure and endstage renal failure (ESRD",anemia of chronic renal failure,renal failure
502912943,7/14/2014 13:21:34,,1322835968,7/14/2014 13:20:56,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,44,71,,,56,81,TUBERCULOSIS,TUBERCULIN,"Anergy TUBERCULOSIS, tuberculin",0-44-71,0-44-71,"Anergy tuberculosis, TUBERCULIN","Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing.",44,71,44,71,56,81,1,RO-may_diagnose,906786,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing",tuberculosis,tuberculin
502912943,7/14/2014 13:27:54,,1322840343,7/14/2014 13:27:31,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,44,71,,,56,81,TUBERCULOSIS,TUBERCULIN,"high risk for TUBERCULOSIS, compromising tuberculin skin",30-35-40-44-58-71-82,40-44-58-71-82-87,"for tuberculosis, compromising TUBERCULIN skin testing.","Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing.",44,71,44,71,56,81,1,RO-may_diagnose,906786,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing",tuberculosis,tuberculin
502912943,7/14/2014 13:40:52,,1322849703,7/14/2014 13:40:49,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,44,71,,,56,81,TUBERCULOSIS,TUBERCULIN,"high risk for TUBERCULOSIS, compromising tuberculin skin",30-35-40-44-58-71-82,40-44-58-71-82-87,"for tuberculosis, compromising TUBERCULIN skin testing.","Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing.",44,71,44,71,56,81,1,RO-may_diagnose,906786,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing",tuberculosis,tuberculin
502912943,7/14/2014 13:47:42,,1322854830,7/14/2014 13:47:26,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,44,71,,,56,81,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",44,71-82-87,TUBERCULIN skin testing.,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing.",44,71,44,71,56,81,1,RO-may_diagnose,906786,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing",tuberculosis,tuberculin
502912943,7/14/2014 13:56:07,,1322860765,7/14/2014 13:55:57,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,44,71,,,56,81,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",44,71,TUBERCULIN,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing.",44,71,44,71,56,81,1,RO-may_diagnose,906786,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing",tuberculosis,tuberculin
502912943,7/14/2014 14:41:12,,1322891816,7/14/2014 14:40:41,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,44,71,,,56,81,TUBERCULOSIS,TUBERCULIN,"high risk for TUBERCULOSIS,",30-35-40-44,44-58-71-82-87,"tuberculosis, compromising TUBERCULIN skin testing.","Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing.",44,71,44,71,56,81,1,RO-may_diagnose,906786,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing",tuberculosis,tuberculin
502912943,7/14/2014 14:46:03,,1322895035,7/14/2014 14:45:44,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,44,71,,,56,81,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",44,71-82-87,TUBERCULIN skin testing.,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing.",44,71,44,71,56,81,1,RO-may_diagnose,906786,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing",tuberculosis,tuberculin
502912943,7/14/2014 14:46:18,,1322895168,7/14/2014 14:46:08,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,44,71,,,56,81,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",44,71,TUBERCULIN,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing.",44,71,44,71,56,81,1,RO-may_diagnose,906786,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing",tuberculosis,tuberculin
502912943,7/14/2014 14:49:38,,1322897122,7/14/2014 14:49:23,instagc,1.0,13763729,USA,"","",75.182.89.225,44,71,,,56,81,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",44,71,TUBERCULIN,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing.",44,71,44,71,56,81,1,RO-may_diagnose,906786,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing",tuberculosis,tuberculin
502912943,7/14/2014 14:51:27,,1322898213,7/14/2014 14:50:29,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,44,71,,,56,81,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",44,71,TUBERCULIN,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing.",44,71,44,71,56,81,1,RO-may_diagnose,906786,"Anergy may occur in groups at high risk for tuberculosis, compromising tuberculin skin testing",tuberculosis,tuberculin
502912944,7/14/2014 12:50:06,,1322814772,7/14/2014 12:49:56,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,29,64,,,44,77,LYMPHADENOPATHY,MONONUCLEOSIS,LYMPHADENOPATHY,29,53-64,"infectious MONONUCLEOSIS,","? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome.",29,64,29,64,44,77,1,RO-disease_has_finding,901586,"? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome",lymphadenopathy,mononucleosis
502912944,7/14/2014 13:08:35,,1322827245,7/14/2014 13:08:08,gifthulk,1.0,25566511,USA,"","",24.164.11.173,29,64,,,44,77,LYMPHADENOPATHY,MONONUCLEOSIS,LYMPHADENOPATHY,29,64,"MONONUCLEOSIS,","? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome.",29,64,29,64,44,77,1,RO-disease_has_finding,901586,"? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome",lymphadenopathy,mononucleosis
502912944,7/14/2014 13:11:11,,1322828864,7/14/2014 13:10:40,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,29,64,,,44,77,LYMPHADENOPATHY,MONONUCLEOSIS,"LYMPHADENOPATHY mononucleosis, autoimmune (rheumatoid arthritis erythematosus, ALPS syndrome.",29-64-79-98-110-139-159-154,29-64-79-90-98-110-124-139-154,"lymphadenopathy MONONUCLEOSIS, autoimmune disease (rheumatoid arthritis systemic erythematosus, ALPS","? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome.",29,64,29,64,44,77,1,RO-disease_has_finding,901586,"? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome",lymphadenopathy,mononucleosis
502912944,7/14/2014 13:15:53,,1322832136,7/14/2014 13:15:49,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,29,64,,,44,77,LYMPHADENOPATHY,MONONUCLEOSIS,benign causes for LYMPHADENOPATHY such as infectious,11-18-25-29-45-50-53,45-50-53-64-79-90,"such as infectious MONONUCLEOSIS, autoimmune disease","? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome.",29,64,29,64,44,77,1,RO-disease_has_finding,901586,"? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome",lymphadenopathy,mononucleosis
502912944,7/14/2014 13:21:02,,1322835561,7/14/2014 13:20:46,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,29,64,,,44,77,LYMPHADENOPATHY,MONONUCLEOSIS,LYMPHADENOPATHY,29,64,"MONONUCLEOSIS,","? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome.",29,64,29,64,44,77,1,RO-disease_has_finding,901586,"? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome",lymphadenopathy,mononucleosis
502912944,7/14/2014 13:31:30,,1322842764,7/14/2014 13:30:58,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,29,64,,,44,77,LYMPHADENOPATHY,MONONUCLEOSIS,LYMPHADENOPATHY,29,53-64,"infectious MONONUCLEOSIS,","? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome.",29,64,29,64,44,77,1,RO-disease_has_finding,901586,"? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome",lymphadenopathy,mononucleosis
502912944,7/14/2014 13:49:27,,1322856094,7/14/2014 13:49:11,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,29,64,,,44,77,LYMPHADENOPATHY,MONONUCLEOSIS,causes for LYMPHADENOPATHY,18-25-29,53-64-79-90,"infectious MONONUCLEOSIS, autoimmune disease","? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome.",29,64,29,64,44,77,1,RO-disease_has_finding,901586,"? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome",lymphadenopathy,mononucleosis
502912944,7/14/2014 14:21:50,,1322878164,7/14/2014 14:21:41,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,29,64,,,44,77,LYMPHADENOPATHY,MONONUCLEOSIS,benign causes for LYMPHADENOPATHY such as infectious,11-18-25-29-45-50-53,45-50-53-64-79-90,"such as infectious MONONUCLEOSIS, autoimmune disease","? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome.",29,64,29,64,44,77,1,RO-disease_has_finding,901586,"? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome",lymphadenopathy,mononucleosis
502912944,7/14/2014 14:31:05,,1322884905,7/14/2014 14:31:02,instagc,1.0,27753923,GBR,"","",188.30.192.65,29,64,,,44,77,LYMPHADENOPATHY,MONONUCLEOSIS,benign causes for LYMPHADENOPATHY such as infectious,11-18-25-29-45-50-53,45-50-53-64-79-90,"such as infectious MONONUCLEOSIS, autoimmune disease","? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome.",29,64,29,64,44,77,1,RO-disease_has_finding,901586,"? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome",lymphadenopathy,mononucleosis
502912944,7/14/2014 14:44:58,,1322894372,7/14/2014 14:44:33,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,29,64,,,44,77,LYMPHADENOPATHY,MONONUCLEOSIS,benign causes for LYMPHADENOPATHY such as infectious,11-18-25-29-45-50-53,45-50-53-64-79-90,"such as infectious MONONUCLEOSIS, autoimmune disease","? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome.",29,64,29,64,44,77,1,RO-disease_has_finding,901586,"? Consider benign causes for lymphadenopathy such as infectious mononucleosis, autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus, ALPS syndrome",lymphadenopathy,mononucleosis
502912945,7/14/2014 12:52:19,,1322816368,7/14/2014 12:52:11,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,58,0,,,69,9,HOT FLASHES,CLONIDINE,tamoxifen associated HOT FLASHES,37-47-58-62,0,CLONIDINE,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,58 62,0,58,0,69,9,1,RO-may_treat,907723,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club,hot flashes,Clonidine
502912945,7/14/2014 12:58:48,,1322820738,7/14/2014 12:58:23,gifthulk,1.0,25566511,USA,"","",24.164.11.173,58,0,,,69,9,HOT FLASHES,CLONIDINE,tamoxifen associated HOT FLASHES,37-47-58-62,0,CLONIDINE,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,58 62,0,58,0,69,9,1,RO-may_treat,907723,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club,hot flashes,Clonidine
502912945,7/14/2014 13:06:14,,1322825518,7/14/2014 13:05:07,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,58,0,,,69,9,HOT FLASHES,CLONIDINE,HOT FLASHES,58-62,0,CLONIDINE,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,58 62,0,58,0,69,9,1,RO-may_treat,907723,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club,hot flashes,Clonidine
502912945,7/14/2014 13:19:01,,1322834232,7/14/2014 13:18:00,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,58,0,,,69,9,HOT FLASHES,CLONIDINE,Clonidine tamoxifen HOT FLASHES postmenopausal breast cancer Breast neoplasms Tamoxifen,0-37-58-62-73-99-106-124-131-153,0-37-58-62-73-99-106-124-131-153,CLONIDINE tamoxifen hot flashes postmenopausal breast cancer Breast neoplasms Tamoxifen,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,58 62,0,58,0,69,9,1,RO-may_treat,907723,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club,hot flashes,Clonidine
502912945,7/14/2014 13:46:02,,1322853400,7/14/2014 13:45:41,elite,1.0,26544151,GBR,"","",188.29.127.144,58,0,,,69,9,HOT FLASHES,CLONIDINE,HOT FLASHES,58-62,0,CLONIDINE,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,58 62,0,58,0,69,9,1,RO-may_treat,907723,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club,hot flashes,Clonidine
502912945,7/14/2014 13:58:48,,1322862463,7/14/2014 13:57:09,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,58,0,,,69,9,HOT FLASHES,CLONIDINE,HOT FLASHES postmenopausal,58-62-73,0-141-145,CLONIDINE Hot flashes,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,58 62,0,58,0,69,9,1,RO-may_treat,907723,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club,hot flashes,Clonidine
502912945,7/14/2014 14:21:24,,1322877790,7/14/2014 14:21:05,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,58,0,,,69,9,HOT FLASHES,CLONIDINE,HOT FLASHES breast cancer,58-62-99-106,0-99-106,CLONIDINE breast cancer,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,58 62,0,58,0,69,9,1,RO-may_treat,907723,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club,hot flashes,Clonidine
502912945,7/14/2014 14:37:04,,1322888999,7/14/2014 14:36:53,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,58,0,,,69,9,HOT FLASHES,CLONIDINE,tamoxifen associated HOT FLASHES,37-47-58-62,0,CLONIDINE,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,58 62,0,58,0,69,9,1,RO-may_treat,907723,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club,hot flashes,Clonidine
502912945,7/14/2014 14:48:25,,1322896453,7/14/2014 14:48:04,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,58,0,,,69,9,HOT FLASHES,CLONIDINE,reducing tamoxifen associated HOT FLASHES in postmenopausal,28-37-47-58-62-70-73,0,CLONIDINE,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,58 62,0,58,0,69,9,1,RO-may_treat,907723,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club,hot flashes,Clonidine
502912945,7/14/2014 14:49:10,,1322896818,7/14/2014 14:49:02,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,58,0,,,69,9,HOT FLASHES,CLONIDINE,tamoxifen associated HOT FLASHES,37-47-58-62,0,CLONIDINE,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,58 62,0,58,0,69,9,1,RO-may_treat,907723,Clonidine was effective for reducing tamoxifen-associated hot flashes in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club,hot flashes,Clonidine
502912946,7/14/2014 12:59:33,,1322821178,7/14/2014 12:59:13,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,100,72,,,116,80,ISCHEMIC COLITIS,ISCHEMIA,spontaneous ISCHEMIC COLITIS,88-100-109,64-72,colonic ISCHEMIA,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality.",100 109,72,100,72,116,80,-1,RO-cause_of,900053,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality",ischemic colitis,ischemia
502912946,7/14/2014 13:00:33,,1322821872,7/14/2014 13:00:18,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,100,72,,,116,80,ISCHEMIC COLITIS,ISCHEMIA,ISCHEMIC COLITIS,100-109,72,ISCHEMIA,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality.",100 109,72,100,72,116,80,-1,RO-cause_of,900053,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality",ischemic colitis,ischemia
502912946,7/14/2014 13:08:07,,1322826876,7/14/2014 13:07:21,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,100,72,,,116,80,ISCHEMIC COLITIS,ISCHEMIA,colonic ischemia ISCHEMIC COLITIS,64-72-100-109,64-72-100-109,colonic ISCHEMIA ischemic colitis,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality.",100 109,72,100,72,116,80,-1,RO-cause_of,900053,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality",ischemic colitis,ischemia
502912946,7/14/2014 13:14:04,,1322830942,7/14/2014 13:13:10,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,100,72,,,116,80,ISCHEMIC COLITIS,ISCHEMIA,ISCHEMIC COLITIS,100-109,72,ISCHEMIA,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality.",100 109,72,100,72,116,80,-1,RO-cause_of,900053,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality",ischemic colitis,ischemia
502912946,7/14/2014 13:14:30,,1322831224,7/14/2014 13:14:13,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,100,72,,,116,80,ISCHEMIC COLITIS,ISCHEMIA,spontaneous ISCHEMIC COLITIS,88-100-109,64-72,colonic ISCHEMIA,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality.",100 109,72,100,72,116,80,-1,RO-cause_of,900053,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality",ischemic colitis,ischemia
502912946,7/14/2014 13:26:53,,1322839699,7/14/2014 13:26:38,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,100,72,,,116,80,ISCHEMIC COLITIS,ISCHEMIA,spontaneous ISCHEMIC COLITIS,88-100-109,64-72,colonic ISCHEMIA,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality.",100 109,72,100,72,116,80,-1,RO-cause_of,900053,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality",ischemic colitis,ischemia
502912946,7/14/2014 13:32:42,,1322843674,7/14/2014 13:31:53,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,100,72,,,116,80,ISCHEMIC COLITIS,ISCHEMIA,spontaneous ISCHEMIC COLITIS,88-100-109,64-72,colonic ISCHEMIA,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality.",100 109,72,100,72,116,80,-1,RO-cause_of,900053,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality",ischemic colitis,ischemia
502912946,7/14/2014 13:49:06,,1322855811,7/14/2014 13:48:51,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,100,72,,,116,80,ISCHEMIC COLITIS,ISCHEMIA,ISCHEMIC COLITIS,100-109,72,ISCHEMIA,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality.",100 109,72,100,72,116,80,-1,RO-cause_of,900053,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality",ischemic colitis,ischemia
502912946,7/14/2014 14:32:39,,1322886029,7/14/2014 14:32:26,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,100,72,,,116,80,ISCHEMIC COLITIS,ISCHEMIA,spontaneous ISCHEMIC COLITIS,88-100-109,64-72,colonic ISCHEMIA,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality.",100 109,72,100,72,116,80,-1,RO-cause_of,900053,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality",ischemic colitis,ischemia
502912946,7/14/2014 14:45:03,,1322894397,7/14/2014 14:44:49,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,100,72,,,116,80,ISCHEMIC COLITIS,ISCHEMIA,ISCHEMIC COLITIS,100-109,72,ISCHEMIA,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality.",100 109,72,100,72,116,80,-1,RO-cause_of,900053,"Evidence: ? A retrospective study showed that the nature of the colonic ischemia (i.e., spontaneous ischemic colitis versus ischemia related to shock from other disease) is predictive of mortality",ischemic colitis,ischemia
502912947,7/14/2014 12:46:52,,1322812595,7/14/2014 12:46:47,clixsense,1.0,24763049,GBR,"","",86.133.47.213,88,18,,,111,31,EPSTEIN-BARR VIRUS (EBV,MONONUCLEOSIS,"other due to EPSTEIN BARR VIRUS (EBV), presenting with high",75-81-85-88-96-101-107-114-125-130,0-4-13-18-33-37-41,"Two patients with MONONUCLEOSIS, one due to","Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",88 96 101 107,18,88,18,111,31,1,RO-has_causative_agent,903519,"Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver",Epstein-Barr virus (EBV,mononucleosis
502912947,7/14/2014 13:23:56,,1322837772,7/14/2014 13:23:46,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,88,18,,,111,31,EPSTEIN-BARR VIRUS (EBV,MONONUCLEOSIS,"EPSTEIN BARR VIRUS (EBV),",88-96-101-107,18,"MONONUCLEOSIS,","Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",88 96 101 107,18,88,18,111,31,1,RO-has_causative_agent,903519,"Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver",Epstein-Barr virus (EBV,mononucleosis
502912947,7/14/2014 13:40:22,,1322849349,7/14/2014 13:40:09,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,88,18,,,111,31,EPSTEIN-BARR VIRUS (EBV,MONONUCLEOSIS,"EPSTEIN BARR VIRUS (EBV),",88-96-101-107,18,"MONONUCLEOSIS,","Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",88 96 101 107,18,88,18,111,31,1,RO-has_causative_agent,903519,"Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver",Epstein-Barr virus (EBV,mononucleosis
502912947,7/14/2014 13:44:28,,1322852304,7/14/2014 13:44:09,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,88,18,,,111,31,EPSTEIN-BARR VIRUS (EBV,MONONUCLEOSIS,"EPSTEIN BARR VIRUS (EBV),",88-96-101-107,18,"MONONUCLEOSIS,","Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",88 96 101 107,18,88,18,111,31,1,RO-has_causative_agent,903519,"Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver",Epstein-Barr virus (EBV,mononucleosis
502912947,7/14/2014 14:01:05,,1322864147,7/14/2014 14:00:46,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,88,18,,,111,31,EPSTEIN-BARR VIRUS (EBV,MONONUCLEOSIS,"EPSTEIN BARR VIRUS (EBV),",88-96-101-107,18,"MONONUCLEOSIS,","Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",88 96 101 107,18,88,18,111,31,1,RO-has_causative_agent,903519,"Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver",Epstein-Barr virus (EBV,mononucleosis
502912947,7/14/2014 14:40:19,,1322891248,7/14/2014 14:40:11,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,88,18,,,111,31,EPSTEIN-BARR VIRUS (EBV,MONONUCLEOSIS,"other due to EPSTEIN BARR VIRUS (EBV), presenting with high",75-81-85-88-96-101-107-114-125-130,0-4-13-18-33-37-41,"Two patients with MONONUCLEOSIS, one due to","Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",88 96 101 107,18,88,18,111,31,1,RO-has_causative_agent,903519,"Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver",Epstein-Barr virus (EBV,mononucleosis
502912947,7/14/2014 14:40:53,,1322891648,7/14/2014 14:40:39,prodege,1.0,28209666,,,"",24.156.173.34,88,18,,,111,31,EPSTEIN-BARR VIRUS (EBV,MONONUCLEOSIS,"EPSTEIN BARR VIRUS (EBV), high",88-96-101-107-130,18,"MONONUCLEOSIS,","Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",88 96 101 107,18,88,18,111,31,1,RO-has_causative_agent,903519,"Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver",Epstein-Barr virus (EBV,mononucleosis
502912947,7/14/2014 14:43:30,,1322893358,7/14/2014 14:42:57,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,88,18,,,111,31,EPSTEIN-BARR VIRUS (EBV,MONONUCLEOSIS,"EPSTEIN BARR VIRUS (EBV),",88-96-101-107,18-44-60-88-96-101-107,"MONONUCLEOSIS, cytomegalovirus (CMV), Epstein Barr virus (EBV),","Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",88 96 101 107,18,88,18,111,31,1,RO-has_causative_agent,903519,"Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver",Epstein-Barr virus (EBV,mononucleosis
502912947,7/14/2014 14:45:10,,1322894458,7/14/2014 14:44:56,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,88,18,,,111,31,EPSTEIN-BARR VIRUS (EBV,MONONUCLEOSIS,"EPSTEIN BARR VIRUS (EBV),",88-96-101-107,18,"MONONUCLEOSIS,","Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",88 96 101 107,18,88,18,111,31,1,RO-has_causative_agent,903519,"Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver",Epstein-Barr virus (EBV,mononucleosis
502912947,7/14/2014 14:46:54,,1322895574,7/14/2014 14:46:47,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,88,18,,,111,31,EPSTEIN-BARR VIRUS (EBV,MONONUCLEOSIS,"EPSTEIN BARR VIRUS (EBV),",88-96-101-107,18,"MONONUCLEOSIS,","Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",88 96 101 107,18,88,18,111,31,1,RO-has_causative_agent,903519,"Two patients with mononucleosis, one due to cytomegalovirus (CMV), and the other due to Epstein-Barr virus (EBV), presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver",Epstein-Barr virus (EBV,mononucleosis
502912948,7/14/2014 12:45:49,,1322811892,7/14/2014 12:45:45,clixsense,1.0,24763049,GBR,"","",86.133.47.213,50,23,,,57,41,ALLERGY,HYPERSENSITIVITIES,"hypersensitivities, type I ALLERGY to house dust",23-43-48-50-58-61-67,0-6-10-23-43-48-50,"Among non occupational HYPERSENSITIVITIES, type I allergy","Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found.",50,23,50,23,57,41,-1,RO-cause_of,900143,"Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found",allergy,hypersensitivities
502912948,7/14/2014 12:55:34,,1322818537,7/14/2014 12:55:30,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,50,23,,,57,41,ALLERGY,HYPERSENSITIVITIES,"hypersensitivities, type I ALLERGY to house dust contact",23-43-48-50-58-61-67-82,0-6-10-23-43-48-50-90,"Among non occupational HYPERSENSITIVITIES, type I allergy allergy","Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found.",50,23,50,23,57,41,-1,RO-cause_of,900143,"Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found",allergy,hypersensitivities
502912948,7/14/2014 12:56:11,,1322818975,7/14/2014 12:55:50,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,50,23,,,57,41,ALLERGY,HYPERSENSITIVITIES,ALLERGY,50,23,"HYPERSENSITIVITIES,","Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found.",50,23,50,23,57,41,-1,RO-cause_of,900143,"Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found",allergy,hypersensitivities
502912948,7/14/2014 13:08:29,,1322827176,7/14/2014 13:07:52,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,50,23,,,57,41,ALLERGY,HYPERSENSITIVITIES,ALLERGY,50,23,"HYPERSENSITIVITIES,","Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found.",50,23,50,23,57,41,-1,RO-cause_of,900143,"Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found",allergy,hypersensitivities
502912948,7/14/2014 13:14:37,,1322831258,7/14/2014 13:14:31,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,50,23,,,57,41,ALLERGY,HYPERSENSITIVITIES,"hypersensitivities, type I ALLERGY to house dust",23-43-48-50-58-61-67,0-6-10-23-43-48-50,"Among non occupational HYPERSENSITIVITIES, type I allergy","Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found.",50,23,50,23,57,41,-1,RO-cause_of,900143,"Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found",allergy,hypersensitivities
502912948,7/14/2014 13:33:44,,1322844416,7/14/2014 13:33:11,clixsense,1.0,27969116,NLD,"","",91.213.37.165,50,23,,,57,41,ALLERGY,HYPERSENSITIVITIES,type I ALLERGY,43-48-50,6-10-23-43-48-50-9,"non - occupational HYPERSENSITIVITIES, type I allergy","Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found.",50,23,50,23,57,41,-1,RO-cause_of,900143,"Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found",allergy,hypersensitivities
502912948,7/14/2014 13:50:19,,1322856599,7/14/2014 13:49:53,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,50,23,,,57,41,ALLERGY,HYPERSENSITIVITIES,"non - occupational hypersensitivities, type I ALLERGY",6-9-23-43-48-50-10,6-10-23-43-48-50,"non occupational HYPERSENSITIVITIES, type I allergy","Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found.",50,23,50,23,57,41,-1,RO-cause_of,900143,"Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found",allergy,hypersensitivities
502912948,7/14/2014 13:56:24,,1322860960,7/14/2014 13:56:07,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,50,23,,,57,41,ALLERGY,HYPERSENSITIVITIES,type I ALLERGY,43-48-50,6-10-23,"non occupational HYPERSENSITIVITIES,","Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found.",50,23,50,23,57,41,-1,RO-cause_of,900143,"Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found",allergy,hypersensitivities
502912948,7/14/2014 14:01:33,,1322864509,7/14/2014 14:01:02,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,50,23,,,57,41,ALLERGY,HYPERSENSITIVITIES,type I ALLERGY,43-50-48,23-43-48-50,"HYPERSENSITIVITIES, type I allergy","Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found.",50,23,50,23,57,41,-1,RO-cause_of,900143,"Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found",allergy,hypersensitivities
502912948,7/14/2014 14:24:31,,1322879954,7/14/2014 14:24:27,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,50,23,,,57,41,ALLERGY,HYPERSENSITIVITIES,"hypersensitivities, type I ALLERGY to house dust",23-43-48-50-58-61-67,0-6-10-23-43-48-50,"Among non occupational HYPERSENSITIVITIES, type I allergy","Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found.",50,23,50,23,57,41,-1,RO-cause_of,900143,"Among non-occupational hypersensitivities, type I allergy to house dust mites and contact allergy to methylchloroisothiazolinone/methylisothiazolinone (Kathon CG) was found",allergy,hypersensitivities
502912949,7/14/2014 12:55:43,,1322818650,7/14/2014 12:55:39,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,64,82,,,69,96,PANIC,PANIC DISORDER,panic disorder (see PANIC Attacks and Panic,43-49-58-64-70-78-82,64-70-78-82-88-100-109-113-115,Panic Attacks and PANIC DISORDER although the 2 conditions,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",64,82 88,64,82,69,96,-1,RO-has_definitional_manifestation,904519,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder",Panic,Panic Disorder
502912949,7/14/2014 12:58:42,,1322820651,7/14/2014 12:58:19,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,64,82,,,69,96,PANIC,PANIC DISORDER,PANIC Attacks,64-70,82-88,PANIC DISORDER,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",64,82 88,64,82,69,96,-1,RO-has_definitional_manifestation,904519,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder",Panic,Panic Disorder
502912949,7/14/2014 13:00:16,,1322821671,7/14/2014 13:00:02,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,64,82,,,69,96,PANIC,PANIC DISORDER,PANIC,64,82-88,PANIC DISORDER,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",64,82 88,64,82,69,96,-1,RO-has_definitional_manifestation,904519,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder",Panic,Panic Disorder
502912949,7/14/2014 13:02:49,,1322823327,7/14/2014 13:02:28,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,64,82,,,69,96,PANIC,PANIC DISORDER,Hyperventilation PANIC,0-64,82-88-0,Hyperventilation PANIC DISORDER,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",64,82 88,64,82,69,96,-1,RO-has_definitional_manifestation,904519,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder",Panic,Panic Disorder
502912949,7/14/2014 13:09:10,,1322827576,7/14/2014 13:08:30,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,64,82,,,69,96,PANIC,PANIC DISORDER,PANIC Attacks,64-70,82-88,PANIC DISORDER,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",64,82 88,64,82,69,96,-1,RO-has_definitional_manifestation,904519,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder",Panic,Panic Disorder
502912949,7/14/2014 13:14:37,,1322831259,7/14/2014 13:13:30,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,64,82,,,69,96,PANIC,PANIC DISORDER,Hyperventilation syndrome panic disorder PANIC Attacks,0-17-43-49-64-70,0-17-64-70-82-88,Hyperventilation syndrome Panic Attacks PANIC DISORDER,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",64,82 88,64,82,69,96,-1,RO-has_definitional_manifestation,904519,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder",Panic,Panic Disorder
502912949,7/14/2014 13:17:15,,1322833104,7/14/2014 13:16:58,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,64,82,,,69,96,PANIC,PANIC DISORDER,PANIC Attacks,64-70,64-70-78-82-88,Panic Attacks and PANIC DISORDER,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",64,82 88,64,82,69,96,-1,RO-has_definitional_manifestation,904519,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder",Panic,Panic Disorder
502912949,7/14/2014 13:18:50,,1322834144,7/14/2014 13:17:38,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,64,82,,,69,96,PANIC,PANIC DISORDER,PANIC,64,82-88,PANIC DISORDER,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",64,82 88,64,82,69,96,-1,RO-has_definitional_manifestation,904519,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder",Panic,Panic Disorder
502912949,7/14/2014 13:46:53,,1322854170,7/14/2014 13:46:36,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,64,82,,,69,96,PANIC,PANIC DISORDER,PANIC Attacks,64-70,82-88,PANIC DISORDER,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",64,82 88,64,82,69,96,-1,RO-has_definitional_manifestation,904519,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder",Panic,Panic Disorder
502912949,7/14/2014 13:47:30,,1322854666,7/14/2014 13:47:03,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,64,82,,,69,96,PANIC,PANIC DISORDER,PANIC,64,82-88,PANIC DISORDER,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",64,82 88,64,82,69,96,-1,RO-has_definitional_manifestation,904519,"Hyperventilation syndrome is separate from panic disorder (see  Panic Attacks and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with panic disorder have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder",Panic,Panic Disorder
502912950,7/14/2014 12:47:22,,1322812947,7/14/2014 12:47:17,clixsense,1.0,24763049,GBR,"","",86.133.47.213,76,155,,,91,161,YERSINIA PESTIS,PLAGUE,+ caused by YERSINIA PESTIS including naturally occurring,60-65-72-76-85-94-104-114,135-142-145-155-162-167-174,plague or pneumonic PLAGUE that occurs following,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism.",76 85,155,76,155,91,161,1,RO-has_causative_agent,903510,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism",Yersinia pestis,plague
502912950,7/14/2014 12:53:02,,1322816859,7/14/2014 12:52:39,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,76,155,,,91,161,YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS including naturally occurring or endemic plague or pneumonic plague,76-85-94-104-114-124-127-135-142-145-155,104-114-124-127-135-142-145-155,naturally occurring or endemic plague or pneumonic PLAGUE,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism.",76 85,155,76,155,91,161,1,RO-has_causative_agent,903510,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism",Yersinia pestis,plague
502912950,7/14/2014 12:54:51,,1322818127,7/14/2014 12:54:46,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,76,155,,,91,161,YERSINIA PESTIS,PLAGUE,+ caused by YERSINIA PESTIS including naturally occurring plague,60-65-72-76-85-94-104-114-135,135-142-145-155-162-167-174-127,endemic plague or pneumonic PLAGUE that occurs following,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism.",76 85,155,76,155,91,161,1,RO-has_causative_agent,903510,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism",Yersinia pestis,plague
502912950,7/14/2014 12:57:16,,1322819646,7/14/2014 12:57:02,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,76,155,,,91,161,YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS,76-85,155,PLAGUE,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism.",76 85,155,76,155,91,161,1,RO-has_causative_agent,903510,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism",Yersinia pestis,plague
502912950,7/14/2014 13:02:18,,1322823001,7/14/2014 13:02:03,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,76,155,,,91,161,YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS,76-85,145-155,pneumonic PLAGUE,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism.",76 85,155,76,155,91,161,1,RO-has_causative_agent,903510,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism",Yersinia pestis,plague
502912950,7/14/2014 13:25:47,,1322838963,7/14/2014 13:25:00,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,76,155,,,91,161,YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS including naturally occurring or endemic plague or pneumonic plague,76-85-94-104-114-124-127-135-142-145-155,104-114-124-127-135-142-145-155,naturally occurring or endemic plague or pneumonic PLAGUE,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism.",76 85,155,76,155,91,161,1,RO-has_causative_agent,903510,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism",Yersinia pestis,plague
502912950,7/14/2014 13:31:38,,1322842858,7/14/2014 13:30:47,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,76,155,,,91,161,YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS including naturally,76-85-94-104,135-142-145-155,plague or pneumonic PLAGUE,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism.",76 85,155,76,155,91,161,1,RO-has_causative_agent,903510,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism",Yersinia pestis,plague
502912950,7/14/2014 13:32:42,,1322843675,7/14/2014 13:31:42,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,76,155,,,91,161,YERSINIA PESTIS,PLAGUE,+ caused by YERSINIA PESTIS including naturally occurring,60-65-72-76-85-94-104-114,135-142-145-155-162-167-174,plague or pneumonic PLAGUE that occurs following,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism.",76 85,155,76,155,91,161,1,RO-has_causative_agent,903510,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism",Yersinia pestis,plague
502912950,7/14/2014 13:51:34,,1322857583,7/14/2014 13:51:17,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,76,155,,,91,161,YERSINIA PESTIS,PLAGUE,YERSINIA PESTIS,76-85,145-155,pneumonic PLAGUE,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism.",76 85,155,76,155,91,161,1,RO-has_causative_agent,903510,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism",Yersinia pestis,plague
502912950,7/14/2014 14:31:37,,1322885341,7/14/2014 14:31:33,instagc,1.0,27753923,GBR,"","",188.30.192.65,76,155,,,91,161,YERSINIA PESTIS,PLAGUE,+ caused by YERSINIA PESTIS including naturally occurring,60-65-72-76-85-94-104-114,135-142-145-155-162-167-174,plague or pneumonic PLAGUE that occurs following,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism.",76 85,155,76,155,91,161,1,RO-has_causative_agent,903510,"132 ,    159  Plague  Alternative for treatment of plague   +    caused by  Yersinia pestis , including naturally occurring or endemic plague or pneumonic plague that occurs following exposure to  Y. pestis in the context of biologic warfare or bioterrorism",Yersinia pestis,plague
502912951,7/14/2014 12:45:54,,1322811924,7/14/2014 12:45:42,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,56,97,,,64,118,GLAUCOMA,STURGE-WEBER SYNDROME,Ahmed GLAUCOMA valve,50-56-65,97-104-110-119-124-134-92,with STURGE WEBER SYNDROME with choroidal hemangioma.,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma.,56,97 104 110,56,97,64,118,-1,RO-has_manifestation,906368,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma,glaucoma,Sturge-Weber syndrome
502912951,7/14/2014 13:25:56,,1322839044,7/14/2014 13:25:36,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,56,97,,,64,118,GLAUCOMA,STURGE-WEBER SYNDROME,Ahmed GLAUCOMA valve,50-56-65,97-104-110-119-124-134,STURGE WEBER SYNDROME with choroidal hemangioma.,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma.,56,97 104 110,56,97,64,118,-1,RO-has_manifestation,906368,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma,glaucoma,Sturge-Weber syndrome
502912951,7/14/2014 13:26:03,,1322839163,7/14/2014 13:25:51,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,56,97,,,64,118,GLAUCOMA,STURGE-WEBER SYNDROME,Ahmed GLAUCOMA valve,50-56-65,97-104-110,STURGE WEBER SYNDROME,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma.,56,97 104 110,56,97,64,118,-1,RO-has_manifestation,906368,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma,glaucoma,Sturge-Weber syndrome
502912951,7/14/2014 13:27:24,,1322840065,7/14/2014 13:26:32,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,56,97,,,64,118,GLAUCOMA,STURGE-WEBER SYNDROME,of an Ahmed GLAUCOMA valve in a,44-47-50-56-65-71-74,83-87-92-97-104-110-119-124-134,old girl with STURGE WEBER SYNDROME with choroidal hemangioma.,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma.,56,97 104 110,56,97,64,118,-1,RO-has_manifestation,906368,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma,glaucoma,Sturge-Weber syndrome
502912951,7/14/2014 13:40:27,,1322849402,7/14/2014 13:40:24,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,56,97,,,64,118,GLAUCOMA,STURGE-WEBER SYNDROME,of an Ahmed GLAUCOMA valve in a,44-47-50-56-65-71-74,83-87-92-97-104-110-119-124-134,old girl with STURGE WEBER SYNDROME with choroidal hemangioma.,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma.,56,97 104 110,56,97,64,118,-1,RO-has_manifestation,906368,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma,glaucoma,Sturge-Weber syndrome
502912951,7/14/2014 14:20:32,,1322877190,7/14/2014 14:20:25,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,56,97,,,64,118,GLAUCOMA,STURGE-WEBER SYNDROME,of an Ahmed GLAUCOMA valve in a,44-47-50-56-65-71-74,83-87-92-97-104-110-119-124-134,old girl with STURGE WEBER SYNDROME with choroidal hemangioma.,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma.,56,97 104 110,56,97,64,118,-1,RO-has_manifestation,906368,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma,glaucoma,Sturge-Weber syndrome
502912951,7/14/2014 14:21:04,,1322877594,7/14/2014 14:20:47,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,56,97,,,64,118,GLAUCOMA,STURGE-WEBER SYNDROME,GLAUCOMA choroidal hemangioma.,56-124-134,97-104-110-134-124,STURGE WEBER SYNDROME choroidal hemangioma.,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma.,56,97 104 110,56,97,64,118,-1,RO-has_manifestation,906368,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma,glaucoma,Sturge-Weber syndrome
502912951,7/14/2014 14:35:14,,1322887748,7/14/2014 14:35:03,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,56,97,,,64,118,GLAUCOMA,STURGE-WEBER SYNDROME,Ahmed GLAUCOMA valve,50-56-65,97-104-110-119-124-134,STURGE WEBER SYNDROME with choroidal hemangioma.,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma.,56,97 104 110,56,97,64,118,-1,RO-has_manifestation,906368,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma,glaucoma,Sturge-Weber syndrome
502912951,7/14/2014 14:48:57,,1322896763,7/14/2014 14:48:44,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,56,97,,,64,118,GLAUCOMA,STURGE-WEBER SYNDROME,Ahmed GLAUCOMA valve,50-56-65,97-104-110,STURGE WEBER SYNDROME,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma.,56,97 104 110,56,97,64,118,-1,RO-has_manifestation,906368,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma,glaucoma,Sturge-Weber syndrome
502912951,7/14/2014 14:49:52,,1322897258,7/14/2014 14:49:31,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,56,97,,,64,118,GLAUCOMA,STURGE-WEBER SYNDROME,Ahmed GLAUCOMA,50-56,97-104-110-119-124-134,STURGE WEBER SYNDROME with choroidal hemangioma.,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma.,56,97 104 110,56,97,64,118,-1,RO-has_manifestation,906368,We present our experience with implantation of an Ahmed glaucoma valve in a 9-year-old girl with Sturge-Weber syndrome with choroidal hemangioma,glaucoma,Sturge-Weber syndrome
502912952,7/14/2014 12:53:32,,1322817203,7/14/2014 12:52:53,gifthulk,1.0,25566511,USA,"","",24.164.11.173,191,130,,,197,142,ANEMIA,EPOETIN ALFA,(severe ANEMIA and or granulocytopenia),183-191-198-202-205,130-138,"EPOETIN ALFA,","4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC.",191,130 138,191,130,197,142,1,RO-may_treat,907861,"4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC",anemia,epoetin alfa
502912952,7/14/2014 13:01:41,,1322822602,7/14/2014 13:01:22,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,191,130,,,197,142,ANEMIA,EPOETIN ALFA,ANEMIA,191,130-138,"EPOETIN ALFA,","4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC.",191,130 138,191,130,197,142,1,RO-may_treat,907861,"4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC",anemia,epoetin alfa
502912952,7/14/2014 13:06:26,,1322825624,7/14/2014 13:05:41,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,191,130,,,197,142,ANEMIA,EPOETIN ALFA,ANEMIA,191,130-138,"EPOETIN ALFA,","4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC.",191,130 138,191,130,197,142,1,RO-may_treat,907861,"4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC",anemia,epoetin alfa
502912952,7/14/2014 13:15:39,,1322831979,7/14/2014 13:14:43,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,191,130,,,197,142,ANEMIA,EPOETIN ALFA,"epoetin alfa, ameliorate hematologic toxicity (severe ANEMIA granulocytopenia) zidovudine therapy AIDS",130-138-162-174-183-191-205-239-250-280-147,130-138-147-162-174-183-191-205-239-250,"EPOETIN ALFA, ameliorate hematologic toxicity (severe anemia granulocytopenia) zidovudine therapy","4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC.",191,130 138,191,130,197,142,1,RO-may_treat,907861,"4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC",anemia,epoetin alfa
502912952,7/14/2014 13:16:22,,1322832534,7/14/2014 13:16:18,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,191,130,,,197,142,ANEMIA,EPOETIN ALFA,hematologic toxicity (severe ANEMIA and or granulocytopenia),162-174-183-191-198-202-205,110-113-125-130-138-144-147-158,"in conjunction with EPOETIN ALFA, to ameliorate the","4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC.",191,130 138,191,130,197,142,1,RO-may_treat,907861,"4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC",anemia,epoetin alfa
502912952,7/14/2014 13:46:49,,1322854070,7/14/2014 13:46:30,elite,1.0,26544151,GBR,"","",188.29.127.144,191,130,,,197,142,ANEMIA,EPOETIN ALFA,ANEMIA,191,130-138,"EPOETIN ALFA,","4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC.",191,130 138,191,130,197,142,1,RO-may_treat,907861,"4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC",anemia,epoetin alfa
502912952,7/14/2014 14:20:26,,1322877090,7/14/2014 14:20:00,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,191,130,,,197,142,ANEMIA,EPOETIN ALFA,ANEMIA AIDS,191-280,130-138-288,"EPOETIN ALFA, AIDS","4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC.",191,130 138,191,130,197,142,1,RO-may_treat,907861,"4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC",anemia,epoetin alfa
502912952,7/14/2014 14:27:17,,1322882083,7/14/2014 14:27:05,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,191,130,,,197,142,ANEMIA,EPOETIN ALFA,hematologic toxicity (severe ANEMIA and or granulocytopenia),162-174-183-191-198-202-205,130-138,"EPOETIN ALFA,","4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC.",191,130 138,191,130,197,142,1,RO-may_treat,907861,"4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC",anemia,epoetin alfa
502912952,7/14/2014 14:30:06,,1322884157,7/14/2014 14:30:03,instagc,1.0,27753923,GBR,"","",188.30.192.65,191,130,,,197,142,ANEMIA,EPOETIN ALFA,hematologic toxicity (severe ANEMIA and or granulocytopenia),162-174-183-191-198-202-205,110-113-125-130-138-144-147-158,"in conjunction with EPOETIN ALFA, to ameliorate the","4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC.",191,130 138,191,130,197,142,1,RO-may_treat,907861,"4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC",anemia,epoetin alfa
502912952,7/14/2014 14:44:46,,1322894231,7/14/2014 14:44:11,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,191,130,,,197,142,ANEMIA,EPOETIN ALFA,(severe ANEMIA,183-191,130-138,"EPOETIN ALFA,","4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC.",191,130 138,191,130,197,142,1,RO-may_treat,907861,"4 ,   25 ,   26 ,   27 ,   31 ,   38 ,   52 ,   54 ,   59 ,   77 ,   130 ,   131 ,   132  Treatment, alone or in conjunction with epoetin alfa, to ameliorate the hematologic toxicity (severe anemia and/or granulocytopenia) associated with zidovudine therapy   +    in adults with AIDS or AIDS-related complex (ARC",anemia,epoetin alfa
502912953,7/14/2014 12:47:34,,1322813054,7/14/2014 12:47:29,clixsense,1.0,24763049,GBR,"","",86.133.47.213,177,92,,,181,101,DRUG,TOLERANCE,administration of the DRUG after the test.,155-170-173-177-182-188-192,68-71-85-92-102-105-111,"an unintoxicated state, TOLERANCE is lost, even","When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test.",177,92,177,92,181,101,-1,RO-has_causative_agent,903512,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test",drug,tolerance
502912953,7/14/2014 13:03:18,,1322823682,7/14/2014 13:03:04,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,177,92,,,181,101,DRUG,TOLERANCE,DRUG,177,92,TOLERANCE,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test.",177,92,177,92,181,101,-1,RO-has_causative_agent,903512,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test",drug,tolerance
502912953,7/14/2014 13:13:09,,1322830313,7/14/2014 13:12:54,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,177,92,,,181,101,DRUG,TOLERANCE,DRUG,177,92,TOLERANCE,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test.",177,92,177,92,181,101,-1,RO-has_causative_agent,903512,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test",drug,tolerance
502912953,7/14/2014 13:45:35,,1322853013,7/14/2014 13:45:20,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,177,92,,,181,101,DRUG,TOLERANCE,DRUG,177,92,TOLERANCE,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test.",177,92,177,92,181,101,-1,RO-has_causative_agent,903512,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test",drug,tolerance
502912953,7/14/2014 13:50:02,,1322856362,7/14/2014 13:49:44,elite,1.0,26544151,GBR,"","",188.29.127.144,177,92,,,181,101,DRUG,TOLERANCE,DRUG,177,92,TOLERANCE,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test.",177,92,177,92,181,101,-1,RO-has_causative_agent,903512,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test",drug,tolerance
502912953,7/14/2014 13:53:54,,1322859179,7/14/2014 13:53:36,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,177,92,,,181,101,DRUG,TOLERANCE,DRUG,177,92,TOLERANCE,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test.",177,92,177,92,181,101,-1,RO-has_causative_agent,903512,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test",drug,tolerance
502912953,7/14/2014 13:54:31,,1322859709,7/14/2014 13:53:20,inboxpounds,1.0,18398050,GBR,"","",87.113.18.171,177,92,,,181,101,DRUG,TOLERANCE,administration of the DRUG after the test.,155-170-173-177-182-188-192,68-71-85-92-102-105-111,"an unintoxicated state, TOLERANCE is lost, even","When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test.",177,92,177,92,181,101,-1,RO-has_causative_agent,903512,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test",drug,tolerance
502912953,7/14/2014 14:20:53,,1322877468,7/14/2014 14:20:47,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,177,92,,,181,101,DRUG,TOLERANCE,administration of the DRUG after the test.,155-170-173-177-182-188-192,68-71-85-92-102-105-111,"an unintoxicated state, TOLERANCE is lost, even","When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test.",177,92,177,92,181,101,-1,RO-has_causative_agent,903512,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test",drug,tolerance
502912953,7/14/2014 14:24:26,,1322879879,7/14/2014 14:24:22,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,177,92,,,181,101,DRUG,TOLERANCE,administration of the DRUG after the test.,155-170-173-177-182-188-192,68-71-85-92-102-105-111,"an unintoxicated state, TOLERANCE is lost, even","When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test.",177,92,177,92,181,101,-1,RO-has_causative_agent,903512,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test",drug,tolerance
502912953,7/14/2014 14:26:08,,1322881165,7/14/2014 14:25:47,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,177,92,,,181,101,DRUG,TOLERANCE,DRUG,177,92,TOLERANCE,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test.",177,92,177,92,181,101,-1,RO-has_causative_agent,903512,"When tolerant rats are later allowed to drink milk from a bottle in an unintoxicated state, tolerance is lost, even when drug exposure is held constant by administration of the drug after the test",drug,tolerance
502912954,7/14/2014 12:58:55,,1322820817,7/14/2014 12:58:44,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,44,80,,,51,107,ASCITES,ADENOCARCINOMA OF THE OVARY,moderate ASCITES,35-44,80-95-98-102,ADENOCARCINOMA OF THE OVARY.,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary.,44,80 95 98 102,44,80,51,107,1,RO-disease_may_have_finding,902568,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary,ascites,adenocarcinoma of the ovary
502912954,7/14/2014 13:08:14,,1322826957,7/14/2014 13:07:53,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,44,80,,,51,107,ASCITES,ADENOCARCINOMA OF THE OVARY,ASCITES adenocarcinoma,44-80,80-95-98-102-44,ascites ADENOCARCINOMA OF THE OVARY.,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary.,44,80 95 98 102,44,80,51,107,1,RO-disease_may_have_finding,902568,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary,ascites,adenocarcinoma of the ovary
502912954,7/14/2014 13:29:56,,1322841758,7/14/2014 13:29:18,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,44,80,,,51,107,ASCITES,ADENOCARCINOMA OF THE OVARY,moderate ASCITES with diagnostic features adenocarcinoma of the ovary.,35-44-52-57-68-80-95-102-98,80-95-98-102,ADENOCARCINOMA OF THE OVARY.,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary.,44,80 95 98 102,44,80,51,107,1,RO-disease_may_have_finding,902568,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary,ascites,adenocarcinoma of the ovary
502912954,7/14/2014 13:31:21,,1322842638,7/14/2014 13:30:45,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,44,80,,,51,107,ASCITES,ADENOCARCINOMA OF THE OVARY,moderate ASCITES adenocarcinoma of the ovary.,35-44-80-95-98-102,35-80-95-98-102-44,moderate ascites ADENOCARCINOMA OF THE OVARY.,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary.,44,80 95 98 102,44,80,51,107,1,RO-disease_may_have_finding,902568,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary,ascites,adenocarcinoma of the ovary
502912954,7/14/2014 13:34:09,,1322844755,7/14/2014 13:33:53,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,44,80,,,51,107,ASCITES,ADENOCARCINOMA OF THE OVARY,moderate ASCITES,35-44,57-68-77-80-95-98-102,diagnostic features of ADENOCARCINOMA OF THE OVARY.,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary.,44,80 95 98 102,44,80,51,107,1,RO-disease_may_have_finding,902568,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary,ascites,adenocarcinoma of the ovary
502912954,7/14/2014 13:38:14,,1322847712,7/14/2014 13:37:56,clixsense,1.0,27969116,NLD,"","",91.213.37.165,44,80,,,51,107,ASCITES,ADENOCARCINOMA OF THE OVARY,ASCITES,44,80-95-98-102-44,ascites ADENOCARCINOMA OF THE OVARY.,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary.,44,80 95 98 102,44,80,51,107,1,RO-disease_may_have_finding,902568,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary,ascites,adenocarcinoma of the ovary
502912954,7/14/2014 13:40:34,,1322849479,7/14/2014 13:40:32,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,44,80,,,51,107,ASCITES,ADENOCARCINOMA OF THE OVARY,presented with moderate ASCITES with diagnostic features,20-30-35-44-52-57-68,57-68-77-80-95-98-102,diagnostic features of ADENOCARCINOMA OF THE OVARY.,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary.,44,80 95 98 102,44,80,51,107,1,RO-disease_may_have_finding,902568,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary,ascites,adenocarcinoma of the ovary
502912954,7/14/2014 14:42:16,,1322892570,7/14/2014 14:42:04,prodege,1.0,28209666,,,"",24.156.173.34,44,80,,,51,107,ASCITES,ADENOCARCINOMA OF THE OVARY,ASCITES,44,80-95-98-102,ADENOCARCINOMA OF THE OVARY.,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary.,44,80 95 98 102,44,80,51,107,1,RO-disease_may_have_finding,902568,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary,ascites,adenocarcinoma of the ovary
502912954,7/14/2014 14:43:46,,1322893614,7/14/2014 14:43:28,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,44,80,,,51,107,ASCITES,ADENOCARCINOMA OF THE OVARY,ASCITES,44,80-95-98-102,ADENOCARCINOMA OF THE OVARY.,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary.,44,80 95 98 102,44,80,51,107,1,RO-disease_may_have_finding,902568,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary,ascites,adenocarcinoma of the ovary
502912954,7/14/2014 14:48:42,,1322896634,7/14/2014 14:48:30,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,44,80,,,51,107,ASCITES,ADENOCARCINOMA OF THE OVARY,ASCITES,44,80-95-98-102,ADENOCARCINOMA OF THE OVARY.,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary.,44,80 95 98 102,44,80,51,107,1,RO-disease_may_have_finding,902568,A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary,ascites,adenocarcinoma of the ovary
502912955,7/14/2014 12:52:31,,1322816493,7/14/2014 12:52:20,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,544,518,,,559,526,TYPE 1 DIABETES,GLARGINE,TYPE 1 DIABETES,544-549-551,510-518,insulin GLARGINE,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis.",544 549 551,518,544,518,559,526,1,RO-may_treat,907694,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis",type 1 diabetes,glargine
502912955,7/14/2014 12:56:49,,1322819416,7/14/2014 12:56:30,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,544,518,,,559,526,TYPE 1 DIABETES,GLARGINE,TYPE 1 DIABETES,544-549-551,518,GLARGINE,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis.",544 549 551,518,544,518,559,526,1,RO-may_treat,907694,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis",type 1 diabetes,glargine
502912955,7/14/2014 13:10:09,,1322828270,7/14/2014 13:09:42,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,544,518,,,559,526,TYPE 1 DIABETES,GLARGINE,TYPE 1 DIABETES,544-549-551,510-518,insulin GLARGINE,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis.",544 549 551,518,544,518,559,526,1,RO-may_treat,907694,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis",type 1 diabetes,glargine
502912955,7/14/2014 13:17:55,,1322833542,7/14/2014 13:16:35,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,544,518,,,559,526,TYPE 1 DIABETES,GLARGINE,Human epidermal growth insulin glargine TYPE 1 DIABETES dyslipidemia Low glycemic,115-121-131-518-544-549-551-575-631-635-510,115-121-131-510-518-544-549-551-575-631-635,Human epidermal growth insulin GLARGINE type 1 diabetes dyslipidemia Low glycemic,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis.",544 549 551,518,544,518,559,526,1,RO-may_treat,907694,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis",type 1 diabetes,glargine
502912955,7/14/2014 13:39:17,,1322848523,7/14/2014 13:38:52,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,544,518,,,559,526,TYPE 1 DIABETES,GLARGINE,in patients with TYPE 1 DIABETES Management of dyslipidemia,527-530-539-544-549-551-561-572-575,492-507-510-518-527-530-539,administration of insulin GLARGINE in patients with,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis.",544 549 551,518,544,518,559,526,1,RO-may_treat,907694,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis",type 1 diabetes,glargine
502912955,7/14/2014 13:53:33,,1322859001,7/14/2014 13:53:11,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,544,518,,,559,526,TYPE 1 DIABETES,GLARGINE,TYPE 1 DIABETES,544-549-551,510-518,insulin GLARGINE,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis.",544 549 551,518,544,518,559,526,1,RO-may_treat,907694,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis",type 1 diabetes,glargine
502912955,7/14/2014 14:43:48,,1322893642,7/14/2014 14:43:29,instagc,1.0,13763729,USA,"","",75.182.89.225,544,518,,,559,526,TYPE 1 DIABETES,GLARGINE,TYPE 1 DIABETES Management,544-549-551-561,518,GLARGINE,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis.",544 549 551,518,544,518,559,526,1,RO-may_treat,907694,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis",type 1 diabetes,glargine
502912955,7/14/2014 14:45:17,,1322894548,7/14/2014 14:45:03,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,544,518,,,559,526,TYPE 1 DIABETES,GLARGINE,TYPE 1 DIABETES,544-549-551,518,GLARGINE,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis.",544 549 551,518,544,518,559,526,1,RO-may_treat,907694,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis",type 1 diabetes,glargine
502912955,7/14/2014 14:45:18,,1322894596,7/14/2014 14:45:08,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,544,518,,,559,526,TYPE 1 DIABETES,GLARGINE,TYPE 1 DIABETES,544-549-551,510-518,insulin GLARGINE,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis.",544 549 551,518,544,518,559,526,1,RO-may_treat,907694,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis",type 1 diabetes,glargine
502912955,7/14/2014 14:49:59,,1322897335,7/14/2014 14:49:41,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,544,518,,,559,526,TYPE 1 DIABETES,GLARGINE,TYPE 1 DIABETES,544-549-551,510-518,insulin GLARGINE,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis.",544 549 551,518,544,518,559,526,1,RO-may_treat,907694,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes  Management of dyslipidemia in children and adolescents with diabetes  Low-glycemic index diets in the management of diabetes: a meta-analysis",type 1 diabetes,glargine
502912956,7/14/2014 13:01:32,,1322822458,7/14/2014 13:01:24,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,38,0,,,64,17,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,COMPLICATIONS OF PREGNANCY.,38-52-55,0-8,ECTOPIC PREGNANCY,Ectopic pregnancy is one of the major complications of pregnancy.,38 52 55,0 8,38,0,64,17,-1,RO-disease_has_finding,901953,Ectopic pregnancy is one of the major complications of pregnancy,complications of pregnancy,Ectopic pregnancy
502912956,7/14/2014 13:07:23,,1322826290,7/14/2014 13:06:44,gifthulk,1.0,25566511,USA,"","",24.164.11.173,38,0,,,64,17,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,COMPLICATIONS OF PREGNANCY.,38-52-55,0-8,ECTOPIC PREGNANCY,Ectopic pregnancy is one of the major complications of pregnancy.,38 52 55,0 8,38,0,64,17,-1,RO-disease_has_finding,901953,Ectopic pregnancy is one of the major complications of pregnancy,complications of pregnancy,Ectopic pregnancy
502912956,7/14/2014 13:14:13,,1322831052,7/14/2014 13:14:07,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,38,0,,,64,17,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,of the major COMPLICATIONS OF PREGNANCY.,25-28-32-38-52-55,0-8-18-21-25,ECTOPIC PREGNANCY is one of,Ectopic pregnancy is one of the major complications of pregnancy.,38 52 55,0 8,38,0,64,17,-1,RO-disease_has_finding,901953,Ectopic pregnancy is one of the major complications of pregnancy,complications of pregnancy,Ectopic pregnancy
502912956,7/14/2014 13:19:32,,1322834525,7/14/2014 13:19:20,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,38,0,,,64,17,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,COMPLICATIONS OF PREGNANCY.,38-52-55,0-8,ECTOPIC PREGNANCY,Ectopic pregnancy is one of the major complications of pregnancy.,38 52 55,0 8,38,0,64,17,-1,RO-disease_has_finding,901953,Ectopic pregnancy is one of the major complications of pregnancy,complications of pregnancy,Ectopic pregnancy
502912956,7/14/2014 13:39:21,,1322848552,7/14/2014 13:39:17,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,38,0,,,64,17,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,of the major COMPLICATIONS OF PREGNANCY.,25-28-32-38-52-55,0-8-18-21-25,ECTOPIC PREGNANCY is one of,Ectopic pregnancy is one of the major complications of pregnancy.,38 52 55,0 8,38,0,64,17,-1,RO-disease_has_finding,901953,Ectopic pregnancy is one of the major complications of pregnancy,complications of pregnancy,Ectopic pregnancy
502912956,7/14/2014 13:51:16,,1322857392,7/14/2014 13:51:04,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,38,0,,,64,17,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,COMPLICATIONS OF PREGNANCY.,38-52-55,0-8,ECTOPIC PREGNANCY,Ectopic pregnancy is one of the major complications of pregnancy.,38 52 55,0 8,38,0,64,17,-1,RO-disease_has_finding,901953,Ectopic pregnancy is one of the major complications of pregnancy,complications of pregnancy,Ectopic pregnancy
502912956,7/14/2014 13:51:23,,1322857430,7/14/2014 13:51:11,elite,1.0,26544151,GBR,"","",188.29.127.144,38,0,,,64,17,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,COMPLICATIONS OF PREGNANCY.,38-52-55,0-8,ECTOPIC PREGNANCY,Ectopic pregnancy is one of the major complications of pregnancy.,38 52 55,0 8,38,0,64,17,-1,RO-disease_has_finding,901953,Ectopic pregnancy is one of the major complications of pregnancy,complications of pregnancy,Ectopic pregnancy
502912956,7/14/2014 13:56:17,,1322860829,7/14/2014 13:56:09,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,38,0,,,64,17,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,COMPLICATIONS OF PREGNANCY.,38-52-55,0-8,ECTOPIC PREGNANCY,Ectopic pregnancy is one of the major complications of pregnancy.,38 52 55,0 8,38,0,64,17,-1,RO-disease_has_finding,901953,Ectopic pregnancy is one of the major complications of pregnancy,complications of pregnancy,Ectopic pregnancy
502912956,7/14/2014 14:03:10,,1322865605,7/14/2014 14:02:56,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,38,0,,,64,17,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,COMPLICATIONS OF PREGNANCY.,38-52-55,0-8,ECTOPIC PREGNANCY,Ectopic pregnancy is one of the major complications of pregnancy.,38 52 55,0 8,38,0,64,17,-1,RO-disease_has_finding,901953,Ectopic pregnancy is one of the major complications of pregnancy,complications of pregnancy,Ectopic pregnancy
502912956,7/14/2014 14:06:01,,1322867448,7/14/2014 14:05:38,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,38,0,,,64,17,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,Ectopic pregnancy COMPLICATIONS OF PREGNANCY.,0-38-52-55-8,0-8,ECTOPIC PREGNANCY,Ectopic pregnancy is one of the major complications of pregnancy.,38 52 55,0 8,38,0,64,17,-1,RO-disease_has_finding,901953,Ectopic pregnancy is one of the major complications of pregnancy,complications of pregnancy,Ectopic pregnancy
502912957,7/14/2014 13:20:21,,1322835112,7/14/2014 13:19:53,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,24,0,,,49,12,COMPLICATION OF PREGNANCY,PREECLAMPSIA,COMPLICATION OF PREGNANCY,24-37-40,0,PREECLAMPSIA,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease.,24 37 40,0,24,0,49,12,-1,RO-disease_has_finding,901762,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease,complication of pregnancy,Preeclampsia
502912957,7/14/2014 13:34:41,,1322845170,7/14/2014 13:34:23,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,24,0,,,49,12,COMPLICATION OF PREGNANCY,PREECLAMPSIA,is a major COMPLICATION OF PREGNANCY and a predictor,13-16-18-24-37-40-50-54-56,0-13-16-18,PREECLAMPSIA is a major,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease.,24 37 40,0,24,0,49,12,-1,RO-disease_has_finding,901762,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease,complication of pregnancy,Preeclampsia
502912957,7/14/2014 13:48:16,,1322855197,7/14/2014 13:47:54,elite,1.0,26544151,GBR,"","",188.29.127.144,24,0,,,49,12,COMPLICATION OF PREGNANCY,PREECLAMPSIA,COMPLICATION OF PREGNANCY,24-37-40,0,PREECLAMPSIA,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease.,24 37 40,0,24,0,49,12,-1,RO-disease_has_finding,901762,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease,complication of pregnancy,Preeclampsia
502912957,7/14/2014 13:52:03,,1322857950,7/14/2014 13:51:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,24,0,,,49,12,COMPLICATION OF PREGNANCY,PREECLAMPSIA,Preeclampsia is a COMPLICATION OF PREGNANCY,0-13-24-37-40-16,0-13-16-24-37-40,PREECLAMPSIA is a complication of pregnancy,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease.,24 37 40,0,24,0,49,12,-1,RO-disease_has_finding,901762,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease,complication of pregnancy,Preeclampsia
502912957,7/14/2014 14:21:46,,1322878077,7/14/2014 14:21:41,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,24,0,,,49,12,COMPLICATION OF PREGNANCY,PREECLAMPSIA,is a major COMPLICATION OF PREGNANCY and a predictor,13-16-18-24-37-40-50-54-56,0-13-16-18,PREECLAMPSIA is a major,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease.,24 37 40,0,24,0,49,12,-1,RO-disease_has_finding,901762,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease,complication of pregnancy,Preeclampsia
502912957,7/14/2014 14:24:52,,1322880282,7/14/2014 14:24:38,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,24,0,,,49,12,COMPLICATION OF PREGNANCY,PREECLAMPSIA,COMPLICATION OF PREGNANCY,24-37-40,0,PREECLAMPSIA,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease.,24 37 40,0,24,0,49,12,-1,RO-disease_has_finding,901762,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease,complication of pregnancy,Preeclampsia
502912957,7/14/2014 14:29:18,,1322883542,7/14/2014 14:29:16,instagc,1.0,27753923,GBR,"","",188.30.192.65,24,0,,,49,12,COMPLICATION OF PREGNANCY,PREECLAMPSIA,is a major COMPLICATION OF PREGNANCY and a predictor,13-16-18-24-37-40-50-54-56,0-13-16-18,PREECLAMPSIA is a major,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease.,24 37 40,0,24,0,49,12,-1,RO-disease_has_finding,901762,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease,complication of pregnancy,Preeclampsia
502912957,7/14/2014 14:48:01,,1322896208,7/14/2014 14:47:48,instagc,1.0,13763729,USA,"","",75.182.89.225,24,0,,,49,12,COMPLICATION OF PREGNANCY,PREECLAMPSIA,COMPLICATION OF PREGNANCY,24-37-40,0,PREECLAMPSIA,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease.,24 37 40,0,24,0,49,12,-1,RO-disease_has_finding,901762,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease,complication of pregnancy,Preeclampsia
502912957,7/14/2014 14:49:28,,1322896972,7/14/2014 14:49:19,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,24,0,,,49,12,COMPLICATION OF PREGNANCY,PREECLAMPSIA,COMPLICATION OF PREGNANCY,24-37-40,0,PREECLAMPSIA,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease.,24 37 40,0,24,0,49,12,-1,RO-disease_has_finding,901762,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease,complication of pregnancy,Preeclampsia
502912957,7/14/2014 14:50:14,,1322897506,7/14/2014 14:50:00,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,24,0,,,49,12,COMPLICATION OF PREGNANCY,PREECLAMPSIA,COMPLICATION OF PREGNANCY,24-37-40,0,PREECLAMPSIA,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease.,24 37 40,0,24,0,49,12,-1,RO-disease_has_finding,901762,Preeclampsia is a major complication of pregnancy and a predictor of future chronic disease,complication of pregnancy,Preeclampsia
502912958,7/14/2014 12:46:57,,1322812614,7/14/2014 12:46:53,clixsense,1.0,24763049,GBR,"","",86.133.47.213,38,120,,,56,133,CUSHING'S SYNDROME,DEXAMETHASONE,"cases of cyclic CUSHING'S SYNDROME are reviewed, and",22-28-31-38-48-57-61-71,106-109-117-120-134-146-154,of results of DEXAMETHASONE suppression testing in,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed.",38 48,120,38,120,56,133,1,RO-may_diagnose,906668,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed",Cushing's syndrome,dexamethasone
502912958,7/14/2014 12:49:10,,1322814128,7/14/2014 12:48:54,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,38,120,,,56,133,CUSHING'S SYNDROME,DEXAMETHASONE,cyclic CUSHING'S SYNDROME,31-38-48,120-134,DEXAMETHASONE suppression,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed.",38 48,120,38,120,56,133,1,RO-may_diagnose,906668,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed",Cushing's syndrome,dexamethasone
502912958,7/14/2014 12:53:58,,1322817568,7/14/2014 12:53:52,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,38,120,,,56,133,CUSHING'S SYNDROME,DEXAMETHASONE,"cases of cyclic CUSHING'S SYNDROME are reviewed, and in",22-28-31-38-48-57-61-71-198,106-109-117-120-134-146-154-225,of results of DEXAMETHASONE suppression testing in discussed.,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed.",38 48,120,38,120,56,133,1,RO-may_diagnose,906668,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed",Cushing's syndrome,dexamethasone
502912958,7/14/2014 13:19:59,,1322834906,7/14/2014 13:18:00,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,38,120,,,56,133,CUSHING'S SYNDROME,DEXAMETHASONE,"cases of cyclic CUSHING'S SYNDROME are reviewed, and",22-28-31-38-48-57-61-71,106-109-117-120-134-146-154,of results of DEXAMETHASONE suppression testing in,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed.",38 48,120,38,120,56,133,1,RO-may_diagnose,906668,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed",Cushing's syndrome,dexamethasone
502912958,7/14/2014 13:27:42,,1322840214,7/14/2014 13:27:17,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,38,120,,,56,133,CUSHING'S SYNDROME,DEXAMETHASONE,cyclic CUSHING'S SYNDROME,31-38-48,106-120-134-146-201-210,of DEXAMETHASONE suppression testing cortisol production,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed.",38 48,120,38,120,56,133,1,RO-may_diagnose,906668,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed",Cushing's syndrome,dexamethasone
502912958,7/14/2014 13:32:15,,1322843241,7/14/2014 13:31:27,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,38,120,,,56,133,CUSHING'S SYNDROME,DEXAMETHASONE,cyclic CUSHING'S SYNDROME dexamethasone suppression,31-38-48-120-134,31-38-120-134-48,cyclic Cushing's syndrome DEXAMETHASONE suppression,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed.",38 48,120,38,120,56,133,1,RO-may_diagnose,906668,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed",Cushing's syndrome,dexamethasone
502912958,7/14/2014 14:01:01,,1322864125,7/14/2014 14:00:28,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,38,120,,,56,133,CUSHING'S SYNDROME,DEXAMETHASONE,CUSHING'S SYNDROME,38-48,120,DEXAMETHASONE,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed.",38 48,120,38,120,56,133,1,RO-may_diagnose,906668,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed",Cushing's syndrome,dexamethasone
502912958,7/14/2014 14:29:48,,1322883956,7/14/2014 14:29:46,instagc,1.0,27753923,GBR,"","",188.30.192.65,38,120,,,56,133,CUSHING'S SYNDROME,DEXAMETHASONE,"cases of cyclic CUSHING'S SYNDROME are reviewed, and",22-28-31-38-48-57-61-71,106-109-117-120-134-146-154,of results of DEXAMETHASONE suppression testing in,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed.",38 48,120,38,120,56,133,1,RO-may_diagnose,906668,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed",Cushing's syndrome,dexamethasone
502912958,7/14/2014 14:36:19,,1322888508,7/14/2014 14:36:00,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,38,120,,,56,133,CUSHING'S SYNDROME,DEXAMETHASONE,cyclic CUSHING'S SYNDROME,31-38-48,120-134,DEXAMETHASONE suppression,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed.",38 48,120,38,120,56,133,1,RO-may_diagnose,906668,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed",Cushing's syndrome,dexamethasone
502912958,7/14/2014 14:41:16,,1322891858,7/14/2014 14:41:04,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,38,120,,,56,133,CUSHING'S SYNDROME,DEXAMETHASONE,"cases of cyclic CUSHING'S SYNDROME are reviewed, and",22-28-31-38-48-57-61-71,106-109-117-120-134-146-154,of results of DEXAMETHASONE suppression testing in,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed.",38 48,120,38,120,56,133,1,RO-may_diagnose,906668,"Previously documented cases of cyclic Cushing's syndrome are reviewed, and the pitfalls in interpretation of results of dexamethasone suppression testing in the presence of spontaneous fluctuations in cortisol production are discussed",Cushing's syndrome,dexamethasone
502912959,7/14/2014 12:52:52,,1322816716,7/14/2014 12:51:54,gifthulk,1.0,25566511,USA,"","",24.164.11.173,75,32,,,91,41,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA:,75-84,32-42-47,MELPHALAN plus prednisone,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.",75 84,32,75,32,91,41,1,RO-may_treat,907938,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials",multiple myeloma,melphalan
502912959,7/14/2014 12:56:11,,1322818980,7/14/2014 12:56:04,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,75,32,,,91,41,MULTIPLE MYELOMA,MELPHALAN,as treatment for MULTIPLE MYELOMA: an overview of patients,58-61-71-75-84-93-96-105-114,0-12-25-32-42-47-58-114,Combination chemotherapy versus MELPHALAN plus prednisone as patients,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.",75 84,32,75,32,91,41,1,RO-may_treat,907938,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials",multiple myeloma,melphalan
502912959,7/14/2014 13:11:28,,1322829088,7/14/2014 13:10:45,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,75,32,,,91,41,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA:,75-84,32,MELPHALAN,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.",75 84,32,75,32,91,41,1,RO-may_treat,907938,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials",multiple myeloma,melphalan
502912959,7/14/2014 13:15:10,,1322831640,7/14/2014 13:14:34,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,75,32,,,91,41,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA:,75-84,32,MELPHALAN,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.",75 84,32,75,32,91,41,1,RO-may_treat,907938,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials",multiple myeloma,melphalan
502912959,7/14/2014 13:16:10,,1322832369,7/14/2014 13:16:06,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,75,32,,,91,41,MULTIPLE MYELOMA,MELPHALAN,as treatment for MULTIPLE MYELOMA: an overview of,58-61-71-75-84-93-96-105,0-12-25-32-42-47-58,Combination chemotherapy versus MELPHALAN plus prednisone as,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.",75 84,32,75,32,91,41,1,RO-may_treat,907938,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials",multiple myeloma,melphalan
502912959,7/14/2014 13:19:52,,1322834837,7/14/2014 13:19:20,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,75,32,,,91,41,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA:,75-84,32,MELPHALAN,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.",75 84,32,75,32,91,41,1,RO-may_treat,907938,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials",multiple myeloma,melphalan
502912959,7/14/2014 13:41:39,,1322850191,7/14/2014 13:41:23,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,75,32,,,91,41,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA:,75-84,32,MELPHALAN,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.",75 84,32,75,32,91,41,1,RO-may_treat,907938,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials",multiple myeloma,melphalan
502912959,7/14/2014 13:53:09,,1322858683,7/14/2014 13:52:52,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,75,32,,,91,41,MULTIPLE MYELOMA,MELPHALAN,treatment for MULTIPLE MYELOMA:,61-71-75-84,0-12-25-32-42-47-58-61,Combination chemotherapy versus MELPHALAN plus prednisone as treatment,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.",75 84,32,75,32,91,41,1,RO-may_treat,907938,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials",multiple myeloma,melphalan
502912959,7/14/2014 14:43:59,,1322893771,7/14/2014 14:43:45,prodege,1.0,28209666,,,"",24.156.173.34,75,32,,,91,41,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA: of,75-84-105,32,MELPHALAN,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.",75 84,32,75,32,91,41,1,RO-may_treat,907938,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials",multiple myeloma,melphalan
502912959,7/14/2014 14:45:39,,1322894829,7/14/2014 14:45:30,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,75,32,,,91,41,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA:,75-84,32,MELPHALAN,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.",75 84,32,75,32,91,41,1,RO-may_treat,907938,"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials",multiple myeloma,melphalan
502912960,7/14/2014 12:56:27,,1322819209,7/14/2014 12:56:07,bitcoinget,1,24792414,USA,"","",166.181.81.129,58,144,,,79,172,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII,58-69,144-150-159-167,ROCKY MOUNTAIN SPOTTED FEVER,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus.,58 69,144 150 159 167,58,144,79,172,1,RO-has_causative_agent,903784,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus,Rickettsia rickettsii,Rocky Mountain spotted fever
502912960,7/14/2014 12:56:52,,1322819434,7/14/2014 12:55:26,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,58,144,,,79,172,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII,58-69,144-150-159-167,ROCKY MOUNTAIN SPOTTED FEVER,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus.,58 69,144 150 159 167,58,144,79,172,1,RO-has_causative_agent,903784,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus,Rickettsia rickettsii,Rocky Mountain spotted fever
502912960,7/14/2014 12:57:01,,1322819503,7/14/2014 12:56:56,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,58,144,,,79,172,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,antigen sequence of RICKETTSIA RICKETTSII amplified specifically a bp,38-46-55-58-69-80-90-103-109,130-134-141-144-150-159-167-173-177-185-112,DNA the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus.,58 69,144 150 159 167,58,144,79,172,1,RO-has_causative_agent,903784,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus,Rickettsia rickettsii,Rocky Mountain spotted fever
502912960,7/14/2014 12:58:01,,1322820155,7/14/2014 12:57:45,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,58,144,,,79,172,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII,58-69,144-150-159-167,ROCKY MOUNTAIN SPOTTED FEVER,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus.,58 69,144 150 159 167,58,144,79,172,1,RO-has_causative_agent,903784,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus,Rickettsia rickettsii,Rocky Mountain spotted fever
502912960,7/14/2014 13:08:57,,1322827409,7/14/2014 13:08:21,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,58,144,,,79,172,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII,58-69,144-150-159-167,ROCKY MOUNTAIN SPOTTED FEVER,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus.,58 69,144 150 159 167,58,144,79,172,1,RO-has_causative_agent,903784,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus,Rickettsia rickettsii,Rocky Mountain spotted fever
502912960,7/14/2014 13:12:30,,1322829768,7/14/2014 13:12:13,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,58,144,,,79,172,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII,58-69,144-150-159-167,ROCKY MOUNTAIN SPOTTED FEVER,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus.,58 69,144 150 159 167,58,144,79,172,1,RO-has_causative_agent,903784,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus,Rickettsia rickettsii,Rocky Mountain spotted fever
502912960,7/14/2014 13:39:32,,1322848687,7/14/2014 13:39:29,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,58,144,,,79,172,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,antigen sequence of RICKETTSIA RICKETTSII amplified specifically a,38-46-55-58-69-80-90-103,130-134-141-144-150-159-167-173-177-185,the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus.,58 69,144 150 159 167,58,144,79,172,1,RO-has_causative_agent,903784,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus,Rickettsia rickettsii,Rocky Mountain spotted fever
502912960,7/14/2014 13:44:50,,1322852487,7/14/2014 13:44:07,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,58,144,,,79,172,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII,58-69,144-150-159-167,ROCKY MOUNTAIN SPOTTED FEVER,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus.,58 69,144 150 159 167,58,144,79,172,1,RO-has_causative_agent,903784,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus,Rickettsia rickettsii,Rocky Mountain spotted fever
502912960,7/14/2014 13:52:51,,1322858494,7/14/2014 13:52:28,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,58,144,,,79,172,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,sequence of RICKETTSIA RICKETTSII,46-55-58-69,130-134-141-144-150-159-167,the genome of ROCKY MOUNTAIN SPOTTED FEVER,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus.,58 69,144 150 159 167,58,144,79,172,1,RO-has_causative_agent,903784,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus,Rickettsia rickettsii,Rocky Mountain spotted fever
502912960,7/14/2014 14:04:08,,1322866224,7/14/2014 14:03:49,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,58,144,,,79,172,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RICKETTSIA RICKETTSII,58-69,144-150-159-167,ROCKY MOUNTAIN SPOTTED FEVER,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus.,58 69,144 150 159 167,58,144,79,172,1,RO-has_causative_agent,903784,A primer pair derived from the 17-kDa antigen sequence of Rickettsia rickettsii amplified specifically a 434-bp DNA fragment from the genome of Rocky Mountain spotted fever and endemic and epidemic typhus,Rickettsia rickettsii,Rocky Mountain spotted fever
502912961,7/14/2014 12:58:19,,1322820357,7/14/2014 12:57:59,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,70,119,,,103,153,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV) infection,70-76-93-99-105,119-128-145,ACQUIRED IMMUNODEFICIENCY SYNDROME.,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.,70 76 93 99,119 128 145,70,119,103,153,-1,RO-has_causative_agent,903607,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome
502912961,7/14/2014 13:09:00,,1322827476,7/14/2014 13:08:36,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,70,119,,,103,153,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME,hematologic HUMAN IMMUNODEFICIENCY VIRUS (HIV) immunodeficiency syndrome.,42-70-76-93-99-128-145,76-99-119-128-145-42,hematologic immunodeficiency (HIV) ACQUIRED IMMUNODEFICIENCY SYNDROME.,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.,70 76 93 99,119 128 145,70,119,103,153,-1,RO-has_causative_agent,903607,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome
502912961,7/14/2014 13:23:34,,1322837566,7/14/2014 13:23:20,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,70,119,,,103,153,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV),70-76-93-99,119-128-145,ACQUIRED IMMUNODEFICIENCY SYNDROME.,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.,70 76 93 99,119 128 145,70,119,103,153,-1,RO-has_causative_agent,903607,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome
502912961,7/14/2014 13:33:14,,1322844127,7/14/2014 13:32:19,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,70,119,,,103,153,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME,Anemia hematologic complication HUMAN IMMUNODEFICIENCY VIRUS (HIV) acquired immunodeficiency syndrome.,0-42-54-70-76-93-99-119-128-145,0-42-54-76-99-119-128-145-93,Anemia hematologic complication immunodeficiency virus (HIV) ACQUIRED IMMUNODEFICIENCY SYNDROME.,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.,70 76 93 99,119 128 145,70,119,103,153,-1,RO-has_causative_agent,903607,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome
502912961,7/14/2014 13:35:54,,1322846002,7/14/2014 13:35:37,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,70,119,,,103,153,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME,hematologic complication in HUMAN IMMUNODEFICIENCY VIRUS (HIV) infection,42-54-67-70-76-93-99-105,99-105-115-119-128-145,(HIV) infection and ACQUIRED IMMUNODEFICIENCY SYNDROME.,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.,70 76 93 99,119 128 145,70,119,103,153,-1,RO-has_causative_agent,903607,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome
502912961,7/14/2014 13:43:24,,1322851543,7/14/2014 13:43:01,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,70,119,,,103,153,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME,hematologic complication in HUMAN IMMUNODEFICIENCY VIRUS (HIV) infection,42-54-67-70-76-93-99-105,99-105-115-119-128-145,(HIV) infection and ACQUIRED IMMUNODEFICIENCY SYNDROME.,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.,70 76 93 99,119 128 145,70,119,103,153,-1,RO-has_causative_agent,903607,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome
502912961,7/14/2014 14:35:30,,1322887960,7/14/2014 14:35:15,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,70,119,,,103,153,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV) infection,70-76-93-99-105,76-93-99-105-115-119-128-145-70,human immunodeficiency virus (HIV) infection and ACQUIRED IMMUNODEFICIENCY SYNDROME.,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.,70 76 93 99,119 128 145,70,119,103,153,-1,RO-has_causative_agent,903607,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome
502912961,7/14/2014 14:40:10,,1322891172,7/14/2014 14:40:05,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,70,119,,,103,153,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME,hematologic complication in HUMAN IMMUNODEFICIENCY VIRUS (HIV) infection and acquired,42-54-67-70-76-93-99-105-115-119,99-105-115-119-128-145,(HIV) infection and ACQUIRED IMMUNODEFICIENCY SYNDROME.,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.,70 76 93 99,119 128 145,70,119,103,153,-1,RO-has_causative_agent,903607,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome
502912961,7/14/2014 14:45:56,,1322894961,7/14/2014 14:45:48,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,70,119,,,103,153,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV),70-76-93-99,119-128-145,ACQUIRED IMMUNODEFICIENCY SYNDROME.,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.,70 76 93 99,119 128 145,70,119,103,153,-1,RO-has_causative_agent,903607,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome
502912961,7/14/2014 14:47:25,,1322895853,7/14/2014 14:47:09,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,70,119,,,103,153,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNODEFICIENCY SYNDROME,hematologic complication in HUMAN IMMUNODEFICIENCY VIRUS (HIV) infection,42-54-67-70-76-93-99-105,99-105-115-119-128-145,(HIV) infection and ACQUIRED IMMUNODEFICIENCY SYNDROME.,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.,70 76 93 99,119 128 145,70,119,103,153,-1,RO-has_causative_agent,903607,Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome,human immunodeficiency virus (HIV,acquired immunodeficiency syndrome
502912962,7/14/2014 12:54:09,,1322817649,7/14/2014 12:53:33,gifthulk,1.0,25566511,USA,"","",24.164.11.173,334,363,,,339,371,ERGOT,ERGOTISM,ERGOT alkaloids,334-340,363,ERGOTISM),"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",334,363,334,363,339,371,1,RO-has_causative_agent,903773,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",ergot,ergotism
502912962,7/14/2014 13:14:19,,1322831096,7/14/2014 13:14:14,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,334,363,,,339,371,ERGOT,ERGOTISM,plasma concentrations of ERGOT alkaloids resulting in,309-316-331-334-340-350-360,340-350-360-363-375-379-391,alkaloids resulting in ERGOTISM) 1 Concomitant use,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",334,363,334,363,339,371,1,RO-has_causative_agent,903773,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",ergot,ergotism
502912962,7/14/2014 13:16:30,,1322832622,7/14/2014 13:16:14,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,334,363,,,339,371,ERGOT,ERGOTISM,ERGOT alkaloids,334-340,363,ERGOTISM),"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",334,363,334,363,339,371,1,RO-has_causative_agent,903773,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",ergot,ergotism
502912962,7/14/2014 13:17:55,,1322833543,7/14/2014 13:17:35,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,334,363,,,339,371,ERGOT,ERGOTISM,ERGOT alkaloids,334-340,340-350-360-363,alkaloids resulting in ERGOTISM),"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",334,363,334,363,339,371,1,RO-has_causative_agent,903773,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",ergot,ergotism
502912962,7/14/2014 13:25:34,,1322838842,7/14/2014 13:24:38,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,334,363,,,339,371,ERGOT,ERGOTISM,plasma concentrations of ERGOT alkaloids,309-316-331-334-340,363,ERGOTISM),"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",334,363,334,363,339,371,1,RO-has_causative_agent,903773,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",ergot,ergotism
502912962,7/14/2014 13:39:57,,1322849038,7/14/2014 13:39:54,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,334,363,,,339,371,ERGOT,ERGOTISM,plasma concentrations of ERGOT alkaloids resulting in,309-316-331-334-340-350-360,340-350-360-363-375-379-391,alkaloids resulting in ERGOTISM) 1 Concomitant use,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",334,363,334,363,339,371,1,RO-has_causative_agent,903773,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",ergot,ergotism
502912962,7/14/2014 13:44:09,,1322852104,7/14/2014 13:43:48,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,334,363,,,339,371,ERGOT,ERGOTISM,ERGOT,334,363,ERGOTISM),"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",334,363,334,363,339,371,1,RO-has_causative_agent,903773,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",ergot,ergotism
502912962,7/14/2014 13:45:52,,1322853217,7/14/2014 13:45:18,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,334,363,,,339,371,ERGOT,ERGOTISM,(increased plasma concentrations of ERGOT alkaloids resulting in ergotism),298-309-316-331-334-340-350-360-363,298-309-316-331-334-340-350-360-363,(increased plasma concentrations of ergot alkaloids resulting in ERGOTISM),"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",334,363,334,363,339,371,1,RO-has_causative_agent,903773,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",ergot,ergotism
502912962,7/14/2014 13:50:11,,1322856503,7/14/2014 13:49:51,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,334,363,,,339,371,ERGOT,ERGOTISM,ERGOT alkaloids,334-340,363,ERGOTISM),"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",334,363,334,363,339,371,1,RO-has_causative_agent,903773,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",ergot,ergotism
502912962,7/14/2014 13:59:10,,1322862781,7/14/2014 13:58:36,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,334,363,,,339,371,ERGOT,ERGOTISM,ERGOT alkaloids,334-340,363,ERGOTISM),"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",334,363,334,363,339,371,1,RO-has_causative_agent,903773,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine",ergot,ergotism
502912963,7/14/2014 13:03:07,,1322823576,7/14/2014 13:02:52,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,19,119,,,57,125,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET,Gilliam SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,0-19-28-38-44,0-119-135,Gilliam SUBSET erythematosus.,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus.,19 28 38 44,119,19,119,57,125,-1,RO-cause_of,900203,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus,subacute cutaneous lupus erythematosus,subset
502912963,7/14/2014 13:16:39,,1322832724,7/14/2014 13:16:10,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,19,119,,,57,125,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,19-28-38-44,119,SUBSET,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus.,19 28 38 44,119,19,119,57,125,-1,RO-cause_of,900203,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus,subacute cutaneous lupus erythematosus,subset
502912963,7/14/2014 13:37:52,,1322847502,7/14/2014 13:37:32,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,19,119,,,57,125,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE),19-28-38-44-58,70-76-85-99-110-112-119-126-129-135-94,lupus specific eruption that identifies a unique SUBSET of lupus erythematosus.,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus.,19 28 38 44,119,19,119,57,125,-1,RO-cause_of,900203,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus,subacute cutaneous lupus erythematosus,subset
502912963,7/14/2014 13:40:05,,1322849121,7/14/2014 13:40:02,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,19,119,,,57,125,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS as a,0-8-19-28-38-44-65-68,99-110-112-119-126-129-135,identifies a unique SUBSET of lupus erythematosus.,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus.,19 28 38 44,119,19,119,57,125,-1,RO-cause_of,900203,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus,subacute cutaneous lupus erythematosus,subset
502912963,7/14/2014 13:43:44,,1322851731,7/14/2014 13:43:25,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,19,119,,,57,125,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE),19-28-38-44-58,119-126-129-135,SUBSET of lupus erythematosus.,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus.,19 28 38 44,119,19,119,57,125,-1,RO-cause_of,900203,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus,subacute cutaneous lupus erythematosus,subset
502912963,7/14/2014 14:02:17,,1322864988,7/14/2014 14:01:34,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,19,119,,,57,125,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,19-28-38-44,19-28-38-44-119,subacute cutaneous lupus erythematosus SUBSET,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus.,19 28 38 44,119,19,119,57,125,-1,RO-cause_of,900203,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus,subacute cutaneous lupus erythematosus,subset
502912963,7/14/2014 14:43:19,,1322893226,7/14/2014 14:43:02,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,19,119,,,57,125,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,19-28-38-44,119,SUBSET,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus.,19 28 38 44,119,19,119,57,125,-1,RO-cause_of,900203,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus,subacute cutaneous lupus erythematosus,subset
502912963,7/14/2014 14:45:29,,1322894734,7/14/2014 14:45:19,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,19,119,,,57,125,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,19-28-38-44,119,SUBSET,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus.,19 28 38 44,119,19,119,57,125,-1,RO-cause_of,900203,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus,subacute cutaneous lupus erythematosus,subset
502912963,7/14/2014 14:45:39,,1322894818,7/14/2014 14:45:25,instagc,1.0,13763729,USA,"","",75.182.89.225,19,119,,,57,125,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,19-28-38-44,119-126-129-135,SUBSET of lupus erythematosus.,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus.,19 28 38 44,119,19,119,57,125,-1,RO-cause_of,900203,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus,subacute cutaneous lupus erythematosus,subset
502912963,7/14/2014 14:48:54,,1322896696,7/14/2014 14:48:36,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,19,119,,,57,125,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,19-28-38-44,119,SUBSET,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus.,19 28 38 44,119,19,119,57,125,-1,RO-cause_of,900203,Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus,subacute cutaneous lupus erythematosus,subset
502912964,7/14/2014 12:47:11,,1322812828,7/14/2014 12:46:41,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,134,85,,,151,91,ATOPIC DERMATITIS,ATOPIC,"perifollicular accentuation, with ATOPIC DERMATITIS (AD) lesions (ADL)",100-115-129-134-141-152-157-165,85-92-97-100-115,"ATOPIC skin or perifollicular accentuation,","The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase.",134 141,85,134,85,151,91,-1,RO-cause_of,900229,"The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase",atopic dermatitis,atopic
502912964,7/14/2014 13:03:35,,1322823842,7/14/2014 13:03:01,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,134,85,,,151,91,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS (AD) lesions,134-141-152-157,85-92,ATOPIC skin,"The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase.",134 141,85,134,85,151,91,-1,RO-cause_of,900229,"The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase",atopic dermatitis,atopic
502912964,7/14/2014 13:08:34,,1322827219,7/14/2014 13:08:17,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,134,85,,,151,91,ATOPIC DERMATITIS,ATOPIC,"perifollicular accentuation, ATOPIC DERMATITIS immunohistochemical",100-115-134-141-174,85-115-174,"ATOPIC accentuation, immunohistochemical","The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase.",134 141,85,134,85,151,91,-1,RO-cause_of,900229,"The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase",atopic dermatitis,atopic
502912964,7/14/2014 13:15:47,,1322832105,7/14/2014 13:15:43,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,134,85,,,151,91,ATOPIC DERMATITIS,ATOPIC,"perifollicular accentuation, with ATOPIC DERMATITIS lesions",100-115-129-134-141-157,69-75-78-85-92-97-100,"(FE), so called ATOPIC skin or perifollicular","The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase.",134 141,85,134,85,151,91,-1,RO-cause_of,900229,"The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase",atopic dermatitis,atopic
502912964,7/14/2014 13:37:36,,1322847289,7/14/2014 13:37:02,clixsense,1.0,27969116,NLD,"","",91.213.37.165,134,85,,,151,91,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS (AD) lesions (ADL),134-141-152-157-165,48-59-69-85-92-97-100-115,"follicular eruptions (FE), ATOPIC skin or perifollicular accentuation,","The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase.",134 141,85,134,85,151,91,-1,RO-cause_of,900229,"The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase",atopic dermatitis,atopic
502912964,7/14/2014 13:45:00,,1322852577,7/14/2014 13:44:29,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,134,85,,,151,91,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS (AD) lesions (ADL),134-141-152-157-165,85-92-97-100-115,"ATOPIC skin or perifollicular accentuation,","The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase.",134 141,85,134,85,151,91,-1,RO-cause_of,900229,"The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase",atopic dermatitis,atopic
502912964,7/14/2014 13:49:02,,1322855786,7/14/2014 13:48:25,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,134,85,,,151,91,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS (AD) lesions (ADL),134-141-152-157-165,85-92,ATOPIC skin,"The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase.",134 141,85,134,85,151,91,-1,RO-cause_of,900229,"The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase",atopic dermatitis,atopic
502912964,7/14/2014 13:51:06,,1322857225,7/14/2014 13:50:51,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,134,85,,,151,91,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,134-141,85,ATOPIC,"The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase.",134 141,85,134,85,151,91,-1,RO-cause_of,900229,"The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase",atopic dermatitis,atopic
502912964,7/14/2014 14:22:11,,1322878395,7/14/2014 14:22:05,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,134,85,,,151,91,ATOPIC DERMATITIS,ATOPIC,"perifollicular accentuation, with ATOPIC DERMATITIS lesions",100-115-129-134-141-157,69-75-78-85-92-97-100,"(FE), so called ATOPIC skin or perifollicular","The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase.",134 141,85,134,85,151,91,-1,RO-cause_of,900229,"The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase",atopic dermatitis,atopic
502912964,7/14/2014 14:24:20,,1322879787,7/14/2014 14:24:17,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,134,85,,,151,91,ATOPIC DERMATITIS,ATOPIC,"perifollicular accentuation, with ATOPIC DERMATITIS lesions",100-115-129-134-141-157,69-75-78-85-92-97-100,"(FE), so called ATOPIC skin or perifollicular","The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase.",134 141,85,134,85,151,91,-1,RO-cause_of,900229,"The purpose of the present study was to compare follicular eruptions (FE), so-called atopic skin or perifollicular accentuation, with atopic dermatitis (AD) lesions (ADL) by immunohistochemical analysis using antibodies to bikunin and tryptase",atopic dermatitis,atopic
502912965,7/14/2014 12:47:28,,1322813015,7/14/2014 12:47:23,clixsense,1.0,24763049,GBR,"","",86.133.47.213,55,0,,,81,13,ECTODERMAL DIFFERENTIATION,DERMOID CYSTS,deriving from the ECTODERMAL DIFFERENTIATION of stem cells.,37-46-51-55-66-82-85-90,0-8-14-18-29,DERMOID CYSTS are congenital lesions,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells.,55 66,0 8,55,0,81,13,-1,RO-disease_may_have_finding,902973,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells,ectodermal differentiation,Dermoid cysts
502912965,7/14/2014 13:02:02,,1322822820,7/14/2014 13:01:50,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,55,0,,,81,13,ECTODERMAL DIFFERENTIATION,DERMOID CYSTS,ECTODERMAL DIFFERENTIATION,55-66,0-8,DERMOID CYSTS,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells.,55 66,0 8,55,0,81,13,-1,RO-disease_may_have_finding,902973,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells,ectodermal differentiation,Dermoid cysts
502912965,7/14/2014 13:02:05,,1322822842,7/14/2014 13:01:47,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,55,0,,,81,13,ECTODERMAL DIFFERENTIATION,DERMOID CYSTS,Dermoid cysts ECTODERMAL DIFFERENTIATION,0-55-66-8,0-8-55-66,DERMOID CYSTS ectodermal differentiation,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells.,55 66,0 8,55,0,81,13,-1,RO-disease_may_have_finding,902973,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells,ectodermal differentiation,Dermoid cysts
502912965,7/14/2014 13:14:33,,1322831247,7/14/2014 13:14:15,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,55,0,,,81,13,ECTODERMAL DIFFERENTIATION,DERMOID CYSTS,ECTODERMAL DIFFERENTIATION,55-66,0-8,DERMOID CYSTS,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells.,55 66,0 8,55,0,81,13,-1,RO-disease_may_have_finding,902973,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells,ectodermal differentiation,Dermoid cysts
502912965,7/14/2014 13:24:18,,1322838013,7/14/2014 13:23:27,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,55,0,,,81,13,ECTODERMAL DIFFERENTIATION,DERMOID CYSTS,deriving from the ECTODERMAL DIFFERENTIATION of stem cells.,37-46-51-55-66-82-85-90,0-8-14-18-29-37,DERMOID CYSTS are congenital lesions deriving,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells.,55 66,0 8,55,0,81,13,-1,RO-disease_may_have_finding,902973,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells,ectodermal differentiation,Dermoid cysts
502912965,7/14/2014 13:39:46,,1322848920,7/14/2014 13:39:43,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,55,0,,,81,13,ECTODERMAL DIFFERENTIATION,DERMOID CYSTS,deriving from the ECTODERMAL DIFFERENTIATION of stem cells.,37-46-51-55-66-82-85-90,0-8-14-18-29,DERMOID CYSTS are congenital lesions,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells.,55 66,0 8,55,0,81,13,-1,RO-disease_may_have_finding,902973,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells,ectodermal differentiation,Dermoid cysts
502912965,7/14/2014 13:47:51,,1322854918,7/14/2014 13:47:37,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,55,0,,,81,13,ECTODERMAL DIFFERENTIATION,DERMOID CYSTS,ECTODERMAL DIFFERENTIATION of stem cells.,55-66-82-85-90,0-8-14-18-29,DERMOID CYSTS are congenital lesions,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells.,55 66,0 8,55,0,81,13,-1,RO-disease_may_have_finding,902973,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells,ectodermal differentiation,Dermoid cysts
502912965,7/14/2014 14:19:38,,1322876611,7/14/2014 14:19:34,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,55,0,,,81,13,ECTODERMAL DIFFERENTIATION,DERMOID CYSTS,deriving from the ECTODERMAL DIFFERENTIATION of stem cells.,37-46-51-55-66-82-85-90,0-8-14-18-29,DERMOID CYSTS are congenital lesions,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells.,55 66,0 8,55,0,81,13,-1,RO-disease_may_have_finding,902973,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells,ectodermal differentiation,Dermoid cysts
502912965,7/14/2014 14:22:47,,1322878757,7/14/2014 14:22:42,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,55,0,,,81,13,ECTODERMAL DIFFERENTIATION,DERMOID CYSTS,deriving from the ECTODERMAL DIFFERENTIATION of stem cells.,37-46-51-55-66-82-85-90,0-8-14-18-29,DERMOID CYSTS are congenital lesions,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells.,55 66,0 8,55,0,81,13,-1,RO-disease_may_have_finding,902973,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells,ectodermal differentiation,Dermoid cysts
502912965,7/14/2014 14:24:35,,1322880013,7/14/2014 14:24:21,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,55,0,,,81,13,ECTODERMAL DIFFERENTIATION,DERMOID CYSTS,Dermoid cysts ECTODERMAL DIFFERENTIATION,0-8-55-66,0-8,DERMOID CYSTS,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells.,55 66,0 8,55,0,81,13,-1,RO-disease_may_have_finding,902973,Dermoid cysts are congenital lesions deriving from the ectodermal differentiation of stem cells,ectodermal differentiation,Dermoid cysts
502912966,7/14/2014 12:46:10,,1322812101,7/14/2014 12:45:56,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,13,78,,,27,103,KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,KIDNEY FAILURE,13-20,78-89-96,"POLYCYSTIC KIDNEY DISEASE,","For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy.",13 20,78 89 96,13,78,27,103,1,RO-has_manifestation,906233,"For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy",kidney failure,polycystic kidney disease
502912966,7/14/2014 12:58:47,,1322820762,7/14/2014 12:58:30,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,13,78,,,27,103,KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,KIDNEY FAILURE,13-20,78-89-96,"POLYCYSTIC KIDNEY DISEASE,","For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy.",13 20,78 89 96,13,78,27,103,1,RO-has_manifestation,906233,"For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy",kidney failure,polycystic kidney disease
502912966,7/14/2014 13:13:58,,1322830870,7/14/2014 13:13:41,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,13,78,,,27,103,KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,KIDNEY FAILURE,13-20,78-89-96,"POLYCYSTIC KIDNEY DISEASE,","For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy.",13 20,78 89 96,13,78,27,103,1,RO-has_manifestation,906233,"For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy",kidney failure,polycystic kidney disease
502912966,7/14/2014 13:27:11,,1322839894,7/14/2014 13:26:53,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,13,78,,,27,103,KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,KIDNEY FAILURE,13-20,78-89-96,"POLYCYSTIC KIDNEY DISEASE,","For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy.",13 20,78 89 96,13,78,27,103,1,RO-has_manifestation,906233,"For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy",kidney failure,polycystic kidney disease
502912966,7/14/2014 13:38:19,,1322847759,7/14/2014 13:38:06,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,13,78,,,27,103,KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,KIDNEY FAILURE,13-20,78-89-96,"POLYCYSTIC KIDNEY DISEASE,","For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy.",13 20,78 89 96,13,78,27,103,1,RO-has_manifestation,906233,"For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy",kidney failure,polycystic kidney disease
502912966,7/14/2014 13:48:49,,1322855580,7/14/2014 13:48:26,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,13,78,,,27,103,KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,KIDNEY FAILURE,13-20,40-49-62-75-78-89-96-114-117-125,"diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE, in lithium nephropathy.","For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy.",13 20,78 89 96,13,78,27,103,1,RO-has_manifestation,906233,"For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy",kidney failure,polycystic kidney disease
502912966,7/14/2014 13:56:40,,1322861079,7/14/2014 13:56:26,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,13,78,,,27,103,KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,KIDNEY FAILURE,13-20,78-89-96,"POLYCYSTIC KIDNEY DISEASE,","For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy.",13 20,78 89 96,13,78,27,103,1,RO-has_manifestation,906233,"For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy",kidney failure,polycystic kidney disease
502912966,7/14/2014 14:02:55,,1322865447,7/14/2014 14:02:37,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,13,78,,,27,103,KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,KIDNEY FAILURE,13-20,78-89-96,"POLYCYSTIC KIDNEY DISEASE,","For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy.",13 20,78 89 96,13,78,27,103,1,RO-has_manifestation,906233,"For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy",kidney failure,polycystic kidney disease
502912966,7/14/2014 14:24:05,,1322879619,7/14/2014 14:24:01,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,13,78,,,27,103,KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,"For example, KIDNEY FAILURE is rapid in",0-4-13-20-28-31-37,49-62-75-78-89-96-105-109-114,"nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE, and slow in","For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy.",13 20,78 89 96,13,78,27,103,1,RO-has_manifestation,906233,"For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy",kidney failure,polycystic kidney disease
502912966,7/14/2014 14:25:06,,1322880503,7/14/2014 14:24:53,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,13,78,,,27,103,KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,KIDNEY FAILURE,13-20,49-78-89-96,"nephropathy, POLYCYSTIC KIDNEY DISEASE,","For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy.",13 20,78 89 96,13,78,27,103,1,RO-has_manifestation,906233,"For example, kidney failure is rapid in diabetic nephropathy, intermediate in polycystic kidney disease, and slow in lithium nephropathy",kidney failure,polycystic kidney disease
502912967,7/14/2014 13:21:05,,1322835590,7/14/2014 13:20:45,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,81,40,,,95,51,VON WILLEBRAND,FACTOR VIII,VON WILLEBRAND disease.,81-85-96,40-47,FACTOR VIII,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.,81 85,40 47,81,40,95,51,1,RO-may_treat,907758,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease,von Willebrand,factor VIII
502912967,7/14/2014 13:34:54,,1322845302,7/14/2014 13:34:49,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,81,40,,,95,51,VON WILLEBRAND,FACTOR VIII,the treatment of VON WILLEBRAND disease.,64-68-78-81-85-96,24-28-33-40-47-52-61-64,and high purity FACTOR VIII products in the,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.,81 85,40 47,81,40,95,51,1,RO-may_treat,907758,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease,von Willebrand,factor VIII
502912967,7/14/2014 13:50:49,,1322856937,7/14/2014 13:50:34,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,81,40,,,95,51,VON WILLEBRAND,FACTOR VIII,VON WILLEBRAND,81-85,40-47,FACTOR VIII,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.,81 85,40 47,81,40,95,51,1,RO-may_treat,907758,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease,von Willebrand,factor VIII
502912967,7/14/2014 14:30:25,,1322884442,7/14/2014 14:30:22,instagc,1.0,27753923,GBR,"","",188.30.192.65,81,40,,,95,51,VON WILLEBRAND,FACTOR VIII,the treatment of VON WILLEBRAND disease.,64-68-78-81-85-96,24-28-33-40-47-52-61-64,and high purity FACTOR VIII products in the,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.,81 85,40 47,81,40,95,51,1,RO-may_treat,907758,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease,von Willebrand,factor VIII
502912967,7/14/2014 14:35:02,,1322887633,7/14/2014 14:34:52,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,81,40,,,95,51,VON WILLEBRAND,FACTOR VIII,VON WILLEBRAND disease.,81-85-96,28-33-40-47,high purity FACTOR VIII,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.,81 85,40 47,81,40,95,51,1,RO-may_treat,907758,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease,von Willebrand,factor VIII
502912967,7/14/2014 14:48:35,,1322896584,7/14/2014 14:48:20,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,81,40,,,95,51,VON WILLEBRAND,FACTOR VIII,VON WILLEBRAND,81-85,40-47,FACTOR VIII,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.,81 85,40 47,81,40,95,51,1,RO-may_treat,907758,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease,von Willebrand,factor VIII
502912967,7/14/2014 14:49:00,,1322896772,7/14/2014 14:48:52,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,81,40,,,95,51,VON WILLEBRAND,FACTOR VIII,VON WILLEBRAND disease.,81-85-96,40-47,FACTOR VIII,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.,81 85,40 47,81,40,95,51,1,RO-may_treat,907758,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease,von Willebrand,factor VIII
502912967,7/14/2014 14:49:07,,1322896789,7/14/2014 14:48:53,instagc,1.0,13763729,USA,"","",75.182.89.225,81,40,,,95,51,VON WILLEBRAND,FACTOR VIII,VON WILLEBRAND disease.,81-85-96,40-47,FACTOR VIII,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.,81 85,40 47,81,40,95,51,1,RO-may_treat,907758,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease,von Willebrand,factor VIII
502912967,7/14/2014 14:49:10,,1322896806,7/14/2014 14:48:58,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,81,40,,,95,51,VON WILLEBRAND,FACTOR VIII,VON WILLEBRAND disease.,81-85-96,40-47-52,FACTOR VIII products,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.,81 85,40 47,81,40,95,51,1,RO-may_treat,907758,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease,von Willebrand,factor VIII
502912967,7/14/2014 14:50:41,,1322897727,7/14/2014 14:50:23,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,81,40,,,95,51,VON WILLEBRAND,FACTOR VIII,the treatment of VON WILLEBRAND disease.,64-68-78-81-85-96,40-47-52-61-64-68-78-81-85-96,FACTOR VIII products in the treatment of von Willebrand disease.,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.,81 85,40 47,81,40,95,51,1,RO-may_treat,907758,The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease,von Willebrand,factor VIII
502912968,7/14/2014 12:45:30,,1322811756,7/14/2014 12:45:26,clixsense,1.0,24763049,GBR,"","",86.133.47.213,132,174,,,142,193,MEDICATION,ADVERSE DRUG EVENTS,that allergy and MEDICATION errors were the,115-120-128-132-143-150-155,155-159-164-174-182-187,the most avoidable ADVERSE DRUG EVENTS.,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events.",132,174 182 187,132,174,142,193,-1,RO-has_causative_agent,903861,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events",medication,adverse drug events
502912968,7/14/2014 12:52:45,,1322816605,7/14/2014 12:52:33,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,132,174,,,142,193,MEDICATION,ADVERSE DRUG EVENTS,MEDICATION errors,132-143,155-174-182-187,the ADVERSE DRUG EVENTS.,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events.",132,174 182 187,132,174,142,193,-1,RO-has_causative_agent,903861,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events",medication,adverse drug events
502912968,7/14/2014 13:09:27,,1322827764,7/14/2014 13:09:12,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,132,174,,,142,193,MEDICATION,ADVERSE DRUG EVENTS,MEDICATION,132,155-174-182-187,the ADVERSE DRUG EVENTS.,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events.",132,174 182 187,132,174,142,193,-1,RO-has_causative_agent,903861,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events",medication,adverse drug events
502912968,7/14/2014 13:23:14,,1322837412,7/14/2014 13:22:30,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,132,174,,,142,193,MEDICATION,ADVERSE DRUG EVENTS,FAMC MEDICATION adverse drug events.,29-132-174-182-187,29-174-182-187-132,FAMC medication ADVERSE DRUG EVENTS.,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events.",132,174 182 187,132,174,142,193,-1,RO-has_causative_agent,903861,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events",medication,adverse drug events
502912968,7/14/2014 13:25:28,,1322838705,7/14/2014 13:25:08,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,132,174,,,142,193,MEDICATION,ADVERSE DRUG EVENTS,MEDICATION,132,174-182-187,ADVERSE DRUG EVENTS.,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events.",132,174 182 187,132,174,142,193,-1,RO-has_causative_agent,903861,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events",medication,adverse drug events
502912968,7/14/2014 13:39:27,,1322848630,7/14/2014 13:39:13,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,132,174,,,142,193,MEDICATION,ADVERSE DRUG EVENTS,MEDICATION,132,174-182-187,ADVERSE DRUG EVENTS.,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events.",132,174 182 187,132,174,142,193,-1,RO-has_causative_agent,903861,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events",medication,adverse drug events
502912968,7/14/2014 13:53:19,,1322858850,7/14/2014 13:53:04,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,132,174,,,142,193,MEDICATION,ADVERSE DRUG EVENTS,MEDICATION errors were,132-143-150,174-182-187,ADVERSE DRUG EVENTS.,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events.",132,174 182 187,132,174,142,193,-1,RO-has_causative_agent,903861,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events",medication,adverse drug events
502912968,7/14/2014 14:23:54,,1322879548,7/14/2014 14:23:51,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,132,174,,,142,193,MEDICATION,ADVERSE DRUG EVENTS,that allergy and MEDICATION errors were the,115-120-128-132-143-150-155,155-159-164-174-182-187,the most avoidable ADVERSE DRUG EVENTS.,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events.",132,174 182 187,132,174,142,193,-1,RO-has_causative_agent,903861,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events",medication,adverse drug events
502912968,7/14/2014 14:30:21,,1322884392,7/14/2014 14:30:18,instagc,1.0,27753923,GBR,"","",188.30.192.65,132,174,,,142,193,MEDICATION,ADVERSE DRUG EVENTS,that allergy and MEDICATION errors were the,115-120-128-132-143-150-155,155-159-164-174-182-187,the most avoidable ADVERSE DRUG EVENTS.,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events.",132,174 182 187,132,174,142,193,-1,RO-has_causative_agent,903861,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events",medication,adverse drug events
502912968,7/14/2014 14:38:03,,1322889682,7/14/2014 14:37:42,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,132,174,,,142,193,MEDICATION,ADVERSE DRUG EVENTS,that allergy and MEDICATION errors were the,115-120-128-132-143-150-155,155-159-164-174-182-187,the most avoidable ADVERSE DRUG EVENTS.,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events.",132,174 182 187,132,174,142,193,-1,RO-has_causative_agent,903861,"Apart from the fact that the FAMC helped to determine the grade of preventability, FAMC allowed one to demonstrate that allergy and medication errors were the most avoidable adverse drug events",medication,adverse drug events
502912969,7/14/2014 12:53:51,,1322817503,7/14/2014 12:53:35,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,136,153,,,141,161,LUPUS,NONLUPUS,LUPUS (LMGN),136-142,153,NONLUPUS,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates.",136,153,136,153,141,161,-1,RO-cause_of,900165,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates",lupus,nonlupus
502912969,7/14/2014 12:55:29,,1322818497,7/14/2014 12:55:24,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,136,153,,,141,161,LUPUS,NONLUPUS,(COX 2) in LUPUS and nonlupus examine,125-130-133-136-149-153-203,136-142-149-153-170-181-224,lupus (LMGN) and NONLUPUS membranous glomerulopathy relationship,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates.",136,153,136,153,141,161,-1,RO-cause_of,900165,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates",lupus,nonlupus
502912969,7/14/2014 12:59:47,,1322821333,7/14/2014 12:59:16,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,136,153,,,141,161,LUPUS,NONLUPUS,LUPUS,136,153,NONLUPUS,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates.",136,153,136,153,141,161,-1,RO-cause_of,900165,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates",lupus,nonlupus
502912969,7/14/2014 13:15:48,,1322832107,7/14/2014 13:15:15,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,136,153,,,141,161,LUPUS,NONLUPUS,LUPUS (LMGN) membranous glomerulopathy,136-142-170-181,153-162-170-181,NONLUPUS (NLMGN) membranous glomerulopathy,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates.",136,153,136,153,141,161,-1,RO-cause_of,900165,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates",lupus,nonlupus
502912969,7/14/2014 13:39:18,,1322848534,7/14/2014 13:38:57,clixsense,1.0,27969116,NLD,"","",91.213.37.165,136,153,,,141,161,LUPUS,NONLUPUS,cyclooxygenase 2 (COX 2) in LUPUS (LMGN) and nonlupus (NLMGN),108-123-125-130-133-136-149-153-162-142,136-142-149-153-170-181-162,lupus (LMGN) and NONLUPUS (NLMGN) membranous glomerulopathy,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates.",136,153,136,153,141,161,-1,RO-cause_of,900165,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates",lupus,nonlupus
502912969,7/14/2014 13:46:18,,1322853610,7/14/2014 13:45:57,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,136,153,,,141,161,LUPUS,NONLUPUS,LUPUS,136,153,NONLUPUS,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates.",136,153,136,153,141,161,-1,RO-cause_of,900165,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates",lupus,nonlupus
502912969,7/14/2014 13:47:41,,1322854823,7/14/2014 13:47:10,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,136,153,,,141,161,LUPUS,NONLUPUS,LUPUS membranous glomerulopathy,136-170-181,153-170-181,NONLUPUS membranous glomerulopathy,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates.",136,153,136,153,141,161,-1,RO-cause_of,900165,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates",lupus,nonlupus
502912969,7/14/2014 14:21:41,,1322878010,7/14/2014 14:21:25,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,136,153,,,141,161,LUPUS,NONLUPUS,LUPUS,136,136-153,lupus NONLUPUS,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates.",136,153,136,153,141,161,-1,RO-cause_of,900165,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates",lupus,nonlupus
502912969,7/14/2014 14:22:35,,1322878608,7/14/2014 14:22:30,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,136,153,,,141,161,LUPUS,NONLUPUS,(COX 2) in LUPUS and nonlupus,125-130-133-136-149-153,136-142-149-153-170-181,lupus (LMGN) and NONLUPUS membranous glomerulopathy,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates.",136,153,136,153,141,161,-1,RO-cause_of,900165,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates",lupus,nonlupus
502912969,7/14/2014 14:48:19,,1322896389,7/14/2014 14:47:59,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,136,153,,,141,161,LUPUS,NONLUPUS,LUPUS,136,153,NONLUPUS,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates.",136,153,136,153,141,161,-1,RO-cause_of,900165,"Thereby, the present study was undertaken to ascertain the immunoexpression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in lupus (LMGN) and nonlupus (NLMGN) membranous glomerulopathy and to examine the possible relationship between this immunoexpresion and inflammatory infiltrates",lupus,nonlupus
502912970,7/14/2014 12:47:44,,1322813148,7/14/2014 12:47:26,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,41,2,,,62,7,STAPHYLOCOCCUS AUREUS,TOTAL,methicillin susceptible STAPHYLOCOCCUS AUREUS (MSSA),17-29-41-56-63,0-2,A TOTAL,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared.",41 56,2,41,2,62,7,-1,RO-has_causative_agent,903655,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared",Staphylococcus aureus,total
502912970,7/14/2014 14:00:17,,1322863495,7/14/2014 14:00:04,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,41,2,,,62,7,STAPHYLOCOCCUS AUREUS,TOTAL,"3,051 methicillin susceptible STAPHYLOCOCCUS AUREUS",11-17-29-41-56,0-2-8-11-17,"A TOTAL of 3,051 methicillin","A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared.",41 56,2,41,2,62,7,-1,RO-has_causative_agent,903655,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared",Staphylococcus aureus,total
502912970,7/14/2014 14:39:00,,1322890316,7/14/2014 14:38:56,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,41,2,,,62,7,STAPHYLOCOCCUS AUREUS,TOTAL,"3,051 methicillin susceptible STAPHYLOCOCCUS AUREUS isolates and",11-17-29-41-56-70-79,0-2-8-11-17,"A TOTAL of 3,051 methicillin","A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared.",41 56,2,41,2,62,7,-1,RO-has_causative_agent,903655,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared",Staphylococcus aureus,total
502912970,7/14/2014 14:47:58,,1322896182,7/14/2014 14:47:44,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,41,2,,,62,7,STAPHYLOCOCCUS AUREUS,TOTAL,STAPHYLOCOCCUS AUREUS,41-56,2,TOTAL,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared.",41 56,2,41,2,62,7,-1,RO-has_causative_agent,903655,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared",Staphylococcus aureus,total
502912970,7/14/2014 14:48:38,,1322896595,7/14/2014 14:48:19,instagc,1.0,13763729,USA,"","",75.182.89.225,41,2,,,62,7,STAPHYLOCOCCUS AUREUS,TOTAL,STAPHYLOCOCCUS AUREUS,41-56,2-8-11-17,"TOTAL of 3,051 methicillin","A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared.",41 56,2,41,2,62,7,-1,RO-has_causative_agent,903655,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared",Staphylococcus aureus,total
502912970,7/14/2014 14:49:25,,1322896943,7/14/2014 14:49:11,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,41,2,,,62,7,STAPHYLOCOCCUS AUREUS,TOTAL,methicillin susceptible STAPHYLOCOCCUS AUREUS,17-29-41-56,2-17,TOTAL methicillin,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared.",41 56,2,41,2,62,7,-1,RO-has_causative_agent,903655,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared",Staphylococcus aureus,total
502912970,7/14/2014 14:50:11,,1322897454,7/14/2014 14:49:52,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,41,2,,,62,7,STAPHYLOCOCCUS AUREUS,TOTAL,methicillin susceptible STAPHYLOCOCCUS AUREUS,17-29-41-56,2-17-29-41-56,TOTAL methicillin susceptible Staphylococcus aureus,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared.",41 56,2,41,2,62,7,-1,RO-has_causative_agent,903655,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared",Staphylococcus aureus,total
502912970,7/14/2014 14:56:01,,1322900929,7/14/2014 14:55:46,instagc,1,18960682,GBR,"","",86.29.147.112,41,2,,,62,7,STAPHYLOCOCCUS AUREUS,TOTAL,methicillin susceptible STAPHYLOCOCCUS AUREUS (MSSA) isolates,17-29-41-56-63-70,2,TOTAL,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared.",41 56,2,41,2,62,7,-1,RO-has_causative_agent,903655,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared",Staphylococcus aureus,total
502912970,7/14/2014 14:56:16,,1322901119,7/14/2014 14:55:41,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,41,2,,,62,7,STAPHYLOCOCCUS AUREUS,TOTAL,methicillin susceptible STAPHYLOCOCCUS AUREUS (MSSA) methicillin resistant S. aureus,17-29-41-56-63-83-95-108-105,2-17-29-41-56-63-83-95-108-105,TOTAL methicillin susceptible Staphylococcus aureus (MSSA) methicillin resistant S. aureus,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared.",41 56,2,41,2,62,7,-1,RO-has_causative_agent,903655,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared",Staphylococcus aureus,total
502912970,7/14/2014 15:03:44,,1322905726,7/14/2014 15:03:22,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,41,2,,,62,7,STAPHYLOCOCCUS AUREUS,TOTAL,methicillin susceptible STAPHYLOCOCCUS AUREUS,17-29-41-56,2-17-29-41-56,TOTAL methicillin susceptible Staphylococcus aureus,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared.",41 56,2,41,2,62,7,-1,RO-has_causative_agent,903655,"A total of 3,051 methicillin-susceptible Staphylococcus aureus (MSSA) isolates and methicillin-resistant S. aureus (MRSA) isolates in Europe were compared",Staphylococcus aureus,total
502912971,7/14/2014 12:46:27,,1322812326,7/14/2014 12:46:22,clixsense,1.0,24763049,GBR,"","",86.133.47.213,97,135,,,105,146,VOMITING,ANTIEMETICS,induced nausea and VOMITING led to development,78-86-93-97-106-110-113,113-125-128-135-147-152-155,development of potent ANTIEMETICS such as the,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron.,97,135,97,135,105,146,1,RO-may_prevent,907406,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron,vomiting,antiemetics
502912971,7/14/2014 12:48:00,,1322813291,7/14/2014 12:47:45,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,97,135,,,105,146,VOMITING,ANTIEMETICS,chemotherapy induced nausea and VOMITING,65-78-86-93-97,128-135,potent ANTIEMETICS,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron.,97,135,97,135,105,146,1,RO-may_prevent,907406,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron,vomiting,antiemetics
502912971,7/14/2014 13:00:00,,1322821474,7/14/2014 12:59:46,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,97,135,,,105,146,VOMITING,ANTIEMETICS,VOMITING,97,135,ANTIEMETICS,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron.,97,135,97,135,105,146,1,RO-may_prevent,907406,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron,vomiting,antiemetics
502912971,7/14/2014 13:35:44,,1322845882,7/14/2014 13:35:28,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,97,135,,,105,146,VOMITING,ANTIEMETICS,VOMITING,97,135,ANTIEMETICS,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron.,97,135,97,135,105,146,1,RO-may_prevent,907406,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron,vomiting,antiemetics
502912971,7/14/2014 13:54:29,,1322859646,7/14/2014 13:53:55,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,97,135,,,105,146,VOMITING,ANTIEMETICS,VOMITING,97,135,ANTIEMETICS,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron.,97,135,97,135,105,146,1,RO-may_prevent,907406,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron,vomiting,antiemetics
502912971,7/14/2014 14:21:18,,1322877747,7/14/2014 14:21:12,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,97,135,,,105,146,VOMITING,ANTIEMETICS,induced nausea and VOMITING led to development,78-86-93-97-106-110-113,113-125-128-135-147-152-155,development of potent ANTIEMETICS such as the,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron.,97,135,97,135,105,146,1,RO-may_prevent,907406,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron,vomiting,antiemetics
502912971,7/14/2014 14:29:44,,1322883908,7/14/2014 14:29:42,instagc,1.0,27753923,GBR,"","",188.30.192.65,97,135,,,105,146,VOMITING,ANTIEMETICS,induced nausea and VOMITING led to development,78-86-93-97-106-110-113,113-125-128-135-147-152-155,development of potent ANTIEMETICS such as the,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron.,97,135,97,135,105,146,1,RO-may_prevent,907406,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron,vomiting,antiemetics
502912971,7/14/2014 14:34:40,,1322887313,7/14/2014 14:34:17,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,97,135,,,105,146,VOMITING,ANTIEMETICS,chemotherapy induced nausea and VOMITING,65-78-86-93-97,128-135,potent ANTIEMETICS,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron.,97,135,97,135,105,146,1,RO-may_prevent,907406,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron,vomiting,antiemetics
502912971,7/14/2014 14:43:55,,1322893756,7/14/2014 14:43:37,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,97,135,,,105,146,VOMITING,ANTIEMETICS,VOMITING,97,135,ANTIEMETICS,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron.,97,135,97,135,105,146,1,RO-may_prevent,907406,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron,vomiting,antiemetics
502912971,7/14/2014 14:44:13,,1322893907,7/14/2014 14:43:30,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,97,135,,,105,146,VOMITING,ANTIEMETICS,VOMITING serotonin antagonists ondansetron and granisetron.,97-159-169-181-197-193,135-159-169-181-193-197,ANTIEMETICS serotonin antagonists ondansetron and granisetron.,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron.,97,135,97,135,105,146,1,RO-may_prevent,907406,51   The identification of neurotransmitter pathways involved in chemotherapy-induced nausea and vomiting led to development of potent antiemetics such as the serotonin antagonists ondansetron and granisetron,vomiting,antiemetics
502912972,7/14/2014 12:53:56,,1322817535,7/14/2014 12:53:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,211,201,,,222,207,SALMONELLAE,NUMBER,SALMONELLAE,211,201,NUMBER,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant.,211,201,211,201,222,207,-1,RO-has_causative_agent,903637,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant,salmonellae,number
502912972,7/14/2014 12:59:46,,1322821332,7/14/2014 12:59:26,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,211,201,,,222,207,SALMONELLAE,NUMBER,SALMONELLAE,211,201,NUMBER,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant.,211,201,211,201,222,207,-1,RO-has_causative_agent,903637,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant,salmonellae,number
502912972,7/14/2014 13:10:08,,1322828269,7/14/2014 13:09:51,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,211,201,,,222,207,SALMONELLAE,NUMBER,SALMONELLAE,211,201,NUMBER,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant.,211,201,211,201,222,207,-1,RO-has_causative_agent,903637,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant,salmonellae,number
502912972,7/14/2014 13:15:14,,1322831677,7/14/2014 13:14:57,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,211,201,,,222,207,SALMONELLAE,NUMBER,SALMONELLAE,211,201,NUMBER,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant.,211,201,211,201,222,207,-1,RO-has_causative_agent,903637,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant,salmonellae,number
502912972,7/14/2014 13:21:42,,1322836116,7/14/2014 13:21:26,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,211,201,,,222,207,SALMONELLAE,NUMBER,SALMONELLAE,211,201,NUMBER,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant.,211,201,211,201,222,207,-1,RO-has_causative_agent,903637,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant,salmonellae,number
502912972,7/14/2014 13:28:01,,1322840446,7/14/2014 13:27:43,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,211,201,,,222,207,SALMONELLAE,NUMBER,SALMONELLAE per 100 ml,211-223-227-231,201-208-211-223-227-231,NUMBER of salmonellae per 100 ml,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant.,211,201,211,201,222,207,-1,RO-has_causative_agent,903637,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant,salmonellae,number
502912972,7/14/2014 13:41:02,,1322849780,7/14/2014 13:41:00,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,211,201,,,222,207,SALMONELLAE,NUMBER,the number of SALMONELLAE per 100 ml,197-201-208-211-223-227-231,185-188-197-201-208-211-223,of effluent the NUMBER of salmonellae per,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant.,211,201,211,201,222,207,-1,RO-has_causative_agent,903637,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant,salmonellae,number
502912972,7/14/2014 13:42:18,,1322850687,7/14/2014 13:41:45,clixsense,1.0,27969116,NLD,"","",91.213.37.165,211,201,,,222,207,SALMONELLAE,NUMBER,drainage of effluent SALMONELLAE,176-185-211-188,188-201-208-211-223,effluent NUMBER of salmonellae per,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant.,211,201,211,201,222,207,-1,RO-has_causative_agent,903637,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant,salmonellae,number
502912972,7/14/2014 13:42:38,,1322850911,7/14/2014 13:42:07,elite,1.0,26544151,GBR,"","",188.29.127.144,211,201,,,222,207,SALMONELLAE,NUMBER,SALMONELLAE,211,201,NUMBER,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant.,211,201,211,201,222,207,-1,RO-has_causative_agent,903637,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant,salmonellae,number
502912972,7/14/2014 13:43:36,,1322851627,7/14/2014 13:43:15,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,211,201,,,222,207,SALMONELLAE,NUMBER,SALMONELLAE,211,201,NUMBER,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant.,211,201,211,201,222,207,-1,RO-has_causative_agent,903637,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the number of salmonellae per 100 ml remains almost constant,salmonellae,number
502912973,7/14/2014 12:49:57,,1322814655,7/14/2014 12:49:38,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,173,121,,,189,128,HYPERSENSITIVITY,ALLERGY,"tuberculin type allergy, antibody mediated HYPERSENSITIVITY and cutaneous basophile hypersensitivity.",130-141-146-155-164-173-190-194-204-214,113-121-130-141-146-155-164-173-190-194-204-214,"contact ALLERGY, tuberculin type allergy, antibody mediated hypersensitivity and cutaneous basophile hypersensitivity.","Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity.",173,121,173,121,189,128,-1,RO-cause_of,900020,"Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity",hypersensitivity,allergy
502912973,7/14/2014 13:03:00,,1322823466,7/14/2014 13:02:31,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,173,121,,,189,128,HYPERSENSITIVITY,ALLERGY,antibody - mediated HYPERSENSITIVITY,155-163-164-173,113-121-130-141-146,"contact ALLERGY, tuberculin type allergy,","Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity.",173,121,173,121,189,128,-1,RO-cause_of,900020,"Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity",hypersensitivity,allergy
502912973,7/14/2014 13:03:09,,1322823591,7/14/2014 13:02:34,gifthulk,1.0,25566511,USA,"","",24.164.11.173,173,121,,,189,128,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,173,121-113,"contact ALLERGY,","Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity.",173,121,173,121,189,128,-1,RO-cause_of,900020,"Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity",hypersensitivity,allergy
502912973,7/14/2014 13:12:24,,1322829713,7/14/2014 13:12:09,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,173,121,,,189,128,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,173,121,"ALLERGY,","Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity.",173,121,173,121,189,128,-1,RO-cause_of,900020,"Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity",hypersensitivity,allergy
502912973,7/14/2014 13:27:56,,1322840355,7/14/2014 13:27:31,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,173,121,,,189,128,HYPERSENSITIVITY,ALLERGY,antibody mediated HYPERSENSITIVITY,155-164-173,121-113,"contact ALLERGY,","Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity.",173,121,173,121,189,128,-1,RO-cause_of,900020,"Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity",hypersensitivity,allergy
502912973,7/14/2014 13:50:01,,1322856360,7/14/2014 13:48:55,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,173,121,,,189,128,HYPERSENSITIVITY,ALLERGY,"contact allergy, tuberculin type allergy, antibody mediated HYPERSENSITIVITY cutaneous basophile hypersensitivity.",113-121-130-141-146-155-164-173-194-204-214,121-130-141-146,"ALLERGY, tuberculin type allergy,","Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity.",173,121,173,121,189,128,-1,RO-cause_of,900020,"Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity",hypersensitivity,allergy
502912973,7/14/2014 14:28:42,,1322883094,7/14/2014 14:28:38,instagc,1.0,27753923,GBR,"","",188.30.192.65,173,121,,,189,128,HYPERSENSITIVITY,ALLERGY,"allergy, antibody mediated HYPERSENSITIVITY and cutaneous basophile",146-155-164-173-190-194-204,101-110-113-121-130-141-146,"features of contact ALLERGY, tuberculin type allergy,","Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity.",173,121,173,121,189,128,-1,RO-cause_of,900020,"Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity",hypersensitivity,allergy
502912973,7/14/2014 14:38:07,,1322889704,7/14/2014 14:37:52,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,173,121,,,189,128,HYPERSENSITIVITY,ALLERGY,antibody mediated HYPERSENSITIVITY,155-164-173,113-121,"contact ALLERGY,","Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity.",173,121,173,121,189,128,-1,RO-cause_of,900020,"Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity",hypersensitivity,allergy
502912973,7/14/2014 14:44:44,,1322894213,7/14/2014 14:44:26,instagc,1.0,13763729,USA,"","",75.182.89.225,173,121,,,189,128,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,173,121,"ALLERGY,","Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity.",173,121,173,121,189,128,-1,RO-cause_of,900020,"Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity",hypersensitivity,allergy
502912973,7/14/2014 14:46:13,,1322895153,7/14/2014 14:45:52,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,173,121,,,189,128,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,173,121,"ALLERGY,","Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity.",173,121,173,121,189,128,-1,RO-cause_of,900020,"Other sensitization procedures are likely to produce more heterogeneous forms of sensitization, with features of contact allergy, tuberculin-type allergy, antibody-mediated hypersensitivity and cutaneous basophile hypersensitivity",hypersensitivity,allergy
502912974,7/14/2014 13:00:59,,1322822165,7/14/2014 13:00:47,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,64,36,,,78,48,PANIC DISORDER,CLOMIPRAMINE,PANIC DISORDER.,64-70,36,CLOMIPRAMINE,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder.",64 70,36,64,36,78,48,1,RO-may_treat,907891,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder",panic disorder,clomipramine
502912974,7/14/2014 13:16:17,,1322832425,7/14/2014 13:16:12,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,64,36,,,78,48,PANIC DISORDER,CLOMIPRAMINE,and placebo in PANIC DISORDER.,49-53-61-64-70,10-21-24-36-49-53-61,"evaluation of paroxetine, CLOMIPRAMINE and placebo in","Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder.",64 70,36,64,36,78,48,1,RO-may_treat,907891,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder",panic disorder,clomipramine
502912974,7/14/2014 13:17:32,,1322833277,7/14/2014 13:16:55,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,64,36,,,78,48,PANIC DISORDER,CLOMIPRAMINE,PANIC DISORDER.,64-70,36,CLOMIPRAMINE,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder.",64 70,36,64,36,78,48,1,RO-may_treat,907891,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder",panic disorder,clomipramine
502912974,7/14/2014 13:19:02,,1322834235,7/14/2014 13:18:48,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,64,36,,,78,48,PANIC DISORDER,CLOMIPRAMINE,PANIC DISORDER.,64-70,36,CLOMIPRAMINE,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder.",64 70,36,64,36,78,48,1,RO-may_treat,907891,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder",panic disorder,clomipramine
502912974,7/14/2014 13:34:50,,1322845242,7/14/2014 13:34:35,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,64,36,,,78,48,PANIC DISORDER,CLOMIPRAMINE,placebo in PANIC DISORDER.,53-61-64-70,10-21-24-36-49-53-61-64-70,"evaluation of paroxetine, CLOMIPRAMINE and placebo in panic disorder.","Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder.",64 70,36,64,36,78,48,1,RO-may_treat,907891,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder",panic disorder,clomipramine
502912974,7/14/2014 13:40:11,,1322849203,7/14/2014 13:40:09,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,64,36,,,78,48,PANIC DISORDER,CLOMIPRAMINE,and placebo in PANIC DISORDER.,49-53-61-64-70,10-21-24-36-49-53-61,"evaluation of paroxetine, CLOMIPRAMINE and placebo in","Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder.",64 70,36,64,36,78,48,1,RO-may_treat,907891,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder",panic disorder,clomipramine
502912974,7/14/2014 13:40:35,,1322849481,7/14/2014 13:40:24,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,64,36,,,78,48,PANIC DISORDER,CLOMIPRAMINE,PANIC DISORDER.,64-70,36,CLOMIPRAMINE,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder.",64 70,36,64,36,78,48,1,RO-may_treat,907891,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder",panic disorder,clomipramine
502912974,7/14/2014 13:43:46,,1322851778,7/14/2014 13:43:33,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,64,36,,,78,48,PANIC DISORDER,CLOMIPRAMINE,PANIC DISORDER.,64-70,36,CLOMIPRAMINE,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder.",64 70,36,64,36,78,48,1,RO-may_treat,907891,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder",panic disorder,clomipramine
502912974,7/14/2014 13:55:45,,1322860505,7/14/2014 13:54:41,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,64,36,,,78,48,PANIC DISORDER,CLOMIPRAMINE,PANIC DISORDER.,64-70,36,CLOMIPRAMINE,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder.",64 70,36,64,36,78,48,1,RO-may_treat,907891,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder",panic disorder,clomipramine
502912974,7/14/2014 13:58:09,,1322861990,7/14/2014 13:57:39,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,64,36,,,78,48,PANIC DISORDER,CLOMIPRAMINE,PANIC DISORDER.,64-70,36,CLOMIPRAMINE,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder.",64 70,36,64,36,78,48,1,RO-may_treat,907891,"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder",panic disorder,clomipramine
502912975,7/14/2014 12:51:08,,1322815509,7/14/2014 12:50:53,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,101,29,,,109,60,SEIZURES,GENERALIZED CONVULSIVE SEIZURES,"stimulation induced SEIZURES,",81-93-101,17-29-41-52,"spontaneous GENERALIZED CONVULSIVE SEIZURES,","In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",101,29 41 52,101,29,109,60,-1,RO-has_definitional_manifestation,904592,"In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology",seizures,generalized convulsive seizures
502912975,7/14/2014 12:55:49,,1322818697,7/14/2014 12:55:44,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,101,29,,,109,60,SEIZURES,GENERALIZED CONVULSIVE SEIZURES,"light stimulation induced SEIZURES, and kindled generalized",75-81-93-101-111-115-123,3-8-17-29-41-52-62-75-81-93,"this species, spontaneous GENERALIZED CONVULSIVE SEIZURES, intermittent light stimulation induced","In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",101,29 41 52,101,29,109,60,-1,RO-has_definitional_manifestation,904592,"In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology",seizures,generalized convulsive seizures
502912975,7/14/2014 13:11:56,,1322829424,7/14/2014 13:11:29,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,101,29,,,109,60,SEIZURES,GENERALIZED CONVULSIVE SEIZURES,"SEIZURES,",101,29-41-52,"GENERALIZED CONVULSIVE SEIZURES,","In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",101,29 41 52,101,29,109,60,-1,RO-has_definitional_manifestation,904592,"In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology",seizures,generalized convulsive seizures
502912975,7/14/2014 13:13:41,,1322830690,7/14/2014 13:13:34,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,101,29,,,109,60,SEIZURES,GENERALIZED CONVULSIVE SEIZURES,"light stimulation induced SEIZURES, and kindled generalized",75-81-93-101-111-115-123,3-8-17-29-41-52-62-75-81,"this species, spontaneous GENERALIZED CONVULSIVE SEIZURES, intermittent light stimulation","In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",101,29 41 52,101,29,109,60,-1,RO-has_definitional_manifestation,904592,"In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology",seizures,generalized convulsive seizures
502912975,7/14/2014 13:46:26,,1322853775,7/14/2014 13:45:53,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,101,29,,,109,60,SEIZURES,GENERALIZED CONVULSIVE SEIZURES,"stimulation - induced SEIZURES,",81-92-101-93,29-41-52-17,"spontaneous GENERALIZED CONVULSIVE SEIZURES,","In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",101,29 41 52,101,29,109,60,-1,RO-has_definitional_manifestation,904592,"In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology",seizures,generalized convulsive seizures
502912975,7/14/2014 14:19:21,,1322876365,7/14/2014 14:19:13,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,101,29,,,109,60,SEIZURES,GENERALIZED CONVULSIVE SEIZURES,"light stimulation induced SEIZURES, and kindled generalized",75-81-93-101-111-115-123,3-8-17-29-41-52-62-75-81,"this species, spontaneous GENERALIZED CONVULSIVE SEIZURES, intermittent light stimulation","In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",101,29 41 52,101,29,109,60,-1,RO-has_definitional_manifestation,904592,"In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology",seizures,generalized convulsive seizures
502912975,7/14/2014 14:36:00,,1322888250,7/14/2014 14:35:42,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,101,29,,,109,60,SEIZURES,GENERALIZED CONVULSIVE SEIZURES,"intermittent light stimulation induced SEIZURES,",62-75-81-93-101,17-29-41-52,"spontaneous GENERALIZED CONVULSIVE SEIZURES,","In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",101,29 41 52,101,29,109,60,-1,RO-has_definitional_manifestation,904592,"In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology",seizures,generalized convulsive seizures
502912975,7/14/2014 14:44:24,,1322894003,7/14/2014 14:44:00,prodege,1.0,28209666,,,"",24.156.173.34,101,29,,,109,60,SEIZURES,GENERALIZED CONVULSIVE SEIZURES,"SEIZURES,",101,29-41-52,"GENERALIZED CONVULSIVE SEIZURES,","In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",101,29 41 52,101,29,109,60,-1,RO-has_definitional_manifestation,904592,"In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology",seizures,generalized convulsive seizures
502912975,7/14/2014 14:47:49,,1322896102,7/14/2014 14:47:29,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,101,29,,,109,60,SEIZURES,GENERALIZED CONVULSIVE SEIZURES,"light stimulation induced SEIZURES,",75-81-93-101,17-29-41-52,"spontaneous GENERALIZED CONVULSIVE SEIZURES,","In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",101,29 41 52,101,29,109,60,-1,RO-has_definitional_manifestation,904592,"In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology",seizures,generalized convulsive seizures
502912975,7/14/2014 14:49:35,,1322897119,7/14/2014 14:49:15,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,101,29,,,109,60,SEIZURES,GENERALIZED CONVULSIVE SEIZURES,"SEIZURES,",101,29-41-52,"GENERALIZED CONVULSIVE SEIZURES,","In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",101,29 41 52,101,29,109,60,-1,RO-has_definitional_manifestation,904592,"In this species, spontaneous generalized convulsive seizures, intermittent light stimulation-induced seizures, and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology",seizures,generalized convulsive seizures
502912976,7/14/2014 12:48:19,,1322813524,7/14/2014 12:48:11,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,61,0,,,65,10,SKIN,DERMATITIS,SKIN,61,0,DERMATITIS,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",61,0,61,0,65,10,1,RO-has_finding_site,905059,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants",skin,Dermatitis
502912976,7/14/2014 12:52:05,,1322816222,7/14/2014 12:51:07,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,61,0,,,65,10,SKIN,DERMATITIS,SKIN,61,0,DERMATITIS,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",61,0,61,0,65,10,1,RO-has_finding_site,905059,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants",skin,Dermatitis
502912976,7/14/2014 12:54:32,,1322817907,7/14/2014 12:54:09,gifthulk,1.0,25566511,USA,"","",24.164.11.173,61,0,,,65,10,SKIN,DERMATITIS,sensitization of the SKIN,40-54-57-61,0,DERMATITIS,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",61,0,61,0,65,10,1,RO-has_finding_site,905059,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants",skin,Dermatitis
502912976,7/14/2014 12:56:30,,1322819205,7/14/2014 12:56:25,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,61,0,,,65,10,SKIN,DERMATITIS,"sensitization of the SKIN by urushiol, the (Toxicodendron)",40-54-57-61-66-69-79-107,0-11-21-26-107,DERMATITIS resulting from irritation (Toxicodendron),"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",61,0,61,0,65,10,1,RO-has_finding_site,905059,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants",skin,Dermatitis
502912976,7/14/2014 13:02:35,,1322823143,7/14/2014 13:02:23,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,61,0,,,65,10,SKIN,DERMATITIS,SKIN,61,0,DERMATITIS,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",61,0,61,0,65,10,1,RO-has_finding_site,905059,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants",skin,Dermatitis
502912976,7/14/2014 13:15:36,,1322831925,7/14/2014 13:15:31,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,61,0,,,65,10,SKIN,DERMATITIS,"sensitization of the SKIN by urushiol, the",40-54-57-61-66-69-79,0-11-21-26,DERMATITIS resulting from irritation,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",61,0,61,0,65,10,1,RO-has_finding_site,905059,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants",skin,Dermatitis
502912976,7/14/2014 13:16:00,,1322832205,7/14/2014 13:15:49,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,61,0,,,65,10,SKIN,DERMATITIS,SKIN,61,0,DERMATITIS,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",61,0,61,0,65,10,1,RO-has_finding_site,905059,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants",skin,Dermatitis
502912976,7/14/2014 13:40:59,,1322849763,7/14/2014 13:40:57,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,61,0,,,65,10,SKIN,DERMATITIS,"sensitization of the SKIN by urushiol, the",40-54-57-61-66-69-79,0-11-21-26,DERMATITIS resulting from irritation,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",61,0,61,0,65,10,1,RO-has_finding_site,905059,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants",skin,Dermatitis
502912976,7/14/2014 13:46:21,,1322853673,7/14/2014 13:45:44,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,61,0,,,65,10,SKIN,DERMATITIS,SKIN,61,0,DERMATITIS,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",61,0,61,0,65,10,1,RO-has_finding_site,905059,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants",skin,Dermatitis
502912976,7/14/2014 13:52:11,,1322858083,7/14/2014 13:51:36,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,61,0,,,65,10,SKIN,DERMATITIS,Dermatitis SKIN,0-61,0-11-21-26,DERMATITIS resulting from irritation,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",61,0,61,0,65,10,1,RO-has_finding_site,905059,"Dermatitis resulting from irritation or sensitization of the skin by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants",skin,Dermatitis
502912977,7/14/2014 12:47:15,,1322812853,7/14/2014 12:47:10,clixsense,1.0,24763049,GBR,"","",86.133.47.213,164,192,,,180,209,SEVERE DYSPLASIA,CARCINOMA IN SITU,"65 with a SEVERE DYSPLASIA, 11 with a",154-157-162-164-171-182-185-190,182-185-190-192-202-205-210-214-216,11 with a CARCINOMA IN SITU and 7 with,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma.",164 171,192 202 205,164,192,180,209,-1,RO-disease_has_finding,901954,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma",severe dysplasia,carcinoma in situ
502912977,7/14/2014 13:11:04,,1322828807,7/14/2014 13:10:47,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,164,192,,,180,209,SEVERE DYSPLASIA,CARCINOMA IN SITU,"SEVERE DYSPLASIA,",164-171,192-202-205,CARCINOMA IN SITU,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma.",164 171,192 202 205,164,192,180,209,-1,RO-disease_has_finding,901954,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma",severe dysplasia,carcinoma in situ
502912977,7/14/2014 13:33:08,,1322844056,7/14/2014 13:32:47,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,164,192,,,180,209,SEVERE DYSPLASIA,CARCINOMA IN SITU,"65 SEVERE DYSPLASIA,",154-164-171,192-202-205,CARCINOMA IN SITU,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma.",164 171,192 202 205,164,192,180,209,-1,RO-disease_has_finding,901954,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma",severe dysplasia,carcinoma in situ
502912977,7/14/2014 13:56:06,,1322860728,7/14/2014 13:55:46,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,164,192,,,180,209,SEVERE DYSPLASIA,CARCINOMA IN SITU,"SEVERE DYSPLASIA,",164-171,192-202-205,CARCINOMA IN SITU,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma.",164 171,192 202 205,164,192,180,209,-1,RO-disease_has_finding,901954,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma",severe dysplasia,carcinoma in situ
502912977,7/14/2014 14:26:55,,1322881750,7/14/2014 14:26:47,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,164,192,,,180,209,SEVERE DYSPLASIA,CARCINOMA IN SITU,"65 with a SEVERE DYSPLASIA,",154-157-162-164-171,182-185-190-192-202-205,11 with a CARCINOMA IN SITU,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma.",164 171,192 202 205,164,192,180,209,-1,RO-disease_has_finding,901954,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma",severe dysplasia,carcinoma in situ
502912977,7/14/2014 14:38:49,,1322890241,7/14/2014 14:38:30,prodege,1.0,28209666,,,"",24.156.173.34,164,192,,,180,209,SEVERE DYSPLASIA,CARCINOMA IN SITU,"SEVERE DYSPLASIA,",164-171,192-202-205,CARCINOMA IN SITU,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma.",164 171,192 202 205,164,192,180,209,-1,RO-disease_has_finding,901954,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma",severe dysplasia,carcinoma in situ
502912977,7/14/2014 14:43:27,,1322893330,7/14/2014 14:42:43,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,164,192,,,180,209,SEVERE DYSPLASIA,CARCINOMA IN SITU,"SEVERE DYSPLASIA,",164-171,192-202-205,CARCINOMA IN SITU,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma.",164 171,192 202 205,164,192,180,209,-1,RO-disease_has_finding,901954,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma",severe dysplasia,carcinoma in situ
502912977,7/14/2014 14:45:08,,1322894433,7/14/2014 14:44:58,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,164,192,,,180,209,SEVERE DYSPLASIA,CARCINOMA IN SITU,"SEVERE DYSPLASIA,",164-171,192-202-205,CARCINOMA IN SITU,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma.",164 171,192 202 205,164,192,180,209,-1,RO-disease_has_finding,901954,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma",severe dysplasia,carcinoma in situ
502912977,7/14/2014 14:49:30,,1322897012,7/14/2014 14:49:14,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,164,192,,,180,209,SEVERE DYSPLASIA,CARCINOMA IN SITU,"65 with a SEVERE DYSPLASIA,",154-157-162-164-171,192-202-205,CARCINOMA IN SITU,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma.",164 171,192 202 205,164,192,180,209,-1,RO-disease_has_finding,901954,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma",severe dysplasia,carcinoma in situ
502912977,7/14/2014 14:49:54,,1322897284,7/14/2014 14:49:39,instagc,1.0,13763729,USA,"","",75.182.89.225,164,192,,,180,209,SEVERE DYSPLASIA,CARCINOMA IN SITU,"SEVERE DYSPLASIA,",164-171,192-202-205,CARCINOMA IN SITU,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma.",164 171,192 202 205,164,192,180,209,-1,RO-disease_has_finding,901954,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a severe dysplasia, 11 with a carcinoma in situ and 7 with an invasive carcinoma",severe dysplasia,carcinoma in situ
502912978,7/14/2014 12:53:19,,1322817086,7/14/2014 12:53:03,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,33,90,,,49,108,HYPERSENSITIVITY,ALLERGIC REACTIONS,HYPERSENSITIVITY,33,90-99,ALLERGIC REACTIONS,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug.",33,90 99,33,90,49,108,-1,RO-cause_of,900097,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug",Hypersensitivity,allergic reactions
502912978,7/14/2014 12:54:18,,1322817798,7/14/2014 12:54:13,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,33,90,,,49,108,HYPERSENSITIVITY,ALLERGIC REACTIONS,20 Sensitivity Reactions HYPERSENSITIVITY Reactions Anaphylaxis and reported,6-10-22-33-50-61-73-109,73-77-83-90-99-109-118-121-131,and other severe ALLERGIC REACTIONS reported on the day,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug.",33,90 99,33,90,49,108,-1,RO-cause_of,900097,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug",Hypersensitivity,allergic reactions
502912978,7/14/2014 13:14:48,,1322831375,7/14/2014 13:14:43,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,33,90,,,49,108,HYPERSENSITIVITY,ALLERGIC REACTIONS,20 Sensitivity Reactions HYPERSENSITIVITY Reactions Anaphylaxis and,6-10-22-33-50-61-73,73-77-83-90-99-109-118-121,and other severe ALLERGIC REACTIONS reported on the,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug.",33,90 99,33,90,49,108,-1,RO-cause_of,900097,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug",Hypersensitivity,allergic reactions
502912978,7/14/2014 13:25:42,,1322838888,7/14/2014 13:25:30,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,33,90,,,49,108,HYPERSENSITIVITY,ALLERGIC REACTIONS,HYPERSENSITIVITY Reactions Anaphylaxis,33-50-61,90-99,ALLERGIC REACTIONS,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug.",33,90 99,33,90,49,108,-1,RO-cause_of,900097,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug",Hypersensitivity,allergic reactions
502912978,7/14/2014 13:45:36,,1322853021,7/14/2014 13:45:14,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,33,90,,,49,108,HYPERSENSITIVITY,ALLERGIC REACTIONS,HYPERSENSITIVITY,33,90-99,ALLERGIC REACTIONS,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug.",33,90 99,33,90,49,108,-1,RO-cause_of,900097,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug",Hypersensitivity,allergic reactions
502912978,7/14/2014 14:21:40,,1322877960,7/14/2014 14:21:34,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,33,90,,,49,108,HYPERSENSITIVITY,ALLERGIC REACTIONS,20 Sensitivity Reactions HYPERSENSITIVITY Reactions Anaphylaxis and,6-10-22-33-50-61-73,73-77-83-90-99-109-118-121,and other severe ALLERGIC REACTIONS reported on the,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug.",33,90 99,33,90,49,108,-1,RO-cause_of,900097,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug",Hypersensitivity,allergic reactions
502912978,7/14/2014 14:44:32,,1322894092,7/14/2014 14:44:12,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,33,90,,,49,108,HYPERSENSITIVITY,ALLERGIC REACTIONS,20 Sensitivity Reactions HYPERSENSITIVITY Reactions Anaphylaxis and,6-10-22-33-50-61-73,73-77-83-90-99-109-118-121,and other severe ALLERGIC REACTIONS reported on the,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug.",33,90 99,33,90,49,108,-1,RO-cause_of,900097,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug",Hypersensitivity,allergic reactions
502912978,7/14/2014 14:44:35,,1322894131,7/14/2014 14:44:13,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,33,90,,,49,108,HYPERSENSITIVITY,ALLERGIC REACTIONS,HYPERSENSITIVITY Reactions Anaphylaxis,33-50-61,90-99,ALLERGIC REACTIONS,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug.",33,90 99,33,90,49,108,-1,RO-cause_of,900097,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug",Hypersensitivity,allergic reactions
502912978,7/14/2014 14:47:06,,1322895683,7/14/2014 14:46:55,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,33,90,,,49,108,HYPERSENSITIVITY,ALLERGIC REACTIONS,HYPERSENSITIVITY Reactions,33-50,83-90-99,severe ALLERGIC REACTIONS,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug.",33,90 99,33,90,49,108,-1,RO-cause_of,900097,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug",Hypersensitivity,allergic reactions
502912978,7/14/2014 14:49:51,,1322897257,7/14/2014 14:49:37,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,33,90,,,49,108,HYPERSENSITIVITY,ALLERGIC REACTIONS,HYPERSENSITIVITY,33,90-99,ALLERGIC REACTIONS,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug.",33,90 99,33,90,49,108,-1,RO-cause_of,900097,"1 ,   20  Sensitivity Reactions  Hypersensitivity Reactions  Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug",Hypersensitivity,allergic reactions
502912979,7/14/2014 12:59:40,,1322821267,7/14/2014 12:59:12,gifthulk,1.0,25566511,USA,"","",24.164.11.173,69,90,,,85,107,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,69-76,90-100-103,CARCINOMA IN SITU,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases.,69 76,90 100 103,69,90,85,107,-1,RO-disease_has_finding,901966,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases,severe dysplasia,carcinoma in situ
502912979,7/14/2014 13:12:08,,1322829529,7/14/2014 13:11:51,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,69,90,,,85,107,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,69-76,90-100-103,CARCINOMA IN SITU,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases.,69 76,90 100 103,69,90,85,107,-1,RO-disease_has_finding,901966,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases,severe dysplasia,carcinoma in situ
502912979,7/14/2014 13:20:06,,1322834968,7/14/2014 13:19:00,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,69,90,,,85,107,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,69-76,90-100-103,CARCINOMA IN SITU,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases.,69 76,90 100 103,69,90,85,107,-1,RO-disease_has_finding,901966,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases,severe dysplasia,carcinoma in situ
502912979,7/14/2014 13:26:18,,1322839306,7/14/2014 13:25:57,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,69,90,,,85,107,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA and carcinoma in situ,69-76-86-90-100-103,69-76-86-90-100-103,severe dysplasia and CARCINOMA IN SITU,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases.,69 76,90 100 103,69,90,85,107,-1,RO-disease_has_finding,901966,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases,severe dysplasia,carcinoma in situ
502912979,7/14/2014 13:27:30,,1322840141,7/14/2014 13:27:11,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,69,90,,,85,107,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,69-76,90-100-103,CARCINOMA IN SITU,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases.,69 76,90 100 103,69,90,85,107,-1,RO-disease_has_finding,901966,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases,severe dysplasia,carcinoma in situ
502912979,7/14/2014 13:40:20,,1322849341,7/14/2014 13:40:16,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,69,90,,,85,107,SEVERE DYSPLASIA,CARCINOMA IN SITU,(43%) of these SEVERE DYSPLASIA and carcinoma in,53-59-62-69-76-86-90-100,69-76-86-90-100-103-108-118-123,severe dysplasia and CARCINOMA IN SITU comprised over half,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases.,69 76,90 100 103,69,90,85,107,-1,RO-disease_has_finding,901966,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases,severe dysplasia,carcinoma in situ
502912979,7/14/2014 13:42:18,,1322850691,7/14/2014 13:42:03,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,69,90,,,85,107,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,69-76,90-100-103,CARCINOMA IN SITU,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases.,69 76,90 100 103,69,90,85,107,-1,RO-disease_has_finding,901966,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases,severe dysplasia,carcinoma in situ
502912979,7/14/2014 13:47:34,,1322854730,7/14/2014 13:47:14,elite,1.0,26544151,GBR,"","",188.29.127.144,69,90,,,85,107,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,69-76,90-100-103,CARCINOMA IN SITU,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases.,69 76,90 100 103,69,90,85,107,-1,RO-disease_has_finding,901966,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases,severe dysplasia,carcinoma in situ
502912979,7/14/2014 13:50:38,,1322856841,7/14/2014 13:50:20,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,69,90,,,85,107,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA and carcinoma in situ,69-76-86-90-100-103,69-76-86-90-100-103,severe dysplasia and CARCINOMA IN SITU,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases.,69 76,90 100 103,69,90,85,107,-1,RO-disease_has_finding,901966,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases,severe dysplasia,carcinoma in situ
502912979,7/14/2014 13:56:30,,1322861008,7/14/2014 13:56:18,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,69,90,,,85,107,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,69-76,90-100-103,CARCINOMA IN SITU,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases.,69 76,90 100 103,69,90,85,107,-1,RO-disease_has_finding,901966,Squamous intraepithelial neoplasia was present in 99 (43%) of these--severe dysplasia and carcinoma in situ comprised over half of the cases,severe dysplasia,carcinoma in situ
502912980,7/14/2014 13:05:06,,1322824680,7/14/2014 13:04:11,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,134,56,,,139,79,LIVER,HEPATOCELLULAR NECROSIS,LIVER,134,56-71,HEPATOCELLULAR NECROSIS,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens.",134,56 71,134,56,139,79,1,RO-has_finding_site,905398,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens",liver,hepatocellular necrosis
502912980,7/14/2014 13:09:36,,1322827884,7/14/2014 13:09:19,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,134,56,,,139,79,LIVER,HEPATOCELLULAR NECROSIS,LIVER,134,56-71,HEPATOCELLULAR NECROSIS,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens.",134,56 71,134,56,139,79,1,RO-has_finding_site,905398,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens",liver,hepatocellular necrosis
502912980,7/14/2014 13:34:25,,1322844987,7/14/2014 13:34:05,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,134,56,,,139,79,LIVER,HEPATOCELLULAR NECROSIS,LIVER specimens.,134-140,56-71,HEPATOCELLULAR NECROSIS,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens.",134,56 71,134,56,139,79,1,RO-has_finding_site,905398,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens",liver,hepatocellular necrosis
502912980,7/14/2014 13:35:11,,1322845469,7/14/2014 13:34:51,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,134,56,,,139,79,LIVER,HEPATOCELLULAR NECROSIS,enhanced myeloperoxidase staining in these LIVER specimens.,91-116-125-128-134-140-100,13-26-35-44-56-71,histological analyses verified significant HEPATOCELLULAR NECROSIS,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens.",134,56 71,134,56,139,79,1,RO-has_finding_site,905398,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens",liver,hepatocellular necrosis
502912980,7/14/2014 13:40:30,,1322849451,7/14/2014 13:40:28,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,134,56,,,139,79,LIVER,HEPATOCELLULAR NECROSIS,staining in these LIVER specimens.,116-125-128-134-140,26-35-44-56-71-80-83-88,analyses verified significant HEPATOCELLULAR NECROSIS as well as,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens.",134,56 71,134,56,139,79,1,RO-has_finding_site,905398,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens",liver,hepatocellular necrosis
502912980,7/14/2014 13:44:44,,1322852426,7/14/2014 13:44:26,elite,1.0,26544151,GBR,"","",188.29.127.144,134,56,,,139,79,LIVER,HEPATOCELLULAR NECROSIS,LIVER,134,56-71,HEPATOCELLULAR NECROSIS,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens.",134,56 71,134,56,139,79,1,RO-has_finding_site,905398,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens",liver,hepatocellular necrosis
502912980,7/14/2014 13:45:52,,1322853234,7/14/2014 13:45:37,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,134,56,,,139,79,LIVER,HEPATOCELLULAR NECROSIS,LIVER,134,56-71,HEPATOCELLULAR NECROSIS,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens.",134,56 71,134,56,139,79,1,RO-has_finding_site,905398,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens",liver,hepatocellular necrosis
502912980,7/14/2014 14:01:28,,1322864419,7/14/2014 14:01:08,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,134,56,,,139,79,LIVER,HEPATOCELLULAR NECROSIS,LIVER specimens.,134-140,44-56-71,significant HEPATOCELLULAR NECROSIS,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens.",134,56 71,134,56,139,79,1,RO-has_finding_site,905398,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens",liver,hepatocellular necrosis
502912980,7/14/2014 14:02:49,,1322865370,7/14/2014 14:02:19,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,134,56,,,139,79,LIVER,HEPATOCELLULAR NECROSIS,hepatocellular necrosis LIVER,56-134-71,56-71,HEPATOCELLULAR NECROSIS,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens.",134,56 71,134,56,139,79,1,RO-has_finding_site,905398,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens",liver,hepatocellular necrosis
502912980,7/14/2014 14:22:09,,1322878384,7/14/2014 14:21:56,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,134,56,,,139,79,LIVER,HEPATOCELLULAR NECROSIS,staining in these LIVER specimens.,116-125-128-134-140,26-35-44-56-71-80-83-88,analyses verified significant HEPATOCELLULAR NECROSIS as well as,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens.",134,56 71,134,56,139,79,1,RO-has_finding_site,905398,"Furthermore, histological analyses verified significant hepatocellular necrosis as well as enhanced myeloperoxidase staining in these liver specimens",liver,hepatocellular necrosis
502912981,7/14/2014 12:49:55,,1322814641,7/14/2014 12:49:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,91,32,,,95,44,PAIN,CLOMIPRAMINE,PAIN relief,91-96,32,CLOMIPRAMINE,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups.,91,32,91,32,95,44,1,RO-may_treat,907851,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups,pain,clomipramine
502912981,7/14/2014 12:52:25,,1322816423,7/14/2014 12:52:12,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,91,32,,,95,44,PAIN,CLOMIPRAMINE,PAIN,91,32,CLOMIPRAMINE,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups.,91,32,91,32,95,44,1,RO-may_treat,907851,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups,pain,clomipramine
502912981,7/14/2014 12:54:54,,1322818142,7/14/2014 12:54:33,gifthulk,1.0,25566511,USA,"","",24.164.11.173,91,32,,,95,44,PAIN,CLOMIPRAMINE,PAIN relief,91-96,32,CLOMIPRAMINE,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups.,91,32,91,32,95,44,1,RO-may_treat,907851,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups,pain,clomipramine
502912981,7/14/2014 13:13:19,,1322830474,7/14/2014 13:13:00,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,91,32,,,95,44,PAIN,CLOMIPRAMINE,PAIN relief,91-96,32,CLOMIPRAMINE,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups.,91,32,91,32,95,44,1,RO-may_treat,907851,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups,pain,clomipramine
502912981,7/14/2014 13:39:28,,1322848667,7/14/2014 13:39:26,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,91,32,,,95,44,PAIN,CLOMIPRAMINE,levomepromazine showed better PAIN relief with tramadol,61-77-84-91-96-103-108,8-18-27-32-45-50-53,comparing tramadol with CLOMIPRAMINE with or without,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups.,91,32,91,32,95,44,1,RO-may_treat,907851,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups,pain,clomipramine
502912981,7/14/2014 14:23:31,,1322879248,7/14/2014 14:23:09,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,91,32,,,95,44,PAIN,CLOMIPRAMINE,PAIN,91,32-91,CLOMIPRAMINE pain,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups.,91,32,91,32,95,44,1,RO-may_treat,907851,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups,pain,clomipramine
502912981,7/14/2014 14:23:50,,1322879475,7/14/2014 14:23:46,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,91,32,,,95,44,PAIN,CLOMIPRAMINE,levomepromazine showed better PAIN relief with tramadol,61-77-84-91-96-103-108,8-18-27-32-45-50-53,comparing tramadol with CLOMIPRAMINE with or without,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups.,91,32,91,32,95,44,1,RO-may_treat,907851,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups,pain,clomipramine
502912981,7/14/2014 14:44:56,,1322894329,7/14/2014 14:44:38,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,91,32,,,95,44,PAIN,CLOMIPRAMINE,PAIN relief,91-96,32,CLOMIPRAMINE,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups.,91,32,91,32,95,44,1,RO-may_treat,907851,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups,pain,clomipramine
502912981,7/14/2014 14:48:39,,1322896600,7/14/2014 14:48:27,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,91,32,,,95,44,PAIN,CLOMIPRAMINE,PAIN relief,91-96,32,CLOMIPRAMINE,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups.,91,32,91,32,95,44,1,RO-may_treat,907851,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups,pain,clomipramine
502912981,7/14/2014 14:48:41,,1322896633,7/14/2014 14:48:26,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,91,32,,,95,44,PAIN,CLOMIPRAMINE,levomepromazine showed better PAIN relief with tramadol,61-77-84-91-96-103-108,8-18-27-32,comparing tramadol with CLOMIPRAMINE,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups.,91,32,91,32,95,44,1,RO-may_treat,907851,1 trial comparing tramadol with clomipramine with or without levomepromazine showed better pain relief with tramadol but no difference in pain intensity between groups,pain,clomipramine
502912982,7/14/2014 12:46:02,,1322812013,7/14/2014 12:45:57,clixsense,1.0,24763049,GBR,"","",86.133.47.213,138,58,,,151,71,CALCIFICATION,PILOMATRICOMA,as common as CALCIFICATION in pilomatricoma.,125-128-135-138-152-155,44-47-55-58-73-84-89,"16 samples of PILOMATRICOMA, indicating that the","Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma.",138,58,138,58,151,71,1,RO-disease_may_have_finding,902676,"Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma",calcification,pilomatricoma
502912982,7/14/2014 12:50:33,,1322815076,7/14/2014 12:50:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,138,58,,,151,71,CALCIFICATION,PILOMATRICOMA,CALCIFICATION,138,58,"PILOMATRICOMA,","Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma.",138,58,138,58,151,71,1,RO-disease_may_have_finding,902676,"Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma",calcification,pilomatricoma
502912982,7/14/2014 12:57:37,,1322819880,7/14/2014 12:57:22,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,138,58,,,151,71,CALCIFICATION,PILOMATRICOMA,CALCIFICATION,138,58,"PILOMATRICOMA,","Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma.",138,58,138,58,151,71,1,RO-disease_may_have_finding,902676,"Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma",calcification,pilomatricoma
502912982,7/14/2014 13:05:55,,1322825268,7/14/2014 13:05:15,gifthulk,1.0,25566511,USA,"","",24.164.11.173,138,58,,,151,71,CALCIFICATION,PILOMATRICOMA,CALCIFICATION,138,58,"PILOMATRICOMA,","Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma.",138,58,138,58,151,71,1,RO-disease_may_have_finding,902676,"Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma",calcification,pilomatricoma
502912982,7/14/2014 13:06:29,,1322825677,7/14/2014 13:05:40,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,138,58,,,151,71,CALCIFICATION,PILOMATRICOMA,"Amyloid deposition pilomatricoma, CALCIFICATION pilomatricoma.",0-8-58-138-155,0-8-58-138-155,"Amyloid deposition PILOMATRICOMA, calcification pilomatricoma.","Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma.",138,58,138,58,151,71,1,RO-disease_may_have_finding,902676,"Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma",calcification,pilomatricoma
502912982,7/14/2014 13:34:21,,1322844933,7/14/2014 13:34:07,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,138,58,,,151,71,CALCIFICATION,PILOMATRICOMA,CALCIFICATION,138,58,"PILOMATRICOMA,","Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma.",138,58,138,58,151,71,1,RO-disease_may_have_finding,902676,"Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma",calcification,pilomatricoma
502912982,7/14/2014 13:40:45,,1322849618,7/14/2014 13:40:42,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,138,58,,,151,71,CALCIFICATION,PILOMATRICOMA,as common as CALCIFICATION in pilomatricoma.,125-128-135-138-152-155,44-47-55-58-73-84-89,"16 samples of PILOMATRICOMA, indicating that the","Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma.",138,58,138,58,151,71,1,RO-disease_may_have_finding,902676,"Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma",calcification,pilomatricoma
502912982,7/14/2014 13:50:50,,1322856952,7/14/2014 13:50:31,elite,1.0,26544151,GBR,"","",188.29.127.144,138,58,,,151,71,CALCIFICATION,PILOMATRICOMA,CALCIFICATION,138,58,"PILOMATRICOMA,","Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma.",138,58,138,58,151,71,1,RO-disease_may_have_finding,902676,"Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma",calcification,pilomatricoma
502912982,7/14/2014 14:01:07,,1322864157,7/14/2014 14:00:18,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,138,58,,,151,71,CALCIFICATION,PILOMATRICOMA,CALCIFICATION in pilomatricoma.,138-152-155,58,"PILOMATRICOMA,","Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma.",138,58,138,58,151,71,1,RO-disease_may_have_finding,902676,"Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma",calcification,pilomatricoma
502912982,7/14/2014 14:05:39,,1322867179,7/14/2014 14:05:22,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,138,58,,,151,71,CALCIFICATION,PILOMATRICOMA,CALCIFICATION,138,58,"PILOMATRICOMA,","Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma.",138,58,138,58,151,71,1,RO-disease_may_have_finding,902676,"Amyloid deposition was encountered in 10 of 16 samples of pilomatricoma, indicating that the deposition of amyloid is nearly as common as calcification in pilomatricoma",calcification,pilomatricoma
502912983,7/14/2014 12:50:43,,1322815200,7/14/2014 12:50:34,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,0,47,,,14,75,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,0,47-55-65,PRIMARY CARNITINE DEFICIENCY.,Hyperammonemia is one of the major symptoms of primary carnitine deficiency.,0,47 55 65,0,47,14,75,1,RO-has_manifestation,906433,Hyperammonemia is one of the major symptoms of primary carnitine deficiency,Hyperammonemia,primary carnitine deficiency
502912983,7/14/2014 13:12:53,,1322830082,7/14/2014 13:12:42,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,0,47,,,14,75,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,0,47-55-65,PRIMARY CARNITINE DEFICIENCY.,Hyperammonemia is one of the major symptoms of primary carnitine deficiency.,0,47 55 65,0,47,14,75,1,RO-has_manifestation,906433,Hyperammonemia is one of the major symptoms of primary carnitine deficiency,Hyperammonemia,primary carnitine deficiency
502912983,7/14/2014 13:28:43,,1322840894,7/14/2014 13:28:15,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,0,47,,,14,75,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA primary carnitine deficiency.,0-47-55-65,47-55-65-0,Hyperammonemia PRIMARY CARNITINE DEFICIENCY.,Hyperammonemia is one of the major symptoms of primary carnitine deficiency.,0,47 55 65,0,47,14,75,1,RO-has_manifestation,906433,Hyperammonemia is one of the major symptoms of primary carnitine deficiency,Hyperammonemia,primary carnitine deficiency
502912983,7/14/2014 13:40:06,,1322849142,7/14/2014 13:39:43,clixsense,1.0,27969116,NLD,"","",91.213.37.165,0,47,,,14,75,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,0,47-55-65-0,Hyperammonemia PRIMARY CARNITINE DEFICIENCY.,Hyperammonemia is one of the major symptoms of primary carnitine deficiency.,0,47 55 65,0,47,14,75,1,RO-has_manifestation,906433,Hyperammonemia is one of the major symptoms of primary carnitine deficiency,Hyperammonemia,primary carnitine deficiency
502912983,7/14/2014 14:00:45,,1322863865,7/14/2014 14:00:33,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,0,47,,,14,75,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,0,47-55-65,PRIMARY CARNITINE DEFICIENCY.,Hyperammonemia is one of the major symptoms of primary carnitine deficiency.,0,47 55 65,0,47,14,75,1,RO-has_manifestation,906433,Hyperammonemia is one of the major symptoms of primary carnitine deficiency,Hyperammonemia,primary carnitine deficiency
502912983,7/14/2014 14:23:19,,1322879117,7/14/2014 14:23:15,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,0,47,,,14,75,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA is one of,0-15-18-22,29-35-44-47-55-65,major symptoms of PRIMARY CARNITINE DEFICIENCY.,Hyperammonemia is one of the major symptoms of primary carnitine deficiency.,0,47 55 65,0,47,14,75,1,RO-has_manifestation,906433,Hyperammonemia is one of the major symptoms of primary carnitine deficiency,Hyperammonemia,primary carnitine deficiency
502912983,7/14/2014 14:25:30,,1322880769,7/14/2014 14:25:21,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,0,47,,,14,75,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,0,47-55-65,PRIMARY CARNITINE DEFICIENCY.,Hyperammonemia is one of the major symptoms of primary carnitine deficiency.,0,47 55 65,0,47,14,75,1,RO-has_manifestation,906433,Hyperammonemia is one of the major symptoms of primary carnitine deficiency,Hyperammonemia,primary carnitine deficiency
502912983,7/14/2014 14:30:47,,1322884676,7/14/2014 14:30:26,instagc,1.0,27753923,GBR,"","",188.30.192.65,0,47,,,14,75,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA is one of,0-15-18-22,29-35-44-47-55-65,major symptoms of PRIMARY CARNITINE DEFICIENCY.,Hyperammonemia is one of the major symptoms of primary carnitine deficiency.,0,47 55 65,0,47,14,75,1,RO-has_manifestation,906433,Hyperammonemia is one of the major symptoms of primary carnitine deficiency,Hyperammonemia,primary carnitine deficiency
502912983,7/14/2014 14:45:23,,1322894619,7/14/2014 14:45:14,instagc,1.0,13763729,USA,"","",75.182.89.225,0,47,,,14,75,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,0,47-55-65,PRIMARY CARNITINE DEFICIENCY.,Hyperammonemia is one of the major symptoms of primary carnitine deficiency.,0,47 55 65,0,47,14,75,1,RO-has_manifestation,906433,Hyperammonemia is one of the major symptoms of primary carnitine deficiency,Hyperammonemia,primary carnitine deficiency
502912983,7/14/2014 14:46:00,,1322895022,7/14/2014 14:45:43,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,0,47,,,14,75,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA primary carnitine deficiency.,0-47-55-65,29-35-44-47-55-65-0,Hyperammonemia major symptoms of PRIMARY CARNITINE DEFICIENCY.,Hyperammonemia is one of the major symptoms of primary carnitine deficiency.,0,47 55 65,0,47,14,75,1,RO-has_manifestation,906433,Hyperammonemia is one of the major symptoms of primary carnitine deficiency,Hyperammonemia,primary carnitine deficiency
502912984,7/14/2014 12:46:32,,1322812389,7/14/2014 12:46:28,clixsense,1.0,24763049,GBR,"","",86.133.47.213,87,171,,,113,188,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic,70-72-82-87-98-114-118-123,163-166-169-171,to be a TRICHOFOLLICULOMA.,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma.,87 98,171,87,171,113,188,-1,RO-disease_has_finding,901731,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma,follicular differentiation,trichofolliculoma
502912984,7/14/2014 12:53:49,,1322817460,7/14/2014 12:53:16,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,87,171,,,113,188,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,87-98,166-169-171,be a TRICHOFOLLICULOMA.,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma.,87 98,171,87,171,113,188,-1,RO-disease_has_finding,901731,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma,follicular differentiation,trichofolliculoma
502912984,7/14/2014 13:20:54,,1322835478,7/14/2014 13:20:24,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,87,171,,,113,188,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION trichofolliculoma.,87-98-171,87-171-98,follicular differentiation TRICHOFOLLICULOMA.,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma.,87 98,171,87,171,113,188,-1,RO-disease_has_finding,901731,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma,follicular differentiation,trichofolliculoma
502912984,7/14/2014 13:40:15,,1322849220,7/14/2014 13:40:12,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,87,171,,,113,188,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic,70-72-82-87-98-114-118-123,163-166-169-171,to be a TRICHOFOLLICULOMA.,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma.,87 98,171,87,171,113,188,-1,RO-disease_has_finding,901731,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma,follicular differentiation,trichofolliculoma
502912984,7/14/2014 13:47:09,,1322854445,7/14/2014 13:46:51,elite,1.0,26544151,GBR,"","",188.29.127.144,87,171,,,113,188,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,87-98,171,TRICHOFOLLICULOMA.,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma.,87 98,171,87,171,113,188,-1,RO-disease_has_finding,901731,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma,follicular differentiation,trichofolliculoma
502912984,7/14/2014 13:53:02,,1322858556,7/14/2014 13:52:14,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,87,171,,,113,188,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,87-98,171,TRICHOFOLLICULOMA.,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma.,87 98,171,87,171,113,188,-1,RO-disease_has_finding,901731,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma,follicular differentiation,trichofolliculoma
502912984,7/14/2014 14:22:42,,1322878689,7/14/2014 14:22:17,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,87,171,,,113,188,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,hamartoma FOLLICULAR DIFFERENTIATION,72-87-98,72-87-163-171-98,hamartoma follicular differentiation to TRICHOFOLLICULOMA.,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma.,87 98,171,87,171,113,188,-1,RO-disease_has_finding,901731,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma,follicular differentiation,trichofolliculoma
502912984,7/14/2014 14:45:42,,1322894842,7/14/2014 14:44:55,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,87,171,,,113,188,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,87-98,171,TRICHOFOLLICULOMA.,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma.,87 98,171,87,171,113,188,-1,RO-disease_has_finding,901731,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma,follicular differentiation,trichofolliculoma
502912984,7/14/2014 14:46:33,,1322895360,7/14/2014 14:46:20,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,87,171,,,113,188,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,87-98,171,TRICHOFOLLICULOMA.,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma.,87 98,171,87,171,113,188,-1,RO-disease_has_finding,901731,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma,follicular differentiation,trichofolliculoma
502912984,7/14/2014 14:46:31,,1322895364,7/14/2014 14:46:14,prodege,1,6579519,USA,OH,Fredericktown,71.55.40.105,87,171,,,113,188,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,87-98,171,TRICHOFOLLICULOMA.,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma.,87 98,171,87,171,113,188,-1,RO-disease_has_finding,901731,We report a nodular lesion that was identified histopathologically as a hamartoma with follicular differentiation and that systematic serial sectioning showed not to be a trichofolliculoma,follicular differentiation,trichofolliculoma
502912985,7/14/2014 12:53:16,,1322817024,7/14/2014 12:53:03,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,41,100,,,56,123,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,TYPE 1 DIABETES,41-46-48,84-100-107-116-91,highly purified BOVINE ISOPHANE INSULIN,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group.,41 46 48,100 107 116,41,100,56,123,1,RO-may_treat,908014,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group,Type 1 diabetes,bovine isophane insulin
502912985,7/14/2014 13:37:54,,1322847492,7/14/2014 13:37:37,clixsense,1.0,27969116,NLD,"","",91.213.37.165,41,100,,,56,123,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,TYPE 1 DIABETES,41-46-48,100-107-116,BOVINE ISOPHANE INSULIN,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group.,41 46 48,100 107 116,41,100,56,123,1,RO-may_treat,908014,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group,Type 1 diabetes,bovine isophane insulin
502912985,7/14/2014 13:48:25,,1322855302,7/14/2014 13:47:57,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,41,100,,,56,123,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,TYPE 1 DIABETES,41-46-48,100-107-116,BOVINE ISOPHANE INSULIN,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group.,41 46 48,100 107 116,41,100,56,123,1,RO-may_treat,908014,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group,Type 1 diabetes,bovine isophane insulin
502912985,7/14/2014 14:22:17,,1322878445,7/14/2014 14:22:11,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,41,100,,,56,123,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,with newly diagnosed TYPE 1 DIABETES were treated with,20-25-31-41-46-48-57-62-70,79-84-91-100-107-116-124-130-136,same highly purified BOVINE ISOPHANE INSULIN twice daily for,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group.,41 46 48,100 107 116,41,100,56,123,1,RO-may_treat,908014,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group,Type 1 diabetes,bovine isophane insulin
502912985,7/14/2014 14:33:25,,1322886527,7/14/2014 14:33:13,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,41,100,,,56,123,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,TYPE 1 DIABETES,41-46-48,84-91-100-107-116,highly purified BOVINE ISOPHANE INSULIN,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group.,41 46 48,100 107 116,41,100,56,123,1,RO-may_treat,908014,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group,Type 1 diabetes,bovine isophane insulin
502912985,7/14/2014 14:44:29,,1322894061,7/14/2014 14:44:12,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,41,100,,,56,123,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,TYPE 1 DIABETES,41-46-48,100-107-116,BOVINE ISOPHANE INSULIN,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group.,41 46 48,100 107 116,41,100,56,123,1,RO-may_treat,908014,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group,Type 1 diabetes,bovine isophane insulin
502912985,7/14/2014 14:45:26,,1322894654,7/14/2014 14:45:04,prodege,1.0,28209666,,,"",24.156.173.34,41,100,,,56,123,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,TYPE 1 DIABETES treated,41-46-48-62,100-107-116,BOVINE ISOPHANE INSULIN,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group.,41 46 48,100 107 116,41,100,56,123,1,RO-may_treat,908014,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group,Type 1 diabetes,bovine isophane insulin
502912985,7/14/2014 14:45:43,,1322894847,7/14/2014 14:45:11,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,41,100,,,56,123,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,TYPE 1 DIABETES,41-46-48,100-107-116,BOVINE ISOPHANE INSULIN,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group.,41 46 48,100 107 116,41,100,56,123,1,RO-may_treat,908014,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group,Type 1 diabetes,bovine isophane insulin
502912985,7/14/2014 14:46:46,,1322895519,7/14/2014 14:46:37,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,41,100,,,56,123,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,TYPE 1 DIABETES,41-46-48,91-100-107-116,purified BOVINE ISOPHANE INSULIN,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group.,41 46 48,100 107 116,41,100,56,123,1,RO-may_treat,908014,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group,Type 1 diabetes,bovine isophane insulin
502912985,7/14/2014 14:50:07,,1322897436,7/14/2014 14:49:54,instagc,1.0,13763729,USA,"","",75.182.89.225,41,100,,,56,123,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,TYPE 1 DIABETES,41-46-48,100-107-116,BOVINE ISOPHANE INSULIN,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group.,41 46 48,100 107 116,41,100,56,123,1,RO-may_treat,908014,Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group,Type 1 diabetes,bovine isophane insulin
502912986,7/14/2014 13:26:43,,1322839577,7/14/2014 13:26:18,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,27,58,,,31,70,GVHD,CYCLOSPORINE,Graft - versus - host disease (GVHD) prophylaxis,0-5-6-12-13-18-26-33,33-45-55-58-75-71,prophylaxis consisted of CYCLOSPORINE and methotrexate.,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate.,,58,27,58,31,70,1,RO-may_prevent,907091,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate,GVHD,cyclosporine
502912986,7/14/2014 13:28:44,,1322840934,7/14/2014 13:28:16,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,27,58,,,31,70,GVHD,CYCLOSPORINE,Graft - versus - host disease (GVHD),0-6-12-13-18-26-5,58,CYCLOSPORINE,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate.,,58,27,58,31,70,1,RO-may_prevent,907091,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate,GVHD,cyclosporine
502912986,7/14/2014 13:36:38,,1322846652,7/14/2014 13:35:44,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,27,58,,,31,70,GVHD,CYCLOSPORINE,Graft versus host disease (GVHD),0-6-13-18-26,58,CYCLOSPORINE,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate.,,58,27,58,31,70,1,RO-may_prevent,907091,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate,GVHD,cyclosporine
502912986,7/14/2014 13:44:21,,1322852197,7/14/2014 13:44:00,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,27,58,,,31,70,GVHD,CYCLOSPORINE,host disease (GVHD) prophylaxis,13-18-26-33,58,CYCLOSPORINE,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate.,,58,27,58,31,70,1,RO-may_prevent,907091,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate,GVHD,cyclosporine
502912986,7/14/2014 13:47:36,,1322854765,7/14/2014 13:47:13,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,27,58,,,31,70,GVHD,CYCLOSPORINE,Graft - versus - host disease (GVHD) prophylaxis,0-5-6-12-13-18-26-33,58-71-75,CYCLOSPORINE and methotrexate.,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate.,,58,27,58,31,70,1,RO-may_prevent,907091,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate,GVHD,cyclosporine
502912986,7/14/2014 13:47:53,,1322854980,7/14/2014 13:47:36,elite,1.0,26544151,GBR,"","",188.29.127.144,27,58,,,31,70,GVHD,CYCLOSPORINE,(GVHD),26,58,CYCLOSPORINE,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate.,,58,27,58,31,70,1,RO-may_prevent,907091,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate,GVHD,cyclosporine
502912986,7/14/2014 14:00:32,,1322863655,7/14/2014 14:00:10,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,27,58,,,31,70,GVHD,CYCLOSPORINE,Graft - versus host disease (GVHD),0-5-6-13-18-26,58,CYCLOSPORINE,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate.,,58,27,58,31,70,1,RO-may_prevent,907091,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate,GVHD,cyclosporine
502912986,7/14/2014 14:19:59,,1322876802,7/14/2014 14:19:54,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,27,58,,,31,70,GVHD,CYCLOSPORINE,host disease (GVHD) prophylaxis consisted of,13-18-26-33-45-55,33-45-55-58-71-75,prophylaxis consisted of CYCLOSPORINE and methotrexate.,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate.,,58,27,58,31,70,1,RO-may_prevent,907091,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate,GVHD,cyclosporine
502912986,7/14/2014 14:36:35,,1322888649,7/14/2014 14:36:21,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,27,58,,,31,70,GVHD,CYCLOSPORINE,Graft versus host disease (GVHD),0-6-13-18-26,58-71-75,CYCLOSPORINE and methotrexate.,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate.,,58,27,58,31,70,1,RO-may_prevent,907091,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate,GVHD,cyclosporine
502912986,7/14/2014 14:44:14,,1322893921,7/14/2014 14:44:01,instagc,1.0,13763729,USA,"","",75.182.89.225,27,58,,,31,70,GVHD,CYCLOSPORINE,(GVHD),26,58,CYCLOSPORINE,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate.,,58,27,58,31,70,1,RO-may_prevent,907091,Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate,GVHD,cyclosporine
502912987,7/14/2014 13:33:15,,1322844147,7/14/2014 13:32:42,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,118,162,,,122,173,LUNG,LUNG CANCER,in normal control LUNG; the difference in,100-103-110-118-124-128-139,139-142-154-162-167-174-178-185,in frequencies between LUNG CANCER and paired normal,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not.",118,162 167,118,162,122,173,1,RO-has_finding_site,905225,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not",lung,lung cancer
502912987,7/14/2014 13:47:08,,1322854434,7/14/2014 13:46:54,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,118,162,,,122,173,LUNG,LUNG CANCER,LUNG;,118,162-167,LUNG CANCER,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not.",118,162 167,118,162,122,173,1,RO-has_finding_site,905225,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not",lung,lung cancer
502912987,7/14/2014 13:55:17,,1322860146,7/14/2014 13:55:01,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,118,162,,,122,173,LUNG,LUNG CANCER,LUNG;,118,162-167,LUNG CANCER,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not.",118,162 167,118,162,122,173,1,RO-has_finding_site,905225,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not",lung,lung cancer
502912987,7/14/2014 14:30:51,,1322884689,7/14/2014 14:30:48,instagc,1.0,27753923,GBR,"","",188.30.192.65,118,162,,,122,173,LUNG,LUNG CANCER,in normal control LUNG; the difference in,100-103-110-118-124-128-139,139-142-154-162-167-174-178-185,in frequencies between LUNG CANCER and paired normal,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not.",118,162 167,118,162,122,173,1,RO-has_finding_site,905225,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not",lung,lung cancer
502912987,7/14/2014 14:46:07,,1322895121,7/14/2014 14:45:52,instagc,1.0,13763729,USA,"","",75.182.89.225,118,162,,,122,173,LUNG,LUNG CANCER,LUNG;,118,162-167,LUNG CANCER,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not.",118,162 167,118,162,122,173,1,RO-has_finding_site,905225,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not",lung,lung cancer
502912987,7/14/2014 14:47:21,,1322895832,7/14/2014 14:47:08,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,118,162,,,122,173,LUNG,LUNG CANCER,control LUNG;,118-110,162-167,LUNG CANCER,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not.",118,162 167,118,162,122,173,1,RO-has_finding_site,905225,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not",lung,lung cancer
502912987,7/14/2014 14:48:03,,1322896232,7/14/2014 14:47:41,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,118,162,,,122,173,LUNG,LUNG CANCER,LUNG; lung cancer,118-162-167,139-142-154-162-167,in frequencies between LUNG CANCER,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not.",118,162 167,118,162,122,173,1,RO-has_finding_site,905225,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not",lung,lung cancer
502912987,7/14/2014 14:48:19,,1322896391,7/14/2014 14:48:01,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,118,162,,,122,173,LUNG,LUNG CANCER,LUNG;,118,162-167,LUNG CANCER,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not.",118,162 167,118,162,122,173,1,RO-has_finding_site,905225,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not",lung,lung cancer
502912987,7/14/2014 14:49:14,,1322896859,7/14/2014 14:48:55,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,118,162,,,122,173,LUNG,LUNG CANCER,LUNG;,118,162-167,LUNG CANCER,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not.",118,162 167,118,162,122,173,1,RO-has_finding_site,905225,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not",lung,lung cancer
502912987,7/14/2014 14:58:04,,1322902351,7/14/2014 14:57:22,rewardsspot,1,17763704,USA,IL,Chicago,67.212.175.123,118,162,,,122,173,LUNG,LUNG CANCER,abnormal transcripts LUNG; in lung cancer,19-28-118-139-162-167,19-28-162-167,abnormal transcripts LUNG CANCER,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not.",118,162 167,118,162,122,173,1,RO-has_finding_site,905225,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between lung cancer and paired normal lung was significant, while that between lung cancer and normal control lung was not",lung,lung cancer
502912988,7/14/2014 12:45:18,,1322811586,7/14/2014 12:45:12,clixsense,1.0,24763049,GBR,"","",86.133.47.213,28,53,,,32,67,FIVE,MILD DYSPLASIA,Aneuploid adenomas included FIVE of 134,0-10-19-28-33-36,36-40-45-53-58-69-72-75,"134 (4%) showing MILD DYSPLASIA, 19 of 107","Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia.",28,53 58,28,53,32,67,-1,RO-disease_has_finding,901942,"Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia",five,mild dysplasia
502912988,7/14/2014 12:57:31,,1322819824,7/14/2014 12:57:17,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,28,53,,,32,67,FIVE,MILD DYSPLASIA,FIVE,28,53-58,"MILD DYSPLASIA,","Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia.",28,53 58,28,53,32,67,-1,RO-disease_has_finding,901942,"Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia",five,mild dysplasia
502912988,7/14/2014 13:09:01,,1322827477,7/14/2014 13:08:13,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,28,53,,,32,67,FIVE,MILD DYSPLASIA,"Aneuploid adenomas FIVE of 134 dysplasia,",0-10-28-33-36-58,0-10-28-36-40-53-58-33,"Aneuploid adenomas five of 134 (4%) MILD DYSPLASIA,","Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia.",28,53 58,28,53,32,67,-1,RO-disease_has_finding,901942,"Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia",five,mild dysplasia
502912988,7/14/2014 13:16:13,,1322832383,7/14/2014 13:16:01,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,28,53,,,32,67,FIVE,MILD DYSPLASIA,FIVE,28,53-58,"MILD DYSPLASIA,","Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia.",28,53 58,28,53,32,67,-1,RO-disease_has_finding,901942,"Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia",five,mild dysplasia
502912988,7/14/2014 13:25:53,,1322839017,7/14/2014 13:24:24,superrewards,1,22551185,GBR,"","",87.113.87.199,28,53,,,32,67,FIVE,MILD DYSPLASIA,"Aneuploid adenomas included FIVE of 134 showing mild dysplasia,",0-10-19-28-33-36-45-53-58,53-58,"MILD DYSPLASIA,","Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia.",28,53 58,28,53,32,67,-1,RO-disease_has_finding,901942,"Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia",five,mild dysplasia
502912988,7/14/2014 13:34:49,,1322845228,7/14/2014 13:34:25,clixsense,1.0,27969116,NLD,"","",91.213.37.165,28,53,,,32,67,FIVE,MILD DYSPLASIA,Aneuploid adenomas included FIVE of 134 (4%),0-10-19-28-33-36-40,53-58,"MILD DYSPLASIA,","Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia.",28,53 58,28,53,32,67,-1,RO-disease_has_finding,901942,"Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia",five,mild dysplasia
502912988,7/14/2014 13:50:48,,1322856936,7/14/2014 13:50:27,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,28,53,,,32,67,FIVE,MILD DYSPLASIA,FIVE,28,53-58,"MILD DYSPLASIA,","Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia.",28,53 58,28,53,32,67,-1,RO-disease_has_finding,901942,"Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia",five,mild dysplasia
502912988,7/14/2014 14:36:52,,1322888831,7/14/2014 14:36:37,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,28,53,,,32,67,FIVE,MILD DYSPLASIA,FIVE,28,53-58,"MILD DYSPLASIA,","Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia.",28,53 58,28,53,32,67,-1,RO-disease_has_finding,901942,"Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia",five,mild dysplasia
502912988,7/14/2014 14:39:58,,1322891034,7/14/2014 14:39:53,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,28,53,,,32,67,FIVE,MILD DYSPLASIA,Aneuploid adenomas included FIVE of 134,0-10-19-28-33-36,36-40-45-53-58-69-72-75,"134 (4%) showing MILD DYSPLASIA, 19 of 107","Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia.",28,53 58,28,53,32,67,-1,RO-disease_has_finding,901942,"Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia",five,mild dysplasia
502912988,7/14/2014 14:44:37,,1322894133,7/14/2014 14:44:08,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,28,53,,,32,67,FIVE,MILD DYSPLASIA,Aneuploid adenomas FIVE,0-10-28,53-58,"MILD DYSPLASIA,","Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia.",28,53 58,28,53,32,67,-1,RO-disease_has_finding,901942,"Aneuploid adenomas included five of 134 (4%) showing mild dysplasia, 19 of 107 (18%) showing moderate dysplasia, and 10 of 28 (36%) showing severe dysplasia",five,mild dysplasia
502912989,7/14/2014 12:45:06,,1322811418,7/14/2014 12:45:01,clixsense,1.0,24763049,GBR,"","",86.133.47.213,119,95,,,126,103,LEPROSY,RIFAMPIN,and dapsone in LEPROSY.,104-108-116-119,71-75-92-95-104-108-116,the pharmacokinetics of RIFAMPIN and dapsone in,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy.",119,95,119,95,126,103,1,RO-may_treat,907630,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy",leprosy,rifampin
502912989,7/14/2014 13:24:50,,1322838317,7/14/2014 13:24:41,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,119,95,,,126,103,LEPROSY,RIFAMPIN,LEPROSY.,119,95,RIFAMPIN,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy.",119,95,119,95,126,103,1,RO-may_treat,907630,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy",leprosy,rifampin
502912989,7/14/2014 13:26:32,,1322839499,7/14/2014 13:25:30,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,119,95,,,126,103,LEPROSY,RIFAMPIN,and dapsone in LEPROSY.,104-108-116-119,71-75-92-95-104-108-116,the pharmacokinetics of RIFAMPIN and dapsone in,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy.",119,95,119,95,126,103,1,RO-may_treat,907630,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy",leprosy,rifampin
502912989,7/14/2014 13:37:01,,1322846837,7/14/2014 13:36:44,clixsense,1.0,27969116,NLD,"","",91.213.37.165,119,95,,,126,103,LEPROSY,RIFAMPIN,dapsone in LEPROSY.,108-116-119,71-75-92-95,the pharmacokinetics of RIFAMPIN,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy.",119,95,119,95,126,103,1,RO-may_treat,907630,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy",leprosy,rifampin
502912989,7/14/2014 13:44:50,,1322852489,7/14/2014 13:44:22,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,119,95,,,126,103,LEPROSY,RIFAMPIN,LEPROSY.,119,95,RIFAMPIN,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy.",119,95,119,95,126,103,1,RO-may_treat,907630,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy",leprosy,rifampin
502912989,7/14/2014 14:03:21,,1322865754,7/14/2014 14:02:50,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,119,95,,,126,103,LEPROSY,RIFAMPIN,LEPROSY.,119,95,RIFAMPIN,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy.",119,95,119,95,126,103,1,RO-may_treat,907630,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy",leprosy,rifampin
502912989,7/14/2014 14:21:58,,1322878272,7/14/2014 14:21:53,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,119,95,,,126,103,LEPROSY,RIFAMPIN,and dapsone in LEPROSY.,104-108-116-119,71-75-92-95-104-108-116,the pharmacokinetics of RIFAMPIN and dapsone in,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy.",119,95,119,95,126,103,1,RO-may_treat,907630,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy",leprosy,rifampin
502912989,7/14/2014 14:29:15,,1322883479,7/14/2014 14:29:13,instagc,1.0,27753923,GBR,"","",188.30.192.65,119,95,,,126,103,LEPROSY,RIFAMPIN,and dapsone in LEPROSY.,104-108-116-119,71-75-92-95-104-108-116,the pharmacokinetics of RIFAMPIN and dapsone in,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy.",119,95,119,95,126,103,1,RO-may_treat,907630,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy",leprosy,rifampin
502912989,7/14/2014 14:38:28,,1322889936,7/14/2014 14:37:02,prodege,1.0,28209666,,,"",24.156.173.34,119,95,,,126,103,LEPROSY,RIFAMPIN,LEPROSY.,119,95,RIFAMPIN,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy.",119,95,119,95,126,103,1,RO-may_treat,907630,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy",leprosy,rifampin
502912989,7/14/2014 14:47:32,,1322895935,7/14/2014 14:47:18,instagc,1.0,13763729,USA,"","",75.182.89.225,119,95,,,126,103,LEPROSY,RIFAMPIN,LEPROSY.,119,95,RIFAMPIN,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy.",119,95,119,95,126,103,1,RO-may_treat,907630,"Venkatesan K, Mathur A, Girdhar BK et al. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy",leprosy,rifampin
502912990,7/14/2014 13:00:51,,1322822034,7/14/2014 13:00:34,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,26,42,,,36,50,GALLSTONES,URSODIOL,GALLSTONES,26,42,URSODIOL,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",26,42,26,42,36,50,1,RO-may_treat,907935,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter",gallstones,ursodiol
502912990,7/14/2014 13:01:56,,1322822739,7/14/2014 13:01:25,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,26,42,,,36,50,GALLSTONES,URSODIOL,GALLSTONES,26,42,URSODIOL,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",26,42,26,42,36,50,1,RO-may_treat,907935,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter",gallstones,ursodiol
502912990,7/14/2014 13:03:31,,1322823784,7/14/2014 13:03:09,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,26,42,,,36,50,GALLSTONES,URSODIOL,GALLSTONES gallstones,26-92,26-42,gallstones URSODIOL,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",26,42,26,42,36,50,1,RO-may_treat,907935,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter",gallstones,ursodiol
502912990,7/14/2014 13:06:43,,1322825829,7/14/2014 13:06:22,gifthulk,1.0,25566511,USA,"","",24.164.11.173,26,42,,,36,50,GALLSTONES,URSODIOL,GALLSTONES,26,42,URSODIOL,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",26,42,26,42,36,50,1,RO-may_treat,907935,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter",gallstones,ursodiol
502912990,7/14/2014 13:14:46,,1322831320,7/14/2014 13:14:30,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,26,42,,,36,50,GALLSTONES,URSODIOL,GALLSTONES,26,42,URSODIOL,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",26,42,26,42,36,50,1,RO-may_treat,907935,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter",gallstones,ursodiol
502912990,7/14/2014 13:41:05,,1322849806,7/14/2014 13:40:53,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,26,42,,,36,50,GALLSTONES,URSODIOL,GALLSTONES,26,42,URSODIOL,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",26,42,26,42,36,50,1,RO-may_treat,907935,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter",gallstones,ursodiol
502912990,7/14/2014 13:43:30,,1322851595,7/14/2014 13:43:13,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,26,42,,,36,50,GALLSTONES,URSODIOL,GALLSTONES,26,42,URSODIOL,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",26,42,26,42,36,50,1,RO-may_treat,907935,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter",gallstones,ursodiol
502912990,7/14/2014 13:55:56,,1322860616,7/14/2014 13:55:44,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,26,42,,,36,50,GALLSTONES,URSODIOL,GALLSTONES,26,42,URSODIOL,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",26,42,26,42,36,50,1,RO-may_treat,907935,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter",gallstones,ursodiol
502912990,7/14/2014 13:59:28,,1322863003,7/14/2014 13:59:11,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,26,42,,,36,50,GALLSTONES,URSODIOL,GALLSTONES occurs,26-51,42,URSODIOL,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",26,42,26,42,36,50,1,RO-may_treat,907935,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter",gallstones,ursodiol
502912990,7/14/2014 14:24:45,,1322880222,7/14/2014 14:24:42,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,26,42,,,36,50,GALLSTONES,URSODIOL,Successful dissolution of GALLSTONES with ursodiol occurs,0-11-23-26-37-42-51,23-26-37-42-51-58-65,of gallstones with URSODIOL occurs rarely in,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",26,42,26,42,36,50,1,RO-may_treat,907935,"Successful dissolution of gallstones with ursodiol occurs rarely in patients with calcified gallstones prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter",gallstones,ursodiol
502912991,7/14/2014 12:56:17,,1322819027,7/14/2014 12:56:12,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,88,151,,,96,168,NICOTINE,DEPENDENT SMOKERS,"body clearance of NICOTINE by 30% in smokers,",70-75-85-88-97-100-104-127,136-139-143-151-161-170-181-185-127,"smokers, in the heavily DEPENDENT SMOKERS, cimetidine did not","Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination.",88,151 161,88,151,96,168,-1,RO-has_causative_agent,903754,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination",nicotine,dependent smokers
502912991,7/14/2014 13:07:53,,1322826671,7/14/2014 13:07:09,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,88,151,,,96,168,NICOTINE,DEPENDENT SMOKERS,NICOTINE,88,151-161,"DEPENDENT SMOKERS,","Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination.",88,151 161,88,151,96,168,-1,RO-has_causative_agent,903754,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination",nicotine,dependent smokers
502912991,7/14/2014 13:14:30,,1322831195,7/14/2014 13:14:25,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,88,151,,,96,168,NICOTINE,DEPENDENT SMOKERS,body clearance of NICOTINE by 30% in,70-75-85-88-97-100-104,136-139-143-151-161-170-181-185,"in the heavily DEPENDENT SMOKERS, cimetidine did not","Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination.",88,151 161,88,151,96,168,-1,RO-has_causative_agent,903754,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination",nicotine,dependent smokers
502912991,7/14/2014 13:33:49,,1322844493,7/14/2014 13:33:16,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,88,151,,,96,168,NICOTINE,DEPENDENT SMOKERS,body clearance of NICOTINE by 30% in,70-75-85-88-97-100-104,136-139-143-151-161-170-181-185,"in the heavily DEPENDENT SMOKERS, cimetidine did not","Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination.",88,151 161,88,151,96,168,-1,RO-has_causative_agent,903754,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination",nicotine,dependent smokers
502912991,7/14/2014 13:35:27,,1322845659,7/14/2014 13:34:26,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,88,151,,,96,168,NICOTINE,DEPENDENT SMOKERS,NICOTINE,88,127-143-151-161,"smokers, heavily DEPENDENT SMOKERS,","Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination.",88,151 161,88,151,96,168,-1,RO-has_causative_agent,903754,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination",nicotine,dependent smokers
502912991,7/14/2014 13:39:43,,1322848842,7/14/2014 13:39:19,clixsense,1.0,27969116,NLD,"","",91.213.37.165,88,151,,,96,168,NICOTINE,DEPENDENT SMOKERS,NICOTINE,88,151-161-170,"DEPENDENT SMOKERS, cimetidine","Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination.",88,151 161,88,151,96,168,-1,RO-has_causative_agent,903754,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination",nicotine,dependent smokers
502912991,7/14/2014 13:45:09,,1322852686,7/14/2014 13:44:46,elite,1.0,26544151,GBR,"","",188.29.127.144,88,151,,,96,168,NICOTINE,DEPENDENT SMOKERS,NICOTINE,88,151-161,"DEPENDENT SMOKERS,","Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination.",88,151 161,88,151,96,168,-1,RO-has_causative_agent,903754,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination",nicotine,dependent smokers
502912991,7/14/2014 13:45:12,,1322852744,7/14/2014 13:44:51,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,88,151,,,96,168,NICOTINE,DEPENDENT SMOKERS,NICOTINE,88,151-161,"DEPENDENT SMOKERS,","Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination.",88,151 161,88,151,96,168,-1,RO-has_causative_agent,903754,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination",nicotine,dependent smokers
502912991,7/14/2014 13:45:21,,1322852831,7/14/2014 13:44:51,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,88,151,,,96,168,NICOTINE,DEPENDENT SMOKERS,NICOTINE,88,151-161,"DEPENDENT SMOKERS,","Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination.",88,151 161,88,151,96,168,-1,RO-has_causative_agent,903754,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination",nicotine,dependent smokers
502912991,7/14/2014 13:46:15,,1322853568,7/14/2014 13:45:19,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,88,151,,,96,168,NICOTINE,DEPENDENT SMOKERS,NICOTINE nicotine elimination.,88-205-214,151-161-205-214,"DEPENDENT SMOKERS, nicotine elimination.","Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination.",88,151 161,88,151,96,168,-1,RO-has_causative_agent,903754,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non-smokers, in the heavily dependent smokers, cimetidine did not appear to alter nicotine elimination",nicotine,dependent smokers
502912992,7/14/2014 12:50:14,,1322814872,7/14/2014 12:49:58,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,71,38,,,75,69,GIST,GASTROINTESTINAL STROMAL TUMORS,gastrointestinal stromal tumors (GIST.,55-63-70-38,38-55-63-70,GASTROINTESTINAL STROMAL TUMORS (GIST.,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST.,,38 55 63,71,38,75,69,-1,RO-has_manifestation,906018,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST,GIST,gastrointestinal stromal tumors
502912992,7/14/2014 13:01:45,,1322822630,7/14/2014 13:01:32,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,71,38,,,75,69,GIST,GASTROINTESTINAL STROMAL TUMORS,KIT positive stromal tumors (GIST.,0-55-63-70-4,0-38-55-63-4,KIT positive GASTROINTESTINAL STROMAL TUMORS,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST.,,38 55 63,71,38,75,69,-1,RO-has_manifestation,906018,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST,GIST,gastrointestinal stromal tumors
502912992,7/14/2014 13:38:04,,1322847613,7/14/2014 13:37:53,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,71,38,,,75,69,GIST,GASTROINTESTINAL STROMAL TUMORS,gastrointestinal stromal tumors (GIST.,55-63-70-38,38-55-63-70,GASTROINTESTINAL STROMAL TUMORS (GIST.,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST.,,38 55 63,71,38,75,69,-1,RO-has_manifestation,906018,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST,GIST,gastrointestinal stromal tumors
502912992,7/14/2014 13:40:55,,1322849731,7/14/2014 13:40:53,clixsense,1.0,7415230,GBR,A7,Birmingham,147.188.47.242,71,38,,,75,69,GIST,GASTROINTESTINAL STROMAL TUMORS,stromal tumors (GIST.,55-63-70,20-25-35-38-55-63,were diagnosed as GASTROINTESTINAL STROMAL TUMORS,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST.,,38 55 63,71,38,75,69,-1,RO-has_manifestation,906018,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST,GIST,gastrointestinal stromal tumors
502912992,7/14/2014 14:31:15,,1322885029,7/14/2014 14:31:11,instagc,1.0,27753923,GBR,"","",188.30.192.65,71,38,,,75,69,GIST,GASTROINTESTINAL STROMAL TUMORS,stromal tumors (GIST.,55-63-70,20-25-35-38-55-63,were diagnosed as GASTROINTESTINAL STROMAL TUMORS,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST.,,38 55 63,71,38,75,69,-1,RO-has_manifestation,906018,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST,GIST,gastrointestinal stromal tumors
502912992,7/14/2014 14:38:36,,1322890100,7/14/2014 14:38:22,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,71,38,,,75,69,GIST,GASTROINTESTINAL STROMAL TUMORS,gastrointestinal stromal tumors (GIST.,55-63-70-38,38-55-63-70,GASTROINTESTINAL STROMAL TUMORS (GIST.,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST.,,38 55 63,71,38,75,69,-1,RO-has_manifestation,906018,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST,GIST,gastrointestinal stromal tumors
502912992,7/14/2014 14:45:51,,1322894892,7/14/2014 14:45:40,instagc,1.0,13763729,USA,"","",75.182.89.225,71,38,,,75,69,GIST,GASTROINTESTINAL STROMAL TUMORS,gastrointestinal stromal tumors (GIST.,55-63-70-38,38-55-63,GASTROINTESTINAL STROMAL TUMORS,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST.,,38 55 63,71,38,75,69,-1,RO-has_manifestation,906018,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST,GIST,gastrointestinal stromal tumors
502912992,7/14/2014 14:48:29,,1322896493,7/14/2014 14:48:20,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,71,38,,,75,69,GIST,GASTROINTESTINAL STROMAL TUMORS,stromal tumors (GIST.,55-63-70,38-55-63,GASTROINTESTINAL STROMAL TUMORS,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST.,,38 55 63,71,38,75,69,-1,RO-has_manifestation,906018,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST,GIST,gastrointestinal stromal tumors
502912992,7/14/2014 14:49:18,,1322896899,7/14/2014 14:49:11,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,71,38,,,75,69,GIST,GASTROINTESTINAL STROMAL TUMORS,stromal tumors,55-63,38-55-63,GASTROINTESTINAL STROMAL TUMORS,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST.,,38 55 63,71,38,75,69,-1,RO-has_manifestation,906018,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST,GIST,gastrointestinal stromal tumors
502912992,7/14/2014 14:50:23,,1322897594,7/14/2014 14:50:11,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,71,38,,,75,69,GIST,GASTROINTESTINAL STROMAL TUMORS,stromal tumors (GIST.,55-63-70,38-55-63,GASTROINTESTINAL STROMAL TUMORS,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST.,,38 55 63,71,38,75,69,-1,RO-has_manifestation,906018,KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST,GIST,gastrointestinal stromal tumors
502912993,7/14/2014 13:13:02,,1322830213,7/14/2014 13:12:48,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,118,167,,,133,170,LYMPHADENOPATHY,CLL,LYMPHADENOPATHY,118,167,CLL.,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL.,118,167,118,167,133,170,-1,RO-disease_may_have_finding,902595,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL,lymphadenopathy,CLL
502912993,7/14/2014 13:14:06,,1322830976,7/14/2014 13:14:01,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,118,167,,,133,170,LYMPHADENOPATHY,CLL,of lymphocytosis and LYMPHADENOPATHY in the differential,97-100-114-118-134-137-141,141-154-164-167,differential diagnosis of CLL.,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL.,118,167,118,167,133,170,-1,RO-disease_may_have_finding,902595,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL,lymphadenopathy,CLL
502912993,7/14/2014 13:35:06,,1322845400,7/14/2014 13:34:55,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,118,167,,,133,170,LYMPHADENOPATHY,CLL,LYMPHADENOPATHY,118,167,CLL.,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL.,118,167,118,167,133,170,-1,RO-disease_may_have_finding,902595,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL,lymphadenopathy,CLL
502912993,7/14/2014 13:42:59,,1322851234,7/14/2014 13:42:45,clixsense,1.0,27969116,NLD,"","",91.213.37.165,118,167,,,133,170,LYMPHADENOPATHY,CLL,and LYMPHADENOPATHY in the differential diagnosis of CLL.,114-118-134-137-141-154-167-164,141-154-164-167,differential diagnosis of CLL.,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL.,118,167,118,167,133,170,-1,RO-disease_may_have_finding,902595,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL,lymphadenopathy,CLL
502912993,7/14/2014 13:48:54,,1322855705,7/14/2014 13:48:20,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,118,167,,,133,170,LYMPHADENOPATHY,CLL,lymphocytosis LYMPHADENOPATHY,100-118,100-167-118,lymphocytosis lymphadenopathy CLL.,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL.,118,167,118,167,133,170,-1,RO-disease_may_have_finding,902595,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL,lymphadenopathy,CLL
502912993,7/14/2014 14:19:17,,1322876338,7/14/2014 14:18:53,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,118,167,,,133,170,LYMPHADENOPATHY,CLL,lymphocytosis LYMPHADENOPATHY CLL.,100-118-167,100-118-167,lymphocytosis lymphadenopathy CLL.,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL.,118,167,118,167,133,170,-1,RO-disease_may_have_finding,902595,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL,lymphadenopathy,CLL
502912993,7/14/2014 14:22:57,,1322878850,7/14/2014 14:22:53,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,118,167,,,133,170,LYMPHADENOPATHY,CLL,of lymphocytosis and LYMPHADENOPATHY in the differential,97-100-114-118-134-137-141,141-154-164-167,differential diagnosis of CLL.,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL.,118,167,118,167,133,170,-1,RO-disease_may_have_finding,902595,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL,lymphadenopathy,CLL
502912993,7/14/2014 14:30:02,,1322884095,7/14/2014 14:29:59,instagc,1.0,27753923,GBR,"","",188.30.192.65,118,167,,,133,170,LYMPHADENOPATHY,CLL,of lymphocytosis and LYMPHADENOPATHY in the differential,97-100-114-118-134-137-141,141-154-164-167,differential diagnosis of CLL.,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL.,118,167,118,167,133,170,-1,RO-disease_may_have_finding,902595,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL,lymphadenopathy,CLL
502912993,7/14/2014 14:32:50,,1322886182,7/14/2014 14:32:40,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,118,167,,,133,170,LYMPHADENOPATHY,CLL,lymphocytosis and LYMPHADENOPATHY,100-114-118,167,CLL.,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL.,118,167,118,167,133,170,-1,RO-disease_may_have_finding,902595,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL,lymphadenopathy,CLL
502912993,7/14/2014 14:38:56,,1322890281,7/14/2014 14:38:49,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,118,167,,,133,170,LYMPHADENOPATHY,CLL,of lymphocytosis and LYMPHADENOPATHY in the differential,97-100-114-118-134-137-141,141-154-164-167,differential diagnosis of CLL.,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL.,118,167,118,167,133,170,-1,RO-disease_may_have_finding,902595,Table -  Laboratory and Other Studies for CLL  Differential Diagnosis  3.6 Consider other causes of lymphocytosis and lymphadenopathy in the differential diagnosis of CLL,lymphadenopathy,CLL
502912994,7/14/2014 12:53:32,,1322817238,7/14/2014 12:53:21,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,82,34,,,110,55,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,"hyperglycemic HYPEROSMOLAR NONKETOTIC COMA,",68-82-95-106,34-43,"DIABETIC KETOACIDOSIS,","Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis.",82 95 106,34 43,82,34,110,55,-1,RO-cause_of,900136,"Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis",hyperosmolar nonketotic coma,diabetic ketoacidosis
502912994,7/14/2014 12:56:55,,1322819443,7/14/2014 12:56:50,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,82,34,,,110,55,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,"ketoacidosis, treatment, hyperglycemic HYPEROSMOLAR NONKETOTIC COMA, and maintenance treatment after",43-57-68-82-95-106-112-116-128-138,0-9-23-34-43-57-68-82-95,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS, treatment, hyperglycemic hyperosmolar nonketotic","Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis.",82 95 106,34 43,82,34,110,55,-1,RO-cause_of,900136,"Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis",hyperosmolar nonketotic coma,diabetic ketoacidosis
502912994,7/14/2014 13:01:13,,1322822274,7/14/2014 13:00:26,gifthulk,1.0,25566511,USA,"","",24.164.11.173,82,34,,,110,55,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,"hyperglycemic HYPEROSMOLAR NONKETOTIC COMA,",68-82-95-106,34-43,"DIABETIC KETOACIDOSIS,","Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis.",82 95 106,34 43,82,34,110,55,-1,RO-cause_of,900136,"Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis",hyperosmolar nonketotic coma,diabetic ketoacidosis
502912994,7/14/2014 13:13:40,,1322830670,7/14/2014 13:13:20,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,82,34,,,110,55,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,"HYPEROSMOLAR NONKETOTIC COMA,",82-95-106,34-43,"DIABETIC KETOACIDOSIS,","Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis.",82 95 106,34 43,82,34,110,55,-1,RO-cause_of,900136,"Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis",hyperosmolar nonketotic coma,diabetic ketoacidosis
502912994,7/14/2014 13:22:15,,1322836556,7/14/2014 13:21:48,clixsense,1.0,27969116,NLD,"","",91.213.37.165,82,34,,,110,55,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,"diagnosis, diabetic ketoacidosis, treatment, hyperglycemic HYPEROSMOLAR NONKETOTIC COMA,",23-43-57-68-82-95-106-34,34-43-57,"DIABETIC KETOACIDOSIS, treatment,","Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis.",82 95 106,34 43,82,34,110,55,-1,RO-cause_of,900136,"Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis",hyperosmolar nonketotic coma,diabetic ketoacidosis
502912994,7/14/2014 13:25:08,,1322838488,7/14/2014 13:24:51,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,82,34,,,110,55,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,"HYPEROSMOLAR NONKETOTIC COMA,",82-95-106,34-43,"DIABETIC KETOACIDOSIS,","Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis.",82 95 106,34 43,82,34,110,55,-1,RO-cause_of,900136,"Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis",hyperosmolar nonketotic coma,diabetic ketoacidosis
502912994,7/14/2014 13:28:26,,1322840726,7/14/2014 13:27:55,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,82,34,,,110,55,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,"ketoacidosis, treatment, hyperglycemic HYPEROSMOLAR NONKETOTIC COMA, and maintenance treatment",43-57-68-82-95-106-112-116-128,0-9-23-34-43-57-68-82,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS, treatment, hyperglycemic hyperosmolar","Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis.",82 95 106,34 43,82,34,110,55,-1,RO-cause_of,900136,"Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis",hyperosmolar nonketotic coma,diabetic ketoacidosis
502912994,7/14/2014 13:41:41,,1322850214,7/14/2014 13:41:18,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,82,34,,,110,55,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,"hyperglycemic HYPEROSMOLAR NONKETOTIC COMA,",68-82-95-106,34-43,"DIABETIC KETOACIDOSIS,","Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis.",82 95 106,34 43,82,34,110,55,-1,RO-cause_of,900136,"Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis",hyperosmolar nonketotic coma,diabetic ketoacidosis
502912994,7/14/2014 13:47:02,,1322854334,7/14/2014 13:46:46,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,82,34,,,110,55,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,"HYPEROSMOLAR NONKETOTIC COMA,",82-95-106,34-43,"DIABETIC KETOACIDOSIS,","Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis.",82 95 106,34 43,82,34,110,55,-1,RO-cause_of,900136,"Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis",hyperosmolar nonketotic coma,diabetic ketoacidosis
502912994,7/14/2014 13:57:00,,1322861298,7/14/2014 13:56:33,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,82,34,,,110,55,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,"hyperglycemic HYPEROSMOLAR NONKETOTIC COMA,",68-82-95-106,34-43,"DIABETIC KETOACIDOSIS,","Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis.",82 95 106,34 43,82,34,110,55,-1,RO-cause_of,900136,"Diabetic ketoacidosis: diagnosis, diabetic ketoacidosis, treatment, hyperglycemic hyperosmolar nonketotic coma, and maintenance treatment after hyperglycemic crisis",hyperosmolar nonketotic coma,diabetic ketoacidosis
502912995,7/14/2014 12:48:10,,1322813425,7/14/2014 12:47:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,106,181,,,112,193,ANEMIA,EPOETIN ALFA,ANEMIA,106,181-189,EPOETIN ALFA.,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa.",106,181 189,106,181,112,193,1,RO-may_treat,907996,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa",anemia,epoetin alfa
502912995,7/14/2014 13:20:51,,1322835421,7/14/2014 13:19:51,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,106,181,,,112,193,ANEMIA,EPOETIN ALFA,"Darbepoetin alfa ANEMIA tumors chemotherapy, epoetin alfa.",0-12-106-136-146-181-189,0-106-136-146-181-189-12,"Darbepoetin alfa anemia tumors chemotherapy, EPOETIN ALFA.","Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa.",106,181 189,106,181,112,193,1,RO-may_treat,907996,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa",anemia,epoetin alfa
502912995,7/14/2014 13:43:58,,1322851959,7/14/2014 13:43:37,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,106,181,,,112,193,ANEMIA,EPOETIN ALFA,ANEMIA,106,181-189,EPOETIN ALFA.,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa.",106,181 189,106,181,112,193,1,RO-may_treat,907996,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa",anemia,epoetin alfa
502912995,7/14/2014 13:53:16,,1322858778,7/14/2014 13:53:02,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,106,181,,,112,193,ANEMIA,EPOETIN ALFA,ANEMIA,106,181-189,EPOETIN ALFA.,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa.",106,181 189,106,181,112,193,1,RO-may_treat,907996,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa",anemia,epoetin alfa
502912995,7/14/2014 14:06:39,,1322867897,7/14/2014 14:06:23,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,106,181,,,112,193,ANEMIA,EPOETIN ALFA,ANEMIA,106,181-189,EPOETIN ALFA.,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa.",106,181 189,106,181,112,193,1,RO-may_treat,907996,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa",anemia,epoetin alfa
502912995,7/14/2014 14:25:19,,1322880633,7/14/2014 14:25:07,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,106,181,,,112,193,ANEMIA,EPOETIN ALFA,ANEMIA solid tumors,106-130-136,181-189-167,comparable EPOETIN ALFA.,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa.",106,181 189,106,181,112,193,1,RO-may_treat,907996,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa",anemia,epoetin alfa
502912995,7/14/2014 14:29:11,,1322883430,7/14/2014 14:29:08,instagc,1.0,27753923,GBR,"","",188.30.192.65,106,181,,,112,193,ANEMIA,EPOETIN ALFA,effective for treating ANEMIA in patients with,83-93-97-106-113-116-125,164-167-178-181-189,is comparable to EPOETIN ALFA.,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa.",106,181 189,106,181,112,193,1,RO-may_treat,907996,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa",anemia,epoetin alfa
502912995,7/14/2014 14:40:04,,1322891105,7/14/2014 14:40:00,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,106,181,,,112,193,ANEMIA,EPOETIN ALFA,effective for treating ANEMIA in patients with,83-93-97-106-113-116-125,164-167-178-181-189,is comparable to EPOETIN ALFA.,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa.",106,181 189,106,181,112,193,1,RO-may_treat,907996,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa",anemia,epoetin alfa
502912995,7/14/2014 14:42:05,,1322892504,7/14/2014 14:41:41,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,106,181,,,112,193,ANEMIA,EPOETIN ALFA,effective for treating ANEMIA in patients,83-93-97-106-113-116,181-189,EPOETIN ALFA.,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa.",106,181 189,106,181,112,193,1,RO-may_treat,907996,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa",anemia,epoetin alfa
502912995,7/14/2014 14:45:56,,1322894962,7/14/2014 14:45:47,prodege,1.0,28209666,,,"",24.156.173.34,106,181,,,112,193,ANEMIA,EPOETIN ALFA,ANEMIA,106,164-181-189,is EPOETIN ALFA.,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa.",106,181 189,106,181,112,193,1,RO-may_treat,907996,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating anemia in patients with solid tumors on chemotherapy, and is comparable to epoetin alfa",anemia,epoetin alfa
502912996,7/14/2014 12:52:11,,1322816298,7/14/2014 12:51:55,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,78,152,,,89,160,BONE MARROW,LEUKEMIA,BONE MARROW,78-83,152,LEUKEMIA,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied.,78 83,152,78,152,89,160,1,RO-disease_has_primary_anatomic_site,902192,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied,bone marrow,leukemia
502912996,7/14/2014 12:55:08,,1322818295,7/14/2014 12:55:04,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,78,152,,,89,160,BONE MARROW,LEUKEMIA,human osteosarcoma cells with BONE MARROW or peripheral blood,54-67-73-78-83-90-93-104-48,133-143-149-152-161-166-83,marrow different types of LEUKEMIA were studied.,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied.,78 83,152,78,152,89,160,1,RO-disease_has_primary_anatomic_site,902192,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied,bone marrow,leukemia
502912996,7/14/2014 13:34:34,,1322845092,7/14/2014 13:34:11,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,78,152,,,89,160,BONE MARROW,LEUKEMIA,osteosarcoma cells with BONE MARROW or peripheral blood cells,54-67-73-78-83-90-93-104-110,133-143-149-152,different types of LEUKEMIA,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied.,78 83,152,78,152,89,160,1,RO-disease_has_primary_anatomic_site,902192,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied,bone marrow,leukemia
502912996,7/14/2014 13:35:08,,1322845422,7/14/2014 13:34:50,clixsense,1.0,27969116,NLD,"","",91.213.37.165,78,152,,,89,160,BONE MARROW,LEUKEMIA,osteosarcoma cells BONE MARROW peripheral blood cells,54-67-78-83-93-104-110,152,LEUKEMIA,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied.,78 83,152,78,152,89,160,1,RO-disease_has_primary_anatomic_site,902192,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied,bone marrow,leukemia
502912996,7/14/2014 13:45:18,,1322852814,7/14/2014 13:45:03,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,78,152,,,89,160,BONE MARROW,LEUKEMIA,BONE MARROW,78-83,152,LEUKEMIA,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied.,78 83,152,78,152,89,160,1,RO-disease_has_primary_anatomic_site,902192,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied,bone marrow,leukemia
502912996,7/14/2014 13:51:34,,1322857587,7/14/2014 13:50:27,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,78,152,,,89,160,BONE MARROW,LEUKEMIA,osteosarcoma BONE MARROW leukemia,78-83-152-54,152-54,osteosarcoma LEUKEMIA,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied.,78 83,152,78,152,89,160,1,RO-disease_has_primary_anatomic_site,902192,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied,bone marrow,leukemia
502912996,7/14/2014 13:52:13,,1322858104,7/14/2014 13:52:02,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,78,152,,,89,160,BONE MARROW,LEUKEMIA,BONE MARROW,78-83,152,LEUKEMIA,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied.,78 83,152,78,152,89,160,1,RO-disease_has_primary_anatomic_site,902192,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied,bone marrow,leukemia
502912996,7/14/2014 14:43:32,,1322893434,7/14/2014 14:43:07,prodege,1.0,28209666,,,"",24.156.173.34,78,152,,,89,160,BONE MARROW,LEUKEMIA,BONE MARROW,78-83,152,LEUKEMIA,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied.,78 83,152,78,152,89,160,1,RO-disease_has_primary_anatomic_site,902192,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied,bone marrow,leukemia
502912996,7/14/2014 14:46:07,,1322895101,7/14/2014 14:45:56,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,78,152,,,89,160,BONE MARROW,LEUKEMIA,BONE MARROW,78-83,152,LEUKEMIA,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied.,78 83,152,78,152,89,160,1,RO-disease_has_primary_anatomic_site,902192,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied,bone marrow,leukemia
502912996,7/14/2014 14:46:34,,1322895334,7/14/2014 14:46:20,instagc,1.0,13763729,USA,"","",75.182.89.225,78,152,,,89,160,BONE MARROW,LEUKEMIA,BONE MARROW,78-83,152,LEUKEMIA,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied.,78 83,152,78,152,89,160,1,RO-disease_has_primary_anatomic_site,902192,Short- and long-term co-cultures of 49 cases of human osteosarcoma cells with bone marrow or peripheral blood cells of patients with different types of leukemia were studied,bone marrow,leukemia
502912997,7/14/2014 12:55:11,,1322818325,7/14/2014 12:55:00,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,22,44,,,26,58,GVHD,CYCLOSPORINE A,GVHD prophylaxis,22-27,44-57,CYCLOSPORINE A,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate.,22,44 57,22,44,26,58,1,RO-may_prevent,907461,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate,GVHD,cyclosporine A
502912997,7/14/2014 13:01:53,,1322822706,7/14/2014 13:01:42,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,22,44,,,26,58,GVHD,CYCLOSPORINE A,GVHD,22,44-57,CYCLOSPORINE A,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate.,22,44 57,22,44,26,58,1,RO-may_prevent,907461,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate,GVHD,cyclosporine A
502912997,7/14/2014 13:31:42,,1322842904,7/14/2014 13:31:14,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,22,44,,,26,58,GVHD,CYCLOSPORINE A,All patients received GVHD prophylaxis with cyclosporine,0-4-13-22-27-39-44,22-27-39-44-57-59-64,GVHD prophylaxis with CYCLOSPORINE A plus methotrexate.,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate.,22,44 57,22,44,26,58,1,RO-may_prevent,907461,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate,GVHD,cyclosporine A
502912997,7/14/2014 13:33:23,,1322844197,7/14/2014 13:32:57,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,22,44,,,26,58,GVHD,CYCLOSPORINE A,GVHD prophylaxis,22-27,44-57,CYCLOSPORINE A,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate.,22,44 57,22,44,26,58,1,RO-may_prevent,907461,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate,GVHD,cyclosporine A
502912997,7/14/2014 13:48:29,,1322855330,7/14/2014 13:48:14,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,22,44,,,26,58,GVHD,CYCLOSPORINE A,GVHD,22,44-57,CYCLOSPORINE A,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate.,22,44 57,22,44,26,58,1,RO-may_prevent,907461,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate,GVHD,cyclosporine A
502912997,7/14/2014 13:49:23,,1322856025,7/14/2014 13:49:10,elite,1.0,26544151,GBR,"","",188.29.127.144,22,44,,,26,58,GVHD,CYCLOSPORINE A,GVHD,22,44-57,CYCLOSPORINE A,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate.,22,44 57,22,44,26,58,1,RO-may_prevent,907461,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate,GVHD,cyclosporine A
502912997,7/14/2014 14:01:46,,1322864618,7/14/2014 14:01:29,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,22,44,,,26,58,GVHD,CYCLOSPORINE A,GVHD prophylaxis with cyclosporine,22-27-44-39,44-57-59-64,CYCLOSPORINE A plus methotrexate.,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate.,22,44 57,22,44,26,58,1,RO-may_prevent,907461,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate,GVHD,cyclosporine A
502912997,7/14/2014 14:04:01,,1322866158,7/14/2014 14:03:22,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,22,44,,,26,58,GVHD,CYCLOSPORINE A,GVHD,22,44-57,CYCLOSPORINE A,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate.,22,44 57,22,44,26,58,1,RO-may_prevent,907461,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate,GVHD,cyclosporine A
502912997,7/14/2014 14:05:21,,1322866958,7/14/2014 14:05:06,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,22,44,,,26,58,GVHD,CYCLOSPORINE A,GVHD prophylaxis,22-27,44-57,CYCLOSPORINE A,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate.,22,44 57,22,44,26,58,1,RO-may_prevent,907461,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate,GVHD,cyclosporine A
502912997,7/14/2014 14:36:57,,1322888929,7/14/2014 14:34:19,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,22,44,,,26,58,GVHD,CYCLOSPORINE A,GVHD,22,22-39-44-57-59-64,GVHD with CYCLOSPORINE A plus methotrexate.,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate.,22,44 57,22,44,26,58,1,RO-may_prevent,907461,All patients received GVHD prophylaxis with cyclosporine A plus methotrexate,GVHD,cyclosporine A
502912998,7/14/2014 12:50:23,,1322814957,7/14/2014 12:49:49,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,109,18,,,118,35,DYSPLASIA,DUODENAL ADENOMAS,DYSPLASIA,109,18-27,DUODENAL ADENOMAS,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas.,109,18 27,109,18,118,35,1,RO-disease_has_finding,901867,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas,dysplasia,duodenal adenomas
502912998,7/14/2014 13:10:29,,1322828508,7/14/2014 13:10:10,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,109,18,,,118,35,DYSPLASIA,DUODENAL ADENOMAS,DYSPLASIA relationship as sporadic,109-119-132-135,18-27,DUODENAL ADENOMAS,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas.,109,18 27,109,18,118,35,1,RO-disease_has_finding,901867,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas,dysplasia,duodenal adenomas
502912998,7/14/2014 13:21:46,,1322836176,7/14/2014 13:21:25,prodege,1.0,27979711,CAN,ON,Stouffville,99.247.121.227,109,18,,,118,35,DYSPLASIA,DUODENAL ADENOMAS,shape DYSPLASIA,103-109,18-27,DUODENAL ADENOMAS,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas.,109,18 27,109,18,118,35,1,RO-disease_has_finding,901867,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas,dysplasia,duodenal adenomas
502912998,7/14/2014 13:30:27,,1322842093,7/14/2014 13:30:00,fusioncash,1.0,6340814,USA,FL,Saint Petersburg,216.186.230.135,109,18,,,118,35,DYSPLASIA,DUODENAL ADENOMAS,size villous shape DYSPLASIA relationship as sporadic,90-95-103-109-119-132-135,14-18-27-36-41-57,and DUODENAL ADENOMAS were morphologically similar;,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas.,109,18 27,109,18,118,35,1,RO-disease_has_finding,901867,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas,dysplasia,duodenal adenomas
502912998,7/14/2014 13:49:41,,1322856200,7/14/2014 13:49:25,elite,1.0,26544151,GBR,"","",188.29.127.144,109,18,,,118,35,DYSPLASIA,DUODENAL ADENOMAS,DYSPLASIA,109,18-27,DUODENAL ADENOMAS,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas.,109,18 27,109,18,118,35,1,RO-disease_has_finding,901867,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas,dysplasia,duodenal adenomas
502912998,7/14/2014 14:22:01,,1322878285,7/14/2014 14:21:42,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.150,109,18,,,118,35,DYSPLASIA,DUODENAL ADENOMAS,Periampullary duodenal adenomas DYSPLASIA,0-18-27-109,0-14-18-27,Periampullary and DUODENAL ADENOMAS,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas.,109,18 27,109,18,118,35,1,RO-disease_has_finding,901867,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas,dysplasia,duodenal adenomas
502912998,7/14/2014 14:23:14,,1322879039,7/14/2014 14:23:11,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,109,18,,,118,35,DYSPLASIA,DUODENAL ADENOMAS,size villous shape DYSPLASIA relationship as sporadic,90-95-103-109-119-132-135,0-14-18-27-36-41-57,Periampullary and DUODENAL ADENOMAS were morphologically similar;,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas.,109,18 27,109,18,118,35,1,RO-disease_has_finding,901867,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas,dysplasia,duodenal adenomas
502912998,7/14/2014 14:47:16,,1322895767,7/14/2014 14:47:04,prodege,1.0,28209666,,,"",24.156.173.34,109,18,,,118,35,DYSPLASIA,DUODENAL ADENOMAS,DYSPLASIA,109,18-27,DUODENAL ADENOMAS,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas.,109,18 27,109,18,118,35,1,RO-disease_has_finding,901867,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas,dysplasia,duodenal adenomas
502912998,7/14/2014 14:47:38,,1322895971,7/14/2014 14:47:23,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,109,18,,,118,35,DYSPLASIA,DUODENAL ADENOMAS,DYSPLASIA,109,18-27,DUODENAL ADENOMAS,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas.,109,18 27,109,18,118,35,1,RO-disease_has_finding,901867,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas,dysplasia,duodenal adenomas
502912998,7/14/2014 14:48:18,,1322896357,7/14/2014 14:48:02,instagc,1.0,13763729,USA,"","",75.182.89.225,109,18,,,118,35,DYSPLASIA,DUODENAL ADENOMAS,DYSPLASIA,109,18-27,DUODENAL ADENOMAS,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas.,109,18 27,109,18,118,35,1,RO-disease_has_finding,901867,Periampullary and duodenal adenomas were morphologically similar; both exhibited the same size-villous shape-dysplasia relationship as sporadic and familial adenomatous polyposis-associated colonic adenomas,dysplasia,duodenal adenomas
502912999,7/14/2014 13:07:50,,1322826621,7/14/2014 13:07:25,neodev,1.0,24578640,USA,IL,Chicago,65.60.20.66,121,83,,,141,97,CALORIE MALNUTRITION,UNDERNUTRITION,CALORIE MALNUTRITION postnatal dystrophy.,121-129-158-168,83-129-158-168,"UNDERNUTRITION, malnutrition postnatal dystrophy.","The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy.",121 129,83,121,83,141,97,-1,RO-cause_of,900164,"The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy",calorie malnutrition,undernutrition
502912999,7/14/2014 13:12:11,,1322829584,7/14/2014 13:11:55,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,121,83,,,141,97,CALORIE MALNUTRITION,UNDERNUTRITION,protein CALORIE MALNUTRITION,113-121-129,83,"UNDERNUTRITION,","The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy.",121 129,83,121,83,141,97,-1,RO-cause_of,900164,"The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy",calorie malnutrition,undernutrition
502912999,7/14/2014 13:18:47,,1322834107,7/14/2014 13:18:21,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,121,83,,,141,97,CALORIE MALNUTRITION,UNDERNUTRITION,protein CALORIE MALNUTRITION,113-121-129,83,"UNDERNUTRITION,","The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy.",121 129,83,121,83,141,97,-1,RO-cause_of,900164,"The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy",calorie malnutrition,undernutrition
502912999,7/14/2014 13:48:13,,1322855163,7/14/2014 13:47:56,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,121,83,,,141,97,CALORIE MALNUTRITION,UNDERNUTRITION,CALORIE MALNUTRITION,121-129,83,"UNDERNUTRITION,","The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy.",121 129,83,121,83,141,97,-1,RO-cause_of,900164,"The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy",calorie malnutrition,undernutrition
502912999,7/14/2014 13:51:20,,1322857412,7/14/2014 13:50:59,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,121,83,,,141,97,CALORIE MALNUTRITION,UNDERNUTRITION,protein CALORIE MALNUTRITION,113-121-129,59-67-70-83-110,"results of intrauterine UNDERNUTRITION, to","The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy.",121 129,83,121,83,141,97,-1,RO-cause_of,900164,"The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy",calorie malnutrition,undernutrition
502912999,7/14/2014 13:53:41,,1322859084,7/14/2014 13:53:20,prodege,1.0,2107590,CAN,ON,Ottawa,99.245.226.211,121,83,,,141,97,CALORIE MALNUTRITION,UNDERNUTRITION,protein CALORIE MALNUTRITION,113-121-129,70-83,"intrauterine UNDERNUTRITION,","The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy.",121 129,83,121,83,141,97,-1,RO-cause_of,900164,"The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy",calorie malnutrition,undernutrition
502912999,7/14/2014 14:00:03,,1322863336,7/14/2014 13:58:59,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,121,83,,,141,97,CALORIE MALNUTRITION,UNDERNUTRITION,protein CALORIE MALNUTRITION,113-121-129,70-83,"intrauterine UNDERNUTRITION,","The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy.",121 129,83,121,83,141,97,-1,RO-cause_of,900164,"The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy",calorie malnutrition,undernutrition
502912999,7/14/2014 14:22:24,,1322878512,7/14/2014 14:22:19,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,121,83,,,141,97,CALORIE MALNUTRITION,UNDERNUTRITION,analogical to protein CALORIE MALNUTRITION in infants with,99-110-113-121-129-142-145-153,59-67-70-83-99-110-113,"results of intrauterine UNDERNUTRITION, analogical to protein","The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy.",121 129,83,121,83,141,97,-1,RO-cause_of,900164,"The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy",calorie malnutrition,undernutrition
502912999,7/14/2014 14:40:27,,1322891361,7/14/2014 14:40:20,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,121,83,,,141,97,CALORIE MALNUTRITION,UNDERNUTRITION,analogical to protein CALORIE MALNUTRITION in infants with,99-110-113-121-129-142-145-153,59-67-70-83-99-110-113,"results of intrauterine UNDERNUTRITION, analogical to protein","The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy.",121 129,83,121,83,141,97,-1,RO-cause_of,900164,"The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy",calorie malnutrition,undernutrition
502912999,7/14/2014 14:46:52,,1322895581,7/14/2014 14:46:35,instagc,1.0,13763729,USA,"","",75.182.89.225,121,83,,,141,97,CALORIE MALNUTRITION,UNDERNUTRITION,protein CALORIE MALNUTRITION,113-121-129,83-70,"intrauterine UNDERNUTRITION,","The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy.",121 129,83,121,83,141,97,-1,RO-cause_of,900164,"The S-f-D infants already at birth showed the symptoms and results of intrauterine undernutrition, analogical to protein-calorie malnutrition in infants with postnatal dystrophy",calorie malnutrition,undernutrition
502913000,7/14/2014 12:48:53,,1322813926,7/14/2014 12:48:37,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,83,97,,,95,113,HYPERTENSION,PHEOCHROMOCYTOMA,"HYPERTENSION, pheochromocytoma, carcinoid syndrome, untreated hyperthyroidism.",83-97-115-125-138-148,70-83-97-115-125-135-138-148,"uncontrolled hypertension, PHEOCHROMOCYTOMA, carcinoid syndrome, or untreated hyperthyroidism.","1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.",83,97,83,97,95,113,-1,RO-disease_may_have_finding,902633,"1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism",hypertension,pheochromocytoma
502913000,7/14/2014 13:01:22,,1322822379,7/14/2014 13:01:00,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,83,97,,,95,113,HYPERTENSION,PHEOCHROMOCYTOMA,"uncontrolled HYPERTENSION,",70-83,97,"PHEOCHROMOCYTOMA,","1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.",83,97,83,97,95,113,-1,RO-disease_may_have_finding,902633,"1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism",hypertension,pheochromocytoma
502913000,7/14/2014 13:15:19,,1322831755,7/14/2014 13:15:01,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,83,97,,,95,113,HYPERTENSION,PHEOCHROMOCYTOMA,"HYPERTENSION,",83,97,"PHEOCHROMOCYTOMA,","1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.",83,97,83,97,95,113,-1,RO-disease_may_have_finding,902633,"1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism",hypertension,pheochromocytoma
502913000,7/14/2014 13:43:14,,1322851416,7/14/2014 13:42:58,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,83,97,,,95,113,HYPERTENSION,PHEOCHROMOCYTOMA,"HYPERTENSION,",83,97,"PHEOCHROMOCYTOMA,","1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.",83,97,83,97,95,113,-1,RO-disease_may_have_finding,902633,"1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism",hypertension,pheochromocytoma
502913000,7/14/2014 13:43:28,,1322851557,7/14/2014 13:43:07,elite,1.0,26544151,GBR,"","",188.29.127.144,83,97,,,95,113,HYPERTENSION,PHEOCHROMOCYTOMA,"HYPERTENSION,",83,97,"PHEOCHROMOCYTOMA,","1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.",83,97,83,97,95,113,-1,RO-disease_may_have_finding,902633,"1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism",hypertension,pheochromocytoma
502913000,7/14/2014 14:03:29,,1322865793,7/14/2014 14:03:12,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,83,97,,,95,113,HYPERTENSION,PHEOCHROMOCYTOMA,"uncontrolled HYPERTENSION,",70-83,83-97,"hypertension, PHEOCHROMOCYTOMA,","1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.",83,97,83,97,95,113,-1,RO-disease_may_have_finding,902633,"1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism",hypertension,pheochromocytoma
502913000,7/14/2014 14:23:03,,1322878912,7/14/2014 14:22:58,fusioncash,1.0,17395678,USA,OK,Oklahoma City,67.67.9.94,83,97,,,95,113,HYPERTENSION,PHEOCHROMOCYTOMA,"patients with uncontrolled HYPERTENSION, pheochromocytoma, carcinoid syndrome,",56-65-70-83-97-115-125,65-70-83-97-115-125-135,"with uncontrolled hypertension, PHEOCHROMOCYTOMA, carcinoid syndrome, or","1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.",83,97,83,97,95,113,-1,RO-disease_may_have_finding,902633,"1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism",hypertension,pheochromocytoma
502913000,7/14/2014 14:39:34,,1322890761,7/14/2014 14:39:08,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,83,97,,,95,113,HYPERTENSION,PHEOCHROMOCYTOMA,"patients with uncontrolled HYPERTENSION, pheochromocytoma, carcinoid syndrome,",56-65-70-83-97-115-125,65-70-83-97-115-125-135,"with uncontrolled hypertension, PHEOCHROMOCYTOMA, carcinoid syndrome, or","1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.",83,97,83,97,95,113,-1,RO-disease_may_have_finding,902633,"1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism",hypertension,pheochromocytoma
502913000,7/14/2014 14:40:24,,1322891346,7/14/2014 14:39:58,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,83,97,,,95,113,HYPERTENSION,PHEOCHROMOCYTOMA,"patients with uncontrolled HYPERTENSION, pheochromocytoma, carcinoid syndrome,",56-65-70-83-97-115-125,65-70-83-97-115-125,"with uncontrolled hypertension, PHEOCHROMOCYTOMA, carcinoid syndrome,","1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.",83,97,83,97,95,113,-1,RO-disease_may_have_finding,902633,"1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism",hypertension,pheochromocytoma
502913000,7/14/2014 14:47:46,,1322896069,7/14/2014 14:47:38,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,83,97,,,95,113,HYPERTENSION,PHEOCHROMOCYTOMA,"uncontrolled HYPERTENSION,",70-83,97,"PHEOCHROMOCYTOMA,","1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.",83,97,83,97,95,113,-1,RO-disease_may_have_finding,902633,"1  Other Precautions  Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism",hypertension,pheochromocytoma
502913001,7/14/2014 12:51:06,,1322815469,7/14/2014 12:50:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,77,90,,,81,99,SKIN,URTICARIA,SKIN,77,90,URTICARIA,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop.,77,90,77,90,81,99,1,RO-has_finding_site,905057,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop,skin,urticaria
502913001,7/14/2014 12:55:22,,1322818442,7/14/2014 12:53:51,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,77,90,,,81,99,SKIN,URTICARIA,SKIN,77,90,URTICARIA,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop.,77,90,77,90,81,99,1,RO-has_finding_site,905057,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop,skin,urticaria
502913001,7/14/2014 12:59:11,,1322820981,7/14/2014 12:58:56,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,77,90,,,81,99,SKIN,URTICARIA,SKIN,77,90,URTICARIA,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop.,77,90,77,90,81,99,1,RO-has_finding_site,905057,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop,skin,urticaria
502913001,7/14/2014 13:05:34,,1322824995,7/14/2014 13:04:48,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,77,90,,,81,99,SKIN,URTICARIA,tolerance in the SKIN urticaria fails,60-70-73-77-90-100,60-70-73-77-90-100,tolerance in the skin URTICARIA fails,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop.,77,90,77,90,81,99,1,RO-has_finding_site,905057,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop,skin,urticaria
502913001,7/14/2014 13:14:42,,1322831276,7/14/2014 13:14:38,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,77,90,,,81,99,SKIN,URTICARIA,tolerance in the SKIN so that urticaria,60-70-73-77-82-85-90,77-82-85-90-100-106-109,skin so that URTICARIA fails to develop.,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop.,77,90,77,90,81,99,1,RO-has_finding_site,905057,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop,skin,urticaria
502913001,7/14/2014 13:46:37,,1322853910,7/14/2014 13:46:16,prodege,1.0,28140821,CAN,ON,Peterborough,24.235.135.244,77,90,,,81,99,SKIN,URTICARIA,SKIN urticaria,77-90,90,URTICARIA,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop.,77,90,77,90,81,99,1,RO-has_finding_site,905057,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop,skin,urticaria
502913001,7/14/2014 14:02:09,,1322864907,7/14/2014 14:01:53,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,77,90,,,81,99,SKIN,URTICARIA,SKIN that,77-85,90,URTICARIA,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop.,77,90,77,90,81,99,1,RO-has_finding_site,905057,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop,skin,urticaria
502913001,7/14/2014 14:38:20,,1322889872,7/14/2014 14:38:08,instagc,1.0,15445601,USA,FL,Jacksonville,24.129.68.254,77,90,,,81,99,SKIN,URTICARIA,SKIN,77,90,URTICARIA,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop.,77,90,77,90,81,99,1,RO-has_finding_site,905057,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop,skin,urticaria
502913001,7/14/2014 14:40:57,,1322891714,7/14/2014 14:40:48,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,77,90,,,81,99,SKIN,URTICARIA,tolerance in the SKIN so that urticaria,60-70-73-77-82-85-90,77-82-85-90-100-106-109,skin so that URTICARIA fails to develop.,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop.,77,90,77,90,81,99,1,RO-has_finding_site,905057,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop,skin,urticaria
502913001,7/14/2014 14:47:47,,1322896094,7/14/2014 14:47:32,instagc,1.0,13763729,USA,"","",75.182.89.225,77,90,,,81,99,SKIN,URTICARIA,SKIN,77,90,URTICARIA,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop.,77,90,77,90,81,99,1,RO-has_finding_site,905057,Repeated exposures over a period of hours induce a state of tolerance in the skin so that urticaria fails to develop,skin,urticaria
502913002,7/14/2014 12:56:24,,1322819163,7/14/2014 12:56:18,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,52,5,,,80,26,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,"(DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA are stressful metabolic",27-33-37-52-65-76-88-92-102,0-5-14-33-37-102,"Both DIABETIC KETOACIDOSIS and hyperglycemic, metabolic","Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",52 65 76,5 14,52,5,80,26,-1,RO-cause_of,900137,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events",hyperosmolar nonketotic coma,diabetic ketoacidosis
502913002,7/14/2014 12:57:58,,1322820086,7/14/2014 12:57:37,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,52,5,,,80,26,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,HYPEROSMOLAR NONKETOTIC COMA,52-65-76,5-14,DIABETIC KETOACIDOSIS,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",52 65 76,5 14,52,5,80,26,-1,RO-cause_of,900137,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events",hyperosmolar nonketotic coma,diabetic ketoacidosis
502913002,7/14/2014 13:02:23,,1322823027,7/14/2014 13:02:12,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,52,5,,,80,26,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,HYPEROSMOLAR NONKETOTIC COMA,52-65-76,5-14,DIABETIC KETOACIDOSIS,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",52 65 76,5 14,52,5,80,26,-1,RO-cause_of,900137,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events",hyperosmolar nonketotic coma,diabetic ketoacidosis
502913002,7/14/2014 13:15:23,,1322831774,7/14/2014 13:15:18,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,52,5,,,80,26,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,"(DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA are stressful",27-33-37-52-65-76-88-92,0-5-14-33-37,"Both DIABETIC KETOACIDOSIS and hyperglycemic,","Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",52 65 76,5 14,52,5,80,26,-1,RO-cause_of,900137,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events",hyperosmolar nonketotic coma,diabetic ketoacidosis
502913002,7/14/2014 13:35:27,,1322845632,7/14/2014 13:35:08,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,52,5,,,80,26,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,HYPEROSMOLAR NONKETOTIC COMA (HHNC),52-65-76-81,5-14-27,DIABETIC KETOACIDOSIS (DKA),"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",52 65 76,5 14,52,5,80,26,-1,RO-cause_of,900137,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events",hyperosmolar nonketotic coma,diabetic ketoacidosis
502913002,7/14/2014 13:47:11,,1322854442,7/14/2014 13:46:49,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,52,5,,,80,26,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,HYPEROSMOLAR NONKETOTIC COMA (HHNC),52-65-76-81,5-14-27-33-37-52-65-76-81,"DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC)","Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",52 65 76,5 14,52,5,80,26,-1,RO-cause_of,900137,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events",hyperosmolar nonketotic coma,diabetic ketoacidosis
502913002,7/14/2014 14:44:55,,1322894351,7/14/2014 14:44:36,clixsense,1.0,6610277,CAN,ON,Oshawa,174.117.79.122,52,5,,,80,26,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,"(DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA",27-33-37-52-65-76,5-14-33-37-52-65-76-81,"DIABETIC KETOACIDOSIS and hyperglycemic, hyperosmolar nonketotic coma (HHNC)","Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",52 65 76,5 14,52,5,80,26,-1,RO-cause_of,900137,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events",hyperosmolar nonketotic coma,diabetic ketoacidosis
502913002,7/14/2014 14:45:04,,1322894404,7/14/2014 14:44:42,prodege,1.0,28209666,,,"",24.156.173.34,52,5,,,80,26,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,HYPEROSMOLAR NONKETOTIC COMA,52-65-76,5-14,DIABETIC KETOACIDOSIS,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",52 65 76,5 14,52,5,80,26,-1,RO-cause_of,900137,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events",hyperosmolar nonketotic coma,diabetic ketoacidosis
502913002,7/14/2014 14:47:08,,1322895695,7/14/2014 14:46:32,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,52,5,,,80,26,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,HYPEROSMOLAR NONKETOTIC COMA,52-65-76,5-14,DIABETIC KETOACIDOSIS,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",52 65 76,5 14,52,5,80,26,-1,RO-cause_of,900137,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events",hyperosmolar nonketotic coma,diabetic ketoacidosis
502913002,7/14/2014 14:48:12,,1322896314,7/14/2014 14:48:05,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,52,5,,,80,26,HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,HYPEROSMOLAR NONKETOTIC COMA,52-65-76,5-14,DIABETIC KETOACIDOSIS,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",52 65 76,5 14,52,5,80,26,-1,RO-cause_of,900137,"Both diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events",hyperosmolar nonketotic coma,diabetic ketoacidosis
502913003,7/14/2014 12:51:05,,1322815466,7/14/2014 12:50:26,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,184,140,,,192,156,HEADACHE,PHEOCHROMOCYTOMA,"HEADACHE),",184,140,"PHEOCHROMOCYTOMA,","Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection.",184,140,184,140,192,156,-1,RO-disease_may_have_finding,902844,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection",headache,pheochromocytoma
502913003,7/14/2014 12:56:49,,1322819411,7/14/2014 12:56:43,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,184,140,,,192,156,HEADACHE,PHEOCHROMOCYTOMA,"SAH, cardiac ischemia (anginal HEADACHE), and intracranial arterial",158-166-175-184-195-199-212-110,115-126-132-140-158-166-110,"SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA, cardiac ischemia","Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection.",184,140,184,140,192,156,-1,RO-disease_may_have_finding,902844,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection",headache,pheochromocytoma
502913003,7/14/2014 12:57:20,,1322819699,7/14/2014 12:56:54,bitcoinget,1.0,24792414,USA,"","",166.181.81.129,184,140,,,192,156,HEADACHE,PHEOCHROMOCYTOMA,"(anginal HEADACHE),",175-184,140-158-166,"PHEOCHROMOCYTOMA, cardiac ischemia","Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection.",184,140,184,140,192,156,-1,RO-disease_may_have_finding,902844,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection",headache,pheochromocytoma
502913003,7/14/2014 12:58:29,,1322820549,7/14/2014 12:58:16,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,184,140,,,192,156,HEADACHE,PHEOCHROMOCYTOMA,"HEADACHE),",184,140,"PHEOCHROMOCYTOMA,","Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection.",184,140,184,140,192,156,-1,RO-disease_may_have_finding,902844,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection",headache,pheochromocytoma
502913003,7/14/2014 13:12:40,,1322829880,7/14/2014 13:11:57,clixsense,1.0,8422649,GBR,B4,Bradford,86.185.23.95,184,140,,,192,156,HEADACHE,PHEOCHROMOCYTOMA,"(anginal HEADACHE),",175-184,140,"PHEOCHROMOCYTOMA,","Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection.",184,140,184,140,192,156,-1,RO-disease_may_have_finding,902844,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection",headache,pheochromocytoma
502913003,7/14/2014 13:19:19,,1322834389,7/14/2014 13:19:06,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,184,140,,,192,156,HEADACHE,PHEOCHROMOCYTOMA,"HEADACHE),",184,140,"PHEOCHROMOCYTOMA,","Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection.",184,140,184,140,192,156,-1,RO-disease_may_have_finding,902844,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection",headache,pheochromocytoma
502913003,7/14/2014 13:31:51,,1322842983,7/14/2014 13:31:29,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,184,140,,,192,156,HEADACHE,PHEOCHROMOCYTOMA,"(anginal HEADACHE),",175-184,140,"PHEOCHROMOCYTOMA,","Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection.",184,140,184,140,192,156,-1,RO-disease_may_have_finding,902844,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection",headache,pheochromocytoma
502913003,7/14/2014 13:33:10,,1322844100,7/14/2014 13:32:50,clixsense,1.0,27969116,NLD,"","",91.213.37.165,184,140,,,192,156,HEADACHE,PHEOCHROMOCYTOMA,"cardiac ischemia (anginal HEADACHE),",158-166-175-184,140,"PHEOCHROMOCYTOMA,","Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection.",184,140,184,140,192,156,-1,RO-disease_may_have_finding,902844,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection",headache,pheochromocytoma
502913003,7/14/2014 13:43:10,,1322851387,7/14/2014 13:42:53,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.58.19,184,140,,,192,156,HEADACHE,PHEOCHROMOCYTOMA,"HEADACHE),",184,140,"PHEOCHROMOCYTOMA,","Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection.",184,140,184,140,192,156,-1,RO-disease_may_have_finding,902844,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection",headache,pheochromocytoma
502913003,7/14/2014 14:01:58,,1322864761,7/14/2014 14:01:48,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,184,140,,,192,156,HEADACHE,PHEOCHROMOCYTOMA,"cardiac ischemia (anginal HEADACHE),",158-166-175-184,115-126-132-140-158-166,"sinusitis, brain tumors, PHEOCHROMOCYTOMA, cardiac ischemia","Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection.",184,140,184,140,192,156,-1,RO-disease_may_have_finding,902844,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, pheochromocytoma, cardiac ischemia (anginal headache), and intracranial arterial dissection",headache,pheochromocytoma
